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Abstract
The overall aim of this thesis was to develop a minimally manipulative, label-free
microfluidic cell separator device which is able to deliver an enriched population
of autologous cells, positive for tissue non-specific alkaline phosphatase (TNAP) via
cell capture using either antibody or non-antibody protein binding. TNAP is a pro-
mineralising cell surface marker and is potentially useful as a marker for isolation of stem
cell populations for use in regenerative therapies. For clinical applications, cells would
be isolated from bone marrow aspirate or orthopaedic surgical waste within intraoperative
time of less than two hours, then paired with an osteoconductive scaffold to provide an
alternative treatment option with potentially accelerated bone repair and regeneration.
Dental Pulp Stomal Cells (DPSCs) which were used as a model system throughout this
work, were shown to express 2.8 ± 1.3 ×105 TNAP molecules on the cells’ surface
and the number of TNAP molecules per TNAP+ cell was not altered by factors such
as passage number, seeding density and cell donor. Following this, a microfluidc cell
separation device was designed and developed for the enrichment of TNAP+ cells, by
capture and subsequent release of TNAP+ DPSCs via a surface functionalised with anti-
TNAP antibodies. The recovered cells demonstrated a TNAP+ enriched population
with up to a two fold enrichment of TNAP+ cells. The device also begun to meet the
requirements for a minimally manipulated cell separation as minimal antibody could be
detected on the surface of the recovered cells. As well, the capture and release mechanism
had minimal effect on the cells’ biological characteristics, as the recovered enriched
population retained a high viability and retained their osteogenic differentiation potential.
The specificity to TNAP on the cells’ surface of previously identified non-antibody
TNAP binding proteins, known as Affimers, was investigated for potential use within
the cell separation technology. Affimer proteins were identified for expression and
purification, and demonstrated specificity to recombinant TNAP protein. However,
there was minimal evidence of specificity to TNAP on the cells’ surface and therefore
subsequent development of the device utilised an anti-TNAP antibody instead.
This thesis demonstrated a novel cell separation technology capable of providing an
enriched population of viable TNAP+ cells with no obvious alterations in their biological




ABS Acrylonitrile butadiene styrene
ALP Alkaline phosphatase
BCA Bicinchoninic acid
BMP Bone morphogenetic proteins
BTSG BioScreening technology screening group
CAD Computer-aided design
CFU-F Fibroblast colony-forming units
CTC Circulating tumor cell
DBM Demineralised bone matrix
DEP Dielectrophoresis
DLD Deterministic lateral displacement
DPSC Dental pulp stem cell
DNA Deoxyribonucleic acid
EDTA Ethylenediaminetetraacetic acid
ELISA Enzyme Linked Immunosorbent Assay
FACS Fluorescence activated cell sorting
FCS Foetal calf serum
FFF Fused filament fabrication
HBE Human bronchial epithelial cell
HRP Horseradish peroxidase
iPSC Induced pluripotent stem cell
LOC Lab-on-chip
MACS Magnetic activated cell sorting
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MSC Mesenchymal stem cell
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PDMS Polydimethylsiloxane
TNAP Tissue non-specific alkaline phosphatase




Acknowledgements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ii
Abstract . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . iii
Abbreviations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . iv
Contents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . v
List of figures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . xii
List of tables . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . xxxi
1 Introduction 1
1.1 Scope of the thesis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
1.2 Clinical need for bone therapies . . . . . . . . . . . . . . . . . . . . . . 2
1.2.1 The biology of bone . . . . . . . . . . . . . . . . . . . . . . . . 2
1.2.2 Bone Structure . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
1.2.3 Bone grafts . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
1.2.4 Fracture healing . . . . . . . . . . . . . . . . . . . . . . . . . . 8
1.2.5 Cell based therapies for bone repair . . . . . . . . . . . . . . . . 9
1.3 Mesenchymal stem cells . . . . . . . . . . . . . . . . . . . . . . . . . . 11
1.3.1 Dental pulp stromal cells . . . . . . . . . . . . . . . . . . . . . . 14
1.3.2 Osteogenic differentiation of mesenchymal stem cells . . . . . . . 15
1.3.3 Tissue non-specific alkaline phosphatase (TNAP) . . . . . . . . . 17
v
1.4 Methods for cell separation . . . . . . . . . . . . . . . . . . . . . . . . . 19
1.4.1 Traditional methods of cell sorting . . . . . . . . . . . . . . . . . 21
1.5 Lab on a chip cell separation methods . . . . . . . . . . . . . . . . . . . 27
1.5.1 Microfluidic device fabrication . . . . . . . . . . . . . . . . . . . 28
1.5.2 Microfluidic methods for cell separation . . . . . . . . . . . . . . 30
1.6 Binding proteins . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44
1.6.1 Antibodies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44
1.6.2 Non-antibody binding proteins . . . . . . . . . . . . . . . . . . . 45
1.6.3 Affimer proteins . . . . . . . . . . . . . . . . . . . . . . . . . . 46
1.7 Thesis aims and objectives . . . . . . . . . . . . . . . . . . . . . . . . . 47
1.7.1 Objectives . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48
2 Possible use of Affimers in cell capture for cell separation 50
2.1 Aim . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 50
2.2 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 50
2.3 Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52
2.4 Tissue culture of DPSCs . . . . . . . . . . . . . . . . . . . . . . . . . . 52
2.4.1 Isolation of dental pulp stromal cells from human teeth . . . . . . 52
2.4.2 Cell expansion . . . . . . . . . . . . . . . . . . . . . . . . . . . 53
2.4.3 Cell counting . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53
2.4.4 Culture of human DPSCs in osteogenic medium . . . . . . . . . 54
2.4.5 Identification of anti-TNAP Affimers . . . . . . . . . . . . . . . 54
2.4.6 Expression of Affimers . . . . . . . . . . . . . . . . . . . . . . . 57
2.4.7 Purification of Affimers . . . . . . . . . . . . . . . . . . . . . . 58
2.4.8 SDS-PAGE Gel Electrophoresis . . . . . . . . . . . . . . . . . . 59
vi
2.4.9 Direct labelling of purified Affimer proteins and calculating the
concentration of labelled Affimer proteins in PBS . . . . . . . . . 61
2.4.10 Sandwich ELISA to investigate the binding of Affimers to
purified TNAP protein . . . . . . . . . . . . . . . . . . . . . . . 62
2.4.11 Flow cytometry analysis of DPSCs using fluorescent labelled
Affimers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 64
2.4.12 Pull-down Assays with TNAP protein and DPSC cell lysate to
determine Affimer binding to TNAP . . . . . . . . . . . . . . . . 65
2.5 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 67
2.5.1 Purification of Affimer proteins . . . . . . . . . . . . . . . . . . 67
2.5.2 Calculating the concentration of labelled Affimer proteins . . . . 68
2.5.3 Sandwich ELISA to confirm Affimer binding to TNAP protein . . 70
2.5.4 Investigating binding of TNAP on the surface of DPSCs with
fluorescently labelled Affimer proteins . . . . . . . . . . . . . . . 71
2.5.5 Pull-down assays to assess Affimer binding to native TNAP
protein in DPSC lysate . . . . . . . . . . . . . . . . . . . . . . . 75
2.6 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 81
2.6.1 Purification and labelling of Affimers . . . . . . . . . . . . . . . 81
2.6.2 Binding characterisation of Affimers . . . . . . . . . . . . . . . . 82
3 Investigating the expression of the pro-mineralising cell surface marker tissue
non-specific alkaline phosphatase at the molecular level at the surface of
dental pulp stromal cells. 87
3.1 Aim . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 87
3.2 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 88
3.3 Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 91
3.3.1 Determination of variation of TNAP expression with DPSC
seeding density using flow cytometry . . . . . . . . . . . . . . . 91
vii
3.3.2 Determining the number of molecules of tissue non-specific
alkaline phosphatase on the surface of dental pulp stromal cells . 92
3.3.3 Localisation of TNAP on the surface of DPSCs . . . . . . . . . . 94
3.3.4 Osteogenic induction of DPSCs . . . . . . . . . . . . . . . . . . 95
3.3.5 Statistical analysis of data . . . . . . . . . . . . . . . . . . . . . 95
3.4 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 96
3.4.1 Expression of TNAP on the surface of DPSCs and identification
of a suitable cell type for a negative control . . . . . . . . . . . . 96
3.4.2 Expression of TNAP by DPSCs is increased with high cell
seeding density . . . . . . . . . . . . . . . . . . . . . . . . . . . 98
3.4.3 Determining the number of molecules of tissue non-specific
alkaline phosphatase on the surface of DPSCs isolated from three
donors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 101
3.4.4 Effect of donor, passage number and seeding density on the
number of molecules of tissue non-specific alkaline phosphatase
on the surface of DPSCs . . . . . . . . . . . . . . . . . . . . . . 107
3.4.5 Effect of osteoinduction on DPSC TNAP expression in the total
cell population and the number of TNAP molecules expressed per
TNAP+ DPSC . . . . . . . . . . . . . . . . . . . . . . . . . . . 110
3.5 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 111
3.5.1 TNAP expression on the surface of DPSCs in the total population 112
3.5.2 The number of TNAP molecules per TNAP+ DPSC . . . . . . . . 113
4 Development of a microfluidic cell separator for enrichment of TNAP+
DPSCs 119
4.1 Aim . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 119
4.2 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 120
4.3 Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 122
viii
4.3.1 Functionalisation of gold surfaces with a self assembling monolayer122
4.3.2 Immobilisation of antibodies onto gold surfaces functionalised
with a SAM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 123
4.3.3 Use of colorimetric assays to demonstrate surface
functionalisation of anti-TNAP antibodies . . . . . . . . . . . . . 123
4.3.4 Microfluidic device fabrication and assembly . . . . . . . . . . . 125
4.3.5 Immobilisation of anti-TNAP antibodies onto functionalised gold
surfaces within the device . . . . . . . . . . . . . . . . . . . . . 128
4.3.6 Cell injection and release on antibody functionalised surfaces
within the device . . . . . . . . . . . . . . . . . . . . . . . . . . 129
4.3.7 Determination of the number of cells bound to the surface
following cell capture or release . . . . . . . . . . . . . . . . . . 131
4.3.8 Flow cytometric analysis of TNAP+ DPSCs before and after cell
capture using the microfluidic device . . . . . . . . . . . . . . . 132
4.3.9 Investigation to determine the possibility of any antibody
attachment to the cells after cell release from the device . . . . . 133
4.3.10 Statistical analysis of data . . . . . . . . . . . . . . . . . . . . . 134
4.4 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 134
4.4.1 Specific capture of DPSCs on the antibody functionalised gold
surface . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 134
4.4.2 Investigation into the impact of antibody density on the
functionalised gold surface . . . . . . . . . . . . . . . . . . . . . 135
4.4.3 Specificity of capture of DPSCs on the antibody functionalised
gold surface at different antibody concentrations . . . . . . . . . 137
4.4.4 Microfluidic device development . . . . . . . . . . . . . . . . . . 140
4.4.5 Specific cell capture of DPSCs within the microfluidic device . . 145
4.4.6 Release of captured DPSCs within the microfluidic device . . . . 147
ix
4.4.7 Quantifying the level of TNAP+ DPSCs before and after cell
separation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 150
4.4.8 Investigation to determine the possibility of any antibody
attachment to the cells after cell release from the device . . . . . 152
4.5 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 154
4.5.1 Functionalsition of gold surfaces with anti-TNAP antibody . . . . 154
4.5.2 Microfluidic device development . . . . . . . . . . . . . . . . . . 157
4.5.3 Capture and release of TNAP+ cells on the antibody
functionalised surface within the device . . . . . . . . . . . . . . 158
5 The effect of use of the microfluidic device for TNAP+ DPSC enrichment on
cell viability and osteogenic differentiation 165
5.1 Aim . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 165
5.2 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 165
5.3 Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 168
5.3.1 Experimental setup . . . . . . . . . . . . . . . . . . . . . . . . . 168
5.3.2 Determination of cell viability using flow cytometric analysis . . 169
5.3.3 Effect of separation on DPSCs proliferation . . . . . . . . . . . . 170
5.3.4 Effect of separation on the ability of DPSCs to undergo
osteogenic differentiation assessed through ALP activity . . . . . 172
5.3.5 Determination of Alkaline phosphatase specific activity (ALPSA)
of DPSCs undergoing osteogenic differentiation . . . . . . . . . . 173
5.3.6 Effect of separation on the ability of DPSCs to undergo
osteogenic differentiation assessed through alizarin red staining . 173
5.4 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 175
5.4.1 Determination of cell viability after capture and release of DPSCs
using the microfludic device and the effect of pH on cell viability
for potential use in the release mechanism. . . . . . . . . . . . . 175
x
5.4.2 The effect of the separation process on DPSCs proliferation . . . 180
5.4.3 Osteogenic differentiation of separated DPSCs characterised by
alkaline phosphatase specific activity . . . . . . . . . . . . . . . 185
5.4.4 Investigating the ability of separated DPSCs to produce a
mineralised matrix . . . . . . . . . . . . . . . . . . . . . . . . . 189
5.5 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 194
5.5.1 Effect of the separation process on cell viability . . . . . . . . . . 194
5.5.2 Effect of the separation process on cell proliferation and
osteogenic potential . . . . . . . . . . . . . . . . . . . . . . . . 197
6 General Discussion, Future Directions and Conclusions 202
6.1 General Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 202
6.1.1 TNAP as a marker to enrich populations of stromal cells . . . . . 203
6.1.2 DPSCs for use as a model system for device optimisation . . . . . 205
6.1.3 Characterisation of a non-antibody TNAP binding proteins for
potential use within the microfluidic cell separator . . . . . . . . 208
6.1.4 Development of a novel microfluidic cell separator for TNAP+
cell enrichment . . . . . . . . . . . . . . . . . . . . . . . . . . . 210
6.1.5 Characterisation of the enriched TNAP population from the
microfluidic device . . . . . . . . . . . . . . . . . . . . . . . . . 213
6.2 Future Directions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 216
6.3 Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 220
Appendix 223
A Demonstrating using flow cytometry that primary anti-TNAP antibodies
can be detected with goat anti-mouse APC secondary antibodies . . . . . 223




1.1 Diagram depicting an osteon present in cortical bone [1] . . . . . . . . . 4
1.3 Diagram demonstrating two different approaches utilising bone marrow
aspirate for bone regeneration. Autologous bone marrow aspirate can
be harvested and then either directly injected into the fracture site or
concentrated to increase the number of BMSCs, before being implanted
with a biomaterial scaffold. For the other approach BMSCs are expanded
ex vivo before being implanted into the fracture site with the appropriate
biomaterial scaffold. [2]. . . . . . . . . . . . . . . . . . . . . . . . . . . 11
1.4 Diagram showing the multilineage potential of MSCs to differentiate into
osteoblasts, adipocytes and chondroblasts [3]. . . . . . . . . . . . . . . . 12
1.5 Diagram demonstrating MSC osteogenic differentiation. Once activated,
MSCs at an early stage of differentiation are known as pre-osteoblasts
and are highly proliferative. The next stage consist of matrix maturation
where MSCs commit to the osteoblast phenotype and begin to express
high levels of alkaline phosphatase. This is followed by the mineralisation
phase where the osteoblasts express high levels of osteocalcin and begin
to deposit a calcified matrix [4]. . . . . . . . . . . . . . . . . . . . . . . 17
1.6 Diagram illustrating whole blood separation by density gradient
centrifugation. The whole blood is mixed with a saline solution and
then carefully layered on top of the centrifugation medium. The layers
are centrifuged with appropriate centrifugal force and time, separating
the whole blood into distinct layers of plasma, mononuclear cells,
centrifugation medium and eythrocytes and granulocytes according to
their respective densities. The required cell population can then be
aspirated for isolation. . . . . . . . . . . . . . . . . . . . . . . . . . . . 23
xii
1.7 Diagram showing cell separation by FACS. A heterogenous population of
cells is incubated with specific fluorescently tagged antibodies. Labelled
cells are passed through a laser source and the signature of each cell is
detected. If the signature is above certain threshold value, the droplet
containing the cell is electrically charged, passes through deflector plates
and is collected in the appropriate tube. From reference ([5]) . . . . . . . 24
1.8 Diagram showing cell separation by MACS. Cells which are labelled with
magnetic nanoparticles conjugated to antibodies targeting a particular
antigen are shown in black, while unlabelled cells are shown in white. The
cell population is passed through a magnetic field retaining the labelled
cells within the column which can then be washed out when the magnetic
field is removed [6]. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26
1.9 Diagram showing the three main types of microfilter designs used for
sized based cell separation adapted from [7]. (a) Weir type filters size
exclude via a planar slit. (b) Pillar type filters are an array of pillars
which exclude cells larger than the spacing between pillars. (c) Cross flow
filters arranged perpendicularly to the channel allow continuous filtration
of small cells, designed to reduced clogging of the filter and offer higher
throughput of the sorting application. . . . . . . . . . . . . . . . . . . . . 32
1.10 Diagram of a spiral microfludic channel which uses inertial forces to sort
cells by size. Cells are separated by their size due to differences in inertial
forces and dean drag, causing them to be focussed in different stream lines
and therefore available for collection. From reference [8]. . . . . . . . . . 33
1.11 Design of continuous flow microfluidic DEP Device used for separation
of MSCs from osteoblasts. Interdigitated electrodes angled at 45◦ are
located on the floor of the microchannel. When an altering AC field is
applied between the electrodes a DEP force is generated which deflects
the osteoblast (which experience stronger DEP forces) laterally into the
desired lower collection outlet. MSCs, which experience weaker DEP
forces, continue on their original trajectory and are collected in the upper
outlet [9]. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36
xiii
1.12 Design of continuous flow microfluidic, acoustophoresis device used for
separation of platelets from white blood cells. The peripheral blood
sample enters the channel from the side described as apheresis product,
while a PBS wash buffer enters from the central input. The mixed cell
population is passed through a transducer generating an acoustic standing
wave across the channel. The larger leukocytes experience a higher
acoustic force and are moved into the pressure node in the centre of the
channel for separation. Adapted from reference [10]. . . . . . . . . . . . 38
1.13 Schematic of typical antibody (IgG) structure consisting of two identical
light and heavy chains. The heavy and light chains contain variable
regions at the N-terminus which makes up two identical antigen binding
regions. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44
1.14 Generalised molecular structure of an Affimer protein showing a single
α-helix and four anti-parallel β-sheets. The amino acids in the variable
binding regions connecting the four anti-parallel β-sheets are highlighted
in pink. (Adapted from [11]) . . . . . . . . . . . . . . . . . . . . . . . . 48
2.1 Schematic of the affinity selection process (”biopanning”) for Affimer
proteins from phage display libraries. For the first screening round,
the immobilised target is incubated with the phage library and then
unbound phage is washed away. The bound phage are then eluted and
amplified in bacteria. The amplified phage are then subject to addition
further selection rounds before selected phage clones are subjected
to DNA sequence analysis and then used for Affimer production and
characterisation. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 56
2.2 Phage ELISA of Affimers from 7 clones incubated on wells immobilised
with human TNAP protein. Phage was detected using a HRP anti-phage
antibody followed by TMB substrate for visualisation. Data was provided
by the BTSG, University of Leeds. Based upon this information, Affimers
G1, D2 and F3 were selected for the characterisation in this thesis. . . . . 57
2.3 Standard curve of unlabelled Affimer protein quantity against band
intensity volume for calculating the concentration of labelled protein. . . 62
xiv
2.4 Schematic of a sandwich ELISA used to determine Affimer binding
to human TNAP protein. The Affimer is fixed by a biotin label to a
streptavidin coated plate, followed by incubation with TNAP protein. The
captured target is then detected with an anti-TNAP antibody, followed
by a HRP conjugated anti-mouse antibody with TMB substrate used for
detection. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 64
2.5 SDS page gel from purification of Affimers from bacterial cell lysates
for (a) D2 (b) F3 (c) G1 Affimers. A 15 % SDS-Page gel stained
using a Coomassie based staining solution was used to confirm the
expression of Affimer proteins. The lanes labels represent: (L) Molecular
weight standard (kDa); (In) Insoluble protein fraction; (S) Soluble protein
fraction; (Un) Unbound protein fraction; (W) First wash of Affimer bound
resin; (Fw) Final wash of Affimer bound resin; (E) Elution fractions 1-4.
Affimers bound to the resin were eultued and the protein bands from the
elutions migrated at the expected molecular weight of Affimers (12 - 14
kDa), as indicated by a red arrow. . . . . . . . . . . . . . . . . . . . . . 68
2.6 SDS page gel of a range of concentrations of unlabelled D2 anti-TNAP
Affimer proteins and with D2 anti-TNAP Affimer proteins labelled with
Alexa Fluor 647 and biotin. (a) Coomassie blue staining of gel. The
band volume intensity decreases with smaller amounts of protein loaded.
(b) Same gel but imaged under red fluorescence light for Alexa Fluor™
647 emission. A signal was only captured from Affimers fluorescently
labelled demonstrating a successful labelling method. . . . . . . . . . . 69
2.7 ELISA to confirm the specific biding of Affimers to human TNAP
protein. Three different concentrations of Affimer were initially incubated
with human TNAP, consisting of (a) 5 µg/mL (b) 2.5 µg/mL (c) 1.25
µg/mL. The results of the ELISA show positive binding when using
Affimers screened against human TNAP protein compared to a non-
specific Affimer control (GFP Aff) and plates not functionalised with
Affimers (No Aff). The absorbance was measured at 450 nm. Data
represented as mean ± SD. n=3. **** = P ≤ 0.0001. . . . . . . . . . . . 70
xv
2.8 Flow cytometry gating used to measure the percentage of TNAP+
DPSCs stained with APC anti-human TNAP antibodies. Histograms
are fluorescence intensity (x axis) against count (y axis). (a) Dotplot
of forward against side scatter with gating set to include intact cellular
bodies. (b) Single-parameter histogram plot for the isotype control where
the gate is set at 98 %. (c) Histogram containing the isotype control and
the anti-TNAP antibody. (d) Histogram containing the same gate at 98 %
for TNAP+ percentage quantification. . . . . . . . . . . . . . . . . . . . 72
2.9 Flow cytometry gating used to measure the percentage of TNAP+ DPSCs
stained with Alex Fluor™ 647 conjugated anti-TNAP Affimers (G1, F3
and D2). Histograms are fluorescence intensity (x axis) against count
(y). (a) Histogram containing anti-GFP Affimers and anti-TNAP (G1, D2
and F3) Affimers. (b) Single-parameter histogram plot for the anti-GFP
Affimer where the gate is set at 98 %. Histogram containing same gate
at 98 % for Affimer binding percentage quantification for (c) G1, (d) D2
and (e) F3 anti-TNAP Affimer proteins. . . . . . . . . . . . . . . . . . . 73
2.10 Graphical representation of flow cytometric analysis for the percentage
of DPSCS at five increasing seeding densities (5×103 cells/cm2 - 1×105)
and 16HBE cells positive for florescence staining with anti-TNAP Alexa
Fluor™ 647 G1, D2 and F3 Affimers and an anti-TNAP APC antibody.
The percentage of cells positively labelled with each of the Affimers
screened against human TNAP protein, did not follow the expected
trend as that seen when using the anti-TNAP antibody, providing limited
evidence of the ability of Affimers to bind to TNAP at the cells surface.
Data represented as mean ± SD. n=3. * = P ≤ 0.05. ** = P ≤ 0.01. ***
= P ≤ 0.001. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 75
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2.11 Pull-down assay utilising anti-TNAP Affimers against purified human
TNAP protein. The anti-TNAP Affimers were able to bind and pull-
down the purified TNAP protein. (a) Western blot showing the pull-
down products of the Affimers after staining with anti-TNAP antibodies
followed by anti-rabbit HRP antibodies with ECL used for detection. (b)
SDS-PAGE of pull-down products stained with coomassie blue. (M)
Protein ladder (kDa); (Cn) Purified TNAP protein control; (G1) G1
Affimer; (D2) D2 Affimer; (F3) F3 Affimer; (yS) Yeast Sumo Affimer.
Bands at expected Affimer molecular weight are indicated by a red arrow. 77
2.12 Pull-down assay utilising anti-TNAP Affimers against cell lysate from
DPSCs cultured in basal and osteoinduction cell culture medium. No
positive signal for TNAP was detected for any Affimer indicating non-
specificity towards TNAP protein in DPSCs. (a) Western blot showing
the pull-down products of the Affimers after staining with anti-TNAP
antibodies, followed by anti-rabbit HRP antibodies with ECL used for
detection. (b) SDS-PAGE of pull-down products stained with coomassie
blue. (M) Protein ladder (kDa); (B) Cell lysate from DPSCs cultured in
basal medium; (O) Cell lysate from DPSCs cultured in osteoinduction
culture medium; (G1 - B) G1 Affimer pull-down in basal cell lysate; (G1
- O) G1 Affimer pull-down in osteoinduction cell lysate; (D2 - B) D2
Affimer pull-down in basal cell lysate; (D2 - O) D2 Affimer pull-down
in osteoinduction cell lysate; (F3 - B) F3 Affimer pull-down in basal cell
lysate; (F3 - O) F3 Affimer pull-down in osteoinduction cell lysate; (yS
- B) Yeast sumo Affimer pull-down in basal cell lysate; (yS - O) Yeast
sumo Affimer pull-down in osteoinduction cell lysate. . . . . . . . . . . . 79
2.13 SDS-PAGE stained with Coomassie blue of pull-down assay utilising
anti-TNAP Affimers against cell lysate obtained from DPSCs cultured
with osteoinduction medium. The bands migrating at 55 kDa and 43 kDa,
highlighted in the red box, were isolated and sent of for mass spectrometry
analysis (Table 2.4). (M) Protein ladder (kDa); (G1) G1 Affimer; (D2) D2
Affimer; (F3) F3 Affimer; (yS) Yeast sumo Affimer. . . . . . . . . . . . . 80
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3.1 Flow cytometry gating used to measure the percentage of TNAP+ DPSCs.
(a) Dotplot of forward against side scatter with gating set to include intact
cellular bodies. (b) Gate set to exclude non-viable cells which are stained
with 7-AAD. (c) Single-parameter histogram plot for the isotype control
where the gate is set at 98%. . . . . . . . . . . . . . . . . . . . . . . . . 92
3.2 Standard curve of TNAP protein generated by serial dilution before
incubation with pNPP. Absorbance was measured at 405 nm. n=3. . . . . 93
3.3 Representative histograms of flow cytometric analysis of TNAP
expression on DPSCs and 16HBE cells. Histograms are fluorescent
intensity (x axis) against count (y). (a) Histogram containing the
unstained population, isotype control and TNAP antibody labelling for
DPSCs. (b) Histogram containing gate set with isotype control at 98%
allowing the percentage of TNAP+ DPSCs to be measured. (c) Histogram
containing the unstained population, isotype control and TNAP antibody
labelling for 16HBE cells. (d) Histogram containing same gate at 98%
for TNAP+ % quantification in 16HBE cells. . . . . . . . . . . . . . . . 97
3.4 Immunofluorescent microscopy for TNAP expression at cells’ surfaces.
Brightfield images were overlayed with the fluorescent channel (red).
(a) 16HBE cells stained with an anti-TNAP antibody showing no
fluorescence. (b) DPSCs stained with an anti-TNAP antibody were
stained across the surface of the cells. Scale bar represents 25 µm. . . . . 98
3.5 Representative histograms of flow cytometric analysis of TNAP
expression by DPSCs cultured at 5×104, 2×104, 1×104 and 5×103
cells/cm2 for one experiment for DPSCs isolated from one donor at
passage 4. Histograms are fluorescent intensity (x axis) against count
(y axis). (a-d) Histogram containing the unstained, isotype control and
TNAP antibody for each seeding density of DPSCs. (e-h) Histograms
containing gate set with isotype control at 98% allowing the percentage of
TNAP+ DPSCs to be measured for each seeding density. The percentage
of DPSCs expressing TNAP increased with an increase in cell seeding
density. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 99
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3.6 Graphical representation of flow cytometric analysis of TNAP expression
by DPSCs with increasing cell seeding density for DPSCs isolated from
three separate donors. There was a trend of an increase in the percentage
of cells expressing TNAP with increasing cell seeding density. Data
represented as mean ± SD. n=3. n.s = not significant. ** = P ≤ 0.01. . . 100
3.7 Graphs showing the effect of seeding density and passage number on the
number of TNAP molecules on the surface of DPSCs isolated from donor
1. (a) Average number of TNAP molecules on the cells surface per DPSC
in the total population. The average number of TNAP molecules on the
cells surface increased with passage number at each seeding density. Data
represented as mean ± SEM. n=3. (b) Representative histogram of flow
cytometric analysis of TNAP expression by DPSCs with increasing cell
seeding density. There was a trend with an increase in the percentage
of cells expressing TNAP with increasing cell seeding density. Data
represented as mean ± SD. n=3. . . . . . . . . . . . . . . . . . . . . . . 102
3.8 Graphs showing the number of TNAP molecules on the surface of TNAP+
DPSCs for donor 1. (a) Number of TNAP molecules on the cells
surface per TNAP + DPSC at each seeding density and different passage
numbers. Data represented as mean ± SEM. n=3. (b) Number of TNAP
molecules per TNAP+ cell across all four passages. The number of TNAP
molecules per TNAP+ DPSC did not alter with cell seeding density. Data
represented as mean ± SD. n=4. . . . . . . . . . . . . . . . . . . . . . . 103
3.9 Graphs showing the effect of seeding density and passage on the number
of TNAP molecules on the surface of DPSCs isolated from donor 2. (a)
Average number of TNAP molecules on the cells surface per DPSC in the
total population. The average number of TNAP molecules on the cells
surface decreased with passage number at each seeding density. Data
represented as mean ± SEM. n=3. (b) Representative histogram of flow
cytometric analysis of TNAP expression by DPSCs with increasing cell
seeding density. There was a trend with an increase in the percentage
of cells expressing TNAP with increasing cell seeding density. Data
represented as mean ± SD. n=3. . . . . . . . . . . . . . . . . . . . . . . 104
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3.10 Graphs showing the number of TNAP molecules on the surface of TNAP+
DPSCs isolated from donor 2. (a) The number of TNAP molecules on the
cells surface per TNAP + DPSC at each seeding density and different
passage numbers. Data represented as mean ± SEM. n=3. (b) The
number of TNAP molecules per TNAP+ cell across all four passages.
The number of TNAP molecules per TNAP+ DPSC was not affected by
cell seeding density. Data represented as mean ± SD. n=4. . . . . . . . . 105
3.11 Graphs showing the effect of seeding density and passage on the number
of TNAP molecules on the surface of DPSCs isolated from donor 3. (a)
Average number of TNAP molecules on the cells surface per DPSC in the
total population. The average number of TNAP molecules on the cells
surface decreased with passage number at each seeding density. Data
represented as mean ± SEM. n=3. (b) Representative histogram of flow
cytometric analysis of TNAP expression by DPSCs with increasing cell
seeding density. The percentage of cells expressing TNAP increased with
cell seeding density. Data represented as mean ± SD. ** = P ≤ 0.01. n=3. 106
3.12 Graphs showing the number of TNAP molecules on the surface of TNAP+
DPSCs isolated from donor 3. (a) Number of TNAP molecules on the
cells surface per TNAP + DPSC at each seeding density and different
passage numbers. Data represented as mean ± SEM. n=3. (b) Number of
TNAP molecules per TNAP+ cell across all four passages. The number of
TNAP molecules per TNAP+ DPSC is not altered by cell seeding density.
Data represented as mean ± SD. n=3. . . . . . . . . . . . . . . . . . . . 107
3.13 Analysing the number of TNAP molecules per TNAP+ cells across
multiple passages and donors. (a) Number of TNAP molecules on the
cells surface per TNAP+ DPSC across all seeding densities from passage
3 to 8. The number of TNAP molecules on the cells surface did not change
with passage number. Data represented as mean ± SD. n=6. (b) Average
number of TNAP molecules per TNAP+ cell across all seeding densities
for three donors. Similar levels of TNAP molecules per TNAP+ were
measured for cells from donor 1 and 2, whilst the number of molecules
was slightly reduced for cells from donor 3. Data represented as mean ±
SD. n=3. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 108
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3.14 Average number of TNAP molecules per TNAP+ DPSCs across five
seeding densities for DPSCs isolated from three different donors. The
number of TNAP molecules on the surface of TNAP+ DPSCs was similar
independent of cell seeding density. Data represented as mean ± SD. n=11.109
3.15 Production of TNAP increases when cultured in osteoinduction
differentiation medium. (a) Flow cytometric analysis of DPSCs cultured
in basal and osteoinduction culture medium. (b) Number of TNAP
molecules on the cells surface per TNAP + DPSC when cultured in
basal and osteoinduction cell culture medium. The percentage of DPSCs
expressing TNAP increases when cells are cultured in osteoinduction
medium. Data represented as mean ± SD. * = P ≤ 0.05. n=3. . . . . . . 111
4.1 Diagram showing device assembly. A 3D printed “flow cell” was used
as the base and holder for valves and microfluidic tubing (not shown in
diagram). The gold surface with assembled SAM was then placed on the
base, followed by the PDMS channels which was then clamped together
by screwing in a perspex lid into the flow cell. Tubing could then be
connected to the PDMS microfluidic channels allowing the surface to be
functionalised with anti-TNAP antibody for cell separation. Scale bar
represents 50 mm. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 126
4.2 3D printed red microfluidic master mould for three parallel channels with
corresponding cured PDMS microfluidic channel designs. The PDMS is
pored into the microfluidic mould, cured and then peeled out. The pillars
at either end are the input and output, where the PTFE tubing is inserted
into. The raised strip between the pillars defines the microfluidic channel.
Scale bar represents 20 mm. . . . . . . . . . . . . . . . . . . . . . . . . 127
4.3 Schematic illustration of the functionalisation of the surface for cell
capture. A monothiol-alkane-PEG carboxylic acid-terminated SAM is
first assembled on a gold electrode. The carboxylic acid groups of the
SAM were then activated with EDC/NHS to which the antibody was
covalently attached. BSA was then used to quench unreacted activated
acid sites. The surface was then ready for the injection of cells. . . . . . . 129
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4.4 Schematic showing injection of cell population into the device. First,
2 ×106 cells/mL were injected into the device at approximately 500
µL/min; all valves were closed, then cells were incubated on the surface
for 5 minutes. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 130
4.5 Schematic illustrating specific cell binding to the antibody-functionalised
gold surface. Plain α-MEM culture medium was flown across the
antibody-functionalised surface at a rate of 100 µL/min, removing
unbound cells, leaving only bound cells in the channel. . . . . . . . . . . 130
4.6 Schematic showing method used for cell release. Cells were released
from the surface by using a programmed flow sequence (1.5 mL/min for
2 seconds, 0.1 mL/sec for 1 second) repeated for 1 minute with either
plain α-MEM culture medium, phosphate buffer at pH 6.5 or pH 8.5. . . . 131
4.7 Figure demonstrating the image processing method used to measure
the number of cells either captured or released from the antibody
functionalised surface. (a) Original image captured (b) Image after
threshold adjustment. (c) Image after application of fill holes tool (arrows
indicate examples of filled cell outlines). (d) Image after watershed tool
used to separate fused cells (Arrows indicate examples of separated fused
cells). These pictures were acquired in the middle of the channel . . . . . 132
4.8 Graph showing the numbers of cells that were attached to 1 cm2 gold
surfaces that were functionalised with 2 µg/mL anti-TNAP antibody.
DPSC and 16HBE cell numbers between 1 ×106 - 0.06 ×106 cells
were incubated on the surface, before being washed and counted. A
much larger number of DPSCs were bound to the anti-TNAP antibody
functionalised surfaces when compared to 16HBE cells. Data shown is
the mean of the cell counts from five images represented as mean ± SEM. 135
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4.9 Graph showing the optical density from 1 cm2 gold surfaces that were
functionalised with 10, 2 and 1 µg/mL anti-TNAP antibody before
a range of human TNAP protein concentrations between 2 and 0.03
µg/mL were incubated on the surface, then washed and detected with
pNPP. Absorbance was measured at 405 nm. The amount of TNAP
protein bound onto the surface correlates with anti-TNAP antibody
concentrations used to functionalise the surface. Error bars represent the
mean ± SEM. n=2. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 136
4.10 Graph showing the optical density from 1 cm2 gold surfaces that were
functionalised with 10, 2 and 1 µg/mL anti-TNAP antibody before a
range of human DPSC numbers between 2 ×106 - 0.06 ×106 cells were
incubated on the surface, before being washed and detected with pNPP.
Absorbance was measured at 405 nm. The amount of DPSCs bound onto
the surface showed a minimal relationship with the anti-TNAP antibody
concentrations used to functionalise the surface. Error bars represent the
measurement error (mean ± SEM.) . . . . . . . . . . . . . . . . . . . . . 138
4.11 Graph showing cell numbers remaining after washing from 1 cm2 gold
surfaces that were functionalised with 10, 2 and 1 µg/mL anti-TNAP
antibody. A range of human DPSCs and 16HBE cell numbers between
1 ×106 - 0.06 ×106 cells were incubated on the surface, before being
washed and counted. A greater number of DPSCs were bound on all
surfaces functionalised with different antibody concentrations compared
to 16HBE cells. The data within the dotted line is presented in Figure
4.12. Data shown is the mean of the cell counts from five images
represented as mean ± SEM. . . . . . . . . . . . . . . . . . . . . . . . . 139
4.12 Graph showing enhanced scale of data surrounded by a dotted line in
Figure 4.11. Gold surfaces (1 cm2) were functionalised with 10, 2 and
1 µg/mL anti-TNAP antibody. 16HBE cell numbers between 1 ×106
- 0.06 ×106 cells were incubated on the surface, before being washed
and counted. The number of 16HBE cells bound was independent of the
concentration of anti-TNAP antibody used to functionalise the surface.
Data shown is the mean of the cell counts from five images represented
as mean ± SEM. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 140
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4.13 (a) Schematic of microfluidic channel assembled over the gold surface
modified with anti-TNAP antibodies immobilised a the SAM layer. The
fluidic path through the channel is shown, with bubble traps utilised to
capture any air that was injected (b) Width and length of microfluidic
channel designs. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 142
4.14 Photograph of 3D printed device capable of running two parallel
microfluidic channels used in this chapter. Two PDMS microchannels
were clamped onto a gold substrate functionalised with monothiol-
alkane-PEG acid SAM before all tubing was connected. . . . . . . . . . . 143
4.15 Photograph of device cabaple of running three parallel microfluidic
channels used in this chapter. A 3D printed flow cell was used to support
all the required tubing and valves. Three PDMS microchannels were
clamped onto a gold surface functionalised with monothiol-alkane- PEG
acid SAM before the tubing was connected. Four way input valves were
used for input into the channel with a stopper valve at the output to allow
necessary incubation in the channel. . . . . . . . . . . . . . . . . . . . . 144
4.16 Microscopy images showing cell capture of DPSCs on the antibody
functionalised surface within the microfluidic device. Cells were injected,
then incubated on the surface for 5 minutes before washing for 10 minutes
with 100 µL/min α-MEM culture medium flow. (a). DPSCs initial
cell injection during 5 minute incubation on the antibody functionalised
surface within the microfluidic device. (b). DPSCs remaining on the
surface after 10 minutes of 100 µL/min α-MEM culture medium flow.
(c). 16HBE cells after initial cell injection during five minute incubation.
(d). 16HBE cells remaining on the surface after 10 minutes of 100 µL/min
α-MEM culture medium flow. Scale bar represents 250 µm. . . . . . . . . 146
4.17 Graph showing percentage of DPSCs cultured at 5×104 cells/cm2 or
5×103 cells/cm2 for 7 days and 16HBE cells, bound on the antibody
functionalised surface within the microfluidic device after a 5 minute
incubation, followed by elution of the unbound cell population with 100
µL/min α-MEM culture medium flow for 10 minutes. Data represented
as mean ± SD. n = 4. * = P ≤ 0.05. *** = P ≤ 0.001. . . . . . . . . . . . 147
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4.18 Microscopy images showing DPSCs bound to the antibody functionalised
surface within the microfluidic device before and after programmed fluid
flow with α-MEM culture medium to enable cell release. (a). DPSCs
remaining bound to the surface after 10 minutes of 100 µL/min α-MEM
culture medium flow. (b). DPSCs remaining after utilising programmed
flow (1.5 mL/min for 2 seconds, followed by 0.1 mL/min for 1 second
and then repeated for 1 minute) in α-MEM culture medium. Scale bar
represents 250 µm. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 149
4.19 Graph showing percentage of DPSCs released from the functionalised
surface within the microfluidic device after removal of unbound cells
using programmed release with pH 7.4 plain α-MEM culture medium,
and phosphate buffer at pH 6.5 and pH 8.5. A 10 minute incubation
using phosphate buffer pH 8.5 prior to programmed release was also
investigated. Data shown as mean ± SD. n = 4. ** = P ≤ 0.01. n.s =
not significant. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 150
4.20 Representative histograms of flow cytometric analysis of TNAP+ DPSCs
for one DPSC donor before and after cell separation. (a). Histogram
containing the unstained, isotype control and anti-TNAP antibody for
DPSCs before cell separation. (b). Histogram containing gate set with
isotype control at 98% allowing the percentage of TNAP+DPSCs to be
measured before cell separation. (c). Histogram containing the unstained,
isotype control and anti-TNAP antibody for DPSCs after cell separation.
(d). Percentage of TNAP+ DPSCs after cell separation. . . . . . . . . . . 151
4.21 Graphs showing the results of flow cytometric analysis for TNAP+
DPSCs before and after cell separation for cells from three different
donors. In all cases DPSCs obtained after binding and elution in the cell
separator showed a significant increase in the TNAP+ cell population.
Data represented as mean ± SD. n = 3 .* = P ≤ 0.05. ** = P ≤ 0.01. . . . 152
xxv
4.22 Graphs showing the results of flow cytometric analysis for DPSCs stained
with goat anti-mouse APC antibody before and after cell separation.
There was no significant difference in the amount of anti-TNAP antibody
detected suggesting that release of bound cells from the device was not
due to antibodies being released from the functionalised surface. Data
shown as mean ± SD. n = 3. . . . . . . . . . . . . . . . . . . . . . . . . 153
5.1 Flow cytometry gating used in measurement of cell viability. Dot plots
of forward scatter against fluorescent intensity with cells previously gated
for intact cellular bodies (Section 3.3.2) (a) Gate set to include whole
population of intact DPSCs. (b) Same gate applied to DPSCs stained
with 7-AAD to exclude non-viable cells. Cells which had a greater
fluorescence intensity due to staining with the 7-AAD stain than the gate
set using the unstained population, were classed as non-viable cells. Cells
remaining within the gate was assumed to represent the percentage of
viable cells. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 170
5.2 Dot plots obtained from flow cytometric analysis from one experiment
investigating the effects of the separation process on cell viability. Dot
plots show forward scatter (x axis) against fluorescence intensity (y axis),
allowing the percentage of viable cells to be determined. Samples of
DPSCs analysed were: (a) Cells held in culture medium for experimental
duration. (b) Cells held in PBS for experimental duration. (c) Cells held
in plain α-MEM for experimental duration. (d) Cells flown through un-
functionalised microfluidic channels at 100 µL/min, and (e) cells which
had been through the full separation procedure of capture and release in
the device. The proportion of non-viable cells shown in blue remained
similar for cells held in the various control buffers, but was increased
in the microfluidic control group and was further increased for the cells
which had undergone capture and release with the device. . . . . . . . . . 176
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5.3 Determination of cell viability after cell capture and release for TNAP+
DPSCs using the microfluidic device. Samples analysed were as
follows: Captured and released cells - DPSCs captured by the antibody
functionalised surface and then released with an increase in fluid
flow using plain α-MEM. Microfluidics - Cells flown through un-
functionalised microfluidic channels at 100 µL/min. PBS - Cells held
in PBS for experimental duration. Plain α-MEM - Cells held in plain α-
MEM for experimental duration. Culture medium - Cells held in culture
medium for experimental duration. The percentage cell viability was
reduced for cells captured and released within the device, demonstrating
an effect of the selection mechanism on cell viability. Data shown as
mean ± SD. n = 3. ** = P ≤ 0.01. . . . . . . . . . . . . . . . . . . . . . 178
5.4 Percentage cell viability of DPSCs held in phosphate buffers ranging from
pH 5.5 - 9.5, compared with controls of DPSCs held in culture medium
and PBS. The percentage cell viability decreased when cells were held in
phosphate buffers with higher pH values. Data shown as mean ± SD. n =
3. **** = P ≤ 0.0001. . . . . . . . . . . . . . . . . . . . . . . . . . . . 179
5.5 The effect on cell viability of capture and release using phosphate buffer at
pH 8.5, for TNAP+ DPSC enrichment using the microfludic device. The
samples analysed for cell viability percentage were as follows: Captured
and released in pH 8.5 phosphate buffer - DPSCs captured by the antibody
functionalised surface and then released with an increase in fluid flow
using phosphate buffer at pH 8.5; pH 8.5 phosphate buffer - Cells held
in culture medium for experimental duration; Microfluidics - Cells flown
through un-functionalised microfluidic channels at 100 µL/min; PBS -
Cells held in PBS for experimental duration; Plain α-MEM - Cells held
in plain α-MEM for experimental duration; Culture medium - Cells held
in culture medium for experimental duration. Cell viability was decreased
for cells which had been held in the phosphate buffer at pH 8.5 and for
cells released from the device using the phosphate buffer at pH 8.5. Data
represented as mean ± SD. n = 3. ** = P ≤ 0.01, **** = P ≤ 0.0001. . . 180
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5.6 Images of DPSCs that had undergone separation using the device then
cultured in basal medium for the duration of 1, 3 and 7 days. This
preliminary qualitative assessment suggested that separation using the
device had not inhibited cell proliferation. Scale bars represent 200 µm. . 181
5.7 Cell proliferation as assessed using Quant-iT™ PicoGreen™ (DNA
content) analysis of DPSCs that had undergone separation in the
device compared with controls of cells that had experienced a constant
microfluidic flow or had been held in plain-α-MEM, PBS and basal
culture medium for the separation duration, before being cultured in
osteoinductive medium. A negative control of un-separated cells cultured
in basal medium (“Culture medium”) was also carried out. The separation
method did not appear to have any effect on DPSC proliferation. Data
represented as mean ± SD. n = 3. *= P ≤ 0.05, ** = P ≤ 0.01. . . . . . . 183
5.8 Alkaline phosphatase specific activity for DPSCs that had undergone
separation in the device compared with controls of cells that had
experienced a constant microfluidic flow or that were held in plain-α-
MEM, PBS and culture medium before being cultured in osteoinductive
medium. A negative control of un-separated cells cultured in basal
medium was also carried out. The separation method did not appear to
have an effect on early DPSC osteogenic differentiation. Data represented
as mean ± SD. n = 3. * = P ≤ 0.05, ** = P ≤ 0.01. . . . . . . . . . . . . 186
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5.9 Photographs of alizarin red stained DPSC monolayers of cells isolated
from three different donors, for DPSCs that had undergone separation
with the microfluidic device compared with appropriate controls, cultured
for 21 days in either osteogenic medium or basal culture medium.
Culture medium - Cells cultured in basal culture medium (no separation).
Osteogenic medium - Cells cultured in osteogenic culture medium (no
separation). Plain α-MEM - Cells held in plain α-MEM for experimental
duration before culture in osteoinductive medium. PBS - Cells held in
PBS for experimental duration before culture in osteoinductive medium.
Microfluidics - Cells flown through un-functionalised microfluidic
channels at 100 µL/min before culture in osteoinductive medium.
Captured and released cells - Cells which had been through the full
separation procedure of capture and release in the microfluidic device.
The arrows indicate areas where the monolayer had detached from the
well plate in the staining procedure. There was a strong deep red staining
in all groups except for the basal culture medium group. . . . . . . . . . 190
5.10 Quantitative measurement of alizarin red stain after 21 days in culture.
The stain was extracted from cell monolayars of alizarin red stained
DPSCs isolated from donor 1 that had undergone separation using the
device, alongside with controls of cells that had experienced a constant
microfluidic flow or held in plain-α-MEM, PBS and culture medium
before being cultured in osteoinductive medium. A negative control of
cells cultured in basal medium was carried out. The separation process
had minimal effect on the ability of the separated DPSCs to produce a
mineralised matrix. Average absorbance readings were taken at 405 nm.
(n=3). **** = P ≤ 0.0001. . . . . . . . . . . . . . . . . . . . . . . . . . 192
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5.11 Light microscope images of alizarin red stained cell monolayer from
DPSCs isolated from donor 1, which had undergone separation within
the microfluidic device compared with appropriate controls, cultured for
21 days in either osteogenic medium or basal culture medium. (a) Cells
cultured in basal culture medium (no separation). (b) Cells cultured
in osteogenic culture medium (no separation). (c) Cells held in plain
α-MEM for experimental duration before cultured in osteoinductive
medium. (d) Cells held in PBS for experimental duration before
being cultured in osteoinductive medium. (e) Cells flown through un-
functionalised microfluidic channels at 100 µL/min before cultured in
osteoinductive medium. (f) Cells which had been through the full
separation procedure of capture and release in the microfluidic device.
Arrows indicate mineralised nodules. Scale bar represents 100 µm. . . . . 193
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with anti-mouse APC before and after separation. (a) Histogram of
the isotype control and before cell population stained with anti-mouse
APC. (b) Histogram containing gate set with isotype control set at
98% measuring the staining of anti-mouse APC before separation. (c)
Histogram of the isotype control and after cell population stained with
anti-mouse APC. (d) Percentage of stained cells after separation . . . . . 223
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1.1 Scope of the thesis
Bone defects resulting from trauma, surgical intervention or diseases such as osteoporosis
and osteoarthritis are major clinical challenges [12]. Non-union bone fractures, where
there is failure for the bone to heal after 6 months, require surgery for the placement of
a bone graft to aid the bone healing process [13]. The current gold standard of treatment
of non-union bone defects is the use of autografts which provide an osetoconductive and
osteoinductive bone graft [14]. However, there are concerns with donor site morbidity,
increased risk of infection and a lack of quality donor tissue. Alternative graft materials
include allografts and xenografts, but again there are concerns with rejection from the
immune response and disease transmission [14]. Cell therapies offer an alternative
approach and the re-implantation of bone marrow mesenchymal stem cells (BMSCs),
which are crucial for bone repair by differentiating down an osteogenic lineage, may be
of benefit [15, 16]. Identification of a sub-population of MSCs which are predisposed to
differentiate towards a mineralising phenotype would be beneficial. Tissue non-specific
alkaline phosphatase (TNAP) is one such candidate marker having been identified as a
pro-mineralising cell surface marker present on the surface of MSCs [17], and therefore
isolation of MSCs expressing TNAP has potential for novel bone regenerative therapies.
The isolation of TNAP+ MSCs would provide an osteoinductive cell population, which
when partnered with a suitable scaffold could lead to enhanced bone healing and
regeneration.
The isolation of cells expressing specific surface markers is crucial in biological research
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and a valuable tool for medical diagnostic and potential therapeutic applications. To date,
the main focus of isolating cells based on surface marker expression is using antibodies
conjugated with fluorescent molecules or magnetic nanoparticles through fluorescent
or magnetic activated cell sorting [5]. Alternative approaches utilising microfluidic
technology to separate cells include the use of hydrodynamics, dielectrophoresis or
acoustophoresis, relying on differences in the cells size, deformability, dielectric or
acoustic response properties [18]. A concern for any sorting technique to deliver a cell
population for therapeutic applications is altering the biological characteristics of the cell
population through the sorting process. Therefore, ideally a cell sorting technique for
therapeutic applications needs to be minimally-manipulative [19], where the separation
method must not alter the relevant biological characteristics of cells or tissues. The main
focus of this thesis was to develop a microfluidic cell separator which by utilising binding
proteins on a functionalised surface could capture and release TNAP+ cells. This aimed
to deliver a minimally manipulated enriched population of cells expressing TNAP which
would have potential in future bone regenerative therapies.
1.2 Clinical need for bone therapies
1.2.1 The biology of bone
Before developing potential solutions for bone therapies it is important to understand
the biology and architecture of bone. The human body consists of 206 bones to form
the skeleton which accounts to approximately 15% of the total body weight [20]. The
main functions of bone are supporting soft tissues and aiding movement of the body from
supporting tissues such as muscles, tendons and ligaments. Bone provides protection
from external harmful effects, such as the ribs protect the heart and lungs. Bone also has
a homeostatic role in providing a mineral deposit for the body, in total 99% of calcium,
85% of phosphate and 50% of magnesium are stored in the bones [20]. The bones also are
a storage of bone marrow and therefore play a role in repair and regeneration of multiple
tissues throughout the body, such as formation of blood cells through haematopoiesis.
Bone is a material made up of around 65% mineral phase, 25% organic collagen-based
matrix and 10% water [21]. The main protein in the matrix is type I collagen which
comprises of about 80% of the total proteins in bone and accounts for 95% of the entire
collagen content [22]. The collagen is arranged in fibrils with bone mineral crystals in
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between the gaps which are able to nucleate allowing the bone matrix to become calcified.
Between collagen fibres in the matrix spindle, plate shaped crystals of hydroxyapatite are
found which are orientated in the same direction of the collagen fibres [22].
1.2.2 Bone Structure
Bone is a complex tissue comprised of cells within an extracellular matrix made up
of organic and inorganic material which is constantly undergoing remodelling. While
there are many different types of bone, they all share the same foundation of mineralised
collagen fibrils. Bone can be divided into two different types at a microscopic level,
consisting of primary and secondary bone. Primary (woven) bone is associated with
developing bone and fracture repair as it is a temporary structure [23]. Unorganised
collagen fibres are deposited by bone forming cells known as osteoblasts, before being
replaced by highly organised secondary bone. This is known as lamellar bone and the
collagen fibrils are arranged in tightly compacted sheets, which take longer to deposit
than woven bone yet provide significantly more strength. At the macroscopic level, bone
is sorted into two distinct types known as cortical bone and trabecular bone. An adult
human skeleton has on average 80% cortical bone and 20% trabecular bone which exist
in different ratios in different bones around the body [24]. Cortical (compact) bone has a
dense and rigid structure that forms the outer shell of most bones and consists of multiple
microscopic columns known as osteons (Figure 1.1) [24]. Each osteon consists of cortical
bone arranged in concentric layers around a central Haversian canal which contains the
bone blood supply. These osteons form a branching network within the cortical bone.
Cortical bone has an outer periosteal surface, which is a fibrous connective tissue that
covers the outer surface of bone (except at joints where the bone is lined with articular
cartilage) that contains blood vessels and progenitor cells. An inner endosteal surface,
which is a thin vascular membrane of connective tissue, lines the medullary cavity which
is mostly comprised of trabecular bone and is where bone marrow is stored. Trabecular
(cancellous) bone is very porous, which gives a spongy appearance. It is also highly
vascular and contains red bone marrow, responsible for haematopoiesis, the production of
red blood cells (Figure 1.2).
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Figure 1.1: Diagram depicting an osteon present in cortical bone [1]
Bone undergoes constant remodelling throughout its lifetime as the bone is renewed to
maintain strength and mineral homeostasis. This is mainly carried out by three bone
cell types, osteoblasts, osteoclasts and osteocytes. Osteoblasts arise from bone marrow
mesenchymal stem cells (BMSCs) which are found in large numbers in the bone marrow
and periosteum. Osteoblasts are bone forming cells which deposit bone matrix and
secrete factors that regulate osteoclasts to control bone remodelling, before they become
embedded in the bone and terminal differentiate into osteocytes. Osteocytes create a
network among themselves and the bone surface, maintaining mineral homeostasis and
are the mechanosensory cells responsible for bone remodelling in response to mechanical
stress of the bone. Osteoclasts are responsible for the removal of mineralised bone
for resorption during bone growth and remodelling [24], and are formed by the fusion
of precursor cells originating from hematopoietic progenitors in the bone marrow [25].
Bone remodelling takes place in four stages. Activation is where pre-osteoclasts are
recruited from the circulation and form osteoclasts, then bind to the bone matrix forming
a bone resorbing compartment beneath the osteoclasts. In this compartment, the bone
is then resorbed in approximately 2-4 weeks by the osteoclasts through the production
of acids and enzymes, before then undergoing apoptosis [24]. The cavities that remain
from resorption are then filled by osteocytes and pre-osteoblasts recruited from the bone
matrix and marrow. The pre-osteoblasts differentiate to osteoblasts and synthesise a new
collagenous organic matrix which can take 4-6 months to complete. Osteoblasts are
either buried within the matrix and differentiate to become osteocytes or again undergo
apoptosis [24]. The end result of the bone remodelling process is the replacement of old,
micro-damaged bone, with new, healthier bone that preserves mechanical strength of the
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skeleton.
Figure 1.2: Diagram depicting cross section of a long bone. [26]
1.2.3 Bone grafts
Bone repair and regeneration is a global challenge with a major clinical need for
enhancing therapies. For example, there was an estimated increase of 45% in disability
due to musculoskeletal disorders in the worldwide population from 1990 to 2010 [12].
To meet this need, bone is the second most commonly transplanted tissue (after blood)
with 2.2 million bone grafts performed worldwide each year at a cost of $2.5 billion
[14] (not including any other indirect costs). A wide variety of methods for repairing
bone defects are available which can be classified as bone grafts, synthetic substitutes
and growth factors [27]. Bone grafting is a surgical procedure which replaces missing
bone and is required mostly to repair complex fractures to aid in healing, provide
strength and improve the function of bone. An ideal bone grafting material would
have osteoinductive, osteoconductive and osseointegration properties. Osteoinductivity
is where undifferentiated and pluripotent cells are stimulated from the surrounding
tissue to develop new bone [28]. An osteoinductive graft material will cause BMSCs
to differentiate down an osteogenic lineage to produce osteoblasts, therefore the graft
induces the formation of bone forming cells. The bone graft can also be osteoconductive,
whereby the graft material acts as a scaffold that provides a framework for blood vessels
and bone growth promoting new bone formation [28]. Osseointegration is the ability of
the graft material to attach to the surrounding bone at the host site without the growth
of a fibrous tissue layer at the site of graft implantation [29]. However, at present, bone
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grafting materials used rarely achieve all features of osteoinductivity, osteoconductivity
and osseointegration.
The current gold standard of bone grafts is the use of autologous bone due to its optimal
osteoinductive, osteoconductive and osteogenic (development and formation of new bone)
properties [30]. The osteogenic potential of an autologous graft derives from the cells
that have survived within the donor graft, along with any osteoinductive proteins and
growth factors present in the graft [14]. The main advantage of using an autograft is
as they are from the patients own body, they do not elicit an immune response which
enhances the chances of graft survival and incorporation at the host site [31]. Bone is
usually harvested from the iliac crest due to the ease of access to good quality and quantity
of cortical or cancellous bone. However the harvest of this bone requires the creation
of a second surgical site which results in many disadvantages such as lengthening the
operation procedure, increasing blood loss, donor site morbidity, cosmetic disadvantages
with an increase in damage and an added risk of infection at the donor site [32, 33].
Also the bone may sometimes not be of good quality, especially within elderly patients,
due to osteoporosis. There is also a risk of further complications arising from the graft
failing post-operatively when normal activity is resumed for the patient, due to cellular
components of the graft not surviving the transplantation process [14]. Depending on the
implant site, there also may be a demand for healthy autograft material outstripping the
supply, particularly in ageing patients.
Other bone substitutes are available for clinical applications, with the use of allograft
tissue regarded as the surgeon’s second option [34]. Allograft bone tissue is
transplanted from one individual (usually cadaveric) to another and used as mineralised
or demineralised, in either a fresh, fresh-frozen or in freeze-dried form [31]. The
osteoinductive potential of allografts is lower than that of autografts due to the lack of
viable cells, yet they do exhibit good osteoconductivity and can be purchased from a
commercial provider [35]. The major advantage of allograft bone is the ready availability
in a wide range of shapes and sizes, avoidance of sacrificing host tissue and no challenges
in donor site morbidity [31]. Fresh allografts are rarely used due to the high risk of
initiating an immune response, instead freeze-dried and frozen allografts are used instead
to minimise the potential for an immune reaction [36]. However the disadvantage utilising
allografts after processing, is the freezing or freeze drying procedure followed by the
required sterilisation procedure can reduce the mechanical strength of the graft, alter the
osteogenic properties of the graft [37] and will increase the production costs of a ready-to-
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use allograft product [38]. There is also a concern with disease transmission with regard to
bone allografts due to bad practice in tissue retrieval or unknown infections being present.
Another alternative to both autografts and allografts is xenografts, which are bone grafts
implanted into a patient that derive originally from a different species. The main
advantages of utilising a xenograft is that it is a bone graft which is osteoconductive,
relatively inexpensive and offers an almost unlimited supply of available material.
However the disadvantages of their use is the risk of causing an immune reaction
and a concern with the transmission of zoonotic diseases and prion infections [31].
Xenografts will lose also their osteoinductive properties during processing to remove
any live cells, which would initiate an immune reaction. Other bone graft substitutes
utilise biological or synthetic materials to provide a scaffold that supports bone growth.
An example of a biological scaffold is demineralised bone matrix (DBM), where cortical
bone has been demineralised to expose the osteoconductive properties of the bone and
act as an osteoinductive scaffold due to the presences of more biologically active bone
morphogenetic proteins (BMPs) and growth factors [32]. However, there is controversy
around the osteoinductive potential of DBM as different batches may have different
healing potential, probably due to non-uniform processing methods [39]. Collagen,
which is a primary component of bone, is another popular biological scaffold due to its
biocompatibility, which allows proliferation and osteogenic differentiation of cells [40].
Synthetic bone grafts have the advantages of being sterile and free from human pathogens
providing an “off the shelf” product, as well as available in unlimited quantities for
different shapes and sizes of bone defect. Synthetic options such as ceramics, coralline
hydroxyapatite and bioactive glass [27], provide an osteoconductive scaffold through their
similarity with the native bone mineral. Synthetic bone grafts should have a similar
mechanical strength to the bone which is being replaced and need to have adequate
toughness to prevent fatigue fracture under cyclic loading. Other disadvantages are
in unpredictable resorption and the potential to trigger an immune reaction due to a
foreign body. Synthetic bone substitutes provide an osteoconductive scaffold for bone
cells and MSCs to attach, proliferate and differentiate, they possess no innate osteogenic
or osteoinductive properties due to the lack of cells or osteoinductive proteins. An
osteoconductive synthetic bone substitute could therefore be combined with the patient’s
own autologous osteogenic progenitor cells, providing an ideal graft material with all
elements of osteogensis, osteoinduction and osteoconduction for bone regeneration.
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1.2.4 Fracture healing
Bone grafting is used to stimulate bone healing in post-traumatic skeletal complications
[14]. Examples include delayed union, where a fracture takes longer than usual to heal,
and non-union fractures, where the bones fail to heal due to additional complications
such as movement of the bone, poor blood supply or infection [14]. Fracture healing
is a complex physiological process, within a few hours of a bone fracture there is loss
of normal architecture in the surrounding bone around the fracture site, blood vessels
disappear and two types of histologically defined fracture healing occur [41]. Primary
fracture healing is a direct attempt of the cells in cortical bone to re-establish the structure
and continuity of the bone once there has been an interruption. Primary fracture healing
is less common as there is no formation of a fracture callus. It does not normally
occur naturally due to requiring the absolute contact of the fragments, without any gap
formation and demands stable fixation [41]. Secondary bone fracture healing is the
most common type of healing, where intramembranous and endochondral ossification
lead to callus formation. Endrochondral ossification is the process by which initially
deposited cartilage is systemically replaced by bone via the bone remodelling process,
whilst intramembranous ossification is the differentiation of mesenchymal stem cells into
osteoblasts, where these cells synthesize and secrete osteoid, the unmineralised organic
component of bone, which is calcified to become woven bone. At the fracture site, a
haematoma is generated which initiates an inflammatory response involving the secretion
of a variety of factors which recruit inflammatory cells and promote angiogenesis.
BMSCs are then recruited from surrounding soft tissues, such as the periosteum and
bone marrow, then proliferate and differentiate into osteogenic cells. A primary callus
is formed between each end of the fracture, consisting of a cartilaginous matrix that
gives the fracture site stability. Revascularisation occurs at the fracture site and then the
cartilaginous callus is mineralised and is replaced with woven bone forming a hard and
mechanically rigid callus [41]. To restore the biomechanical properties of the new woven
bone to that of pre-fracture bone, remodelling must occur. The hard callus is resorbed
by osteoclasts and then osteoblasts deposit a lamellar bone structure re-establishing the
biomechanical properties.
The “diamond” concept describes four main elements needed for fracture fixation. The
first element is the complex and well-orchestrated interactions from a very vibrant cell
population at the beginning of the cellular repair process. BMSCs are recruited from
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the bone marrow to areas of high and low cell density, where there is high cell density
MSCs differentiate to cells with an osteoblastic phenotype [42]. The second element is
the secretion of growth factors, where the haematoma that develops at the fracture site is
a source of a variety of signalling molecules that are secreted from the wide range of cells
present (endothelial cells, platelets, macrophages, monocytes, BMSCs, chondrocytes,
osteocytes and osteoblasts), which initiate cellular events and pathways leading to repair
of the fracture. The third element is the extra cellular matrix which provides a scaffold
for these interactions to take place. The material used to heal the fracture needs to be
osteoconductive and can be enriched with osteoinductive factors. The fourth element
which is also mandatory for repair is the mechanical stability of the fracture allowing a
callus to form so loads can be applied across the fracture line to initiate further healing.
The transmission of load across the fracture allows the callus to mature from woven
to lamellar bone. All four of these factors need to be considered equally when using
regenerative therapies for bone regeneration.
1.2.5 Cell based therapies for bone repair
While autologous bone grafts are a form of cell therapy regularly used to treat delayed
union and non-union fracture grafts, surgeons are looking for new therapies which
overcome the limitations associated with bone grafting procedures (summarised above).
BMSCs are crucial for bone repair as they differentiate into osteogenic cells and bone
marrow provides a source of BMSCs with strong osteogenic potential which can be
readily extracted. Cell therapy offers an alternative to autologous bone grafting for bone
repair. Here bone progenitor cells, such as BMSCs, are implanted into the injury site
either directly or in combination with a biomaterial scaffold and/or growth factors. The
technique of injecting autologous bone marrow aspirate as a source of BMSCs directly
into the injury site was first described in 1991 [15]. Here 18 out of 20 patients who
received injections of bone marrow aspirate at the site of a non-union bone fracture
achieved full bone union. Another option is increasing the number of BMSCs in the bone
marrow aspirate before re-injecting them percutaneously into the fracture site. BMSCs
concentrated from bone marrow aspirate via centrifugation showed an increased healing
rate [16]. One study showed that full bone healing was achieved in non-union fractures
when a concentration of 2,835 ± 1,160 progenitors/cm3 was used in 20 cm3 of bone
marrow aspirate. Bone union failed in patients who received un-concentrated bone
9
marrow aspirate of 634 ± 187 progenitors/cm3 with the same volume of bone marrow
aspirate [16].
BMSCs are a rare cell population; only 0.001 - 0.01 % of mononuclear cells from bone
marrow are BMSCs [43], which means to achieve the required amount and concentration
of autologous progenitor cells required to heal bone defects, large amounts of bone
aspirate needs to be taken from the patient. This leads to issues of a lack of good quality
cells in some cases and donor site morbidity. Any purification process approved for
BMSC concentration may alter their phenotype and affect their differentiation potential.
Yet increasing the population of BMSCs would enhance bone healing. This can be
achieved by extracting bone marrow aspirate and then isolating and culturing BMSCs
ex vivo for expansion of the population (Figure 1.3). These progenitor cells can then
be placed with osteoconductive biomaterial scaffolds to enhance the rate of bone healing
(Figure 1.3) [44]. For example, autologous MSCs which had been isolated and cultured ex
vivo were placed on an osteoconductive hydroxyapatite scaffold before being implanted
into the bone defect. The three patients that received this treatment showed graft
integration within two months and full bone healing was achieved with no adverse effects
[45]. In another study patients with large bone defects were treated with expanded
cultured BMSCs that had been seeded onto a hydroxyapatite ceramic scaffold [44].
Fusion was achieved in all patients 5 to 7 months after surgery and complete integration
of the implants was maintained 6 to 7 year post-operative. A comparative study has
been carried out comparing patients who had received 15 million autologous BMSCs
ex vivo expanded compared with patients who had received an autograft from the illiac
crest for treatment of a non-union long bone fracture. Whilst all patients who received
both treatments achieved successful bone union in a year, patients who had received the
BMSC treatment demonstrated initial accelerated healing and functional improvement
[46]. However, to obtain sufficient numbers of cells, significant cell amplification is
required ex vivo which comes with various risks associated. Multiple replication of MSCs
poses the risks of telomere shortening therefore accumulating genetic and epigenetic
abnormalities, leading to a reduction in mineralisation potential [47]. Ex vivo expansion
of MSCs for bone repair is also a costly personalised, therapeutic procedure that raises
technical and regulatory issues leading to a longer route to mass market. Therefore an
alternative to ex vivo expansion of BMSCs for use in orthopaedic surgeries, is desirable.
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Figure 1.3: Diagram demonstrating two different approaches utilising bone marrow
aspirate for bone regeneration. Autologous bone marrow aspirate can be harvested and
then either directly injected into the fracture site or concentrated to increase the number
of BMSCs, before being implanted with a biomaterial scaffold. For the other approach
BMSCs are expanded ex vivo before being implanted into the fracture site with the
appropriate biomaterial scaffold. [2].
1.3 Mesenchymal stem cells
Mesenchymal stem cells (MSCs) are multipotent stromal cells which are capable of self-
renewal and multilineage differentiation. The term had been used to describe stem cells
which were isolated from bone marrow, but has evolved to include a variety of multipotent
cells which have been isolated from different human tissues such as MSCs isolated from
synovial membrane [48], adipose tissue [49], skeletal muscle [50] and dental pulp [51,
17]. There is great potential in the use of MSCs in tissue repair and regeneration, however
defining the characteristics of this unique cell population remains a challenge. In 2006, the
Mesenchymal and Tissue Stem Cell Committee of the International Society for Cellular
Therapy (ISCT) published a minimum criteria for defining a cell as an MSC [52]. They
11
proposed three different criteria to identify MSCs; the first is that MSCs must adhere to
plastic when placed in tissue culture flasks. This is in accordance with the studies of
Friedenstein et al in 1970. Friedenstein, who by many is considered to be the discoverer
of MSCs, isolated adherent fibroblast-like cells from bone marrow in vitro, which gave
rise to fibroblastic colonies (subsequently named colony forming unit-fibroblast, CFU-
F) [52] and was able to show the multilineage potential of these cells [53]. The second
criterion involved the expression of cell surface markers and that ≥ 95% of the MSC
population must have positive expression of CD105, CD73 and CD90, and also have
negative expression (≤ 2% positive) of CD45, CD34, CD14 or CD11b, CD79 or CD19
and HLA class II. Finally the cells must be able undergo tri-lineage differentiation into
osteoblasts, adipocytes and chondroblasts, thus having a multilineage potential (Figure
1.4). This was brought to worldwide attention by Pittenger et al in 1999, who were able
to differentiate MSCs isolated from bone marrow aspirate into three distinct lineages in
vitro using induction media in tissue culture [54].
Figure 1.4: Diagram showing the multilineage potential of MSCs to differentiate into
osteoblasts, adipocytes and chondroblasts [3].
However, criteria have not been uniformly embraced and are disputed. Some authors state
that the three positive markers defined are co-expressed in cells in a wide range of tissues,
and research has identified other markers that can be considered for MSC definition. For
example, Stro-1 is a known MSC marker and when the cell population is negative for
Stro-1, CFU-Fs do not form [55]. However Stro-1 is unlikely to be a unique MSC marker
as its expression is not exclusive to MSCs, its expression is not universal for all MSC
types [56] and the expression of Stro-1 has been shown to vary when MSCs are cultured
in vitro [57]. The effect of culturing MSCs has been shown to cause changes in the
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expression profiles of certain surface antigens. MSCs that had been isolated direct from
bone marrow aspirate using the expression of CD105 without culturing had high levels
of certain surface antigens, such as the negative selection marker CD45 [58]. However,
expression of these markers was at much lower levels when analysed in MSC populations
that had been expanded in culture, therefore MSCs may undergo phenotypic changes from
the culture process. The ISCT criteria describe MSCs that have been isolated by plastic
adherence and grown in culture, yet ignores the critical fact of how MSCs biological
characteristics could differ in vivo compared with when grown in culture. The third ISCT
criterion of MSCs multilineage potential has also been argued not to imply any true stem
cell properties but are just the accumulation of hydrophobic, mineralised and polyanionic
material from culture in response to artificial chemical cues [59]. This has raised the
argument that the criteria stated for defining MSCs are just simply shared features of
connective tissue cells and do not imply any true stem-cell properties found in vivo [60].
The criteria of cell self renewal and the multi differentiation potential are what define
MSCs as stem cells, but whilst these characteristics have been well characterised in vitro
there are no clear reports of these characteristics displayed by non-manipulated MSCs in
vivo.
The difficulty with phenotyping MSCs in vivo, are obvious when considering the small
percentage of MSCs (approximately 0.001-0.01%) that are present within the bone
marrow [54]. The true identity of MSCs in vivo is still under debate with current
theories raising the possibility that MSCs may be derived from fibroblasts or pericytes.
Fibroblasts are found in the body’s connective tissue which synthesise collagen. They
share similarities with MSCs with plastic adherence, cell morphology and general markers
of MSCs and human dermal fibroblasts have been shown to be able to undergo tri-lineage
differentiation towards the three main mesenchymal-derived tissues [61]. As MSCs have
been isolated from a wide range of tissue sources which are rich with vascularity, it is
hypothesised that there is a link between MSCs and vascular pericytes, the cells which
line the outer surfaces of blood vessels. Cells with MSC markers have been shown to co-
express pericyte markers (CD146+, CD34-, CD45-, CD56-) linking them together and are
able to undergo multilineage differentiation and so may conform to an MSC identity [62].
However, the pericyte niche theory cannot explain MSCs which have been isolated from
avascular tissue sources such as articular cartilage [63] and nucleus pulposus [64]. There
have also been studies showing that MSCs from bone marrow and other adult tissues can
differentiate into other lineages from embryonic layers not of mesodermal orgin, such as
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neuronal [65] and epithelial cells [66]. However, the available evidence for self renewal
is too limited for them to be classed as true stem cells. MSCs have also been thought
to act as a circulating cell much in the same way hematopoietic stem cells are able to
migrate back and forth to their marrow niche in response to chemokines and growth
factors. MSCs systematically infused into rodent models were seen at a greater number in
sites of injury [67], however, the presence of distinct MSC colonies has not been detected
within peripheral blood [68]. This shows that circulating MSCs are extremely rare, but
the possibility of MSCs which are mobilised from the marrow following injury via growth
factors still remains.
1.3.1 Dental pulp stromal cells
Dental pulp stromal cells (DPSCs) were first isolated from dental pulp in 2000 by
Gronthos et al [51] showing these cells could form densely calcified nodules. These
cells are located within the connective tissue known as the dental pulp within the
innermost part of the tooth, which is a tissue that has a high regenerative capacity
responding to a variety of damage and is responsible for the maintenance and repair of
the periodontal tissue and its associated immune system [69]. The cells isolated were
similar to BMSCs in that they adhered to plastic, were clonogenic and highly proliferative,
and exhibited differentiation potential into an odontoblastic cell type. Furthermore,
DPSCs have been shown to be able to undergo in vitro differentiation into adipogenic,
chondrogenic and osteogenic cell lineages similar to BMSCs [70, 71, 72]. There is no
unique marker that identifies DPSCs, but these cells have been shown to express key
MSC markers such as CD73, CD90 and CD105 and STRO-1 [17, 73]. The self renewable
capability of DPSCs has been demonstrated through transplantation of human DPSCs into
immunocompromised mice which yielded human odontoblasts that deposited a dentin-
pulp like tissue [74]. Whilst DPSCs and BMSCs are regulated by similar factors and
share a common protein expression profile these populations differ in their proliferative
ability and differential potential in vitro. Both populations are enhanced in their ability
to develop into distinct tissues representative of their source micro-environments. Whilst
sharing similar osteogenic potential, the chondrogenic and adipogenic ability of DPSCs
appears weaker than that of BMSCs [75]. Conversely the neurogenicity of DPSCs may
be more potent than that of BMSCs, most probably due to their neural crest origin. Here
it has been shown DPSCs have the ability to differentiate down myogenic and neurogenic
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lineages, giving rise to a potential regenerative therapy for neurological conditions [76].
Whilst DPSCs multilineage differentiation potential has been demonstrated, it is their
osteogenic differentiation capability which is of particular interest here. They have
been identified as a potential stem cell source for dental tissue engineering and bone
regeneration as they are capable of producing mineralised matrix in monolayer culture
[77]. DPSCs showed osteogenic differentiation profiles similar to that of bone formation
with the expression of typical osteoblast markers such as alkaline phosphatase, collagen
type I, osteocalcin and osteopontin [71]. It has been demonstrated that DPSCs can
differentiate to osteoblast pre-cursors and then osteoblasts, where they deposit a calcified
extracellular matrix similar to woven bone tissue, which when transplanted into rats was
able to form lamellar bone with osteocytes, without the use of an additional scaffold
[78]. They have also been shown to undergo osteogenic differentiation in vitro in
combination with a variety of biomaterial scaffolds, for example on 3D bioglass scaffolds
[79], collagen and titanium scaffolds [75]. When scaffolds seeded with DPSCs were
implanted into immunocompromised animals, mineralised tissue formation was observed
[79, 75]. DPSCs mixed together with hydroxyapatite/tricalcium powder implanted
subcutaneously into mice formed lamellae bone [80] and when DPSCs seeded onto
absorbable polylacticcoglycolic acid scaffolds were implanted into rats, bone nodule
formation was demonstrated [81]. DPSCs are a stem cell source which is easily accessible
from tissue which is routinely discarded (e.g. from impacted third molars), have a high
efficiency from extraction within the pulp, and deciduous teeth provide a source which
can be banked for future potential regenerative therapies. However, the main drawback
for regenerative therapies involving DPSCs are the low cell numbers extracted from the
pulp. Therefore generating enough DPSC numbers for a clinically relevant regenerative
therapy would require ex vivo expansion which may be problematic due to changes in the
cell phenotype from telemore shortening [82], resulting in a reduction in cell proliferation
and mineralising potential.
1.3.2 Osteogenic differentiation of mesenchymal stem cells
Mesenchymal stem cells undergo several stages of differentiation and proliferation whilst
undergoing osteogenesis. The osteogenic differentiation of MSCs in vitro is well
characterised (Figure 1.5). Osteogenic differentitaion of MSCs in vitro is initiated by
culturing in the presence of dexamethasone, ascorbic acid and β-glycerol phosphate,
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which induces the expression of the key transcription factor for osteogenesis, Runx2,
increases the expression of type I collagen and provides a source of phosphate for
hydroxyapatite mineral formation [83]. Runx2 is an early osteogenic transcription factor,
once activated, MSCs begin to commit to an osteogenic lineage [84]. Runx2 is considered
the central control gene for MSCs to differentiate to an osteoblast phenotype. Runx2
knockout mice have skeletons lacking ossification and osteoblast development is arrested
[85]. When Runx2 is activated, the cells are defined as pre-osteoblasts, they then undergoe
a three stage differentiation process in vitro [86]. The first stage, occurring early at day
1 to 4, is the onset of the proliferation phase where the number of cells is increased and
cells express collagen and fibronectin for deposition of an extracellular matrix. This is
then followed by an early cell differentiation leading to a maturation of the extracellular
matrix, occurring approximately from day 5 to 14, in which there is an increase in
protein expression of alkaline phosphatase, whilst also expressing a collagen type I extra
cellular matrix for mineralisation. The levels of alkaline phosphatase then peak and
start to decline, initiating the final terminal differentiation stage for mineral deposition.
From day 14 to 28, there is a high expression of osteocalcin and osteopontin, which in
turn promote deposition of calcium and phosphate in the extracellular matrix to make
hydroxyapatite, the mineral substance of bone [87] (Figure 1.5). After this stage the MSC
has differentiated into a mature osteoblast, which can then further differentiate into an
osteocytes which are the terminally differentiated cells that regulate bone homeostasis.
Whilst osteogenic differentiation is well characterised in vitro, it is important to further
understand the mechanisms in vivo, in the absence of specific osteoinductive culture
medium, where these factors and chemical cues may not be present in the natural
environment. MSCs in vivo are found within a stem cell niche which is a dynamic
microenvironment that responds to local or systemic cues, influencing stem cell fate. In
bone this consists of a variety of cell types such as immune cells, blood cells, osteoclasts,
osteoblasts, fibroblasts and osteocytes. The stem cell niche consists of interactions
with supporting cells, secretory factors and the extracellular matrix to maintain the self
renewal of MSCs [88], ensure that there are sufficient numbers and ultimately direct MSC
differentiation down the required fate [89]. For example, in vitro studies have shown that
osteoblasts and osteocytes are key regulators in MSC osteogenic differentiation, as both
cell types are capable of stimulating MSC osteogenesis in co-culture experiments without
the use of an osteoinductive medium. Osteocytes produce a greater osteogenic response
in MSCs than osteoblasts, yet greatest mineralisation was seen when both osteoblasts and
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osteocytes are cultured together with MSCs [90]. This demonstrates the importance of the
stem cell niche on stem cell fate and supports the hypothesis that osteocytes communicate
with inactive osteoblasts to recruit MSCs from the marrow for osteogenic differentiation
and subsequently new bone formation.
Figure 1.5: Diagram demonstrating MSC osteogenic differentiation. Once activated,
MSCs at an early stage of differentiation are known as pre-osteoblasts and are highly
proliferative. The next stage consist of matrix maturation where MSCs commit to the
osteoblast phenotype and begin to express high levels of alkaline phosphatase. This
is followed by the mineralisation phase where the osteoblasts express high levels of
osteocalcin and begin to deposit a calcified matrix [4].
1.3.3 Tissue non-specific alkaline phosphatase (TNAP)
The alkaline phosphatase (ALP) hydrolases are a group of three membrane bound
isoenzymes. In humans, two are found within the intestine (IAP) and placenta (PLAP),
being tissue specific, while the third is tissue non-specific ALP (TNAP) which is
found in a wide variety of tissues including bone, liver and kidney [91]. The tissue
specific ALPs are located on chromosome 2, whilst the tissue non-specific ALP is
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located on chromosome 1 and has approximately 50% sequence homology to the tissue-
specific ALPs [92]. The ALP hydrolases are catalysts which are responsible for the
dephosphorylation of a wide range of molecules that are involved in multiple biological
processes and generally catalyse the hydrolysis of phosphate esters. The main difference
between TNAP and the other ALP isoenzymes is its non-specific tissue distribution,
however it is found within skeletal tissues where it plays an important function in bone
mineralisation.
TNAP plays a key role in the mineralisation of hard tissues; its action provides free
phosphate for the nucleation and growth of hydroxyapatite crystals and TNAP also
hydrolyses pyrophosphate, which is an inhibitor of bone mineral formation [93]. TNAP
has been found to be expressed on the surface of human adult MSCs isolated from
different tissue sources [94, 17] and has been identified as a marker to isolate MSCs
from a mixed population. It was discovered that the marker “mesenchymal stem cell
antigen” (MSCA-1), used in aiding identification of MSC populations, is identical to
TNAP [95]. TNAP has been used as a selective marker for the isolation of MSCs from
a mixed population. Cells which were TNAP+ may favour differentiation towards an
osteogenic or adipogenic lineage, at the expense on chondrogenesis [96]. Functionally
distinct subpopulations of TNAP+ MSCs have been isolated using the marker CD56
(TNAP+CD56- and TNAP-CD56+) to purify and characterise MSCs subpopulations from
bone marrow aspirate [94]. CD56 is a cellular marker found on neuronal cells (also
known as neural cell adhesion molecule, N-CAM), lymphocytes and skeletal cells with
roles in cell-cell adhesion, but CD56 has also been used for isolation of multipotent
cells from skeletal muscle which were able to differentiate into fat and bone. Here
slightly different results were reported, as cells which were MSCA-1/TNAP- were able
to differentiate into chondrocytes when they were also CD56+, whereas adipocytes only
emerged from MSCA-1/TNAP+ CD56- cells. However, osteoblasts could be obtained
from both MSCA-1/TNAP+ CD56+ and MSCA-1/TNAP+ CD56- cells [94]. MSC
subpopulations which have been isolated and are distinct in their differential potential
could potentially be used for treatment of disease and within regenerative therapies.
TNAP+ MSCs have been identified as an MSC subpopulation with a potential source for
orthopaedic tissue engineering, as TNAP+ expression is thought to be an early predictive
marker of the osteogenic differentiation potential. Several reports have suggested that
MSCs expressing TNAP accelerate or induce osteogenic differentiation [97]. There is
variable expression of TNAP in MSC populations and MSCs expressing TNAP have less
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multipotency capacity, but a greater capacity for ostoegenic differentiation [96]. TNAP+
MSCs have been shown to be associated with the production of greater amounts of
mineralised matrix, which occurs at an earlier time point, and have a higher level of
osteogenic gene expression when compared to TNAP- MSCs [96]. However, TNAP-
MSCs retained their differentiation potential and were capable of differentiation into
osteogenic, adipogenic and chondrogenic lineages. When TNAP is inhibited using small
interfering RNA or a tetramisole (an inhibitor of ALP activity) in human or mouse
osteoblasts, there was minimal matrix mineralisation under osteogenic conditions, with
a reduction in the expression of osteocalcin, which is a marker of mature osteoblasts
[98, 99]. TNAP has also been shown to be expressed in human dental pulp stem cells
(DPSCs), along with the common MSC markers CD73 and CD90, and has thus been
identified as a source for use in regenerative therapies [17]. It has been shown that TNAP+
expression of DPSCs increases with high density cell culture. Cells released from digested
tissue showed expression of TNAP at around 2-10% of the total cell population and this
then increased to 26% after 14 days in culture without osteoinductive cues. It was then
found that this increase in TNAP expression was due to an increase in cell density as
DPSCs which had been seeded at higher densities expressed higher levels of TNAP after
7 days in culture [17]. This increased TNAP expression is likely to be due to inhibition
of proliferation, and therefore cells are beginning to differentiate towards an osteogenic
lineage. Therefore TNAP is a useful marker for the isolation of DPSCs and MSCs, with
a high mineralising potential for potential uses in bone regenerative therapies.
1.4 Methods for cell separation
The ability to be able to isolate specific cell populations holds great potential for
regenerative medicine and tissue engineering. It allows cells to be separated into unique
populations, or enriched, from a heterogeneous starting population. Heterogeneous
cell populations can contain rare cell types, which, if enriched, can be of great use
clinically, including mesenchymal stem cells (MSCs). The separation of stem cells from
a heterogeneous population may hold potential for tissue engineering and therapeutic use
due to their multipotency. Examples include the isolation and reinfusion of isolated
peripheral blood stem cells for the reconstitution of haematopoiesis for patients who
have lost immune cells due to chemotherapy [100] and the separation of bone marrow
stem cells with a high potential to induce angiogenesis for myocardial regeneration after
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myocardial infarction [101].
When assessing the efficacy of any cell separation, there are three main considerations
to take into account: Enrichment, Purity, and Recovery. Enrichment is the concentration
of a particular target cell type via the removal of other non-target cells. Purity relates
to the enrichment of the cells of interest from the heterogeneous population by known
factors associated with those cells. Within a separated fraction, the percentage of target
cells compared to isolated non-targeted cells can be calculated. However a thorough
understanding of the original cell population which to base the selection criteria on is
important when defining purity. A separation may yield a cell population with a high
percentage of purity for the target molecule, but within that ‘pure’ population there could
be a heterogeneous mixture of cells which express the same target. Therefore it is always
helpful to use a term relating to the enrichment or depletion of target cells when reporting
the outcomes of a cell separation [5]. Recovery is the term to describe the percentage of
cells which are obtained post sorting compared to the number of total cells or target cells
in the original population. The total recovery is the measurement of separated cells versus
total cell count and will provide a insight into the separation efficiency. Target recovery
defines the number of target cells in the separated population versus target cells in the
original cell suspension and provides a better measure of true separation efficiency [5].
For isolation of stem cells for use in a therapeutic device for clinical treatments, any cells
implanted must be minimally manipulated stem cells, as described by the EU directive
No. 1394/2007 [19] where the separation method must not alter the relevant biological
characteristics of cells or tissues. This is due to little research into cells that have
been ‘manipulated’ and the unknown cellular effects when implanted which could be
of a harmful nature. A therapeutic device consisting of cells isolated with a minimally
manipulated cell separation method will be considered a class III medical device, reducing
the cost of development and time to get the product to market. This section will discuss
the large variety of cell separation methods currently available. The separation methods
which are the most widely used that are commercially available rely on mainly three
methodologies of adherence, density and antibodies. A variety of new experimental
techniques which are not yet commercially available for research applications will also
be discussed.
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1.4.1 Traditional methods of cell sorting
Adherence
Adherence separation is the simplest and cheapest method of separation and relies on the
differences in cellular adhesion in heterogeneous populations. Adherence separation is
the first criterion as proposed by the ISCT for the isolation of MSCs [52]. This method
is routinely used in the isolation of cells from digested tissues, with an example being the
separation of dental pulp stromal cells (DPSCs), where the dental pulp is enzymatically
digested and filtered. This suspension is then plated onto tissue culture plates, and the
adherent stromal cells are then passaged after a period of culture, with the non-adherent
cells being negatively selected as they are washed away during passage [51]. Also
cell types which rapidly proliferate on the surface of the culture plate will outcompete
other adherent cells, permitting further enrichment to be achieved. This is a routinely
used technique in tissue culture which is effective due to its low cost and simplicity.
However adherence based cell separation is limited by not being very specific, having
long processing times for cells to attach and the reliance of cells of interest adhering.
Increasing the specificity of cell attachment using techniques based on intelligent
surfaces for cell adhesion has been reported. Polymer brushes of varying lengths to
capture different cells based on their unique adhesion properties, have shown to exhibit
temperature dependent cell attachment and detachment, this is via long polymer chains
that can switch from a hydrophilic swollen state, to a compact hydrophobic state via a
switch in temperature. Various cell types were able to attach to the polymer brushes at
high temperatures (37◦C) and then when incubated at lower temperatures (20◦C), different
cell types would detach at different rates, due to the adjustment of the surface wettability
and unique differences in cells adhesion properties [102]. This method has been applied
to the isolation of human bone marrow mesenchymal stem cells where only MSCs in a
mixture of other bone marrow derived cells were able to adhere to the polymer brushes.
These could then can be detached from the surface by incubating at lower temperatures
[103]. However despite this progress, other methods of cell separation are usually
employed to obtain high cell purity due to the lack of specificity of adherence. Current
adherence based cell separation is therefore only used in applications where unique cell
subpopulations are not required.
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Centrifugation
Centrifugation is a common laboratory technique used to sort cells which relies on
differences in cell density. Large numbers of cells can be sorted relative to a separation
gradient. A centrifugal force is applied to the heterogeneous mixed cell population in
suspension in a test tube and sedimentation occurs where the densest cells are at the
bottom of the tube, allowing distinct phases containing different cell types to be separated.
The centrifugal force and the density of the separation medium (usually sugar based)
can be altered for separation of a desired cell type. Clinically, the most common use
of this technique has been apheresis of whole blood, where due to the constituents of
blood (plasma, platelets, mononuclear cells and erythrocytes and granulocytes) having
distinct density profiles (Figure 1.6), the required blood component can be isolated for
the treatment of a variety of conditions, such as the removal of leukocytes from patient’s
blood for treat of leukaemia [104]. Centrifugation is also used as a method for isolation of
MSCs from bone marrow aspirate. Here the aspirate is combined with a solution of known
separation density gradient then centrifuged to obtain the mononucleated fraction of bone
marrow containing the MSCs. The MSCs can then be isolated and expanded by adhering
to tissue culture plastic [105]. Centrifugation cell sorting has also been used clinically
to prepare bone marrow samples concentrated with respect to MSCs for enhanced bone
healing [60]. However, high specificity can be hard to achieve when using centrifugation,
as cell types that have relatively similar densities cannot be separated [5]. Therefore
centrifugation can only be used when specificity is not a necessity.
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Figure 1.6: Diagram illustrating whole blood separation by density gradient
centrifugation. The whole blood is mixed with a saline solution and then carefully
layered on top of the centrifugation medium. The layers are centrifuged with appropriate
centrifugal force and time, separating the whole blood into distinct layers of plasma,
mononuclear cells, centrifugation medium and eythrocytes and granulocytes according to
their respective densities. The required cell population can then be aspirated for isolation.
Antibody-Based Techniques
The most commonly used cell separation techniques that utilise antibody labelling are
fluorescence-activated cell sorting (FACS) and magnetic-activated cell sorting (MACS).
These techniques share the principle of using antibodies to bind to specific antigens
on the cell surface to isolate populations of interest. The antibodies are conjugated
with either a fluorophore (in the case of FACS) or magnetic nanoparticles (for MACS),
allowing specific cell populations to be isolated [5]. FACS separation works by passing
cells labelled with fluorescent antibodies in a liquid suspension through a light source or
laser, where the fluorescent signature of each cell is measured. If this is above or below
a certain threshold, the droplet which contains the cell is electrically charged and passes
through deflector plates to direct the cells to the appropriate collection tubes [106, 107]
(Figure 1.7). MACS utilises antibodies labelled with magnetic nanoparticles to isolate
a population of cells with a specific surface marker. The labelled heterogeneous cell
population is passed through a column subject to a magnetic field, and the labelled cells
are retained in the column, while unlabelled cells pass through. The magnetic field
can then be removed and the positively selected labelled cells collected by washing the
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column [6] (Figure 1.8).
Figure 1.7: Diagram showing cell separation by FACS. A heterogenous population of
cells is incubated with specific fluorescently tagged antibodies. Labelled cells are passed
through a laser source and the signature of each cell is detected. If the signature is above
certain threshold value, the droplet containing the cell is electrically charged, passes
through deflector plates and is collected in the appropriate tube. From reference ([5])
The main difference between FACS and MACS is the specificity and time taken to analyse
samples. FACS relies on separating individual cells at a rate of approximately 107 cells
per hour, while MACS is able to analyse cells in bulk at a rate of 107 cells per 15 minutes
[6]. MACS is widely used as a research tool due to the rapid, batch wise processing
with only relatively small and inexpensive equipment needed. However, MACS is limited
to one individual marker at a time, while a number of different specific subpopulations
of cells can be isolated from FACS due to the ability to isolate cells using multiple
morphological and fluorescent cell signatures (various antibodies specific to different
targets can be combined using different fluorescent labels and cells can be separated by
size and granularity from forward and side scatter). However, using a greater number of
fluorophores can mean populations are harder to differentiate due to signal spillover [108].
Whilst FACS provides more specificity than MACS, sorting via FACS takes several hours
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longer, thus consideration of the intended requirements and future cell use is needed to
determine which technique to use.
While antibody-cell separation techniques are the gold standard due to the high level of
purity that can be achieved, they still suffer from various limitations. Cell isolation with
MACS or FACS relies on the use of cell surface markers and therefore antibodies which
are commercially available for the desired marker. Antibody quality can vary, where
commercially available manufactured antibodies may also bind to other surrounding
antigens on the cells surface or not to the desired target [109]. The desired population
may also lack unique markers or express changes in antigens at the surface when they
differentiate. For example, a unique cell surface marker for MSCs has not been identified
and MSCs express markers associated with many other cell types [110]. Another
limitation is that cells bound with antibodies and magnetic nanoparticles may have
unknown cellular effects in solid tissue, that could result in a loss of cell function or
viability which could affect patient recovery. Antibody-based cell separation techniques
are also associated with high costs because of the required reagents, complex machinery
and the technical expertise necessary for operation [8]. These high unit costs and sample
processing costs make it difficult for antibody based cell separation to be used in a clinical
application. Also the slow preparation times to label a population of cells combined
with limited throughput and processing speeds of the actual separation also limits their
translation into a clinical setting [5].
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Figure 1.8: Diagram showing cell separation by MACS. Cells which are labelled with
magnetic nanoparticles conjugated to antibodies targeting a particular antigen are shown
in black, while unlabelled cells are shown in white. The cell population is passed through
a magnetic field retaining the labelled cells within the column which can then be washed
out when the magnetic field is removed [6].
MACS separation has been approved to be use clinically in various applications. MACS
had been used to yield a high purity of CD34+ progenitors which have been isolated
from peripheral blood to repopulate a patients blood after chemotherapy [111]. Another
interesting application in a clinical setting was using MACS to eliminate non-viable
sperm cells via targeting of annexin V expression (a marker of apoptosis) where fertility
treatment using intracytoplasmic sperm injection into human oocytes is performed [112].
Here pregnancy rates were increased when apoptotic sperm cells were eliminated using
MACS. FACS is not widely used clinically for cell therapies as there is difficulty with
regards to the sterility of the fluidics. To prevent cross contamination between samples
a single use fluidic system needs to be developed. MACS offers greater specificity than
centrifugation for clinical use, yet it has not been taken up as routine for common clinical
cell separations, for example in blood apheresis, due to the high costs compared to the
centrifugation techniques.
Panning
Panning is a similar technique to adherence cell separation, but uses antibodies to select
specific cell types which increases the specificity of the selected population. Antibodies
which are able to bind to specific cell surface antigens are coated onto plastic or glass
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surfaces. Heterogeneous cell populations are then incubated on these dishes and cells
are captured with the desired target antigen. Non-specifically bound cells are washed off
and the adherent population is the cells which have bound to the antibody [113]. Cells
attached via the antibody can be removed by gentle, but repeated pipetting. The technique
has also been used in the process of negative selection to remove unwanted cell types from
a population [114]. However, this technique is limited by the use of antibodies previously
discussed and having to apply unnecessary force on the cells when removing them from
the antibodies through repeated pipetting or scraping in an ice cold buffer.
1.5 Lab on a chip cell separation methods
Cell separation using lab on the chip methods offers novel ways to separate cells. These
methods have been developed to sort cells without the use of labelled antibodies or
non-antibody binding proteins, utilising the difference between cellular characteristics
to be able to sort cells where a separation force is dependent on the cells physical
properties. The proposed markers that are used to sort cells label-free include cell
size, shape, density and also their deformability, electrical and mechanical properties
[7]. Microfluidic devices have also been developed to sort cells expressing a specific
antigen of choice through antibody binding. The lab on the chip method of sorting
cells operates on a microfluidic scale which offers many advantages. The advance of
manufacturing processes, such as 3D printing, has reduced the cost of such devices
and made manufacturing simpler. Microfluidic devices are usually small and therefore
transportable (however it must be noted that the associated experimental equipment, such
as pumps and microscopes, may not be) so can be used not just in the laboratory for
research purposes, but also in other areas such as in medical diagnostic or in clinical
applications. To date the majority of the literature with these devices focuses on the
capture of circulating tumour cells or CD4+ leukocyte counting [7]. Therefore the
development of a stem cell separation device with the minimally invasive capture and
recovery of cells, would present novel research into the potential use of stem cells for cell
therapy.
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1.5.1 Microfluidic device fabrication
Microfluidic devices provide a powerful platform where by small volumes of fluid (pL
to µL volume) can be precisely controlled in fluidic channels with a small cross-section
area (typically less than 1mm) and there has recently been particular interest in the use
of microfluidics for biological applications and diagnostics as it allows the scale down of
sample volumes.
The laws of physics remain the same as in macroscopic systems, but at the microscale
there is a predominance of different forces. At the microscale, fluid flow exhibits a number
of characteristic features such as viscosity, diffusion and surface tension becoming
increasingly more important, with mixing occurring on slower timescales. For fluid flow
almost all microfluidic systems operate in either the creeping regime or the laminar flow
regime. This flow regime can be assessed by Reynolds number, a dimensionless quantity





Here p is the liquid density, v is the velocity of the liquid, L is a characteristic linear
dimension, e.g. the diameter of the tube or the microfluidic channel height and µ is the
viscosity of the liquid. The Reynolds number describes the ratio of inertial forces to
viscous forces, where typically is the Reynolds number is below 2300 the fluid flow will
most likely be laminar and if above 2600 the flow will most likely be completely turbulent.
Laminar fluid flow is where the fluid layers slide in parallel, with no eddies, swirls or
currents normal to the flow itself and fluid velocity within the same layer is constant. A
turbulent flow regime is opposite to laminar flow, in that it is chaotic and fluid velocity is
different across the fluid layer and across the width of the channel [115]. Due to the small
channel sizes used within microfluidic devices there is a formation of laminar flow due to
a reduction in the influence of inertial forces compared to frictional forces.
The two main methods of propelling fluid around a microfluidic device are the use
of pressure driven methods (hydrodynamic) or electrokinetics [116]. The use of
hydrodynamics requires a difference of pressure at the inlet and outlet. This can be
created by having a vacuum at the outlet, with the inlet at atmospheric pressure to “pull”
the fluid through the system. Alternatively positive pressure can be applied at the inlet,
usually via a syringe pump, whilst the outlet is at atmospheric pressure to “push” the fluid
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through. The flow rate in pressure driven flow is also determined by the resistance in
the microchannel which is dictated by the shape of the channels [116]. Another method
that can be used to move fluid through the channels is electrokinetic flow which is the
movement of molecules via an electric field due to their charges [116].
Microfluidic devices used to be mainly fabricated on silicon and glass substrates which
required access to cleanroom facilities and specific knowledge and expertise meaning the
manufacture costs of the resulting devices was high. In the late 1990s the introduction of
soft lithography meant that microstructures could be made much more cheaply without
the need for clean room facilities, opening up the field of microfluidics to a wider
range of researchers and applications. Soft lithography is a technique used to fabricate
replicating structures for creation of microfluidic systems [117]. It is referred to as “soft”
as an elastomer is usually used to fabricate the nano/micro structures. This provides
an alternative to other forms of lithography such as photolithography and electron
beam lithography and is a convenient, effective and low-cost method [117]. The most
commonly used elastomer for soft lithography is poly(dimethylsiloxane) (PDMS). It is
created by mixing base polymer to curing agent in a weight ratio of 1:10, this forms
the liquid PDMS prepolymer. The PDMS is then cured by applying heat and becomes
a hydrophobic elastomer. The stiffness of the PDMS can be altered depending on the
curing time and by differing ratios of base to cross linker. PDMS has many advantages
as a choice of material in microfluidic systems, and is compatible with use in biological
applications as it allows gaseous exchange, is nontoxic to cells and impermeable to water
[116]. It is optically transparent down to 230 nm, which is useful in biological studies
as a direct visualisation of the contents in the micro-channels can be observed through a
microscope. PDMS has advantages over traditional materials such as silicon and glass.
It is relatively inexpensive when compared with silicon and glass meaning new concepts
can be tested easily. It is also very flexible, which aids removal from moulds without
breakage, and is easily bonded to other surfaces without the use of high temperatures or
adhesives [116].
Other alternatives to the manufacture of microfluidc devices include injection moulding
and hot embossing. Injection moulding utilises injecting heated thermoplastic into a
mould cavity, cooling and removing the cast, whilst hot embossing is a process where
thermoplastics become viscous liquids at high temperature and are precisely shaped using
a mould, pressure and heat [118]. However the main limitation with both techniques is the
material restriction to thermoplastics with difficultly in the fabrication of complex three-
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dimensional structures and high mould fabrication costs [118]. A more recent and novel
technology providing an alternative to the soft lithography process for the fabrication
of microfluidic devices is 3D printing, which is an industry that has seen the price of
printers drop rapidly to a point where 3D printers are now accessible to many more
research laboratories. This has led to an increase in replica moulding as an effortless and
cost effective method for the fabrication and duplication of microstructures. While the
choice to print 3D microchips directly would be favourable, due to a significant reduction
in manufacture time and cost, it is limited by a lack of choice in available materials
which do not have the advantageous properties of PDMS. Comina et al used the Miicraft
3D printer to successfully generate PDMS-based devices by producing a 3D printed
template which replaced the expensive and time consuming processes of clean room and
photolithographic fabrication [119]. The templates’ reusability, short manufacture time
and low costs enable flexibility in optimisation of devices as the cost of multiple iterations
is greatly reduced. However, PDMS does not cure when placed directly onto the surface
of the templates due to the chemistry of the proprietary resin used within the 3D printer
inhibiting the polymerisation of the PDMS. The surface of the template must either be
protected with a PDMS compatible material, such as Teflon, or undergo oxygen plasma
treatment to prevent the PDMS from sticking such that when cured can be peeled off
easily [120]. Truly 3D microfluidic channels have also been fabricated from a one-step
moulding of 3D printed micro-structures [120]. This demonstrates a technique which
would save time, cost and effort to fabricate 3D microfluidics allowing more researchers
to bypass the barriers associated with microfluidics.
1.5.2 Microfluidic methods for cell separation
Hydrodynamic separation
Separating cells by their physical properties such as size and deformability, enables
enrichment without the need for extrinsic antibody labelling. The main benefit with
these techniques is the ability to continuously separate cells. These devices are highly
dependent on flow rate, sample concentration and device design which together provide a
convenient cell separation which is highly reproducible. Size is a commonly used label-
free separation criteria, where larger cells can be filtered out from the heterogeneous
population using microfilters in the device. The cell sample is passed through filters
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enabling cells to be separated by their size and deformability. Here, cells which are
smaller than the filter size pass through and are collected, being separated from the larger
cells. Different types of microfilters are available (Figure 1.9) such as weir, pillar, cross-
flow and membrane [7]. Weir type filters separate cells via a planar slit which only allows
small cells and molecules to pass through. Pillar-type filters have an array of pillars which
exclude cells that are larger than the space between the pillars creating critical size cut
offs. However, this design is usually avoided as cells become trapped between the posts
and this leads to a disruption of the flow due to clogging of the device. Membrane filters
separate cells using specific pore sizes which restrict cells above a critical size, however
at high concentrations this can also lead to clogging. To reduce clogging, cross flow
filtration arranges filters perpendicularly to primary channel flow, these filters remove the
small cells allowing the rejected larger cells to continue in the primary direction of flow.
The ability of cells to deform and to become compressed and stretched to approach a
thickness equal to that of their membrane makes it hard to sort specific cell types using
microfilters. These filters have primarily been used in blood based sorting due to distinct
differences in diameter and deformability between red blood cells and white blood cells.
Cross flow filtration has been shown to be superior in blood filtration with an ability to
allow red blood cells to pass and to trap between 70-80 % of white blood cells from whole
blood when compared with the other filter sized separation techniques [121].
The use of microfilters has been reported in the isolation of viable circulating tumour cells
(CTCs) with high capture efficiency [122]. Whilst microfilters have been shown to exhibit
several advantages, including high capture efficiency and continuous cell processing,
there are few reported studies of the use of microfilters in separation of progenitor/stem
cells. The principle of using size based exclusion has been applied to the separation of
embryonic bodies (aggregates of pluripotent stem cells) which have a larger dynamic size
range of up to 300 µm and require a separation technique without the use of external forces
which could subsequently affect cell differentiation. Here three pillars were placed with
precise spacing into the flow path diverting cells of different sizes into specific flow paths
for collection [123]. Three distinct size groups of embryonic bodies were recovered with
a viability 92%. With a filter based separation, further analysis is needed downstream
of separation to ensure that any deformation caused by cells “squeezing through” pores
does not alter their biological characteristics or phenotype. Alongside this the other major
issues of clogging and saturation of the filter from large continuous volumes of cells for
separation, may result in irregular flow patterns and loss of filtration ability.
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Figure 1.9: Diagram showing the three main types of microfilter designs used for sized
based cell separation adapted from [7]. (a) Weir type filters size exclude via a planar
slit. (b) Pillar type filters are an array of pillars which exclude cells larger than the
spacing between pillars. (c) Cross flow filters arranged perpendicularly to the channel
allow continuous filtration of small cells, designed to reduced clogging of the filter and
offer higher throughput of the sorting application.
Deterministic lateral displacement (DLD) is a method used to sort cells based on size
using a periodic array of microposts through which cells are flown. Cells which
are smaller than a critical hydrodynamic diameter move with a convective flow in a
straight path, whereas cells whose diameter is larger than the critical hydrodynamic
diameter move in a direction directed by the layout of the array, being usually displaced
horizontally as a function of size [18]. With this device, clogging is less likely to occur
as cells continuously flow through and out of the device. This technique has potential
for use within tissue engineering. Green et al in 2009 [124] used DLD as a method to
separate large epithelial cells from smaller fibroblast cells in a model for digested cardiac
tissue. The DLD cell separation device had a 90% efficiency in recovering the larger
cell population and demonstrated potential use in tissue engineering applications as this
technique is able to deliver a large population of separated cells from a continuous high
throughput. Even with a continuous flow, as with microfilter based separation, DLD
devices are prone to clogging at high flow rates or with increased cell concentrations.
The efficiency of DLD devices would decrease when trying to distinguish cell types
that are closer in size and as the DLD separation process involves multiple collisions
between microposts, the possible effects on cell viability and biological function need
to be properly assessed. DLD devices have been designed to enrich human skeletal
progenitor cells, which are reported to be larger and stiffer than other cells present in the
bone marrow [125]. The micropost array of the DLD device deflects the large cells into a
specific channel for collection and it was shown that cells remain viable after separation
with the capacity to form clonogenic cultures [126]. This separation technique begins to
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show promise for DLD devices in stem cell enrichment for use in clinical applications.
Microfluidic devices have also been developed to separate cells using inertial forces.
Here microfluidic channels with a spiral design can separate cells based on their size and
deformability, as cells migrate into designated flow steams derived from the interaction
of differential inertial lift force and dean drag forces as they flow through the curved
channels [127, 128, 129]. This technique has many advantages for cell separation in that
it has high throughput rates, thus able to process large samples to isolate rare cells and
there is a high recovery of cells after separation. For example, a spiral shaped inertial
microfluidic device has been designed to sort MSCs from mouse bone marrow samples
[127]. This is based upon the principle that the MSCs were about 60% larger in diameter
compared with the average diameter of cells found in bone marrow samples and thus
would experience an increased inertial force allowing them to be focused into a specific
outlet for separation. From the device, 73% of MSCs were able to be recovered and this
population was enriched six fold, with the cells retaining a high degree of viability and
proliferation ability after separation. However, whilst promising aspects with high flow
rates for large cell throughputs, this technique suffers from low purity with respect to
target cells [127, 129] and therefore this inertial cell separation method needs improving
or to be combined with an accompanying cell separation method to increase specificity.
Figure 1.10: Diagram of a spiral microfludic channel which uses inertial forces to sort
cells by size. Cells are separated by their size due to differences in inertial forces and
dean drag, causing them to be focussed in different stream lines and therefore available
for collection. From reference [8].
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Dielectrophoresis
Dielectrophoresis (DEP) is a method used to separate cells using an electric field gradient.
When cells are present within a non-uniform field, a net force is applied to the cell due to
polarisation when present in a medium with different dielectric properties [7]. A cell’s
extrinsic and intrinsic characteristics (such as ion gradients, organelle structure, etc)
varies its response to the electric field and therefore the force that the cell experiences.
This leads to the cells being attracted or repulsed from the electrode allowing for
separation. DEP devices have shown the capacity to separate a large number of cell types
with applications in monitoring cell viability and changes occurring at the cell surface
or intrinsically [130, 131]. DEP sorting has shown success in sorting a wide range of
cell types and is able to distinguish bacteria, blood cells, cancer cells, circulating tumour
cells and many more [7]. The technique has also shown applications in the enrichment
and separation of stem cells from their differentiated progenies [132]. The first example
of DEP for use in stem cell isolation was the enrichment and separation of CD34+
haematopoietic stem cells from a heterogeneous population [133]. A six-fold enrichment
of CD34+ cells was achieved, however, the final purity at 6% was low. Putative stem
cells have also been isolated from enzyme-digested adipose tissue using a combination
of DEP and field-flow fractionation [134].
Dielectrophoresis cell separation has also been considered for isolating rare cells which
are potentially useful in regenerative therapies. Flanagan et al in 2008, were able to
separate stem cells from their differentiated progeny by differences in their dielectric
properties [135]. Their DEP device was able to separate neural stem cells (NSCs),
differentiated neurons and astrocytes by their different dielectric properties. Populations
of NSCs which were more likely to differentiate into astrocytes and neurons were also able
to be isolated. However this technique used a batch flow method where cells were trapped
then released after separation, requiring precise control over the electrokinetic force and
fluid flow to achieve separation. Dielectrophersis has also been used to isolate osteoblasts,
where a population of cells was incubated on a surface with dielectrophoretic rings
and then a dielectrophoretic force trapped the cells with specific dielectric properties.
Whilst demonstating high purity in the capture of target cells the recovery of cells
was very low, as this is not a continuous separation technique [136]. Continuous-flow
microfluidic devices for sorting stem cells allow higher collection efficiency and a greater
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cell recovery. For example, human MSCs were sorted from their differentiated progeny
using a continuous flow microfluidic DEP device (Figure 1.12). Osteoblasts experienced
a stronger dielectrophoretic force compared to BMSCs and are deflected laterally into the
lower outlet, while BMSCs experience a weaker force and remain on a straight path [9].
This showed a high collection efficiency of 92% for BMSCs with a purity of up to 84%,
demonstrating the potential of this label free cell sorting method. DEP devices have been
designed to separate BMSCs from a heterogenous cell population increasing the purity of
the captured mesenchymal stem cells from 33% to 83.5%, with 90% of the BMSCs still
viable after separation [137].
These are promising results but future work needs to focus not on the separation of
immortalised MSCs cell lines, but the separation of clinical samples for potential use
in future regenerative therapies. Whilst dielectrophoresis methods have been used for
cell separation they suffer from low throughput if looking to be used within a clinical
setting. For future therapeutic use, there also needs to be consideration in minimising cell
destruction from high DEP forces and maintaining a high cell viability after separation
when using an appropriately conductive suspension medium. One of the largest problems
is that it can be difficult to detect the differences between target and non-target cells,
as multiple cell types are likely to have partially overlapping DEP cross over frequencies.
For DEP cell separation to become truly accessible comprehensive data of DEP properties
for different cell types and how their DEP characteristics may change in different
biological states, needs to be developed.
Field-flow fractionation
Field flow fractionation describes a method of cell separation where a field is applied
perpendicularly to the direction of the primary channel flow. This field could be electrical,
magnetic, centrifugal or gravitational. The field applied drives the cells into different
laminar flows which are present within the main channel. It is an elution technique, where
cells positioned at precise distances from the channel wall will experience differences
in parabolic flow. Cells within the middle of the channel will be transported out faster
than those nearest the channel walls. The separation of cells occurs due to differences
in their size, density and intra/extra cellular properties [7]. This method of separation is
beneficial to cells due to low shear stresses and minimal handling. Field flow fractionation
has been used in combination with dielectrophoresis to separate putative stem cells from
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Figure 1.11: Design of continuous flow microfluidic DEP Device used for separation of
MSCs from osteoblasts. Interdigitated electrodes angled at 45◦ are located on the floor
of the microchannel. When an altering AC field is applied between the electrodes a DEP
force is generated which deflects the osteoblast (which experience stronger DEP forces)
laterally into the desired lower collection outlet. MSCs, which experience weaker DEP
forces, continue on their original trajectory and are collected in the upper outlet [9].
adipose tissue [134]. The cells are separated by applying a dielectrophoretic force which
exploits differences in the cells’ dielectric properties and therefore the cell membrane and
cytoplasmic architecture. Cell types that experience a strong levitation force at relatively
higher frequencies elute first, while dense cell types that levitate at lower frequencies elute
later. Using this method, stem cells recognised by the putative stem cell markers, NG2
and nestin, were enriched 14-fold and 5-fold respectively [134]. Gravitational field-flow
fractionation is another method which has been used to purify, distinguish and sort MSCs
from clinical samples, using gravitational force as a method to produce separation elutes
of cell populations [138]. While field-flow fractionation provides label free cell sorting
which will not harm cells, scale up is needed for its use in a clinical setting in order to
sort the large cell numbers required for isolation of rare stem cell populations.
Acoustophoresis
Label free acoustic fluidic systems sort cells based on size and density, utilising the
principle of generating an acoustic standing wave between two sound sources. Cells
situated within this wave experience acoustic radiation forces and then, depending on
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their physical properties versus the surrounding medium, cells will migrate to either the
pressure nodes or antinodes. The standing wave can be applied over a microchannel
where cells are flowing in laminar flow which acts as a filter and cells retain their position
once out of the sound wave, enabling separation. This technique has been used in the
separation of red blood cells, platelets and leukocytes [139]. Cells were separated in
accordance with their size and density, where they would first be separated at the pressure
antinodes, towards the edge of the channel and then migrated inwards toward the node
(channel centre) at different rates dependent on cellular size. The use of acoustic sorting to
separate out viable from non-viable mammalian cells using the principal that cells which
have undergone apoptosis are smaller experience differences in acoustic forces [140].
Standing acoustic waves have also been used to separate platelets from progenitor cells, as
the collection of a large number of unwanted platelets is an unwanted side effect in blood
apheresis [10]. Here platelets were depleted from peripheral blood cell samples for future
use in hematopoietic stem cell transplantation. By applying an acoustic standing wave on
a population of continuous flowing peripheral blood cells, the platelets are deflected into
different collection channels and up to 89% of the platelets were depleted from the sample.
The same principle has then been applied to the separation of CD4+ lymphocytes from
peripheral blood progenitor cells, however, to isolate marker specific populations cells
need to be immunolabeled. As acoustic forces on cells are defined by cell size density and
deformability, targeting cells with antibody conjugated microbeads can change the cell
properties compared to non-target cells, allowing them to be separated by acoustophoresis
under a continuous laminar flow [141]. The CD4 labelled lymphocytes were separated
with a purity of 87% and with an efficiency of 65%, which was comparable to cells
isolated by MACS. The isolated cells were viable after separation and retained their
functional proliferation capacity. The main limitation of acoustopheriesis is that cells
have to be separated by size. Where this is not possible, they need to be labelled
with antibodies to change their acoustic properties. This would make it difficult to
isolate progenitor cells in complex clinical samples which may contain cells of multiple
overlapping sizes. Altering the acoustic properties with the use of antibody labelling will
not be an improvement on traditional antibody labelling cell sorting, as acoustic sorting
as of yet cannot achieve the high cell throughputs compared with MACS.
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Figure 1.12: Design of continuous flow microfluidic, acoustophoresis device used for
separation of platelets from white blood cells. The peripheral blood sample enters the
channel from the side described as apheresis product, while a PBS wash buffer enters from
the central input. The mixed cell population is passed through a transducer generating an
acoustic standing wave across the channel. The larger leukocytes experience a higher
acoustic force and are moved into the pressure node in the centre of the channel for
separation. Adapted from reference [10].
Magnetophoresis
Unlike the majority of magnetic sorting devices which require labelling with small
paramagnetic nanoparticles, label free separation via magnetophoresis sorts cells by
magnetic susceptibility related to their natural iron content. Cells with different amounts
of iron are deflected into different flow paths by the strength of the magnetic force they
experience and so can be isolated. These microfluidic devices have been used to isolate
erythrocytes and are able to enrich hematopoietic progenitor stem cells by means of
negative selection by removing leukocytes [142], delivering a 104 fold enrichment of
the progenitor cell population. However, as magnetophoresis is only really suitable for
separation of blood cells due to their natural iron content, different approaches have had
to be developed to isolate other cell types in a label free manner. For example, bacterial
cells have been suspended in ferrofluids that exert magnetic buoyancy forces on cells
dependent on their size, shape or deformability and deflect them into different laminar
flow paths for separation [143]. This method requires cells to be suspended in a ferrofluid
with a high concentration of magnetic nanoparticles and so the biocompatibility of the
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ferrofluid along with analysis of the cells function after separation needs to be properly
assessed. Therefore it seems likely the use of magnetophoresis as a separation method for
stem cells for clinical use would not be an appropriate option.
Optical Tweezers
Optical solutions for the separation and analysis of single cells have been developed with
application for uses in cell sorting. In this case, separation is achieved by using highly
focused optical beams which trap cells due to differences in the refractive index of the
cell and the surrounding forces. This produces scattering forces which move objects away
from the light source and gradient forces which move cells to the focusing maxima (the
point of highest intensity) [18]. Cells become trapped when the gradient forces overcome
the scattering forces, allowing analysis and separation of single cells. This technique has
been combined with dielectrophoersis to allow high-resolution patterning of electrodes in
real time and was able to separate live and dead cells [144]. However, optical tweezers
are limited by low throughput and efficiencies of separation. There are no demonstrations
of cell separation in a large cell sample being isolated in a continous flow, making it an
unlikely viable method for clinical use.
Adhesion
Adhesion based cell separation utilises the dynamic interaction between cells and a
substrate. Adhesion is an easy to operate, simple and quick separation process where
cell-surface interactions are modulated by engineering the adhesion substrate to capture
cells of specific interest and the shear stress from fluid flow in microfluidic devices.
The use of cell adhesion has been applied for separation of breast cancer cells from
epithelial cells on either flat or nanostructued polymer surfaces. Cells were incubated
on the different surfaces before being released with an increased flow rate. For both
surfaces, at all flow rates, the epithelial cells were more adhesive than the breast cancer
cells and the breast cancer cells could be enriched two fold when collected from the
device [145]. This method has also been demonstrated in the isolation of undifferentiated
induced human pluripotent stem cells (iPSC) from other cell types in culture [146]. By
exploiting the differences in adhesion strength between different cell types, human iPSCs
were detached from the surface by generating a specific shear stress via laminar flow
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within the microfluidic channel [146]. The label free isolated cells were enriched to a
95-99% purity with high viability and retention of normal transcriptional profiles and
differentiation potential. Cell adhesiveness has also been used as a biophysical marker
for cancer stem cell isolation where adhesive stem cells were captured in microchannels
which were coated with basement membrane extract [147]. However, the use of cell
adhesion usually requires a period of culture on the substrate before detachment of
specific cell types, therefore throughput is limited by the surface area of the substrate
used for capture. The long culture periods for the cells to attach to the surface means this
may not be a practical method for any clinical cell separation.
Antibody/Binding protein functionalised surfaces
Antibody based cell separation which does not rely on extrinsic labelling of the
cells mostly exploits the specific interaction of cell surface antigens with an antibody
functionalised surface, similar to the panning method of cell separation described
previously. An early example of this was the creation of a microfluidic device with
a surface consisting of an array of 100 µm microposts which were functionalised with
anti-epithelial cell-adhesion molecule antibodies to capture circulating tumor cell (CTCs)
[148]. This device was able to capture CTCs with a 99% sensitivity success rate
providing a tool for patient diagnostics. However, with studies involving isolation of
CTCs, downstream analysis on cell viability and function has rarely been performed due
to this not being a requirement in diagnostic applications. A similar device design was
also used to capture CTCs with a high capture efficiency of 97%, followed by enzymatic
digestion using trypsin to release CTCs captured on an antibody functionalised surface
has been demonstrated [149]. Yet again, there are no reported results on the downstream
analysis of whether the biological characteristics of the captured cells were altered by the
separation process.
One interesting approach for the capture of cells using antibodies is to use microfluidic
devices which have been developed using thermoresponsive polymers as anchors for
attaching capture antibodies on the surface of microchannels. When above a critical
temperature, the polymer is hydrophobic and interacts strongly with the attached proteins,
allowing for immobilisation of antibodies. Below a critical temperature, the polymer
becomes hydrophilic, reducing the interaction with proteins, and therefore desorption is
possible. The polymer matrix provides temperature dependent modulation of capture or
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release functionality for enrichment of cell populations for a specific surface marker. This
technique had been used in the capture and release of CTCs demonstrating a high capture
efficiency of 95% of all tumour cells [150]. Once the device was cooled below the critical
temperature, up to 95% of the cells were released from the surface. Cell viability was
measured at 91% after release. The same principle was also applied within a device to
enrich CD4+ cells from blood. In this case where 94% of the released cells were viable,
but the reported release effiency was low at 59% [151]. A CD34 antibody was also used
for capture of CD34+ stem cells from whole blood, with 90% viability after release,
showing the potential of the technology for rare stem cell isolation [151]. This approach
allows cells which are attached to the functionalised surface to be released without the use
of shear stress or enzyme digestion. However, it must be noted that the released population
would still have the antibody attached to the target cell surface antigen and therefore
thorough assessment into whether this interaction affects the biological characteristics of
the cell needs to be undertaken.
An alternative approach is the use of “cell rolling” which has been utilised as a cell
separation technique to isolate cells from an antibody functionalised surface. Here
surfaces are coated with a specific antibody and the velocity of the cell passing over the
surface is determined by the surface area density of the target cell surface receptor. The
interaction between the cells and the functionalised surface is dependent on the varying
levels of expression of the target marker on the cells surface. For example, it has been
reported that there is a difference in rolling velocities between CD34+ cells compared
to CD34- cells, when passing over an anti-CD34 antibody functionalised surface [152].
This principle has been applied for the isolation of MSCs with a high osteoblastic
differentiation potential using a column functionalised with anti-CD34 antibodies [153].
Cells with a higher expression of CD34, a marker associated with the selection and
enrichment of stem cells for bone marrow transplants, are eluted from the column later
and the collected cell populations demonstrate a higher osteogenic potential.
The cell rolling technique has also been applied within a microfluidic device for the
enrichment of induced pluripotent stem cells (iPSCs) [154]. An antibody specific to
iPSCs was immobilised on the microfluidic channel and iPSCs were collected from later
fractions when passed through the device, increasing the enrichment of iPSCs two fold
when compared to the original cell suspension [154]. Again, the same technique has
been applied to isolate multiple myeloma, a plasma cancer cell, with a capture efficiency
between 40-70% [155]. Whilst good efficiency and specificity have been demonstrated
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with these devices, the isolated cell numbers that are required for further analysis are still
a significant problem, resulting in the need for in vitro expansion for downstream use.
Similar to other antibody based cell separation methods, whilst cells specific for a marker
can be isolated there may be biological heterogeneity in the separated population, where
different cell types have varying levels of marker expression. The purity of the separated
population will also be affected by the non-specific interaction of non-target cells to the
functionalsied surface. Further studies are needed to assess whether transient interactions
between the cell and the antibody have any effects on cell phenotype. For this technique
to be classed as a minimal manipulation separation, the biological characteristics of the
cell need to remain the same after cell separation.
A summary table has been made on the following page (Table 1.1) which summarises
these novel microfluidic devices where they have been utilised in applications relevant to
this thesis, mainly the separation of stem or progenitor cells. Any relevant information in
efforts to begin meeting a minimal manipulation criteria has also been summarised, along
with the limitations of utilising that separation method for the targeted application in this
thesis.
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Table 1.1: A summary of novel microfluidic devices discussed focused on the target
application within this thesis. Please note “-” has been used to populate the table when
there is no demonstration of the separation of a relevant cell population to this thesis or
where no further studies have been carried out to characterise if the separation has begun




Antibodies (immunoglobulins) are the most commonly used binding proteins in research
and therapeutic applications. They are used extensively in research applications such
as ELISA, immunohistochemistry, immunoprecipitation and flow cytometry. They also
have a critical role in cell separation techniques such as FACS and MACS. Antibodies
are proteins of the immune system where they protect the body from foreign antigens,
recognising specific target molecules and binding to them with potentially high affinity.
Antibodies are ‘Y’ shaped molecules of around 150-170 kDa molecular weight. Their
structure consists of two smaller polypeptide identical (“light”) chains around 25 kDa
and two larger, identical (“heavy”) chains around 50 kDa in size (Figure 1.13). The
heavy chains are covalently linked together by disulphide bonds and each heavy chain is
similarly linked to a light chain. Both light and heavy chains contain variable regions
at the N-terminals whilst the regions at the C-terminus are constant in their primary
sequences. The antibody binding region is located at the N-terminus of both the light
and heavy chains providing each antibody with two identical antigen binding sites.
Figure 1.13: Schematic of typical antibody (IgG) structure consisting of two identical
light and heavy chains. The heavy and light chains contain variable regions at the N-
terminus which makes up two identical antigen binding regions.
Whilst antibodies are excellent research and therapeutic tools which are used extensively
they are not without disadvantages. Their relatively large size can make their interaction
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with the target unpredictable. This is a particular issue when bound to solid surfaces,
where antibodies suffer from a loss in specificity and affinity leading to non-specific
binding to the surface or to other regions of the antibody [156]. Manufacturing antibodies
is an expensive and time consuming process requiring the use of animals or mammalian
cell culture [157]. There are also major issues concerning use of antibodies as research
tools such as batch to batch variability and cross reactivity to non-target proteins [109].
The poor validation of commercially available antibodies has been highlighted as a major
issue in biological research [158], resulting in a waste of materials, time and money with
an estimated US $350 million dollars wasted annually on antibodies which are not fit for
purpose [159]. Therefore, alternatives have been proposed to replace antibodies.
1.6.2 Non-antibody binding proteins
Protein engineering offers the manufacture of non-antibody binding proteins which have
the specificity and affinity characteristic of antibodies, but with improved properties based
on rational design. A non-immunoglobulin protein scaffold is used to form a new binding
protein by modifying or implementing a new binding site onto the scaffold [160]. The
candidate protein scaffold should be strong and robust with a monomeric structure which
allows for easy genetic engineering. The protein scaffolds usually exhibit a compact
and structurally rigid core which lacks disulphide bonds and glycosylation sites. Within
the protein scaffold there are variable binding regions, where changes in the amino acid
sequence at this location need to occur without disturbing the overall structure of the
protein to generate new antigen binding sites [161]. Alternative antibody binding proteins
are usually obtained by first the creation of a random library with mutagenesis with the
protein scaffold focused on the unstructured variable loop regions before selection of
the variants against the required target by phage, yeast or ribosome display or other
similar approaches [162]. They are often expressed in microbial hosts minimising the
need for mamammlian cells or any use of animals in their production. Bioengineering
of the binding proteins also allows desirable features to be engineered into the proteins
according to their required use within biotechnology research. Ideally the binding proteins
should have excellent affinity and specificity for the target of interest. They should also
exhibit thermodynamic, chemical and enzymatic stability [161].
Over 50 non-antibody protein scaffolds have been designed for target binding for use
in a variety of applications including research, therapeutics and diagnostics. Aptamers
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are oligonucleotides or peptides that bind specifically to target molecules with a variable
region of about 40 nucleotide bases which confers each Aptamer with a unique 3
dimensional structure and potential ligand binding capability. Aptamers have be utilised
within microfludic devices and have show promise in the high-affinity capture of CTCs
and have also been utilised in a range of bio-sensing applications [18]. Nanobodies
are another alternative non-antibody binding protein which are based on single-domain
antibody fragments that contain the unique structural and functional properties of
naturally-occurring heavy chain. Another example of non-antibody binding proteins
includes monobodies, which are novel binding proteins consisting of a protein scaffold
of the fibronectin type III domain [163]. They can be selected by methods such as
phage display and are small (10 kDA), monomeric binding proteins which do not contain
disulphide bonds and can be easily over expressed in E. Coli. Affibodies are also small
(6 kDa) non-antibody binding proteins which are based on the immunoglobulin-binding
region of staphylococcal protein-A. Phage display is used to select affibodies which
contain target-binding regions developed by the randomisation of 13 surface residues
[164]. The few non-antibody binding proteins described here represent a small proportion
of a growing number of novel binding proteins which are useful tools in therapeutics,
diagnostics or as biological research tools.
1.6.3 Affimer proteins
Non-antibody binding proteins, known as Affimers (Figure 1.4), were developed and
characterised at the University of Leeds [165]. Affimers are engineered protein binders
based on a photocystatin protein scaffold [165]. They are small in size (13-14 kDa)
consisting of a 92 amino acid sequence with the protein scaffold containing two variable
loop regions, nine amino acids in length. These variable loop regions act as the
antigen binding regions. Randomisation in the sequences allows for the generation of an
established Affimer library of 1×1010 clones [165]. Affimers are a single-domain protein
which lack disulfide bridges and glycosylation sites. They have a high thermal stability
(melting point of approximately 101 ◦C) and are stable in a variety of buffers across a wide
range of pH values. Affimers are produced by expression in bacteria, removing the need
for animals and increasing batch to batch reproducibility. These small, versatile and stable
binding proteins can be engineered to bind to targets with high affinity and selectivity.
Over 350 successful screens have been performed by the Bioscreening Technology Group
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(BSTG) at the University of Leeds to isolate Affimers against a broad range of targets [11].
Affimers were first well characterised in specificity and affinity against yeast SUMO
protein [165]. Since then, Affimers have been identified for a wide variety of target
molecules and have been used in a range of biochemical and cell biology assays such as
ELISA, pull down assays and western blotting [11]. In addition, as the Affimer scaffold
and the variable sequences do not contain cysteine, a single cysteine can be inserted at
the C-terminus of the protein and utilised allowing Affimers to be labelled for further
use in cell biology applications. For example, fluorescently labelled Affimers specific for
tubulin have been used for cell imaging in fixed cells and the staining patterns observed
were similar when compared to that of an antibody [11]. Affimers have also been utilised
in labelling actin in live and fixed cells [166], and their use has also been demonstrated
within super resolution microscopy [11]. Affimer proteins have been used in a broad
range for scientific research applications similar to the use of antibodies.
The potential use of Affimers in diagnostic applications has been demonstrated through
their use in label-free biosensors. Affimers have a high stability when bound to solid
surfaces due to their high melting temperature and this increases the shelf life of the
proteins when bound to solid surfaces. An impedimetric biosensor was constructed
by cross linking Affimers onto a gold electrode functionalised with a carboxylic acid
terminated self assembling monolayer. The Affimers were raised against anti-myc tag
IgG and the sensor was capable of measuring concentrations of anti-myc tag antibodies
in the range of 6.7 to 330 pM [167]. The same principle has also been applied to develop
a label-free biosensor utilising Affimer proteins for the detection of human interleukin-8
(IL-8) in serum [168] based upon the change in phase of impedance. This showed that
these non-antibody binding proteins have potential use in biosensors for diagnostics and
can also be implemented to other applications for biotechnology and biomedical research.
1.7 Thesis aims and objectives
This literature review has presented the clinical need for novel bone regeneration and
repair, the potential for cell-based therapies to meet that need and the current methods
that are available to deliver label free cell separation for use in such therapies. There
remains a specific need for utilising the specificity of antibodies or non-antibody binding
proteins for isolation of specific sub-populations of cells based upon identification
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Figure 1.14: Generalised molecular structure of an Affimer protein showing a single α-
helix and four anti-parallel β-sheets. The amino acids in the variable binding regions
connecting the four anti-parallel β-sheets are highlighted in pink. (Adapted from [11])
of cell surface markers. Tissue non-specific alkaline phosphatase (TNAP) has been
identified as a pro-mineralising marker present on the surface of BMSCs and DPSCs,
therefore cells expressing TNAP can be targeted for isolation to deliver a population of
cells with enhanced bone regeneration ability. This specific population of cells would
provide the osteoinductive potential for bone formation and when combined with an
osteoconductive scaffold could potentially lead to enhanced bone repair and regeneration
in a clinical setting. The overall aim of this thesis was to deliver this osteoinductive cell
source through the development of a minimally manipulative, label-free microfluidic cell
separator device which is able to deliver an enriched population of autologous TNAP+
cells via cell capture using either antibody or non-antibody protein binding. For clinical
applications, cells would be isolated from bone marrow aspirate or orthopaedic surgical
waste within intra operative time of less than two hours.
1.7.1 Objectives
The main objective of this thesis was to deliver a working prototype for a microfluidic cell
separation device to demonstrate proof of principle of enriching a population of TNAP+
cells together with an initial characterisation of the resulting enriched cell population. For
this to be achieved, the following specific objectives were identified.
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To:
• Characterise previously identified anti-TNAP Affimers for their binding to TNAP
present on the surface of DPSCs, to determine their potential use within a
microfluidic cell separator (Chapter 2).
• Investigate and characterise the expression of TNAP on the surface of DPSCs and
determine whether the number of TNAP molecules on the surface of DPSCs is
affected by seeding density, passage number or donor (Chapter 3).
• Design and develop a microfluidic cell separator which captures TNAP+ DPSCs via
a surface functionalised with a binding protein, followed by subsequent cell release
for the enrichment of TNAP+ cells (Chapter 4).
• Investigate if use of the microfluidic device and the capture and release mechanism
used to provide an enriched population of TNAP+ DPSCs would affect the cells’




Possible use of Affimers in cell capture
for cell separation
2.1 Aim
The aim of this chapter was to characterise non-antibody binding proteins, known as
Affimers, which had previously been selected against human TNAP protein using phage
display. The Affimers needed to be characterised to demonstrate specific biding to TNAP
protein expressed on the surface of DPSCs. This would then enable Affimers to be
utilised for immobilisation on a surface within a microfluidic device for the capture and
enrichment of TNAP+ DPSCs.
2.2 Introduction
Antibodies are exquisite tools in biomedical research due to their ability to recognise
and bind to an antigen with high specificity and affinity. They are used extensively
within therapeutic and biological research applications, especially in cell and protein
characterisation, and enrichment of target molecules. However they are not without their
limitations. Antibodies are large, complex proteins with a molecular mass of around
150 kDA, consisting of four polypeptide chains which require disulphide bonds and
glycosylation for stability [169]. Antibody production is expensive and time consuming,
requiring the use of animals or mammalian cell culture which can result in batch to
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batch variations [160]. There is also concern for the validation and reproducibility of
commercially available antibodies [158], resulting in a waste of materials, time and money
across biological research. There is an estimated US $350 million dollars wasted annually
on antibodies not fit for purpose [159]. Therefore alternatives to antibodies based on
engineered non-antibody binding proteins are desirable and may address and overcome
these issues to replace antibodies.
Affimers are one such non-antibody binding protein which could replace antibodies in
some applications. Unlike antibodies, they are a single polypeptide chain, based on a
photocystatin scaffold with two variable loop regions, each nine amino acids in length,
acting as antigen binding regions. These randomised sequences allowed the creation of
an Affimer phage library of 1×1010 clones, which has been used to screen for Affimers
against required target molecule [165]. There have been over 350 successful screens
performed by the Bioscreening Technology Group (BSTG) at the University of Leeds to
isolate Affimers against a broad range of targets [11]. Affimers have a molecular mass
of 12-14 kDa. The scaffold is a single-domain protein which lacks disulfide bridges and
glycosylation sites and has high thermal stability (melting point of approximately 101
◦C) along with stability in a variety of buffers across a wide range of pH values [11].
Following selection, Affimers are produced on a large scale by expression in bacteria,
removing the need for animals and increasing batch to batch reproducibility. These small,
versatile and stable binding proteins can be selected to bind to targets with high affinity,
specificity and selectivity.
Affimers have previously been selected against a variety of target molecules and used
in a wide range of biochemical and cell biology assays such as ELISA (enzyme-linked
immunosorbent assay), pull-down assays and Western blotting [11]. The Affimer scaffold
and the two variable binding regions do not contain cysteine, which allows for the
insertion of a single cysteine at the C-terminus of the protein scaffold. The cysteine
can be used after purification, allowing Affimers to be labelled at a specific site. Labelled
Affimers have been used for cell imaging in live and fixed cells [166], including with super
resolution microscopy [11]. Affimers have also been immobilised onto functionalised
surfaces for use as recognition molecules in label-free biosensors [167, 168]. An Affimer
can be rapidly isolated with an engineered specificity for a variety of purposes in
biomedical research, however, just as with antibodies it is essential that Affimers are fully
characterised to ensure specificity and reproducibility against the target of interest.
Before commencement of this PhD project, Affimers had been identified against TNAP
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protein using the phage display technique (see section 2.4.5) by the BioScreening
Technology Screening Group (BTSG) at the University of Leeds. The Affimers were
identified for potential use in the development of a microfluidic cell separating technology,
where they could be immobilised onto a gold substrate functionalised with a self
assembling monolayer for the capture and release of TNAP+ DPSCs to deliver an enriched
population. This chapter focuses on characterisation of these Affimers in their ability to
bind specifically to native TNAP on the surface of DPSCs. Affimers were purified and
their specificity to purified recombinant human TNAP protein was analysed. Affimer
specificity to TNAP on the surface of DPSCs was investigated by first fluorescently
labelling Affimer proteins for use in flow cytometry analysis with DPSCs, followed by
pull-down assays aiming to isolate TNAP protein present in cell lysate from DPSCs.
This aimed to fully characterise the previously identified Affimers with respect to their
specificity to TNAP protein on the cells surface and provide a specific non-antibody
binding protein alternative to anti-TNAP antibodies for use in the development of a cell
separation technology to enrich TNAP+ DPSCs.
2.3 Methods
2.4 Tissue culture of DPSCs
2.4.1 Isolation of dental pulp stromal cells from human teeth
The work discussed in this chapter and the rest of the thesis required the isolation and
in vitro culture of dental pulp stromal cells (DPSCs). This method of isolation is well
documented and it has been shown to isolate DPSCs positive for CD73, CD90 and CD105,
but negative for control markers of CD31 and CD45 which is a standerdised crietria
for identifiying MSCs by the ISCT [17]. DPSCs were obtained from the University
of Leeds School of Dentistry Research Tissue Bank (07/H1306/93+5) with full ethical
consent. Pulps were obtained from extracted impacted third molars from male and female
donors aged between 21-46 years. DPSCs were isolated courtesy of Dr. Matt Tomlinson,
Division of Oral Biology, School of Dentistry prior to banking. The external tooth surface
was washed with PBS with the surrounding soft tissue attachments removed using a sterile
scalpel, then briefly immersed in 70% ethanol before being held and cracked open in a
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vice to expose the dental pulp. The pulp was removed and finely cut using a sterilised
scalpel, before being digested with 3 mg/mL collagenase I (Invitrogen, UK) and 4 mg/mL
dispase (Roche, Germany) dissolved in α-MEM culture medium (Corning, UK). Digests
were incubated at 37◦C, 5% CO2 until dissolved, then seeded onto 75 cm2 cell culture
flasks and incubated at 37◦C, 5 % CO2 in a basal culture medium comprised of α-MEM
culture medium (Corning, UK) supplemented with 10% foetal calf serum (FCS) (Sigma-
Aldrich, UK), 2mM L-glutamine (Sigma-Aldrich, UK), 100 units/mL penicillin/100 g/mL
streptomycin (Sigma-Aldrich, UK).
2.4.2 Cell expansion
Adherent DPSCs were cultured until cells were ∼80-90 % confluent before passaging.
To remove cells from the surface, DPSCs were incubated with 5 mL of trypsin, 0.25 %
trypsin/0.02 % EDTA (Sigma-Aldrich, UK) at 37◦C for several minutes. DPSCs could be
then removed by gentle agitation before trypsin activity was neutralised by the addition
of an equal volume of cell culture medium. The cell suspension was then spun down at
200×g for 5 minutes. The cell pellet was resuspended in culture medium before cells
were counted (see below) and seeded at different densities according to experimental
design. Cell culture medium was changed the following day after passaging and then
changed every 3-4 days to expand cell populations. Early cell passages were stored in
liquid nitrogen for future use. DPSCS were used between passage 2-7 in all experiments.
2.4.3 Cell counting
Throughout this work, two methods of cell counting were utilised. The first method
to determine cell numbers utilised a hemacytometer where 50 µL of cell suspension
was mixed with an equal volume of trypan blue (Sigma-Aldrich, UK) and 20 µL of
the suspension was added into a hemacytometer and manually counted under a light
microscope. Cells which were stained blue were determined as non-viable and not
counted. Viable cells in the 4 corner squares were counted and as the specific volume
of each square was 100 nL, the total number of cells can be calculated by multiplying the
average cell count by the trypan blue dilution factor, then by 10,000 and then by the total
volume of cell suspension being counted. The second method of using the Scepter 2.0
Handheld Automated Cell Counter (Merck, Germany) was utilised where multiple cell
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counts were required as it is able to provide accurate cell counts in 30 seconds. Here,
50 µL of cell suspension was diluted in 950 µL of basal culture medium before being
measured. The total number of cells was calculated by multiplying by the dilution factor
and then the total volume of cell suspension.
2.4.4 Culture of human DPSCs in osteogenic medium
To drive dental pulp stromal cells towards an osteogenic lineage, cells were cultured in
StemMACS OsteoDiff Media, human (Miltenyi Biotec, USA). Cells were seeded at the
required experimental density into tissue culture wells (as described in section 2.4.2),
and were allowed to attach overnight in basal culture medium before exchanging with
osteogenic medium. Medium was then changed every 3-4 days for the required culture
period.
2.4.5 Identification of anti-TNAP Affimers
Prior to commencement of this PhD research project, potential anti-TNAP Affimers
screened against human TNAP protein using the phage library had been identified. The
process by which this was undertaken is briefly explained here. Affimer proteins selected
against purified TNAP protein were screened and produced via the Affimer phage display
library, with all work described in this section carried out by the BioScreening Technology
Screening Group (BSTG) at the Faculty of Biological Sciences, University of Leeds.
Phage display relies on the use of bacteriophage, which are viruses that contain DNA and
infect bacteria then use the host machinery to self-replicate. For Affimer development, the
M13 filamentous phage was used. M13 phage comprises a number of coat proteins with
two principally used for protein display, about 2700 copies of pVIII the major coat protein
and five copies of pIII, a minor coat protein arranged in a thin flexible tube surrounding
a circular single-stranded DNA molecule [170]. To create the phage display library, the
Affimer protein coding region was first inserted into the minor coat protein gene, then the
recombinant DNA was incorporated into a phagemid vector (called pBSTG1) which is
a DNA based cloning vector [165, 170]. For the Affimer coding region, the scaffold
remains constant whereas the variable antigen binding regions are randomised which
results in a large pool of sequence variants inserted into the phagemid. The phagemid
is then introduced into bacteria, along with helper phage, which results in a large library
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of bacteriophage particles. Each bacterial cell produces copies of a single bacteriophage
comprising a unique Affimer sequence displayed on the pIII minor coat protein of the
bacteriophage particles.
The biopanning process to select for the anti-TNAP Affimers began by first immobilising
the target protein (human TNAP protein, Sino Biological, China) onto a solid substrate
(Figure 2.1). This was achieved by labelling the protein with biotin and immobilising onto
a streptavidin coated plate. Prior to the first selection round, a pre-panning step against
the streptavidin plate was carried out, by incubating the phage library onto a streptavidin
plate and removing the supernatant. This would eliminate any non-specific phage which
bind to the streptavidin plate. The pre-panned unbound phage were then used for the first
selection round. Phage were incubated onto the streptavidin plate with biotinylated target,
followed by washing to remove any unbound phage (Figure 2.1). The specifically bound
phage were then eluted from the target with the addition of glycine-HCl (pH 2.2), then
neutralised with Tris-HCL (pH 9.1), and then further eluted with triethylamine followed
by neutralising with Tris-HCl (pH 7). The high and low pH buffers destabilise the Affimer
binding site of the phage which is then eluted from the target. The eluted phage were then
amplified by reinfecting bacteria along with helper phage.
The amplified phage library was then used for a second screening round using streptavidin
coated magnetic beads. The biotin labelled target protein was bound to the beads before
incubation with the amplified phage, the beads were washed to remove unbound phage
followed by elution and subsequent phage amplification as in the first round. For the final
selection round, the biotinylated target was immobilised onto Pierce NeutrAvidin coated
plates before incubation, washing and elution (Figure 2.1). The phage selected in the
final round were then amplified and the ability of the Affimer displayed phage to bind to
the selected target was demonstrated by a phage ELISA. Here the selected phage were
incubated with the biotinylated target immobilised on streptavidin wells and following
washing, the bound phage was detected with a horseradish peroxidase (HRP) labelled,
anti-phage antibody and 3,3,5,5-tetramethylbenzidine (TMB) was used as the substrate to
detect the HRP. The results for the phage ELISA demonstrated seven Affimers, which
had been identified by phage display against TNAP protein (Figure 2.2). Phage that
demonstrated binding to the target were then isolated and sequenced to identify Affimers
with unique sequences in their binding regions. From this, Affimers G1, D2 and F3 were
selected for in depth further characterisation as they displayed the highest affinity from
the phage ELISA results and all had unique amino acid sequences (Table 2.1). The DNA
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Figure 2.1: Schematic of the affinity selection process (”biopanning”) for Affimer proteins
from phage display libraries. For the first screening round, the immobilised target is
incubated with the phage library and then unbound phage is washed away. The bound
phage are then eluted and amplified in bacteria. The amplified phage are then subject
to addition further selection rounds before selected phage clones are subjected to DNA
sequence analysis and then used for Affimer production and characterisation.
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Figure 2.2: Phage ELISA of Affimers from 7 clones incubated on wells immobilised with
human TNAP protein. Phage was detected using a HRP anti-phage antibody followed
by TMB substrate for visualisation. Data was provided by the BTSG, University of
Leeds. Based upon this information, Affimers G1, D2 and F3 were selected for the
characterisation in this thesis.
coding sequences of the Affimers were then subcloned into an expression vector (pET11a)
prior to expression in bacteria (see section 2.4.6) for subsequent purification by exploiting
an added C-terminal His tag.




Table 2.1: Table depicting the amino acid sequences from the anti-TNAP Affimers
variable binding region.
2.4.6 Expression of Affimers
The expression of Affimers was performed by the BioScreening Technology Group
(BSTG) at the University of Leeds. The Affimer-pET11a plasmid was transformed into
BL21-Gold (DE3) competent cells (Life Technologies, USA). As a first step, 30 µL of
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competent cells were thawed before the addition of 10 ng DNA. This was incubated on
ice for 30 minutes before being heat shocked in a water bath at 42◦C for 45 seconds. Then
cells were incubated on ice for 2 minutes before the addition of 450 µL of SOC medium
(Super optimal broth - 20 g tryptone, 5 g yeast extract and 0.5 g NaCl with 0.2 % (w/v)
glucose) and incubation at 37◦C for 1 hour with shaking at 230 rpm. Then, 100 µL of the
transformation mixture was plated onto Lysogeny broth (LB) agar plates containing 100
µg/mL carbenicillin plates before incubating at 37◦C overnight.
From the overnight culture 2-3 transformants were picked and grown in 2 mL of LB
broth (1 % (w/v) tryptone, 0.5 % (w/v) NaCl, 0.5 % (w/v) yeast extract) with 100 µg/mL
carbenicillin with 1 % (w/v) glucose and grown overnight at 37◦C. Meanwhile, 50 mL
of LB medium was placed at 37◦C in a 250 mL flask overnight to warm. Then 100 µL
of 50 mg/mL carbenicillin was added to the pre-warmed medium with 625 µL of the
overnight culture. The culture was grown until its optical density at 600 nm reached 0.8.
The cultures were then induced by adding isopropyl β-D-1-thiogalactopyronoside (IPTG)
to a final concentration of 0.5 mM. The culture was then incubated for 6 hours at 30◦C
with shaking at 150 rpm. The cells were then harvested by centrifugation at 4816 ×g for
15 minutes. The supernatant was removed and the pellet was stored at -20◦C until ready
for purification.
2.4.7 Purification of Affimers
From this point onwards, the work reported was conducted by the author. The cell pellets
prepared as described above were thawed and resuspended in 1 mL of lysis buffer (50 mM
NaH2PO4, 300 mM NaCl, 20 mM imidazole, 10 % glycerol, pH 7.4) supplemented with
lysozyme, triton X-100, benzonase nuclease and protease inhibitor cocktail (Table 2.2).
The solution was transferred to a 2 mL microcentrifuge tube and incubated on a rotator at
room temperature for 20 minutes. The solution was then incubated in a water bath at 50◦C
for 20 minutes to denature endogenous proteins, followed by centrifugation at 16,000 ×g
to pellet the cell debris and insoluble proteins. Meanwhile, 300 µL of Ni2+-nitrilotriacetic
acid (Ni2+-NTA) resin was resuspended in 1 mL of lysis buffer, centrifuged at 1000 ×g
to sediment the resin and the buffer removed. Supernatant containing the soluble proteins
was transferred to the washed resin and incubated on a rotator at room temperature for
2 hours. Afterwards, the suspension was centrifuged at 1000 ×g for 1 minute to pellet
the Affimer-bound resin. The supernatant was transferred to a fresh tube and stored at
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−20◦C to check for any remaining unbound Affimer. The resin was then placed into
a 5 mL Pierce centrifuge column before repeatedly washing with wash buffer (50 mM
NaH2PO4, 500 mM NaCl, 20 mM Imidazole, pH 7.4) by gravity flow until the absorbance
of the wash buffer at 280 nm was consistently below 0.09. The His-tagged Affimer was
then eluted with 500 µL of elution buffer (50 mM NaH2PO4, 300 mM NaCl, 300 mM
imidazole, 10 % glycerol at pH 7.4). The concentration of the Affimers were determined
by reading at 280 nm absorbance on a NanoDrop Lite Spectrophotometer (Thermo Fisher,
UK), as described by equation 2.1. The purification and expression was confirmed using
a 15 % SDS-PAGE gel (Section 2.4.8).
A(280nm) = ε(280nm)× c× p (2.1)
Equation used to calculate the concentration of Affimers, A(280 nm) is the UV-visible
absorbance measured at 280 nm, c is the concentration of Affimers (mg/mL), ε(280nm)
is the extinction coefficent at 280 nm and p is the path length of the NanoDrop instrument.
Reagents
Volume for
50 mL culture pellet
Lysozyme (10 mg/mL) 10 µL (0.1 mg/mL)
Benzonase® Nuclease, purity > 99% (25 U/µL) 0.4 µL (10 U/mL)
Halt protease inhibitor cocktail (100×) 10 µL (1×)
Lysis buffer to a total volume of 1 mL
Table 2.2: Table listing the reagents used to lyse bacterial cells for the purification of
Affimer proteins.
2.4.8 SDS-PAGE Gel Electrophoresis
Throughout this chapter, proteins, Affimer proteins or cell lysate were separated using
a 12 % or 15 % (depending on the size of the protein target) resolving gel at pH 8.8
overlayed with a 4 % stacking gel at pH 6.8 using a Mini- ProteanIII electrophoresis
systems (Bio-Rad laboratories Ltd., UK), based upon the method of Laemmli (1970)
[171]. Polyacrylamide gels were formed using ProtoGel® buffers (National Diagnostics,
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USA) consisting of ProtoGel® acrylamide (30 % (w/v) acrylamide, 0.8 % (w/v) bis-
acrylamide stock solution 37.5:1), ProtoGel® resolving buffer (1.5 M Tris-HCL, 0.4 %
(w/v) SDS, pH 8.8) and Protogel® stacking buffer (0.5 M Tris HCL 0.4 % (w/v) SDS, pH
8.8). The volumes needed to make up one gel are shown in Table 2.3. For a 15 % gel,
5 mL of ProtoGel® acrylamide and 0.165 mL water were used instead. Then, 50 µL/25
µL of 10 % ammonium persulfate and 10 µL/5 µL of TEMED (Bio-Rad laboratories Ltd.,
UK) are added to the resolving/stacking gel solutions. Afterwards, 5 mL of resolving gel
solution was placed between 1 mm glass gel plates followed by 1 mL stacking gel solution
with a 15 well gel comb. After the gel had polymerised, the gel comb was removed and
1x tris-glycine running buffer (10x stock: 0.1 % (w/v) SDS, 250 mM Tris-base, 192 mM
glycine) was added into the formed wells ensuring there were no trapped air bubbles.
Reagents Resolving gel (12%) Stacking gel (4%)
Water distilled 1.165 mL 3.05 mL
ProtoGel® acrylamide 4 mL 0.65 mL
ProtoGel® buffer 2.6 mL Resolving buffer 1.25 mL Stacking buffer
Glycerol 2.125 mL 0 mL
Table 2.3: Volumes of reagents needed to make one 12 % polyacrylamide gel consisting
of a 12 % resolving gel overlayed with a 4 % stacking gel.
All protein samples to be analysed by SDS-PAGE were diluted, 3:1, in a 4× sample
buffer consisting of 2 % (w/v) SDS; 50 mM Tris-HCL, pH 7; 5 % (v/v) glycerol and
0.01 % (w/v) bromophenol blue tracking dye with 5 % (v/v) mercaptoethanol added for
reducing conditions. A 15 µL protein sample was then mixed with 5 µL sample buffer
(4×) before the solution was heated for 2 minutes at 95◦C. After heating the samples
where placed on ice for 5 minutes before 10-20 µL of protein samples were loaded into
each well of the SDS gel. Then 3 µL of Precision Plus Protein™ all blue prestained protein
standards (10-250 kDa) (Bio-Rad Laboratories Ltd., UK) were loaded in the wells at each
end of the gel. Electrophoresis was carried out using the Mini- Protean Tetra system
(Bio-Rad laboratories Ltd., UK) in 1 × tris-glycine running buffer (10× stock: 0.25 M
Tris, 1.92 M Glycine and 1 % (w/v) SDS) at 200 V at a constant voltage for one hour at
room temperature. Gels were then removed and stained with Instant Blue™ Coomassie
based staining solution (Expedeon, USA) for one hour before being washed twice for 10
minutes each in deionised water. After staining, the gel was imaged on the ChemiDoc™
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MP Imaging System (Bio-Rad laboratories Ltd., UK).
2.4.9 Direct labelling of purified Affimer proteins and calculating the
concentration of labelled Affimer proteins in PBS
Affimers were purified using the method described in section 2.4.7. Directly after
purification, the cysteine at the C-terminus end of the Affimer protein was targeted with
a maleimide conjugated to a desired label. A 2 mM stock of Biotin-maleimide (Sigma-
A-ldrich, UK) and a 2 mM stock of Alexa Fluor™ 647 C2 maleimide (Sigma-Aldrich,
UK) was made up in dimethyl sulfoxide (DMSO). Purified binders were diluted to 0.8
mg/mL with elution buffer, then 30 µL of 2 mM Alexa Fluor™ 647-maleimide stock
solution was added, to 500 µL of the Affimer solution, mixed and incubated for 2 hours at
room temperature. Excess label was removed using a 0.5 mL 7 K Molecular Weight Cut-
Off (MWCO) Slide-A-Lyzer™ Dialysis Cassettes (Thermo Fisher, UK). After incubation
with the label Affimer sample was injected into the dialysis cassette and placed in 5 L of
100 mM PBS, pH 7.4 with stirring at 4◦C for 2 hours. The PBS was then changed and left
for a further 2 hours before changing again and leaving overnight. Afterwards the labelled
Affimer solution was recovered from the cassette, then aliquoted at a desired volume and
snap frozen in liquid nitrogen.
The concentration of the fluorescently labelled Affimer proteins in PBS solution was
calculated using a standard curve generated by measuring band volume intensity of a
range of known concentrations of the unlabelled Affimer proteins on a 15 % SDS-PAGE
gel (Section 2.4.8). A range of concentrations of the unlabelled Affimer proteins was
prepared using a 1:1 to 1:32 dilution in PBS. The unlabelled and biotin labelled Affimer
protein concentrations were calculated using a bicinchoninic acid (BCA) assay (Thermo
Scientific, UK) according to the manufacture instructions. Here, bovine serum albumin
(BSA) (Thermo Scientific, UK) at concentrations from 0 to 2 mg/mL was prepared for use
as a standard curve for protein concentration measurement. A Pierce™ BCA protein assay
kit (Thermo Scientific, UK) was utilised by preparing the working reagent consisting
of a 50:1 ratio of BCA Reagent A (containing sodium carbonate, sodium bicarbonate,
bicinchoninic acid and sodium tartrate in 0.1 M sodium hydroxide) to BCA Reagent B
(containing 4 % cupric sulphate). Then, 25 µL aliquots of each standard and Affimer
sample were pipetted in triplicate into a 96 well plate. Following this, 200 µL of the
working reagent was added to each well before incubation at 37◦C for 30 minutes. The
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absorbance was then measured at 562 nm on a Varioskan Flash multimode microplate
reader (Model 3001, Thermo scientific, UK). The absorbance measured from the Affimer
samples was then compared to the absorbance measured from the BSA protein standard
curve to calculate the concentrations of the Affimer samples.
Affimer samples were mixed in a 3:1 ratio with 4× loading buffer in non-reducing
conditions, heated at 95◦C for 2 minutes before 10 µL of each known standard and
unknown sample was loaded into the gel wells. The gel was run at 150 V for 1 hour and
30 minutes, before being removed and imaged under red fluorescence for the detection of
Alexa Fluor 647 using a ChemiDoc™ MP Imaging System (Bio-Rad laboratories Ltd.,
UK). The gel was then stained with Coomassie blue staining solution (Expedeon, USA)
and after washing to remove excess stain, the stained gel was imaged. Images were then
analysed using Image Lab 6.0 software (Bio-Rad laboratories Ltd., UK). The band volume
intensity for each band was measured against the known protein quantity allowing the
concentration of the fluorescent labelled Affimer protein to be calculated (Figure 2.3).
Figure 2.3: Standard curve of unlabelled Affimer protein quantity against band intensity
volume for calculating the concentration of labelled protein.
2.4.10 Sandwich ELISA to investigate the binding of Affimers to
purified TNAP protein
A sandwich ELISA ((Enzyme-Linked Immunosorbent Assay) was used to characterise
Affimer binding to human TNAP protein. To perform the sandwich ELISA (as shown in
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Figure 2.4), a Pierce™ streptavidin coated high capacity 96-well plate (Thermo Fisher,
UK) was washed three times in wash buffer of PBS-T (PBS-Tween 0.05 %). Then 100
µL of three concentrations (5, 2.5 and 1.25 µg/mL) of anti-TNAP D2, F3, G1 Affimers
together with a non-TNAP specific control (anti-GFP Affimer) all labelled with biotin
were incubated on the streptavidin coated plate at room temperature with shaking (30
rpm) for 2 hours. Each Affimer was bound, with three repeats each, on the 96 well plate.
The plates were then washed three times with PBS-T. Afterwards, 50 µL of 1 µg/mL
of human TNAP protein (Sinobiological, China) was added and incubated for 1 hour at
room temperature. Again the plate was washed three times in PBS-T. Then, 100 µL of 1
µg/mL of anti-human TNAP mouse antibody (Biolegend, USA) was added and incubated
for 1 hour at room temperature. The plate was washed three times with PBS-T. Next,
goat anti-mouse HRP antibody (Biolegend, USA) was diluted 1:2000 in 2× blocking
buffer (Sigma-Aldrich, UK) and 100 µL was aliquoted per well before incubating at room
temperature for 1 hour. Then the plate was washed three times with PBS-T. In each well,
100 µL of TMB substrate solution (Sigma-Aldrich, UK) was added and incubated at room
temperature for 30 minutes with protection from light. The reaction was then stopped with
the addition of sulphuric acid. The photometric absorbance of the wells was measured at
450 nm using a plate reader (Varioskan Flash, Thermo Scientific, UK).
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Figure 2.4: Schematic of a sandwich ELISA used to determine Affimer binding to human
TNAP protein. The Affimer is fixed by a biotin label to a streptavidin coated plate,
followed by incubation with TNAP protein. The captured target is then detected with
an anti-TNAP antibody, followed by a HRP conjugated anti-mouse antibody with TMB
substrate used for detection.
2.4.11 Flow cytometry analysis of DPSCs using fluorescent labelled
Affimers
To determine whether the labelled Affimers were able to identify and bind to TNAP at
DPSC cell surfaces, flow cytometry analysis was used. DPSCs were seeded at five seeding
densities (1×105, 5×104, 2×104, 1×104 and 5×103 cells/ cm2) and cultured for a period
of 7 days with basal culture medium changed every 3-4 days (Section 2.4) as they do
not express TNAP. Human bronchial epithelial (16HBE) cells were used as a negative
control (see Section 3.4.1). Cells were removed from the surface by trypsinisation before
being resuspended in FACS buffer (0.5 % BSA, 2 mM EDTA and 10 µL of FcR blocking
solution). To the cells to be labelled with the Affimers, 2 µg/mL of the non-specific
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unlabelled GFP Affimer was added for 20 minutes at room temperature to block any
interactions between the Affimer scaffold and the cells surface. The cells were then
labelled with 2 µg/mL per 5×106 cells with either an Alexa Fluor™ 647 anti-TNAP
Affimer (G1, D2 and F3) or Alexa Fluor™ 647 anti-GFP Affimer for the non-specific
binding control. Cells were also labelled with Allophycocyanin (APC) conjugated anti-
human TNAP antibody or APC mouse IgG1, isotype control antibody (both Biolegend,
USA) at 5 µL per 1×106 cells in a total volume of 100 µL. For all labelling, cells were
incubated for 20 minutes in the dark at room temperature. Following the Affimer/antibody
incubation, 900 µL of FACS buffer was added and cells were spun down at 200×g for 5
minutes before being washed again in 1 mL of FACS buffer, before being centrifuged
and resuspended in 500 µL FACS buffer. Samples were then analysed using a CytoFLEX
(Beckman Coulter, USA) using 640 nm laser excitation. Analysis of acquired data was
performed using the CytExpert software (Beckman coulter, USA).
2.4.12 Pull-down Assays with TNAP protein and DPSC cell lysate to
determine Affimer binding to TNAP
DPSCs between passage 3-7 were seeded onto T75 culture flasks at 5×105 cells/cm2 and
allowed to attach in basal culture medium overnight. DPSCs were then cultured for 7
days in either basal culture medium or osteoinduction medium, StemMACS OsteoDiff
Medium (Miltenyi Biotec, USA) with medium changes every 3-4 days. After the culture
time, cells were removed from the flask with trypsin, then pelleted by centrifugation at
1000×g for 5 minutes. The supernatant was removed and the cell pellet was washed
twice with ice cold PBS by pelleting each time. After washing, cells were lysed with 0.5
mL of filter sterilised cell lysis buffer (25 mM Tris-HCl, 150 mM NaCl, 5% glycerol,
0.1% triton X-100 and 1× Halt protease inhibitor cocktail at pH 7). The cell solution was
resuspended into 1.5 mL microcentrifuge tubes and incubated at 4◦C for 45 minutes on
a Stuart SB2 fixed speed rotator (20 rpm). The lysed cells were then pelleted to remove
cell debris at 12,000 rpm for 20 minutes and the supernatant was stored in a clean 1.5 mL
tube.
Prior to the pull-down, purified Affimers within the elution buffer were desalted to remove
the imidazole using 0.5 mL Zeba™ Spin Desalting Columns 7 K MWCO (Thermo
Scientific, UK) according to the manufacturers’ instructions. For the pull-down assay with
TNAP protein, 500 ng of human TNAP protein (SinoBiological, China) was incubated
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with 100 µL of 0.65 mg/mL Affimer solution overnight at 4◦C on a Stuart SB2 fixed speed
rotator (20 rpm). For cell lysate pull-downs, 100 µL of cell lysate was incubated with 100
µL of 0.65 mg/mL Affimers on a rotator (20 rpm) overnight at 4◦C. Then, 30 µL of Ni2+-
nitrilotriacetic acid (Ni2+-NTA) resin was washed in wash buffer (50 mM NaH2PO4, 500
mM NaCl, 20 mM Imidazole and 0.1 % Tween at pH 7.4) by centrifuging the resin at
1000×g for 1 minute and resuspending in 15 µL of wash buffer. The overnight incubated
solutions of Affimers and cell lysate or TNAP protein were each added to the washed
resin and incubated at 4◦C for 90 minutes on a rotator (20 rpm). After incubation, the
slurry was spun down at 1000×g for 1 minute, the supernatant was removed and the
saturated slurry was then washed 5 times with 500 µL wash buffer by centrifuging as
described previously. After the fifth wash, the supernatant was removed and 20 µL of
elution buffer (50 mM NaH2PO4, 300 mM NaCl, 300 mM Imidazole, 10 % Glycerol at
pH 7.4) was added to the slurry and incubated at 4◦C for 15 minutes on a rotator (20 rpm)
to elute Affimer-protein complexes. The resin and elution buffer slurry was centrifuged
at 1000×g for 1 minute and the supernatant containing Affimer-protein complexes was
collected. The samples were then run on a 15 % SDS-PAGE gel (Section 2.4.8) before
transferring onto nitrocellulose membranes for Western blotting, described fully below.
For Western blot analysis, proteins from the SDS-PAGE polyacrylamide gels were
transferred onto a 0.2 µm nitrocellulose membrane (Bio-Rad laboratories Ltd., UK) using
the Mini Trans-Blot Cell Western blotting system (Bio-Rad laboratories Ltd., UK). The
nitrocellulose membranes, 2× filter paper, 2× foam pads and the unstained separated
gels were soaked in transfer buffer (25 mM Tris-base, 190 mM glycine and 20% (v/v)
methanol). The Western blot cassette was assembled in the following order: foam pad,
filter paper, separated protein gel, nitrocellulose, filter paper and foam pad. The cassette
was placed in a tank filled with transfer buffer, along with an ice block within the tank
to prevent overheating. Proteins in the gel were transferred across onto the nitrocellulose
membranes at 60 V for 1 hour. After transfer, the membranes were blocked by incubating
with 5% (w/v) milk powder (Bio-Rad laboratories Ltd., UK) in TBS (10 mM Tris, 0.5
M NaCl, pH 7.5) for 1 hour at room temperature. The membranes were then incubated
with a 1:3000 dilution of primary anti-human alkaline phosphatase, Tissue Non-Specific
monoclonal antibody (ab108337, AbCam, UK) diluted in 1 % BSA in TBS-T (TBS +
0.05% Tween, pH 7.5) overnight on a rocker at 4◦C. The membrane was then washed
3 times for 5 minutes each in TBS-T. Afterwards the membrane was incubated with
a 1:10,000 dilution of secondary goat anti-rabbit IgG conjugated to HRP polyclonal
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antibody (ab6721, AbCam, UK) diluted in a 5 % solution of blotting grade blocker non fat
dry milk dissolved in distilled water for 1 hour at room temperature. The membrane was
then washed 4 times for 5 minutes each in TBS-T, followed by one wash in TBS. The HRP
was detected by incubation in 1 mL of SuperSignal™ West Pico Plus Chemiluminescent
Substrate for 5 minutes before being detected on a ChemiDoc™ MP Imaging System
(Bio-Rad laboratories Ltd., UK).
2.5 Results
2.5.1 Purification of Affimer proteins
Expression of recombinant Affimer protein was carried out using an IPTG induction
method by the BTSG, University of Leeds (as described in Section 2.4.5). After
expression, each Affimer was purified using a Ni2+-NTA resin via the Affimers’ His-tag
residues as described in Section 2.4.7. The resin was repeatedly washed with wash buffer,
with fractions from the first and last wash retained to check if all unbound protein had
been removed and there are no unbound Affimers remaining. The bound Affimers were
removed from the resin with four elutions using the elution buffer. A 15 % SDS-PAGE gel
was used to confirm the expression of purified Affimer (Figure 4.22). Samples from all
four elutions of each binder were run on the gel together with fractions from the insoluble,
soluble, unbound, first and last resin wash. The expression of Affimers was confirmed in
the soluble fraction, this was best demonstrated in the gel for D2 Affimer (Figure 2.5 (a)),
as in the other gels (Figure 2.5 (b) and (c)) the soluble gel band was too dense due to
an excess of protein loaded. The first and last wash in all gels confirmed the removal of
unwanted proteins non-specifically bound to the resin. For all three anti-TNAP Affimers
(D2, F2 and G1) the elution bands migrated between the theoretical molecular weights of
Affimers (12 - 14 kDa). When the elutions were pulled together and the absorbance at
280 nm was measured using the Nanodrop, the following protein yields were achieved:
2.29 mg for D2, 1.33 mg for F3 and 1.69 mg for G1.
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Figure 2.5: SDS page gel from purification of Affimers from bacterial cell lysates for (a)
D2 (b) F3 (c) G1 Affimers. A 15 % SDS-Page gel stained using a Coomassie based
staining solution was used to confirm the expression of Affimer proteins. The lanes
labels represent: (L) Molecular weight standard (kDa); (In) Insoluble protein fraction;
(S) Soluble protein fraction; (Un) Unbound protein fraction; (W) First wash of Affimer
bound resin; (Fw) Final wash of Affimer bound resin; (E) Elution fractions 1-4. Affimers
bound to the resin were eultued and the protein bands from the elutions migrated at the
expected molecular weight of Affimers (12 - 14 kDa), as indicated by a red arrow.
2.5.2 Calculating the concentration of labelled Affimer proteins
To calculate the concentration of the Affimer proteins in PBS, for use within flow
cytometry, a BCA assay was used with unlabelled and biotin labelled Affimers. However
for the fluorescently labelled Affimers, the Alexa Fluor™ 647 label would interfere with
the colorimetry of the BCA assay and therefore would prevent accurate determination of
the concentration. A range of known concentrations of the unlabelled Affimer protein
were separated on a 15 % SDS-PAGE gel alongside the fluorescent and biotin labelled
Affimers. The gels were stained with Coomassie blue, then imaged, before a standard
curve of band volume intensity against protein quantity was used to find the concentration
of the fluorescently labelled Affimers. The Coomassie staining of the SDS-PAGE gel
(Figure 2.6 (a)) was able to provide evidence of successful labelling. As the gel was
run under non-reducing conditions, the majority of proteins in the unlabelled dilutions
existed as dimers due to the presence of the single cysteine in the Affimer scaffold.
Two distinct protein bands appeared, between 24 -25 kDa and 12-14 kDA, the lower
band approximates to the theoretical molecular weight of monomeric Affimers (12 - 14
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kDa) and as the higher molecular weight band is twice that of the lower band, it was
most likely an Affimer dimer. However, when labelled with Alexa Fluor™ 647, the
majority of protein migrated between 14-15 kDa which corresponds to the theoretical
molecular weight of Affimers labelled with Alexa Fluor™ 647. The label couples with
the free cysteine and therefore the labelled Affimer can no longer form dimers as the free
cysteines are no longer available, and the majority of protein was therefore monomeric.
The same result was observed with proteins labelled with biotin, where the majority of
protein migrated between 12-14 kDa corresponding to the theoretical molecular weight
of Affimers labelled with biotin. The band volume intensities for both bands of the
unlabelled Affimers were used to produce a standard curve against the protein quantity to
be able to calculate the concentration of fluorescently labelled Affimer proteins. The same
gel was also imaged for red fluorescence prior to Coomassie staining and proteins which
had been labelled were the only ones to emit a signal demonstrating successful labelling
with Alexa Fluor™ 647 (Figure 2.6 (b)).
Figure 2.6: SDS page gel of a range of concentrations of unlabelled D2 anti-TNAP
Affimer proteins and with D2 anti-TNAP Affimer proteins labelled with Alexa Fluor 647
and biotin. (a) Coomassie blue staining of gel. The band volume intensity decreases with
smaller amounts of protein loaded. (b) Same gel but imaged under red fluorescence light
for Alexa Fluor™ 647 emission. A signal was only captured from Affimers fluorescently
labelled demonstrating a successful labelling method.
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2.5.3 Sandwich ELISA to confirm Affimer binding to TNAP protein
A sandwich ELISA was used to confirm whether the Affimers could bind specifically to
purified human TNAP protein. In the assay, the Affimers selected against TNAP (D2,
F3 and G1) were compared to a negative control of an Affimer selected for binding to
green fluorescent protein (GFP). The Affimers were bound to the streptavidin coated
plate via a biotin label and were then challenged with human TNAP protein as described
previously. To investigate successful binding of TNAP protein, a primary anti-human
TNAP antibody was applied followed by a secondary anti-mouse IgG HRP antibodies.
Colorimetric detection of the TMB substrate was utilised to detect bound HRP labelled
antibody. Across all three concentrations of Affimer proteins (5, 2.5 and 1.25 µg/mL)
there was a significant increase ( P ≤ 0.0001) in the binding of TNAP protein for all
anti-TNAP Affimers (D2, F3 and G1) when compared to the negative control (anti-GFP
Affimer). Whilst the GFP Affimer showed reduced binding when compared to the TNAP
Affimers there was a slight increase in the optical density at the higher concentration of 5
µg/mL indicating some potential non-specific binding with this Affimer.
Figure 2.7: ELISA to confirm the specific biding of Affimers to human TNAP protein.
Three different concentrations of Affimer were initially incubated with human TNAP,
consisting of (a) 5 µg/mL (b) 2.5 µg/mL (c) 1.25 µg/mL. The results of the ELISA show
positive binding when using Affimers screened against human TNAP protein compared
to a non-specific Affimer control (GFP Aff) and plates not functionalised with Affimers
(No Aff). The absorbance was measured at 450 nm. Data represented as mean ± SD.
n=3. **** = P ≤ 0.0001.
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2.5.4 Investigating binding of TNAP on the surface of DPSCs with
fluorescently labelled Affimer proteins
Whilst the sandwich ELISA results had shown that Affimers were capable of binding to
purified human TNAP protein, it was highly important to characterise the specificity of
binding of the anti-TNAP Affimers to the native conformation of TNAP protein on the
surface of DPSCs. This was due to needing to fulfil the requirements for a potential role
of the Affimer in a cell separation technology for the capture of TNAP+ DPSCs. Affimers
were labelled with Alexa Fluor™ 647, as described in section 2.6. Alexa Fluor™ 647
was chosen as the label because the excitation and emission maxima are nearly identical
to that of APC, which is conjugated to the anti-TNAP antibodies utilised in the following
experiment. DPSCs were seeded at five increasing seeding densities (5×103 - 1×105
cells/cm2) and cultured for a period of 7 days, with medium changed every 3-4 days.
Culturing DPSCs at higher seeding densities increases the expression of TNAP on the
surface of DPSCs (Section 3.4.2) [17]. As the level of TNAP expression can be controlled
in DPSCs by varying seeding density, the amount of bound anti-TNAP Affimer binding
proteins detected would have been expected to follow a similar trend in the positive
fluorescence staining which is seen when using the anti-TNAP antibodies. This would
provide confirmation that the Affimers were binding to TNAP protein on the surface of
DPSCs.
To calculate the percentage of TNAP positive cells using the antibody, the number of
positive events were first gated on forward and size scatter distinguishing cells by size
and granularity. This allows cell debris to be excluded so only intact cells are further
analysed (Figure 2.8 (a)). Then to asses the percentage of TNAP+ cells, cells were stained
with an isotype control and a gate was set at 98 % which was used as a negative control
in differentiating non-specific binding signal during antibody binding (Figure 2.8 (b)).
Any positive staining past 98 % was then taken to be significant and characterised as the
percentage of TNAP+ DPSCs (Figure 2.8 (c and d)). For the Affimer staining the same
principal was applied, (Figure 2.9). A gate was set at 98% of the fluorescence intensity
of the anti-GFP Affimer to account for any non-specific Affimer binding (Figure 2.9 (b)).
Any positive signal past the 98 % gate would be classed as potential TNAP+ signal from
binding with the anti-TNAP Affimers G1, D2 and F3 (Figure 2.9 (c, d and e)). The
percentage of positively stained DPSCs with anti-TNAP Affimers (G1, D2 and F3) could
then be compared to the percentage obtained using the anti-human TNAP antibody with
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Figure 2.8: Flow cytometry gating used to measure the percentage of TNAP+ DPSCs
stained with APC anti-human TNAP antibodies. Histograms are fluorescence intensity (x
axis) against count (y axis). (a) Dotplot of forward against side scatter with gating set to
include intact cellular bodies. (b) Single-parameter histogram plot for the isotype control
where the gate is set at 98 %. (c) Histogram containing the isotype control and the anti-
TNAP antibody. (d) Histogram containing the same gate at 98 % for TNAP+ percentage
quantification.
the same samples, to assess Affimers ability to bind to TNAP on the cells surface.
When DPSCs cultured at increasing cell seeding densities were stained with anti-TNAP
antibody, the levels of TNAP expression increased with increased cell seeding density as
expected [17]. At the low seeding densities (5×103 cells/cm2), 3.7 ± 3.1 % of DPSCs
were found to express TNAP after 7 days. This was significantly increased (P ≤ 0.01)
when compared to 17.59 ± 5.4 % at high seeding densities (1×105 cells/ cm2) (Figure
2.10). 16HBE cells had minimal staining with the anti-TNAP antibody as they are TNAP
negative (Section 3.4.1) and were therefore used as a negative control. For all three anti-
TNAP Affimers there was no consistent increase in the percentage of cells positive for
fluorescent staining with increasing TNAP expression as demonstrated when cells were
stained with the anti-TNAP antibody. At the highest seeding density (1×105 cells/cm2),
2.3 ± 0.9 % of cells were positive for fluorescent staining with the G1 Affimer, 7.1 ± 5.7
% with the D2 Affimer and 5.8 ± 2.7 % with the F3 Affimer which were all decreased
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Figure 2.9: Flow cytometry gating used to measure the percentage of TNAP+ DPSCs
stained with Alex Fluor™ 647 conjugated anti-TNAP Affimers (G1, F3 and D2).
Histograms are fluorescence intensity (x axis) against count (y). (a) Histogram containing
anti-GFP Affimers and anti-TNAP (G1, D2 and F3) Affimers. (b) Single-parameter
histogram plot for the anti-GFP Affimer where the gate is set at 98 %. Histogram
containing same gate at 98 % for Affimer binding percentage quantification for (c) G1,
(d) D2 and (e) F3 anti-TNAP Affimer proteins.
significantly (P ≤ 0.001, ≤ 0.05 and ≤ 0.01) when compared to the cells positive for
fluorescent staining with the anti-TNAP antibody.
The percentage of cells stained with G1 Affimer remained constant and consistently low
across all seeding densities providing no evidence that there was any specific binding of
the G1 Affimer to TNAP protein on the surface of DPSCs. The D2 and F3 Affimers
did have significantly increased levels of staining of 18.7 ± 3.5 % and 19.7 ± 9.7 %
at the 1×104 cells/cm2 seeding density compared to 6.7 ± 4.5 % of cells positive for
antibody staining which demonstrated the Affimers were binding to the DPSCs (Figure
2.10). There was a high percentage of staining with the D2 Affimer at seeding densities
between 2×104 - 5×103 cells/cm2, but the percentage of positive cells then decreased at
higher seeding densities, counter to expectation and in contrast to the results using anti-
TNAP antibodies. The percentage of cells positive for F3 Affimer staining varied between
19.7 - 5.3 % with the highest percentage of positive cells occurring at 1×104 cells/cm2.
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Whilst both the D2 and F3 Affimer positively stained DPSCs, the percentage of positive
cells did not follow the expected trend of an increase of positive staining with cell seeding
density as seen from the anti-TNAP antibody data, both here and previously. Therefore
no conclusion could be made about the ability of these Affimers to bind specifically to
TNAP protein on the surface of DPSCs.
16HBE cells showed minimal staining with the anti-TNAP antibody (0.4 ± 0.4 %) which
was to be expected as 16HBE cells are negative for TNAP expression (Section 3.4.1). For
the Affimers, 5.5 ± 2.6 % of 16HBE cells were positive for staining with D2 which was
significantly greater (P ≤ 0.01) compared to the anti-TNAP antibody. For 16HBE cells
stained with the F3 Affimer, 4.9 ± 1.8 % were positive which was again significantly
increased when compared to the anti-TNAP antibody (Figure 2.10). This suggested that
there was non-specific binding of the Affimers to the surface of the 16HBE and therefore
these Affimers would most likely be binding non-specifically on the surface of DPSCs
as well. The flow cytometry results did not provide evidence that the Affimers were able
to bind specifically to TNAP on the cells surface. None of the Affimers followed the
expected trend of an increase in the percentage of cells positive for fluorescent staining
with increasing cell seeding density for greater amounts of TNAP expression. The G1
Affimer showed minimal cell binding, while the F3 and D2 did show certain increases but
this was not consistent with the anti-TNAP antibody data. Further investigation into the
ability of G1, D2 and F3 Affimers to bind TNAP was needed before they were ruled out
for use in a cell separation device to capture DPSCs based on TNAP expression.
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Figure 2.10: Graphical representation of flow cytometric analysis for the percentage of
DPSCS at five increasing seeding densities (5×103 cells/cm2 - 1×105) and 16HBE cells
positive for florescence staining with anti-TNAP Alexa Fluor™ 647 G1, D2 and F3
Affimers and an anti-TNAP APC antibody. The percentage of cells positively labelled
with each of the Affimers screened against human TNAP protein, did not follow the
expected trend as that seen when using the anti-TNAP antibody, providing limited
evidence of the ability of Affimers to bind to TNAP at the cells surface. Data represented
as mean ± SD. n=3. * = P ≤ 0.05. ** = P ≤ 0.01. *** = P ≤ 0.001.
2.5.5 Pull-down assays to assess Affimer binding to native TNAP
protein in DPSC lysate
Pull-down assays, also known as immunoprecipitation assays, are utilised to isolate
and concentrate proteins, typically achieved by relying on specific antibody binding.
However, in the following experiments, anti-TNAP Affimers were used instead of
antibodies to provide further analyses into the specificity of Affimers for purified TNAP
protein and for native TNAP protein within DPSC lysates. The first pull-down assay
was carried out in order to assess the specificity of Affimers to bind to purified TNAP
protein. The G1, F3 and D2 anti-TNAP Affimers, along with an anti-yeast sumo Affimer
[165] used as a negative control, were incubated with TNAP protein overnight. The
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Affimer-protein solution was then incubated with a Ni2+-NTA resin, Affimers would
be immobilised onto the resin via their His-tag residues, as a complex with any bound
protein. Unbound TNAP protein was then removed with several washing steps, before
the Affimer-protein complexes were eluted off the resin. The pulled down complexes of
protein were then analysed by SDS-PAGE and western blotting to separate the Affimer
and TNAP protein (Figure 2.11).
Two identical SDS-PAGE gels were analysed, one was stained with Coomassie stain
while the other was used for Western blot analysis. SDS-PAGE of the pull-down products
showed bands migrating between 12-14 kDa (the estimated molecular weight of Affimers)
indicating successful elution of Affimers from the Ni2+-NTA resin (Figure 2.11 (b)). The
other gel was transferred onto a nitrocellulose membrane for western blot analysis and
probed with anti-TNAP antibodies, followed by anti-rabbit HRP antibodies, with the
HRP detected using an enhanced chemiluminescence substrate (Figure 2.11 (a)). Positive
detection for TNAP protein was seen for G1, D3 and F3 Affimer pull-down products. This
was at the same molecular weight as seen with the positive signal from with the positive
control of purified TNAP protein. While the predicted molecular mass of TNAP is 55
kDa based on primary sequence data, as a result of glycosylation [172] the TNAP protein
migrates as an approximately 65-70 kDa band. Minimal signal was detected with the
pulled down product of the negative control yeast sumo Affimer, indicating the yeast sumo
Affimer was not binding specifically to TNAP protein. The results from this pull-down
assay demonstrated the successful method of immobilisation and elution of Affimers on
the Ni2+-NTA resin, followed by confirming the results seen with the sandwich ELISA
(Section 2.5.3) that the anti-TNAP Affimer proteins were capable of binding to purified
human TNAP protein.
The results using purified TNAP protein in Affimer pull-down assays, had confirmed
specificity of anti-TNAP Affimers for purified human TNAP protein. However, further
evidence supporting the Affimer specificity to native TNAP present on the surface of
DPSCs was required if they were to to be used in the development of a cell separation
device. The same experiment was therefore then repeated with DPSC lysate, from cells
which had been cultured in basal and osteoinduction culture medium for 7 days. Culturing
DPSCs in osteoinduction medium differentiates them towards an osteogenic lineage and
TNAP expression is increased as it is an early marker of cell osteogenic differentiation.
From section 3.4.5 it was shown that for DPSCs cultured in the basal culture medium,
24.8 ± 9.7 % were found to express TNAP after 7 days and this was increased to 50.9
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Figure 2.11: Pull-down assay utilising anti-TNAP Affimers against purified human TNAP
protein. The anti-TNAP Affimers were able to bind and pull-down the purified TNAP
protein. (a) Western blot showing the pull-down products of the Affimers after staining
with anti-TNAP antibodies followed by anti-rabbit HRP antibodies with ECL used for
detection. (b) SDS-PAGE of pull-down products stained with coomassie blue. (M)
Protein ladder (kDa); (Cn) Purified TNAP protein control; (G1) G1 Affimer; (D2) D2
Affimer; (F3) F3 Affimer; (yS) Yeast Sumo Affimer. Bands at expected Affimer molecular
weight are indicated by a red arrow.
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± 12.7 % for DPSCs that were cultured in osteoinduction medium. By performing the
pull-down with DPSCs cultured in osteoinduction medium it would be expected that
a greater quantity of TNAP would be available for binding by the Affimers. Also a
difference in signal from the pull-down samples with cell lysate obtained from DPSCs
in osteoinductive culture compared to cell lysate obtained from DPSCs cultured in basal
medium would provide confirmation of Affimer specificity to TNAP protein on the cells
surface. The SDS-PAGE of the pull-down products showed bands migrating between
12-14 kDa indicating successful elution of Affimers off the Ni2+-NTA resin along with
a variety of other protein bands at higher molecular weight from the cell lysate (Figure
2.12 (b)). There was a clear difference in the staining of proteins present in the pull-
down band sample intensities between the three anti-TNAP Affimers (G1, D2 and F3)
and that of the yeast sumo Affimer, indicating minimal protein binding with the yeast
sumo Affimer as expected. However it seemed the anti-TNAP Affimers were also binding
large numbers of non-specific proteins present in the lysate. When conducting Western
blot analysis (Figure 2.12 (a)), a positive signal for human TNAP protein was detected in
DPSCs lysates obtained from both the basal and oseoinduction culture medium, however
no signal for TNAP protein was detected with the pull-down samples from anti-TNAP
Affimers. Therefore the anti-TNAP Affimers were most likely binding to non-specific
proteins in the cell lysate and not native TNAP protein as desired.
Pull-down assays using DPSCs lysate obtained from the osteogenic cell culture using all
Affimers was carried out and then analysed by SDS-PAGE (Figure 2.13). There were
clearly visible protein bands migrating outside of the expected Affimer molecular weight
(12-14 kDa) for all pull-down samples when the anti-TNAP Affimers were used. This
indicated that proteins from the cell lysate were being pulled down by forming Affimer-
protein complexes. In contrast the yeast sumo Affimer pull down samples had minimal
protein bands apart from the expected Affimer protein band, demonstrating minimal non-
specific binding. There were two intense protein bands, migrating at approximately 55
kDa and 43 KDa, close to the expected molecular weight of human TNAP protein (55
kDa) for all anti-TNAP Affimer pull-down samples. These protein bands were then
excised and sent for protein identification by mass spectrometry (Mass Spectrometry
Facility, Faculty of Biological Sciences, University of Leeds). The detected sequences
were then searched against human proteins in the SwissProt database. For all anti-TNAP
Affimers the highest coverage percentage of peptides was identified as beta tublin for the
55 kDa protein band and Actin for the 43 kDa migrating protein band (Table 2.4). This
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Figure 2.12: Pull-down assay utilising anti-TNAP Affimers against cell lysate from
DPSCs cultured in basal and osteoinduction cell culture medium. No positive signal for
TNAP was detected for any Affimer indicating non-specificity towards TNAP protein in
DPSCs. (a) Western blot showing the pull-down products of the Affimers after staining
with anti-TNAP antibodies, followed by anti-rabbit HRP antibodies with ECL used for
detection. (b) SDS-PAGE of pull-down products stained with coomassie blue. (M)
Protein ladder (kDa); (B) Cell lysate from DPSCs cultured in basal medium; (O) Cell
lysate from DPSCs cultured in osteoinduction culture medium; (G1 - B) G1 Affimer pull-
down in basal cell lysate; (G1 - O) G1 Affimer pull-down in osteoinduction cell lysate;
(D2 - B) D2 Affimer pull-down in basal cell lysate; (D2 - O) D2 Affimer pull-down in
osteoinduction cell lysate; (F3 - B) F3 Affimer pull-down in basal cell lysate; (F3 - O) F3
Affimer pull-down in osteoinduction cell lysate; (yS - B) Yeast sumo Affimer pull-down
in basal cell lysate; (yS - O) Yeast sumo Affimer pull-down in osteoinduction cell lysate.
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Figure 2.13: SDS-PAGE stained with Coomassie blue of pull-down assay utilising anti-
TNAP Affimers against cell lysate obtained from DPSCs cultured with osteoinduction
medium. The bands migrating at 55 kDa and 43 kDa, highlighted in the red box, were
isolated and sent of for mass spectrometry analysis (Table 2.4). (M) Protein ladder (kDa);
(G1) G1 Affimer; (D2) D2 Affimer; (F3) F3 Affimer; (yS) Yeast sumo Affimer.
demonstrated that not only did the Affimers lack specificity for native TNAP present in
the DPSC lysate, they were binding to highly abundant intracellular cytoskeletal proteins.
From these data it could be concluded that the anti-TNAP Affimers were not suitable for
use in the development of a microfluidic cell separator device and for the time being an
anti-TNAP antibody would provide an appropriate alternative.
Affimer Band size (kDa) Coverage (%) Protein description
G1
55 51 Tubulin beta chain
43 50 Actin, cytoplasmic
F3
55 31 Tubulin beta chain
43 43 Actin, cytoplasmic
D2
55 76 Tubulin beta chain
43 51 Actin, cytoplasmic
Table 2.4: Table depicting the protein identified from the highest sequence coverage from
the peptides obtained from protein bands from the G1, F3 and D2 Affimer pull-down




Affimer proteins are novel, non-antibody binding proteins which are very versatile, having
been isolated for a large range of different targets [173]. They aim to resolve issues with
using antibodies for research or therapeutic applications such as poor characterisation,
stability issues and variability in batch production. Affimers are small proteins with
remarkable thermal stability and have been shown to be specific to the targets they were
screened against, for use in a wide range of applications [173]. An Affimer protein which
was specific for TNAP on the cell surface, with a known affinity, would be desirable in the
development of a cell separation device aiming to enrich cells by capturing them via their
expression of TNAP molecules. However, as with antibodies, it is essential that Affimers
are first fully characterised to ensure specificity and reproducibility against the target of
interest. This chapter focused on the characterisation of Affimer proteins which had been
previously identified through phage display, when a phage library was screened against
purified recombinant human TNAP protein. The Affimer proteins that had been identified
needed to be fully characterised for specificity to the native conformation of TNAP on
the surface of DPSCs, so that the Affimers could be utilised in the development of a cell
separation technology.
2.6.1 Purification and labelling of Affimers
Prior to commencement of the PhD, Affimer proteins had been previously identified
through phage display, where the Affimer phage library was screened against purified
recombinant human TNAP protein. The phage ELISA data provided was used to
identify anti-TNAP Affimer sequences (G1, D2 and F3) which were cloned into bacterial
expression vectors, following transformation into bacteria for protein expression [165].
The Affimers were then purified using a nickel resin to isolate the Affimer proteins via
their His-tag residue from bacterial cell lysate. For the three anti-TNAP Affimers purified,
the samples taken from the proteins eluted off the resin after washing showed migrating
protein bands between 12-14 kDa, which is the expected size for Affimers [165].
An expression construct with a cysteine at the C-terminal end of the Affimer sequence
was created, allowing the identified anti-TNAP Affimers with a cysteine to be purified. As
this was the only cysteine residue present in the scaffold it allowed targeted modification
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and the attachment of a label conjugated to a maleimide group, altering the Affimer for
different research applications. The cysteine was targeted with the maleimide additions
of Alexa Fluor™ 647 or biotin. This is a specific covalent coupling method which is
highly specific and efficient [174]. Affimers left unlabelled with this cysteine residue
formed disulphide bonds, which could be seen via the presence of dimers on non-reducing
SDS-PAGE gels. When Affimers were labelled directly post purification, the majority of
Affimers (approximately 80 %) were monomeric indicating successful labelling, as the
labelled Affimer can no longer form dimers as the free cysteines were no longer available.
The Affimers labelled with Alexa Fluor™ 647 could also be identified when the gel was
imaged under red fluorescent light, providing further evidence of a successfully labelled
Affimer which could be used to characterise binding through flow cytometry experiments.
2.6.2 Binding characterisation of Affimers
Two individual assays were able to provide confirmation that each of the three Affimers
was able to bind specifically to the purified human TNAP protein it was screened against.
The first was a sandwich ELISA method utilising anti-TNAP Affimers immobilised by a
biotin label to a streptavidin coated plate, to capture purified TNAP protein, which was
detected with an anti-TNAP antibody, followed by an anti-mouse HRP labelled antibody
detected by a TMB assay. All anti-TNAP Affimers demonstrated higher HRP substrate
turnover than that of the anti-GFP Affimer, used as a negative control, for a range of
different Affimer concentrations. This suggested specificity of these Affimers to bind to
the purified TNAP protein. Confirmation of Affimer binding to the purified TNAP protein
was also seen through pull-down assays. All pulled down samples obtained from using the
anti-TNAP affimers and purified TNAP protein, showed positive signal with anti-TNAP
antibodies in Western blots. These results were able to confirm Affimer binding to the
purified human TNAP protein, for which the Affimers were initially selected against.
Prior to further in depth characterisation of the Affimers with purified human TNAP
protein, it was important to characterise the anti-TNAP Affimers’ ability to bind to the
native conformation of TNAP on the surface of DPSCs. This was due to their potential
final application for use in a cell separation technology, to be immobilised upon a surface
in a microfluidic device for TNAP+ cell capture and enrichment. Flow cytometry is a
common research technique used to analyse cell surface markers by staining cells with
fluorescently labelled antibodies [5]. DPSCs have been used throughout this project as
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they provided a tuneable system, where the number of DPSCs expressing TNAP can
be increased directly by increasing cell seeding density (Section 3.4.2) [17]. Therefore,
by staining DPSCs cultured at increasing seeding densities with Alexa Fluor™ 647
labelled anti-TNAP Affimers, the percentage of DPSCs that were positively stained was
calculated and compared to measurements taken with an anti-TNAP antibody to provide
confirmation of anti-TNAP Affimers’ binding to TNAP on the cells’ surface. An anti-GFP
Affimer, not specific for the target of interest, was used as a non-specific control to gate
any non-specific Affimer binding. Cells which had a fluorescent intensity greater than this
gate were deemed positively stained.
To ensure staining with equal amounts of Affimers, the concentration of the labelled
Affimers needed to be measured. This was achieved by running a SDS-PAGE gel with
a dilution series of the unlabelled Affimers which were of known concentrations, to
generate a standard curve from band volume intensity, and comparing this to the band
volume intensity of the fluorescent labelled Affimers to calculate their concentration.
In the flow cytometry experiments, when the DPSCs were stained with anti-TNAP
antibodies the expected result of an increasing level of TNAP expression with increasing
cell seeding density was observed. The 16HBE cells, which do not express TNAP, showed
no binding with the anti-TNAP antibody. However, when using the anti-TNAP Affimers
the results differed considerably. The G1 Affimer showed minimal staining across all
seeding densities of DPSCs, suggesting that binding to TNAP protein on the cells surface
was not occurring and that G1 Affimers failed to identify native TNAP. A potential reason
for this is could be that the epitope recognised by the Affimer is no longer available for
recognition and binding when in the native confirmation of TNAP on the cell surface.
From this result, the G1 Affimer could be excluded for any potential use in the cell
separation technology. The D2 and F3 Affimers did show positive staining, however,
this did not follow the observed trend as seen when DPSCs were stained with antibodies.
At seeding densities of 1 ×105 and 5 ×104 cells/cm2, where DPSCs express the highest
levels of TNAP, the percentage of positively stained DPSCs was decreased compared to
the antibody staining. There was also a higher percentage of cells stained with Affimers at
lower seeding densities compared to the higher seeding densities, therefore not following
the known correlation of TNAP expression. The D2 and F3 Affimers were also seen to
stain 16HBE cells, indicating binding to non-specific proteins on the cells surface as these
cells does not express TNAP. Therefore it seemed unlikely that the Affimers were binding
specifically to TNAP on the surface of DPSCs, however further confirmation was needed
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before ruling out the use of these Affimer proteins in the cell separation technology.
The pull-down assay was used as another experimental technique to confirm if Affimers
were capable of binding to the native confirmation of TNAP from DPSCs. DPSC lysate
was incubated with G1, D2 and F3 anti-TNAP Affimers. Afterwards the Affimer, and
therefore any bound proteins, were pulled down by immobilising the Affimer to a nickel
resin via the His-tag residue. When the pulled down samples were analysed by SDS-
PAGE there was a variety of protein bands above the expected molecular weight for
Affimer migrating protein bands (12-14 kDa) indicating that proteins had been pulled
down by all anti-TNAP Affimers. This result was not observed when a well characterised
anti-yeast sumo Affimer [165], was used as a negative control. When gels were transferred
to nitrocellulose membranes and probed with anti-TNAP antibodies, there was no positive
signal for TNAP for any of the Affimer pull-down samples. Therefore the anti-TNAP
Affimers were not binding specifically to the native conformation of TNAP in the DPSC
lysate. In the pulled down samples, prominent migrating bands from the pulled down
products at 55 kDa and 43 kDA, which could have conceivably been related to TNAP,
were sent for protein identification by mass spectrometry analysis. For all anti-TNAP
Affimers, these bands were identified as beta-tubulin and actin which are abundant
intracellular cytoskeletal proteins [175, 176]. Therefore even if these Affimers were found
to be specific to TNAP protein in the DPSC lysate, they were binding non-specifically to
other cellular proteins.
The successful isolation of Affimers is highly dependent on the quality of the antigen
used [165], in this case purified TNAP protein. The antigen may change its confirmation,
segregate or denature during the immobilisation onto the surface used for phage display
[177]. Membrane proteins, such as TNAP, contain hydrophobic transmembrane domains
and may also have extended extracellular regions made up of multiple domains [178].
Therefore, as the structure of the recombinant protein may differ radically from the native
TNAP protein, Affimers which are specific for the recombinant, but not to the native
protein, seem to have been identified in this case. However, the Affimers were also found
to bind non-specifically to non-target proteins. As the success of the Affimer screen is
dependent on the source of the commercial antigen, results may vary with antigens from
different sources as a result of differing purity or contamination with other proteins. This
has been reported before where screens against several sources of tenascin C from several
commercial suppliers were used, only one source allowed the selection of suitable Affimer
[173]. Therefore a solution to select a more suitable Affimer would be to screen again
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against a different commercial source of recombinant TNAP protein, however this was
not undertaken due to time constraints where the same problem may potentially arise
again, and the fact that a suitable antibody based solution had been found.
An enhanced solution would be to perform the phage display against TNAP+ DPSCs
instead of the recombinant TNAP protein used here, so that any Affimers raised were
specific for native conformation of TNAP protein on the cell surface membrane. However,
cell based panning has many difficulties. The target protein may be of low density and
there is a high background of non-target proteins [177]. Phage particles may bind non-
specifically to the cells via their coat proteins so non-specific phage would be eluted also
alongside the specifically bound phage. Yet, cell based panning with phage libraries has
been used to succesfully isolate monoclonal antibodies which were specific for native
membrane proteins [177, 179, 180] and would be an attractive alternative for the isolation
of Affimers specific to TNAP on the surface of DPSCS. An example of where monoclonal
antibodies have been identified using cell based panning is where mammalian cells were
engineered to express an abundance of target antigen along with GFP, then a pre-panning
of the phage library against non-specific cell lines depleted the phage library of phage
which bind non-specifically, before the remaining phage were exposed to the cells over
expressing the target. After washing, cells were sorted using FACS to collect the GFP
target cells and the phage was eluted and amplified before the process was repeated [179].
This is a method which demonstrates how antibodies against membrane proteins can be
isolated without the use of recombinant purified proteins.
To date, the use of the Affimer phage library in Leeds has been utilised to successfully
identify 350 Affimers with a variety of different targets [165]. Affimers have been
shown to be utilised in biomedical research techniques such as ELISA, pull-downs and
Western blotting [11]. Affimers have also be identified to native cell proteins, and have
been been used in cell imaging applications [11]. Affimers have also been immobilised
onto functionalised surfaces for use as recognition molecules in label-free biosensors
[167, 168]. The ability to insert a single cysteine at the C-terminal end of the Affimer
scaffold also allows Affimers to be immobilised onto the surface at the desired orientation.
The cell separator which was developed as described in the following chapters utilises
EDC/NHS chemistry to cross link antibodies via primary amine groups to the carboxylic
acid terminated self assembling monolayer. However, as many primary amine groups are
present within the antibody structure [169], due to the presence of amino acids such as
lysine, there is a high probability that the antibodies would be immobilised to the surface
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in an inappropriate orientation and their antibody binding regions would not be available.
By attaching the Affimers via the cysteine group, the proteins can be immobilised onto
a surface in a desired orientation with all binding regions available to capture TNAP+
cells. Had the Affimers demonstrated successful binding to native TNAP on the surface
of DPSCs a further more detailed characterisation of Affimers binding would have taken
place. The Affimers’ affinity when bound to a gold surface functionalised with a SAM,
would have been measured using a method such as surface plasmon resonance [168].
There is a greater advantage of using an Affimer instead of an antibody as the capture
molecule within a microfluidic cell isolation device. They are small proteins which are
stable in a wide variety of buffers across a variety of pH and when attached to surfaces.
The main advantage of utilising Affimers instead of a commercially bought antibody
within the development of a cell separation device would be the the ability to have a
large pool of Affimers specific to TNAP to characterise affinity from the phage display
selection process. Ideally multiple Affimers which were specific to TNAP on the surface
of DPSCs with a range of affinities would have been identified and the most appropriate
Affimer could have been selected in the development of the cell separation device. An
Affimer specific for TNAP, but with a relatively weak affinity, would have been desirable
as it would potentially allow for specific capture of DPSCs to the functionalised surface,
but would also allow cells to be released from the surface with minimal manipulation.
Using an antibody could have problems in potentially too high affinity for target to
recover captured cells and also there are concerns with validation and batch to batch
reproducibilty of antibodies hindering the development of an ‘of-the-shelf’ separation
device with antibodies. Therefore selecting non-antibody binding proteins which are well
characterised would be of significant interest in the further development of a microfluidic
device to capture and enrich TNAP+ DPSCs. However due to the lack of an available
Affimer at the time of the present work, anti-TNAP antibodies were utilised instead to
demonstrate proof of principle of the cell separation technology to enrich TNAP+ DPSCs.
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Chapter 3
Investigating the expression of the
pro-mineralising cell surface marker
tissue non-specific alkaline phosphatase
at the molecular level at the surface of
dental pulp stromal cells.
3.1 Aim
The aim of this chapter was to investigate the expression of the pro-mineralising cell
surface marker tissue non-specific alkaline phosphatase (TNAP), at the molecular level at
the surface of dental pulp stromal cells (DPSC). The proposed cell separation technology
for enrichment of TNAP+ DPSCs, requires the capture of DPSCs via the specific
interaction of TNAP molecules on the cells’ surface with an antibody-functionalised
surface. In addition to being a marker for pro-mineralising cells, TNAP expression by
human DPSCs has been shown to increase with cell seeding density in culture, providing
a tunable system for use in optimisation of the proposed cell separation device [17].
However it was not known whether the number of TNAP molecules expressed by a
single DPSCs differs depending on the cell seeding density, donor type and passage
number which would affect future cell separation experiments. This chapter describes
the determination of the number of TNAP molecules on the surface of individual DPSCs
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for a better understanding of the starting population before separation.
3.2 Introduction
The alkaline phosphatase (ALP) hydrolases are a group of three isoenzymes that are
catalysts responsible for the dephosphorylation of a wide range of molecules that are
involved in a large spectrum of biological processes [93]. Of these isoenzymes two
are tissue specific, residing in intestine and placental tissues, while the third tissue non-
specific ALP (TNAP) is found in a variety of tissues including bone, liver and kidney [91].
TNAP is expressed as a 55 kDa ectoenzyme and is a glycosyl-phosphatidylinositol (GPI)
anchored membrane protein present on the surface of the cells plasma membrane [95].
TNAP appears to play a key role in the mineralisation of hard tissues; its action releases
free phosphate that can participate in the nucleation and growth of hydroxyapatite crystals.
TNAP also hydrolyses pyrophosphate, which is an inhibitor of bone matrix formation
[93]. TNAP is therefore a useful marker used in in vitro assays for early osteogenic
cell differentiation as TNAP gene expression and protein levels are enhanced as cells
undergo osteogenic differentiation, with TNAP playing a key role in the formation of
calcified tissue [181]. Therefore, TNAP is a potentially useful cell surface marker to
target populations of cells with a high osteogenic potential.
Dental pulp stromal cells have been identified as possessing populations of cells with
stem cell like characteristics, capable of colony formation with a high proliferation, self
renewal capability and the ability to undergo multi-lineage differentiation in vitro [74].
DPSCs have a high osteogenic potential [51] and can be seen as a potential cell source
for use in bone tissue engineering [17]. They are an easy to access cell source which
can be banked, especially for deciduous teeth, and are capable of mass expansion in
in vitro culture [51]. However they are present in small numbers within a low tissue
volume, leading to limited cell numbers that can be obtained from a single pulp. Therefore
isolated DPSCs would most likely require ex vivo expansion for sufficient cell numbers
for therapeutic use [51]. However, a significant limitation of extensive cell expansion is
eventual proliferation decline and cellular senescence, accompanied by altered cellular
behaviour and impaired regenerative potential, all of which are significant problems for
future use in regenerative therapies [82]. The ability to isolate cells which are pre-
disposed to differentiate towards a mineralising phenotype would be beneficial for the
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development of autologous stem cell therapies which do not require cell expansion.
TNAP has also been identified as a marker for bone marrow stem cell (BMSC) selection
[94]. Here TNAP has been described as “mesenchymal stem cell antigen-1”, however
this is identical to TNAP [95]. TNAP+ MSCs which have been isolated shown an
increase in their osteogenic capability compared to TNAP- MSCs [96]. TNAP is also
expressed on the surface of DPSCs and it has been shown that increased cell densities and
culture durations enhanced the expression of TNAP on the surface of DPSCs [17]. This
suggests that TNAP expression in DPSCs is upregulated in association with the inhibition
of proliferation and DPSCs are able to begin to undergo osteogenic differentiation in the
absence of any additional osteoinductive cues. This makes TNAP an attractive cell marker
to target in the development of novel cell separation technologies, as TNAP+ BMSCs and
DPSCs with high mineralising potential could be selected for use in bone regenerative
therapies.
The work described in the next chapter of this thesis outlines the development of
a microfluidic cell separator used for marker based enrichment of TNAP+ DPSCs.
The cell capture of TNAP+ DPSCs is achieved using anti-human TNAP antibodies
immobilised onto a gold surface functionalised with a carboxylic acid terminated self
assembling monolayer. The starting number of TNAP+ DPSCs before cell separation
can be controlled as a result of DPSCs increasing TNAP expression with seeding density,
providing a tuneable model for optimising cell surface capture [17]. In addition, for a
surface based capture system, the main limitation for capturing sufficient cell numbers
is the functionalised surface area. By increasing the original cell seeding density, a
greater number of DPSCs expressing TNAP and are available for capture. This enables
a greater number of cells for further downstream analysis of the captured population
after subsequent release. The interaction for cell capture occurs through TNAP antibody
binding and so it was important to get an understanding of how the number of molecules
per cell affects binding efficacy. Cell stimulation can change the expression of molecules,
and can also alter the amount of molecules on the cells surface [182]. Changes in the
amount of molecules at different seeding densities, passage and donors may lead to
varying results in cell capture which would prelude accurate comparison between cell
populations. Therefore a novel method was developed to measure the number of TNAP
molecules on the surface of DPSCs.
As TNAP is an enzyme which is responsible for dephosphorylation, it can also turnover
non-biological substrates such as para-nitrophenylphosphate (pNPP) [183], cleaving the
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inorganic phosphate with the resulting product, para-nitrophenol, yellow in colour. The
absorbance can be measured and this is a regularly used method in the quantification
of TNAP activity. The quantification of ALP in cell lysate is a common experimental
technique, especially in identifying early stage osteogenic differentiation [71, 79] and
ALP on the surface of whole cells has been quantified using PNPP [184]. The number
of molecules on the surface of TNAP+ DPSCs was calculated by comparing enzymatic
activity of single DPSCs to a standard curve of a known number of molecules of
human TNAP protein and then using flow cytometry data to provide a measurement for
percentage of TNAP+ cells. This provided a method for calculation of TNAP molecules
on the surface of TNAP+ DPSCs. It was then investigated how the number of molecules
changed depending on donor, passage and seeding density.
The main objectives in this chapter were to:
1. Confirm the expression of TNAP on the surface of DPSCs and investigate whether
human bronchial epithelial cells (16HBE) were a suitable negative control.
2. Confirm through repeat experiments that the expression of DPSCs is increased with
high cell seeding density.
3. Develop a methodology to calculate the number of molecules of TNAP on the
surface of individual DPSCs.
4. Investigate the effects of donor, passage, osteogenic differentiation and seeding
density on the number of molecules of TNAP on the surface of DPSCs.
These objectives aimed to characterise the expression of TNAP at the molecular level
in more detail and were necessary for the future development of a novel cell separation
device to enrich a population of TNAP+ cells for use in bone repair.
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3.3 Methods
3.3.1 Determination of variation of TNAP expression with DPSC
seeding density using flow cytometry
The percentage of TNAP+ DPSCs within a mixed DPSC population was measured using
flow cytometry. DPSCs were seeded into T75 culture flasks at 5 seeding densities (1×105,
5×104, 2×104, 1×104 and 5×103 cells/cm2 respectively) and cultured in basal culture
medium at 37◦C, 5% CO2 for a period of 7 days, with medium changes every 3-4 days.
Cells for flow cytometry analysis were removed from the culture flask with the addition of
5 mL of 0.25 % trypsin/0.02 % EDTA as described previously, before the cell pellet was
spun down. Recovered cells were resuspended in FACS buffer consisting of PBS, 0.5%
BSA, 2 mM EDTA (all Sigma-Aldrich, UK) and 10 µL of FcR blocking solution per
1×106 cells (Miltenyi Biotec, USA). The cells were then labelled with allophycocyanin
(APC) anti-human TNAP antibody or APC mouse IgG1, isotype control antibody (both
Biolegend, USA) at 5 µL per 1×106 cells in a total volume of 100 µL for 20 minutes in
the dark at room temperature. Following antibody incubation, 900 µL of FACS buffer was
added and cells were spun down at 200×g for 5 minutes before being washed again in
1 mL of FACS buffer, spun down and resuspended in 500 µL FACS buffer. To assess
viability, cells were stained with 5 µL of 7-AAD (Biolegend, USA) in 500 µL cell
suspension. Samples were then analysed using a CytoFLEX (Beckman coulter, USA)
at 488 nm and 640 nm laser excitations. Analysis of acquired data was performed using
the CytExpert software (Beckman coulter, USA).
To calculate the percentage of TNAP+ cells using flow cytometry, the events were first
gated on forward and size scatter which allows cells to be distinguished between their
size and granularity, and allows cell debris to be excluded, so only intact cells are further
analysed (Figure 3.1. (a)). The intact cells were then gated using a 7-AAD viability
dye which enters compromised cellular membranes binding to double-stranded DNA and
allows for exclusion of non-viable cells (Figure 3.1. (b)). Then, to assess the percentage
of TNAP+ cells, cells were incubated with an allophycocyanin (APC) labelled isotype
control antibody, which are used as an important negative control in differentiating non-
specific binding from specific antibody binding. A separate population was labelled with
an APC labelled anti-human TNAP antibody. The gate was then set at 98% of the negative
control. Any positive staining was then taken to be as significant and characterised as the
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percentage of TNAP+ DPSCs (Figure 3.1. (c)).
Figure 3.1: Flow cytometry gating used to measure the percentage of TNAP+ DPSCs. (a)
Dotplot of forward against side scatter with gating set to include intact cellular bodies. (b)
Gate set to exclude non-viable cells which are stained with 7-AAD. (c) Single-parameter
histogram plot for the isotype control where the gate is set at 98%.
3.3.2 Determining the number of molecules of tissue non-specific
alkaline phosphatase on the surface of dental pulp stromal cells
DPSCs were seeded onto 6 well tissue culture plates at 5 different seeding densities
(1×105, 5×104, 2×104, 1×104 and 5×103 cells/cm2 respectively) to increase expression
of TNAP as previously reported [17]. Cells were allowed to adhere overnight and then the
basal culture medium was changed. Cells were then cultured in basal medium at 37◦C,
5% CO2 for a period of 7 days with medium changed every 3-4 days. DPSCs were then
detached from the wells with trypsin and resuspended in basal medium before counted
with a Scepter 2.0 Handheld Automated Cell Counter (Merck, Germany) as described in
section 2.4.3. To assess the average number of TNAP molecules present of the surface
of a mixed population of DPSCs an ALP assay was developed using a human TNAP
protein standard. The cell suspension was spun down again and resuspended in the assay
buffer (consisting 10 mL 1.5 M alkaline buffer solution (Sigma-Aldrich, UK) with 20
mL of distilled water), at a concentration of 4×106 cells/mL. The assay was carried out
with triplicate repeats in a 96 flat-bottomed well plate (Sigma-Aldrich, UK). Human bone
alkaline phosphatase recombinant protein (Sinobiological, China) at 0.25 mg/mL was
diluted in assay buffer to 1 µg/mL, then a two fold serial dilution was made from 1000
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ng/mL to 2 ng/mL in assay buffer, with assay buffer used to provide a blank reading. Then,
10 µL of each cell sample and TNAP protein standard were added to the appropriate wells
in triplicate. Then, 90 µL of p-nitrophenyl phosphate liquid substrate system solution
(Sigma-Aldrich, UK) was added to each well and incubated at 37◦C for 30 minutes,
before the reaction was stopped with the addition of 100 µL of 1M NaOH solution.
The absorbance was measured at 405 nm on a Varioskan Flash multimode microplate
reader (Model 3001, Thermo scientific, UK). The absorbance of de-phosphorylated pNPP
produced by a given number of DPSCs cultured at different densities was then compared
to the absorbance of de-phosphorylated pNPP produced by a TNAP protein standard curve
(Figure 3.2).
Figure 3.2: Standard curve of TNAP protein generated by serial dilution before incubation
with pNPP. Absorbance was measured at 405 nm. n=3.
Comparing the TNAP activity of DPSCs to a standard curve produced from the activity of
TNAP protein, allows the amount of TNAP within that quantity of DPSCs to be measured.
For this study, 4×104 cells per well were used, therefore the average amount of TNAP
per cell could be quantified. As live cells instead of cell lysate were used, the amount of
TNAP measured was taken as the amount present on the surface of the cells. To assess the
average level of TNAP molecules within a mixed population of TNAP+/TNAP- cells, the
number of moles of TNAP present of the surface of DPSCs was calculated by dividing the
quantity of TNAP on the cells surface by the molecular weight of TNAP. This was taken
as 55 kDa from the manufacturers datasheet and confirmed from the Uniprot database
[185]. From this the number of TNAP molecules could be calculated using the Avogadro
constant, which therefore enables the average number of TNAP molecules across the total
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population (both TNAP+/TNAP- cells) present on the cell surfaces to be calculated at five





Equation used to calculate the average number of TNAP molecules on the surface of
DPSCs in a mixed (TNAP+/TNAP-) population. N is the average number of molecules
per DPSC, t is the concentration of TNAP protein (g/mL), v is the volume of the cell
suspension used for the assay (mL), Ac is Avogadros constant (6.02 × 1023 mol−1), n is
number of cells and Mw is the molecular weight of TNAP (g/mol).
The method described above allows for the calculation of the average number of TNAP
molecules per DPSC within a mixed population of TNAP+/TNAP- cells. Cells used in
the experiment were taken at the same passage number, and from the same donor, as
those used in the flow cytometry experiments described previously. This was carried out
for DPSCs from three different donors. From the flow cytometry analysis of DPSCs at
different seeding densities the percentage of TNAP+ cells in the mixed population was
measured (Section 3.3.1). This therefore allowed the number of TNAP molecules per
TNAP+ cell to be determined at five different seeding densities, for multiple passages and
for three different donors.
3.3.3 Localisation of TNAP on the surface of DPSCs
It was important to attempt to visualise TNAP on the surface of DPSCs to ensure that
the it was not all localised to one particular area on the cell’s surface which could be
problematic when developing devices which rely on TNAP capture for cell separation.
DPSCs and 16HBE cells were seeded into six well plates at 1×104 cells/ cm2 in triplicate,
allowed to adhere overnight and then the basal culture medium was changed. Cells were
then cultured in basal medium at 37◦C, 5% CO2 for a period of 7 days with medium
changed every 3-4 days. For imaging, the cell culture medium was removed and the plate
was washed with PBS for 3 × 5 minutes before fixation in 10% neutral buffered formalin
solution (Sigma-Aldrich, UK) for 15 minutes. Fixed cells were then washed with PBS
for 3 × 5 minutes. Cells were then incubated with 1 µg/mL of APC anti-human TNAP
antibody diluted in PBS (Same antibody as used in section 3.3.1) on a rocking platform
before being washed with PBS for 3 × 5 minutes. Samples were then imaged and captured
94
using a Leica TCS SP8 confocal microscope (Leica Microsystems, Germany) using 633
nm laser excitation.
3.3.4 Osteogenic induction of DPSCs
In order to investigate whether the number of TNAP molecules on the surface of DPSCs
alters when cells are cultured in osteogenic medium, cells needed to be cultured in
osteoinductive medium. Two samples of DPSCs isolated from the same donor were
seeded at 5×104 cells/cm2 in either T75 culture flasks or 6 well plates. Cells were left
to attach overnight with basal culture medium at 37◦C, 5% CO2 as described previously
(section 2.4.2). The medium was then replaced with basal culture medium in one sample
and the other was replaced with the osteogenic induction medium, StemMACS OsteoDiff
Media, human (Miltenyi Biotec, USA). The medium for each sample was then changed
every 3-4 days, as fully described in section 2.4.4. After 7 days in culture, the percentage
of TNAP+ cells was determined using flow cytometry and the number of TNAP molecules
per cell in the mixed population (TNAP+/TNAP- cells) was measured as described fully
above to provide a final measurement of the number of TNAP molecules per TNAP+ cell.
3.3.5 Statistical analysis of data
All measurements were performed in at least triplicate and graphs displayed as the mean
± standard error of the mean (SEM) or ± standard deviation (SD) depending on the
measurement taken. Test for gaussian distribution was carried utilising Shapiro-Wilk test,
with normally distributed data between two samples analysed using an unpaired t-test.
For multiple comparisons between three or more samples, ANOVA multiple comparisons
test with Tukey modification was used. All analyses were carried out in Graphpad Prism
6. For all graphs, no significance = P> 0.05, * = P ≤ 0.05,** = P ≤ 0.01,*** = P ≤ 0.001
and **** = P ≤ 0.0001.
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3.4 Results
3.4.1 Expression of TNAP on the surface of DPSCs and identification
of a suitable cell type for a negative control
A negative control cell population that does not express TNAP on the cells surface was
needed for much of the work under-taken within this thesis. The human bronchial
epithelial (16HBE) cell line, isolated from the surface epithelium of healthy human
bronchi should not express TNAP on the cells surface, making it a potential candidate
for a negative control cell population for work throughout this thesis. Flow cytometric
analysis was used to measure TNAP expression by DPSCs and 16HBE cells (Figure 3.3).
DPSCs were seeded at 5×104 cells/cm2, cultured for 7 days in basal culture medium and
16HBE cells were seeded at 1×104 cells/cm2 cultured in basal culture medium until 90 %
confluency had been achieved. Cells were then detached from culture flasks and stained
with an isotype control APC labelled antibody and anti-TNAP APC antibody, described in
section 3.3.1. For the DPSCs, 35 % was were found to express TNAP (Figure 3.3. (a and
b)), while there was negligible (0.3%) staining of 16HBE cells using the same antibody
(Figure 3.3. (c and d)). This result demonstrated TNAP expression in DPSCs and verified
16HBE cells as an appropriate negative control for use throughout this work.
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Figure 3.3: Representative histograms of flow cytometric analysis of TNAP expression on
DPSCs and 16HBE cells. Histograms are fluorescent intensity (x axis) against count (y).
(a) Histogram containing the unstained population, isotype control and TNAP antibody
labelling for DPSCs. (b) Histogram containing gate set with isotype control at 98%
allowing the percentage of TNAP+ DPSCs to be measured. (c) Histogram containing
the unstained population, isotype control and TNAP antibody labelling for 16HBE cells.
(d) Histogram containing same gate at 98% for TNAP+ % quantification in 16HBE cells.
The expression and distribution of TNAP at the cells surface was also confirmed
qualitatively using confocal microscopy. 16HBE cells showed no positive fluorescence
staining after labelling with TNAP antibodies (Figure 3.4 (a)) supporting the flow
cytometry results. In contrast, DPSCs were positively labelled with the TNAP antibody,
confirming again that they do express TNAP at the cells’ surface (Figure 3.4 (b)). This
result also allowed visualisation of the localisation of expression of TNAP at the surface
of DPSCs. These images revealed that TNAP was apparently not localised at any specific
location and was expressed uniformly across the cells’ surfaces. This was important when
developing functionalised surfaces to capture cells by their expression of TNAP.
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Figure 3.4: Immunofluorescent microscopy for TNAP expression at cells’ surfaces.
Brightfield images were overlayed with the fluorescent channel (red). (a) 16HBE cells
stained with an anti-TNAP antibody showing no fluorescence. (b) DPSCs stained with an
anti-TNAP antibody were stained across the surface of the cells. Scale bar represents 25
µm.
3.4.2 Expression of TNAP by DPSCs is increased with high cell
seeding density
Previous data has shown that when culturing DPSCs at increasing seeding densities for
a period of 7 days in basal culture medium, there was a rise in the percentage of cells
expressing TNAP at higher seeding densities [17]. It was important that these results
could be replicated in order to use this tuneable model of TNAP expression for cell
capture within the microfluidic cell separator. Cells were seeded at five increasing seeding
densities (1×105, 5×104, 2×104, 1×104 and 5×103 cells/cm2 respectively) and cultured
in basal culture medium for a period of 7 days with medium changed every 3-4 days.
TNAP expression was then assessed with antibody staining and flow cytometric analysis.
For this work, DPSCs isolated from three different donors were analysed to account for
any donor variability, with cells analysed between passage 3-8. The gating mechanism
for flow cytometry for one experiment of four seeding densities to measure the percentage
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of cells expressing TNAP is shown in Figure 3.6. Here 34.6 % of DPSCs were found to
express TNAP at high seeding densities (5×104 cells/cm2) compared to just 5.6 % at low
seeding densities (5×103 cells/cm2).
Figure 3.5: Representative histograms of flow cytometric analysis of TNAP expression
by DPSCs cultured at 5×104, 2×104, 1×104 and 5×103 cells/cm2 for one experiment
for DPSCs isolated from one donor at passage 4. Histograms are fluorescent intensity (x
axis) against count (y axis). (a-d) Histogram containing the unstained, isotype control and
TNAP antibody for each seeding density of DPSCs. (e-h) Histograms containing gate set
with isotype control at 98% allowing the percentage of TNAP+ DPSCs to be measured
for each seeding density. The percentage of DPSCs expressing TNAP increased with an
increase in cell seeding density.
The reproducibility of expression was then analysed for the same five seeding densities
for DPSCs isolated from three different donors between passage 3-8 (Figure 3.6). DPSCs
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Figure 3.6: Graphical representation of flow cytometric analysis of TNAP expression
by DPSCs with increasing cell seeding density for DPSCs isolated from three separate
donors. There was a trend of an increase in the percentage of cells expressing TNAP
with increasing cell seeding density. Data represented as mean ± SD. n=3. n.s = not
significant. ** = P ≤ 0.01.
isolated from donor 1 had a higher percentage of cells expressing TNAP on the surface
compared with DPSCs isolated from donor 2 and 3. At low seeding densities (5×103
cells/cm2), 14.4 ± 10.8 % DPSCs isolated from donor 1 expressed TNAP compared to
50.5 ± 21.5 % of cells expressing TNAP at high seeding densities (1×105 cells/cm2).
Whilst this was not a significant difference (P >0.05), the trend of increasing TNAP
expression with increasing cell density was present. For DPSCs isolated from donor 2,
at low seeding densities, 3.1 ± 3.1 % of DPSCs were found to express TNAP whilst at
the high seeding density, 18.5 ± 8.2 % expressed TNAP. Whilst again this what not a
significant statistical difference, there was a trend of increasing seeding density with an
increase in TNAP expression. In DPSCs isolated from donor 3, 22.5 % ± 0.8 % expressed
TNAP at the high seeding density where significantly different (P ≤ 0.01) when compared
100
to the TNAP expression of 7.2 ± 3.2 % at the low seeding density. Across all DPSCs
isolated from three donors there was an increase in the percentage of DPSCs expressing
TNAP with cell seeding density. These results would then used for the development of a
cell separation technology and to measure the number of molecules present on the surface
of TNAP+ DPSCs as described in the following section.
3.4.3 Determining the number of molecules of tissue non-specific
alkaline phosphatase on the surface of DPSCs isolated from
three donors
Before the development of a cell separator to capture DPSCs via the binding of TNAP
molecules on the cells surface to anti-TNAP antibodies, a more detailed analysis of the
molecular TNAP expression density on the surface of cells and how it varies with different
seeding densities needed to be undertaken. An understanding of the number of TNAP
molecules on the cells’ surface and if this number is affected by the different seeding
densities would provide a thorough characterisation of the cell population before any
separation. To account for any variations in the number of TNAP molecules between
DPSCs from different donors or at different passage number, DPSCs isolated from
three different donors were analysed across a range of passages (passage 3-8). The
average number of TNAP molecules on the surface of DPSCs was quantified using a p-
Nitrophenylphosphate (pNPP) assay as described previously (Section 3.3.2). The average
number of TNAP molecules in the mixed population of TNAP+/TNAP- DPSCs was then
quantified.
The average number of TNAP molecules on the cells surface in the mixed population for
DPSCs isolated from donor 1 was quantified (Figure 3.7 (a)). For all seeding densities,
there was an increase in the number of TNAP molecules on the cells surface from passage
4 to 8. The average number of TNAP molecules increased 3.6 times from passage 4 to
8 across all seeding densities. For each passage analysed, the average number of TNAP
molecules in the mixed population of TNAP+/TNAP- cells was increased with increased
seeding density, which was the same trend seen with previous flow cytometry results
where the percentage of TNAP+ cells in the mixed population increased with seeding
density. Analysis by flow cytometry (Figure 3.7 (b)) on cells from donor1 showed a
gradual increase in TNAP expression which correlated to an increasing seeding density,
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Figure 3.7: Graphs showing the effect of seeding density and passage number on the
number of TNAP molecules on the surface of DPSCs isolated from donor 1. (a) Average
number of TNAP molecules on the cells surface per DPSC in the total population. The
average number of TNAP molecules on the cells surface increased with passage number
at each seeding density. Data represented as mean ± SEM. n=3. (b) Representative
histogram of flow cytometric analysis of TNAP expression by DPSCs with increasing cell
seeding density. There was a trend with an increase in the percentage of cells expressing
TNAP with increasing cell seeding density. Data represented as mean ± SD. n=3.
as expected.
The flow cytometry analysis enabled the percentage of TNAP+ DPSCs to be measured
at each seeding density and passage for DPSCs isolated from donor 1, using the same
seeding densities and passages to calculate the average number of TNAP molecules in the
mixed (TNAP+/TNAP-) populations. By measuring the percentage of TNAP+ cells uisng
flow cytometry, an estimate of the number of TNAP+ cells used in the TNAP+/TNAP-
population was made. Therefore the number of TNAP molecules per TNAP+ DPSC can
be measured directly. In the DPSCs isolated from donor 1, when the number of TNAP
molecules per TNAP+ cell was calculated for each separate passage (Figure 3.8 (a)) there
was no obvious trend to suggest that the number of TNAP molecules altered with passage
number. When combining the passages to calculate the number of TNAP molecules per
TNAP+ cell for each seeding density (Figure 3.8 (b)) there was no statistical significant
difference between all the seeding densities when compared to one another. The number
of TNAP molecules at higher seeding densities (1×105 cells/cm2) was 3.3 ± 0.6 ×105,
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Figure 3.8: Graphs showing the number of TNAP molecules on the surface of TNAP+
DPSCs for donor 1. (a) Number of TNAP molecules on the cells surface per TNAP +
DPSC at each seeding density and different passage numbers. Data represented as mean
± SEM. n=3. (b) Number of TNAP molecules per TNAP+ cell across all four passages.
The number of TNAP molecules per TNAP+ DPSC did not alter with cell seeding density.
Data represented as mean ± SD. n=4.
was not statistically significant when compared to the 2.4 ± 0.6 ×105 TNAP molecules
at lower seeding densities (5×103 cells/cm2). Across all seeding densities and passages
the average number of TNAP molecules per TNAP+ DPSCs for cells from donor 1 was
3.0 ± 0.7 ×105. As the results show that the levels of TNAP molecules did not vary with
seeding density, it can be assumed that each TNAP+ DPSC expresses the same amount of
TNAP molecules on it’s surface for all TNAP+ DPSCs isolated from this donor.
The same analysis was applied to DPSCs isolated from two different donors to account for
any donor variability. For DPSCs from donor 2, the average number of TNAP molecules
per cell in the total population of DPSCs decreased from passage 3 compared to passage
6 (Figure 3.9 (a)). The levels of TNAP molecules at passage 3 were much higher than
those of the other passages. The average number of TNAP molecules across all seeding
densities was 3.1 times larger at passage 3 compared to passage 6. This was the opposite
of the results for cells isolated from donor 1, illustrating donor variability. Again the
average number of TNAP molecules at each passage was increased with seeding density
as seen in previous flow cytometry results (Section 3.4.2). Whilst there was no statistical
significance in the TNAP expression of DPSCs at higher seeding densities compared to
lower seeding densities (Figure 3.9 (b)), the results again followed the expected trend of
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Figure 3.9: Graphs showing the effect of seeding density and passage on the number of
TNAP molecules on the surface of DPSCs isolated from donor 2. (a) Average number
of TNAP molecules on the cells surface per DPSC in the total population. The average
number of TNAP molecules on the cells surface decreased with passage number at each
seeding density. Data represented as mean ± SEM. n=3. (b) Representative histogram
of flow cytometric analysis of TNAP expression by DPSCs with increasing cell seeding
density. There was a trend with an increase in the percentage of cells expressing TNAP
with increasing cell seeding density. Data represented as mean ± SD. n=3.
an increase in the percentage of cells expressing TNAP with seeding density.
Again the flow cytometric data was combined with the average number of TNAP
molecules in the TNAP+/TNAP- population to calculate the average number of TNAP
molecules per TNAP+ cell. For cells isolated from donor 2, when the number of TNAP
molecules were analysed at each separate passage there was again no obvious trend in the
data, suggesting that the number of TNAP molecules expressed per cell was independent
of passage number (Figure 3.10 (a)). The results for the average number of TNAP
molecules per TNAP+ DPSC across all passages showed that there was no significance
difference in expression with seeding density (Figure 3.10 (b)). At low seeding densities
(5×103 cells/cm2), there was an increased number of TNAP molecules of 5.2 ± 1.1 ×105
when compared to the 3.1 ± 2 ×105 TNAP molecules at the higher seeding density
(1×105 cells/cm2), however this was not statistically significant. Interestingly the number
of TNAP molecules per TNAP+ DPSC, for cells isolated from donor 2, across all passages
and seeding densities was 3.5 ± 1.5 ×105 TNAP molecules which was a very similar
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Figure 3.10: Graphs showing the number of TNAP molecules on the surface of TNAP+
DPSCs isolated from donor 2. (a) The number of TNAP molecules on the cells surface per
TNAP + DPSC at each seeding density and different passage numbers. Data represented
as mean ± SEM. n=3. (b) The number of TNAP molecules per TNAP+ cell across all
four passages. The number of TNAP molecules per TNAP+ DPSC was not affected by
cell seeding density. Data represented as mean ± SD. n=4.
value to that for DPSCs isolated from donor 1. Again these results confirmed for a
separate DPSC donor that the levels of TNAP molecules per TNAP+ cell did not vary
with cell seeding density, meaning all TNAP+ cells express a similar number of TNAP
molecules on the cells surface.
A population of DPSCs isolated from a third donor was then analysed. For DPSCs
from donor 3, the average number of TNAP molecules per cell in the TNAP+/TNAP-
population decreased from passage 5 to passage 7 (Figure 3.11 (a)). This result showed
the same trend observed for cells from donor 2, but was opposite to that of cells from
donor 1, demonstrating how the expression of TNAP at the molecular level can vary
when cells are isolated from different donors. The number of TNAP molecules increased
with seeding density when all passages were averaged together, agreeing with the results
from the flow cytometric analysis. For cells isolated from donor 3, the percentage of
TNAP expression at lower seeding densities was significantly increased (P ≤ 0.01) when
compared to the higher seeding density (Figure 3.11 (b)). This confirmed the expected
trend of TNAP expression increasing with cell seeding density.
The percentage of TNAP+ cells was then used to calculate the number of TNAP molecules
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Figure 3.11: Graphs showing the effect of seeding density and passage on the number of
TNAP molecules on the surface of DPSCs isolated from donor 3. (a) Average number
of TNAP molecules on the cells surface per DPSC in the total population. The average
number of TNAP molecules on the cells surface decreased with passage number at each
seeding density. Data represented as mean ± SEM. n=3. (b) Representative histogram
of flow cytometric analysis of TNAP expression by DPSCs with increasing cell seeding
density. The percentage of cells expressing TNAP increased with cell seeding density.
Data represented as mean ± SD. ** = P ≤ 0.01. n=3.
per TNAP+ DPSC which were isolated from donor 3. There was no observed trend
between the number of TNAP molecules per TNAP+ cell with passage number (Figure
3.12 (a)). This was the same result that was found for cells from donors 1 and 2. When
the number of TNAP molecules was calculated across all three passages, there was no
significant difference in the number of TNAP molecules per TNAP+ cell with seeding
density (Figure 3.12 (b)). There was no statistical difference between the highest amount
of TNAP molecules of 2.4 ± 0.4 ×105 measured at 5×104 cells/cm2, when compared to
the lowest measurement of 1.1 ± 0.8 ×105 TNAP molecules at 1×104 cells/cm2. These
results showed that on average, each TNAP+ DPSCs expressed the same number of TNAP
molecules even at different seeding densities, and this agreed with the results found in
DPSCs isolated from both donor 1 and 2. These results in this section demonstrated large
error bars, this is mainly due to experimental variation such as variation within cell counts
which are critical to the calibration curve used. An automatic cell counter was utilised to
reduce this source of error, alternatively to reduce errors bars across all experiments more
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repeat readings would be required.
Figure 3.12: Graphs showing the number of TNAP molecules on the surface of TNAP+
DPSCs isolated from donor 3. (a) Number of TNAP molecules on the cells surface per
TNAP + DPSC at each seeding density and different passage numbers. Data represented
as mean ± SEM. n=3. (b) Number of TNAP molecules per TNAP+ cell across all four
passages. The number of TNAP molecules per TNAP+ DPSC is not altered by cell
seeding density. Data represented as mean ± SD. n=3.
3.4.4 Effect of donor, passage number and seeding density on
the number of molecules of tissue non-specific alkaline
phosphatase on the surface of DPSCs
The data for the average number of TNAP molecules per TNAP+ DPSCs was then
combined for all donors and seeding densities, to investigate whether passage number
affected the number of TNAP molecules on the DPSC surface (Figure 3.13 (a)). Data for
the different cell seeding density groups were averaged together across the results from
DPSCs isolated from three different donors determine whether passage number affects
the number of TNAP molecules per TNAP+ cell. The results showed that from passage
3 to passage 8, the number of TNAP molecules per TNAP+ cell remained consistent,
with no significant differences obtained when the number of TNAP molecules per cell
were compared to each other at different passages. Therefore TNAP+ DPSCs appear to
express an equal number of TNAP molecules independently of passage number.
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The results from the cells isolated from different donors were combined and analysed for
the average number of TNAP molecules per TNAP+ DPSCs, across multiple passages
and at all seeding densities (Figure 3.13 (b)). The average number of TNAP molecules
per TNAP+ cell was 3.0 ± 0.5 ×105 for donor 1. This was closely similar to the result
obtained using cells from donor 2 (3.5 ±1.1 ×105) with no statistical significance between
them. However, the average number of TNAP molecules per TNAP+ DPSCs was reduced
for DPSCs isolated from donor three to 1.7 ± 0.5 ×105, and this was a statistically
significant decrease when compared to cells from donor 2 (P ≤ 0.01) and to donor 1
(P ≤ 0.05). Therefore these results demonstrate some degree of donor variability with the
amount of TNAP molecules on the surface of DPSCs.
Figure 3.13: Analysing the number of TNAP molecules per TNAP+ cells across multiple
passages and donors. (a) Number of TNAP molecules on the cells surface per TNAP+
DPSC across all seeding densities from passage 3 to 8. The number of TNAP molecules
on the cells surface did not change with passage number. Data represented as mean ±
SD. n=6. (b) Average number of TNAP molecules per TNAP+ cell across all seeding
densities for three donors. Similar levels of TNAP molecules per TNAP+ were measured
for cells from donor 1 and 2, whilst the number of molecules was slightly reduced for
cells from donor 3. Data represented as mean ± SD. n=3.
The final results combined from DPSCs isolated from all three donors showed that seeding
density does not alter TNAP expression at the molecular level at the level of the individual
cell. Cells which are TNAP+ produce the same number of TNAP molecules irrespective
of seeding density. The number of TNAP molecules for TNAP+ cells was then averaged
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across all donors at each seeding density (Figure 3.14). These results demonstrated that
even accounting for donor variability, the average number of TNAP molecules per TNAP+
cell was not statistically significant when each seeding density was compared to one
another. A final average of 2.8 ± 1.3 ×105 TNAP molecules across all seeding densities,
accounting for donor variability and passage number was obtained. The measurements
ranged from a minimum of 1.1 ×105 TNAP molecules to a maximum of 6.5 ×105
TNAP molecules. Therefore an estimation can be made that each TNAP+ cell expresses
on average 2.8 ± 1.3 ×105 TNAP molecules on the cells surface irrespective of cell
seeding density. The amount of TNAP molecules present on TNAP+ cells stays similar
independently of cell seeding density and cells which are TNAP+ produce equal amounts
of TNAP molecules. This data could then be taken forward in developing a cell separation
technology targeting capturing DPSCs by their expression of TNAP molecules for bone
repair, which is explored in detail in the next chapter.
Figure 3.14: Average number of TNAP molecules per TNAP+ DPSCs across five seeding
densities for DPSCs isolated from three different donors. The number of TNAP molecules
on the surface of TNAP+ DPSCs was similar independent of cell seeding density. Data
represented as mean ± SD. n=11.
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3.4.5 Effect of osteoinduction on DPSC TNAP expression in the total
cell population and the number of TNAP molecules expressed
per TNAP+ DPSC
The effect of TNAP expression in the total population and the number of TNAP molecules
per TNAP+ DPSC was investigated when DPSCs were cultured for 7 days at the same
seeding density of 5×104 cells/cm2 in either basal or osteoinduction medium. The
percentage of cells expressing TNAP was then determined by flow cytometry, as described
in section 3.3.1. For cells cultured in the basal medium, 24.8 ± 9.7 % of the total
population were found to express TNAP after 7 days, this was significantly increased
(P<0.05) to 50.9 ± 12.7 % when DPSCs were cultured in osteoinduction medium for
the same time period (Figure 3.15 (a)). This increase in TNAP expression must be
expected if the DPSCs were differentiating towards an osteogenic lineage. Using this
data, the number of molecules per TNAP+ cell was determined for DPSCs cultured in
basal or osteoinduction medium. When cultured in basal medium the number of TNAP
molecules per TNAP+ cell was 2.3 ± 1.6 ×105, which was similar to previous results
(Figure 3.14). This was increased to 4.9 ± 2.7 ×105 TNAP molecules when cultured
in osteoinduction medium, however when compared to basal medium this result was not
statistically significant (Figure 3.15 (b)). When cells are cultured at high seeding densities
or under osteoinduction conditions, the number of cells expressing TNAP increases in the
total population. Yet regardless, the number of TNAP molecules per TNAP+ cell is not
significantly increased. This suggests that while more cells are recruited to an osteogenic
lineage, the amount of TNAP molecules on the surface of differentiating cells stays the
same.
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Figure 3.15: Production of TNAP increases when cultured in osteoinduction
differentiation medium. (a) Flow cytometric analysis of DPSCs cultured in basal
and osteoinduction culture medium. (b) Number of TNAP molecules on the cells
surface per TNAP + DPSC when cultured in basal and osteoinduction cell culture
medium. The percentage of DPSCs expressing TNAP increases when cells are cultured
in osteoinduction medium. Data represented as mean ± SD. * = P ≤ 0.05. n=3.
3.5 Discussion
DPSCs have been identified as having a high mineralising potential and the expression of
tissue non-specific alkaline phosphatase on the cells surface has been highly characterised
[51, 77, 17]. However, for the development of a cell separator to isolate cells by binding
to TNAP molecules on the cells surface, further understanding of TNAP expression at
a molecular level was required. The main aim of this chapter was to develop a method
to enable calculation of the number of TNAP molecules on the surface of DPSCs and to
investigate how this might vary with multiple donors, passage number and cell seeding
densities. Previous research has shown that DPSCs increase TNAP expression with
increasing cell seeding density [17]. What was not known was whether the increase
in cells expressing TNAP at high cell densities was also accompanied by increased
expression of TNAP molecules at the individual cell level. Given that the method to be
used in this thesis for cell separation relies on the binding of an antigen-antibody complex,
further investigation into the number of molecules expressed on the surface of DPSCs was
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undertaken; any differences in donor variability, passage number and cell seeding density
in the number of TNAP molecules per cell was also investigated.
3.5.1 TNAP expression on the surface of DPSCs in the total
population
TNAP expression has been shown to increase with cell seeding density for whole
populations [17]. This was also needed to be confirmed for the work to be carried out
throughout this thesis. The effect of increasing cell seeding density on TNAP expression
for DPSCs isolated from three individual donors was therefore assessed. DPSCs
populations for each donor demonstrated the expected gradual increase in the percentage
of cells expressing TNAP with increasing seeding density. Averaging the percentage of
cells expressing TNAP at each seeding density for different donors, demonstrated that
the upregulation of TNAP expression from the lowest seeding density was increased 4
fold when compared to the percentage of cells expressing TNAP at the highest seeding
density. This effect could be a consequence associated with an inhibition of proliferation
and an increase in differentiation. Differentiation of cells is often associated with a
switch from a proliferating phenotype to a differentiating one [186]. Embryonic stem
cells (ESC) have been shown to undergo differentiation at high cell density when cell-cell
contacts have formed, inhibiting proliferation [187] and markers of osteogenesis in ESC
are upregulated at high seeding density [188] indicating a role for cell-cell contacts in
ostoegenic differentiation. Contact inhibition has also been shown to have a role in the
osteogenesis of primary osteoblasts. When osteoblasts were cultured at high density in
pellets or as monolayer cultures, there was an enhanced expression of osteogenic genes
compared to low density monolayer cultures [189]. DPSCs seeded at higher densities are
able to reach a confluent cell monolayer quickly, they could then cease to proliferate due
to contact inhibition, and then begin to differentiate. Mitotically inactivated DPSCs which
cannot proliferate upregulate TNAP [17], providing further evidence that DPSCs switch
to a differentiating state when proliferation is inhibited.
Cell-cell contacts as well as the inhibition of proliferation play an important part in stem
cell differentiation. However, for other mesenchymal stromal cells there are contradicting
results on the effect of seeding density on their differentiation potential. Whilst increased
seeding density of human bone marrow MSCs has been shown to increase the rate
of adipogenesis or chondrogenesis in vitro [190], contradicting results have shown no
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apparent effect of cell density on adipogenic differentiation [191]. One potential reason
for these differences in results could be the importance of cell type and tissue source on
progenitor cell differentiation through specific cell-cell contacts. In murine bone marrow
MSCs, osteogenic cultures at low seeding densities were shown to have higher levels
of mineralisation compared to cultures at high cell seeding densities [192]. However,
the opposite result was reported with human bone marrow MSCs where high seeding
density was shown to increase osteogenic gene expression and mineralisation [190]. This
demonstrates a role for specific cell-cell contacts in the inhibition of proliferation and
switching to a differentiating state. For example for human periosteum-derived cells
(hPDC) the osteogenic potential was not altered by seeding density [190]. This has also
been demonstrated in cells from the oral cavity, where DPSCs showed a greater amount
of ALP expression in culture at high seeding densities for 7 days compared to human
gingival fibroblasts (hGF) [17]. It may also explain the reason behind the differences in
TNAP expression levels between different donors, where at high cell seeding densities
DPSCs isolated from donor 1 had higher levels of TNAP expression compared to cells
from donor 2 and 3. Therefore cell type and source also have an influence on the
differentiation from cell-cell contacts.
3.5.2 The number of TNAP molecules per TNAP+ DPSC
Whilst the percentage of TNAP+ DPSCs altered with seeding density, it was not known
whether the number of TNAP molecules on TNAP+ cells surfaces were also altered.
Quantification of molecules on a cell surface is most commonly achieved with the use
of quantitative flow cytometry in comparison to fluorescently labelled standard beads.
Here, beads are conjugated with a known number of molecules of either a fluorophore
or the specific antigen. The antigen conjugated beads are then targeted with antibodies
coupled with a fluorophore in a 1:1 ratio and the fluorescent signals between the beads
and cells can be compared to provide quantification [193]. The beads conjugated with
fluorophore are then compared with cells that are labelled with antibodies that have the
same fluorophore conjugated in a 1:1 ratio. The number of bound fluorophore conjugated
antibodies per cell in a sample is then derived by comparing the fluorescent signal with the
standard curve of fluorophore beads [194]. This is equivalent to the number of molecules
of a specific antigen per cell. However, quantitative flow cytometry is dependent on
many factors such as antibody clone, fluorophore and conjugation chemistry which can
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all affect the final estimation. Qualitative flow cytometry is also reliant on antibody
valency, therefore the exact number of surface molecules can not be calculated precisely
with bivalent antibodies [195]. However as TNAP is an isoenzyme [196] it provides a
unique opportunity to compare the enzyme activity of cell surface TNAP directly to a
known number of TNAP molecules by comparing substrate turnover. However it must
be noted that this methodology developed relies on the assumption that the recombinant
TNAP protein and TNAP on the surface of cells have the same enzymatic activity for
validation of the calibration curve. This is justifiable as a human source of TNAP protein
was utilised, as well as all experimental conditions were kept the same for both protein
and cells.
The number of TNAP molecules per TNAP+ DPSC was quantified for cells isolated
from three different donors, multiple passages and seeding densities. Donor variability
was observed when initially calculating average number of TNAP molecules per cell in
the mixed (TNAP+/TNAP-) population. For DPSCs isolated from donor 1, the average
number of TNAP molecules in the whole cell population increased with passage number,
while cells from donor 2 and 3 experienced a decrease in the number of TNAP molecules
across multiple passages. As the number of molecules per TNAP+ cell did not alter with
passage or seeding density, this observed difference in the whole population was most
likely due to change in the percentage of TNAP+ cells in the population. A decrease in
TNAP expression may be explained by a reduction in the cells’ osteogenic differentiation
capability across increasing multiple passages. Serial passaging of BMSCs has shown
a reduction of osteogenic differentiation capability due to cell ageing, from telomere
shortening as a result of cellular replication, with a gradual decrease in proliferation
potential [197, 198]. However donor age and health has been shown to also affect
the osteogenic potential of BMSCs [198] which could explain the increase in TNAP
molecules expression across passages for cells isolated from donor 1. Yet multiple
passages did not affect the average number of TNAP molecules per TNAP+ cell which
suggests that early passage has no effect on the upregulation of TNAP at the individual cell
once expression has begun. These results demonstrate the complexity of the osteogenic
differentiation response across multiple passage and donor types which need to be
considered before any cell therapy application.
The tuneable model of varying the percentage and therefore the number of cells with
seeding density was required to reliably produce sufficient numbers of TNAP+ cells for
capture in the microfluidic device using an anti-TNAP antibody functionalised surface.
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However as the cell capture mechanism occurs through binding of TNAP molecules on
the cell surface with an antibody on the device it was important to determine if the number
of TNAP molecules varied on an individual cell basis with either passage, cell seeding
density or the cell’s donor. These data were derived from calculating the average number
of TNAP molecules in the mixed cell population (TNAP+/TNAP-) and then taking into
account the percentage of DPSCs expressing TNAP from flow cytometry data. This gave
the number of TNAP molecules per TNAP+ cell. Here it was shown that across cells
isolated from each donor there was no difference in the number of TNAP molecules
expressed by individual TNAP+ cells between varying seeding densities. This was
independent of donor. This result shows that even though the inhibition of proliferation
through increasing seeding density causes TNAP- cells to upregulate TNAP, cells which
are TNAP+ produce the same amount of TNAP molecules regardless of seeding density.
Remarkably, for TNAP+ DPSCs isolated from donors 1 and 2, the average number of
TNAP molecules per TNAP+ cell across all five seeding densities was very similar, at 3.0
± 0.5 ×105 molecules for cells from donor 1 compared to 3.5 ±1.1 ×105 molecules for
cells from donor 2. DPSCs isolated from donor 3 did show a decrease to 1.7 ± 0.5 ×105
molecules compared to the cell populations isolated from the other two donors suggesting
some donor variability in TNAP molecular expression on the surface of DPSCs. This
is most likely due to factors such as age and health of the donor/cells, which can have
signifiant variability on the differentiation potential of DPSCs [199]. Even DPSCs from
donors of similar age have previously shown inherent differences in differentiation ability
[200].
The final calculation of the number of TNAP molecules per TNAP+ DPSC across multiple
passages, seeding densities and three donors was 2.8 ± 1.3 ×105 TNAP molecules, with
the measurements ranging from a minimum of 1.1 ×105 TNAP molecules to a maximum
of 6.5 ×105 TNAP molecules. Whilst no other study has undertaken this calculation for
TNAP on any cell source, the final number can be compared with other molecules which
have been quantified on the surface of cells. For example, quantitative flow cytometry
has been used to show that there are 9.8 ×104 CD4 molecules on the surface of T cells
[193]; Whilst CD14 a marker present on the surface of monocytes was found to be 1.2 ±
0.2 ×105 molecules and 3.3 ± 0.8 ×103 molecules at the surface of neutrophils [182]. In
dendritic cells, quantitative flow cytometry was used to calculate the number of molecules
of CD80 on the cells surface at 1.3 ± 0.2 ×105 molecules and CD86 at 2.1 ± 0.4 ×105
molecules [195]. In all these studies the number of molecules lies in the scale between
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103 - 105 molecules, this is in agreement with the same value that was calculated for the
number of TNAP molecules of TNAP+ DPSCs.
The effect on the percentage of TNAP+ DPSCs in the total population and the number
of TNAP molecules per TNAP+ cell was investigated when DPSCs were cultured in
osteoinduction medium. DPSCs in osteoinduction culture medium for 7 days showed
a significant two fold increase in the percentage of cells expressing TNAP compared
to cells cultured in basal culture medium for the same time period, suggesting early
osteogenic differentiation. However, there was no statistical difference in the number
of TNAP molecules per TNAP+ cell for DPSCs cultured at the same seeding density
in basal medium (2.3 ± 1.6 ×105) compared to osteoinduction medium (4.9 ± 2.7
×105). It has been shown that DPSCs increase of TNAP expression from the inhibition of
proliferation suggests DPSCs are able to commit down an osteogenic lineage without any
osteoinductive cues [17]. However the introduction of osteoinductive cues differentiates
cells into the TNAP+ phenotype, but the expression of TNAP molecules does not change
on the single cell level which agrees with previous results found with no change in the
number of TNAP molecules per TNAP+ cells with varying seeding densities. It would
be of interest in future work to determine the number of TNAP molecules at specific
stages of cell osteogenic differentiation for isolation of the most beneficial stage of cell
differentiation for bone repair and to analyse gene expression of ALP at the transcript
level compared to the protein level.
A single cell analysis approach to the quantification of TNAP molecules on the cells
surface could potentially provide a more accurate measurement, however this population
based-approach was utilised due to ease of access of all current experimental materials
and adapted readily available experimental protocols to provide the TNAP quantification
without a lot of methodology development. This enabled the PhD research to progress
to answering the main research question of developing and testing a microfluidic cell
capture device. The current model developed provides an estimation on the number of
TNAP molecules per TNAP+ DPSCs, however it does not take into account variations
of cell size which would therefore affect the density of TNAP molecules on the surface
of DPSCs. It has been shown that MSCs in late-passage increase in cell size due to a
higher proportion of senescent cells [201]. Therefore even if there is a similar number
of TNAP molecules per TNAP+ cells across a range of passages, cells at a later passage
may be significantly larger than those at early passage and therefore these cells would
have a lower density of TNAP molecules on the cells surface. This would be important
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to consider as the cell separation mechanism used to capture cells in this PhD research
involves the interaction of TNAP at the cells surface with anti-TNAP antibodies attached
to a functionalised surface, and the surface density of TNAP could be an important
parameter in cell capture efficiency. Potential future experiments could investigate the
density of TNAP at the cell surface by taking direct measurements of cell size when
attached to culture plates or by using FSC/SSC plots from flow cytometry experiments.
Therefore investigations into changes of TNAP density at the cell surface due to factors
such as donor, seeding density or passage could provide a thorough characterisation of
target cells before cell separation, but as a beginning into developing a proof-of-concept
cell separation device the overall number of TNAP molecules alongside a measurement
for average cell size to quantify TNAP density on the cells surface was deemed sufficient.
This investigation to calculate the number of TNAP molecules per DPSC was undertaken
to achieve further understanding of the cell population to be separated prior to device
development. The results shown were then taken forward in the development of a
microfluidic cell separator to enrich TNAP+ DPSCs with an antibody immobilised
surface. The flow cytometry and fluorescence microscopy images confirmed TNAP
expression on the surface of DPSCs and also confirmed no TNAP expression on the
surface of 16HBE cells. This enabled 16HBE cells to be used in all future work as a
negative cell control for non-specific binding on the bio-functionalised surface. Taking the
final average value of 2.8 ×105 TNAP molecules on the surface of DPSCs, an estimation
of the TNAP molecules density at the cells surface can be made. The average diameter
of a DPSC on a flat surface was measured at ∼ 23 µm which agrees with the diameter of
MSCs which is between 18 - 30 µm when spread on tissue culture plates [202]. Taking the
assumption that the shape of a DPSCs is a sphere, the total cell surface area is estimated
at 1.6 ×103 µm2. The fluorescence microscopy images confirmed that TNAP was not
localised to any one area on the cell surface of DPSCs, demonstrating TNAP expression
across the whole cell surface. This is important as a flat surface is used for cell capture,
meaning the orientation on which the cell is exposed to the surface will not alter if the cell
surface TNAP is available for binding. From these results the density of TNAP molecules
at the cells surface of DPSCs can be estimated at 169 TNAP molecules per µm2. This
data was then used to estimate if there were enough TNAP molecules on the cells surface
for capture with a surface functionalised with anti-TNAP antibody for the development
of a cell enrichment device.
The next chapter explores the development of a microfluidic cell separator for TNAP+
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DPSCs cell capture through an anti-TNAP antibody immobilised surface. As the amount
of TNAP molecules present on TNAP+ DPSCs remained similar independently of cell
seeding density, the capture efficiency in the microfluidic device for DPSCs with different
levels of expression of TNAP from culturing at different seeding densities could be
directly compared. This would then enable a method to demonstrate the specificity of bio-
functionalised surface for cell capture. As the device requires DPSCs to be captured by
the interaction of an anti-TNAP antibody with the TNAP molecules on the cells surface,
if the amount of TNAP molecules had altered drastically according to donor, passage
or seeding density this could have potentially confounded the data for cell capture. As
the number of TNAP molecules stays similar direct comparison of the capture of cells
at different seeding densities and passages can be made. Therefore equal numbers of
TNAP molecules at the surface of DPSCs are assumed and the cell enrichment is taken
directly from the TNAP+ percentage before and after separation. All this data is then
taken forward for the development of a novel medical device for DPSC enrichment for
potential use in bone repair.
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Chapter 4
Development of a microfluidic cell
separator for enrichment of TNAP+
DPSCs
4.1 Aim
The aim of this chapter was to develop a minimally manipulative, label-free cell separator
technology for autologous stem cell enrichment for skeletal tissue repair. As mentioned
in section 1.3.3, Tissue non-specific alkaline phosphatase (TNAP) has been identified
as a pro-mineralising cell surface marker present on the surface of dental pulp stem
cells (DPSC) and bone marrow mesenchymal stem cells (BMSC). Therefore the ability
to isolate TNAP+ cell populations with minimal cell manipulation offers a potential
autologous cell therapy for enhanced skeletal repair and regeneration. The proposed
technology is based on the covalent attachment of anti-TNAP antibodies onto a gold
substrate, coupled with microfluidic technology to allow binding and subsequent release
of TNAP specific stromal cells. This would then generate a TNAP enriched cell
population to allow re-implantation within intraoperative time.
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4.2 Introduction
The ability to deliver an enriched population of autologous TNAP+ stromal cells in
intraoperative time, defined here as less than two hours, from surgical waste or bone
marrow aspirate, may lead to more promising bone repair and regeneration when paired
with the correct scaffold. The work in this chapter utilised dental pulp stromal cells
(DPSCs) for the development of a novel cell separator combing microfluidic technology
with an anti-TNAP antibody functionalised substrate. DPSCs were used as a cell source as
they are an easily accessible source of human mesenchymal stromal cells. As described
in the previous chapter, the ability to increase the number of cells that are TNAP+ by
increasing the seeding density, whilst the amount of TNAP molecules on the surface
does not change, provides a tuneable model to develop a TNAP+ cell capture technology
[17]. TNAP is a pro-mineralising cell surface molecule and is able to upregulate
production of TNAP without any osteoinductive cues [17, 96] (as described in section
1.3.3). Therefore, TNAP has been identified as a potential cell marker to isolate cells
which have a high osteogenic potential and are predisposed to differentiate towards a
mineralising phenotype. Delivering an enriched population of TNAP+ cells would be
potentially beneficial as a cell source for skeletal tissue engineering for enhanced repair
and regeneration.
Ideally, a device to enrich autologous stromal cells for skeletal repair would be classed as a
minimally manipulative treatment as described in EU directive No. 1394/2007 (Advanced
Therapy Medicinal Products) [19]. This is defined as being where the cells’ biological
characteristics, physiological functions or structural properties relevant for the intended
repair and regeneration have not been altered by the cell separation procedure. The
desirability of minimal manipulation is due to the high risk of potential adverse effects
of the reimplantation of manipulated cells altered by the separation process. It also paves
a quicker path to regulatory approval as a medical device for clinical use. Therefore,
delivering a population which is not only label-free, but unaffected by the separation
procedure, is highly important to demonstrate minimal manipulation.
BMSCs and DPSCs are currently isolated from bone marrow aspirate or dental pulp
respectively utilising density based separation and the adherent property of cells onto
plastic culture dishes [54, 51]. However to isolate individual cell populations based on
the expression of specific cell surface markers, fluorescence activated cell sorting (FACS)
or magnetic activated cell sorting (MACS) are the gold standard techniques commonly
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used [5]. However, cell labelling is a time consuming, costly and laborious process
with cell separation occurring over several hours in the case of FACS. Cell labelling
may also result in unintended adverse effects on cell phenotype, such as an alteration in
proliferation and differentiation potential [203], and there may be unknown adverse tissue
effects when used in a clinical setting. Therefore, a label-free cell separation method to
enrich cells based on cell surface marker expression in an intraoperative time period is
highly desirable.
Alternative techniques and devices which utilise antibodies for cell separation without
labelling have been developed. As discussed in chapter 1, microfluidic devices have been
designed where antibodies are immobilised onto polymer surfaces to capture circulating
tumour cells from whole blood [204] and have used a combination of enzymatic treatment
with shear force from fluid flow to release captured cells from the surface [149]. Columns
immobilised with anti-CD34 antibody have been developed to enrich osteoblastic cells
[153]. Here cells are separated by taking various fractions of cell populations as they
are eluted out of the column as the velocity of the cell is reduced due to binding of
the cell marker to an antibody functionalised surface, therefore cells positive for the
marker of interest are eluted slower [153]. The same principle has been applied to
microfluidic devices to enrich induced pluripotent stem cells with antibodies against
stage-specific embryonic antigen 1 [205]. These devices provide novel ways to enrich
cells based on their cell surface markers without the use of any antibody labelling
procedure. However, these studies are limited by low cell throughputs and processing
speeds when compared to conventional (FACS or MACS) cell sorting techniques [5], as
well as minimal characterisation of the enriched cell populations.
The work in this chapter focuses on the development of a microfluidic cell separator
for enrichment of a TNAP+ DPSC population. This would deliver a label-free enriched
TNAP cell population, which is minimally manipulated within an intraoperative time
period. First, the immobilisation of anti-TNAP antibodies onto a gold substrate
functionalised with a self-assembled monolayer for the specific capture of TNAP+ DPSCs
was investigated. This was based on the established process used to functionalise gold
surfaces with antibodies or binding proteins for use in biosensing applications [168, 167].
The development of PDMS microchannels allowed the use of microfluidic technology to
flow cell populations across an antibody functionalised surface. The capture specificity
and cellular release from the functionalised surface in the microfluidic device was then
investigated. Cells released from the functionalised surface were then characterised to
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determine any TNAP enrichment, with the potential for cells being released with antibody
still attached also investigated.
The main objectives in this chapter were to:
1. Demonstrate the attachment of anti-TNAP antibodies to a gold substrate that is
functionalised with a carboxylic acid terminated self-assembled monolayer.
2. Investigate whether that TNAP+ DPSCs can specifically bind to the bio-
functionalised substrate.
3. Design, build and test a microfluidic device to house the bio-functionalised
substrate enabling TNAP+ DPSC populations to be captured and released with
fluidic flow.
4. Quantify the level of TNAP+ DPSC enrichment before and after cell separation.
5. Determine if cells are released without the binding antibody still attached, to begin
to meet the requirements for minimal cell manipulation.
These objectives together aim to deliver a microfluidic cell separation device with the
ability to enrich label-free TNAP+ DPSCs in a short intraoperative time period. This
could then provide an appropriate autologous cell source for potential use in skeletal tissue
engineering applications.
4.3 Methods
4.3.1 Functionalisation of gold surfaces with a self assembling
monolayer
To develop a surface which cells could be captured via an antibody, gold surfaces were
fabricated and functionalised with a self assembling monolayer (SAM) before anti-
TNAP antibodies were immobilised onto the surface. Gold wafers were fabricated by
evaporating a 15 nm titanium (Ti) layer, followed by a 85 nm gold (Au) layer, onto
polished silicon/silicon oxide wafers by electron beam evaporation. S1813 photoresist
(Shipley, USA) was spun at 5000 rpm and then wafers were cut by diamond scribe into
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24 mm × 34 mm or 1 cm2 die. The gold surfaces were then sonicated in 100% acetone
for 10 minutes twice, followed by sonicating in 100% ethanol twice. The cleaned gold
surfaces were then immersed in fresh 100% ethanol before being immersed into a 1
mM ethanolic solution of carboxylic-acid-terminated monothiol-alkane-PEG (HS-C11-
EG6-OCH2-COOH, ProChimia Surfaces, Poland) with 5% acetic acid to form a SAM.
The gold surfaces were incubated at room temperature for 48 hours which allowed a
well ordered SAM to form [168]. Once the SAM had formed the surface was ready for
immobilisation of antibodies and then the surface was rinsed with 100% ethanol and then
dried with nitrogen gas.
4.3.2 Immobilisation of antibodies onto gold surfaces functionalised
with a SAM
Antibodies needed to be immobilised onto a SAM functionalised gold surface for
development of a cell capture surface for use in the microfluidic cell separation device.
Antibodies were immobilised on the cleaned gold electrode surface by first rinsing the
surface functionalised with a SAM (Section 4.3.1) with 100 mM 2-(N-morpholino)
ethanesulfonic acid (MES buffer) at pH 5.5. The carboxylic acid head group of the SAM
was activated by exposure to a 1:1 mixture of 100mM of N-hydroxysuccinimide (NHS)
and 400mM of 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC)
(GE Healthcare, USA) in 100 mM MES buffer 5.5 for 15 minutes. After activation the
surface was rinsed with 100mM MES buffer at pH 5.5. The surface was then incubated
with the desired concentration of anti-human TNAP antibody (Biolegend, USA) in 10mM
acetate buffer at pH 5.5 for 30 minutes at room temperature. Afterwards the surface was
incubated in a 1% bovine serum albuim (BSA) solution to block the surface and reduce
non-specific binding and therefore is an anti-fouling agent.
4.3.3 Use of colorimetric assays to demonstrate surface
functionalisation of anti-TNAP antibodies
To demonstrate the ability of gold substrate to be functionalised, antibody was covalently
attached to the surface before being incubated with TNAP protein and DPSCs. Silicon
wafers with an evaporated gold surface were scribed into 1 cm ×1 cm die (Section 4.3.1).
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A monothiol-alkane-PEG acid SAM was then assembled upon the surface (as described
in section 4.3.1). After 48 hours the gold chips were transferred to a 24 well plate. They
were then washed in 100% ethanol three times for five minutes each, followed by three
washes in MES buffer pH 5.5 again for five minutes each. Then the SAM was activated
by exposure to a 1:1 ratio of 100 mM of N-hydroxysuccinimide (NHS) and 400 mM of
1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC) (GE Healthcare,
USA) in 100 mM MES buffer pH5.5, for 15 minutes. Surfaces were then washed three
times for 5 minutes each in MES buffer, before three dilutions (10, 2 and 1 µg/mL) of
anti-human TNAP antibody (referred throughout as anti-TNAP) (Biolegend, USA) were
incubated on the surface in 10 mM pH 5.5 acetate buffer for covalent attachment. Seven
surfaces were prepared for each antibody dilution, 21 in total. The functionalised gold
surfaces were then incubated with the antibody dilutions for 30 minutes before the excess
was washed away with three washes of five minute each with PBS, and then incubated in
a 1% BSA solution for 2 hours. Afterwards, the 1% BSA solution was washed off with
PBS (3 times for 5 minutes each). The functionalised gold substrates were then incubated
with either TNAP protein, DPSCs (TNAP+) or 16HBE (TNAP- control cells). For the
protein, six dilutions (2 - 0.03 µg/mL) in PBS of human TNAP (Sinobiological, China)
were incubated on the functionalised surfaces for 1 hour with gentle shaking (30 rpm).
Then, surfaces were washed four times for five minutes each in PBS with gentle shaking
(30 rpm). As human TNAP protein is an enzyme responsible for the dephosphorylation
of a variety of molecules [206] (Section 1.3.3), the presence of TNAP captured on the
surface can therefore be detected by the enzymatic activity. TNAP activity was detected
using p-nitropenyl phosphate (pNPP), which is a substrate that is dephosphorylated by
TNAP leaving a 4-nitrophenol product that is yellow in colour that can be measured at an
absorbance of 405 nm. TNAP protein bound to the surface was detected by incubating
with 400 µL pNPP for 30 minutes at 37◦C. The reaction was stopped with the addition
of 400 µL of NaOH; 100 µL was then transferred into 96 well plates six times for repeat
readings to account for measurement error before the absorbance was measured at 405
nm.
Cell binding onto the surfaces functionalised with antibodies was also investigated. The
same method was used as that described above, but instead of TNAP protein, six dilutions
of DPSCs or 16HBE cells in plain α-MEM (Invitrogen, UK) were used (2 ×106 - 0.03
×106 cells). Cell samples at each concentration were incubated onto the surfaces which
had been functionalised with 10, 2 and 1 µg/mL anti-TNAP antibody for 15 minutes
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with shaking. Then surfaces were washed four times for five minutes each in PBS with
gentle shaking (30 rpm). After washing, five images at random areas of the surface were
taken using a Olympus BX60 fluorescence microscope and cells were counted using the
process described in section 4.3.7. For DPSCs the number of cells bound to the surface
was also measured by ALP activity using pNPP. 16HBE are TNAP- and therefore cannot
be detected by TNAP on the cells surface. Briefly, 400 µL of pNPP was incubated for 30
minutes at 37◦C. The reaction was stopped with the addition of 400 µL of NaOH and then
100 µL was transferred into 96 well plates six times to account for measurement error
before the absorbance was measured at 405 nm.
4.3.4 Microfluidic device fabrication and assembly
A microfluidic device for cell separation using an antibody functionalised surface was
developed as described in section 4.4.4. A flow cell, including support for all valves and
tubing to allow precise control of flow through the channel was designed on Solidworks
(Dassault Systemes, France) 3D computer aided design software (Figure 4.1), before
being 3D printed using a purpose built in-house 3D printer. The flow cell (Figure 4.1)
consisted of a base which allowed alignment of the gold substrate functionalised with
a SAM. The valves used in this project consisted of a 4-port right angle flow switching
valve (Upchurch scientific, UK) and a 2 way stopper valve (Upchurch scientific, UK).
The 4 port valves allowed flow switching between the input, waste output and input into
the microfluidic channel with minimal dead volume within the valve, minimising the risk
of air bubbles entering the channel. The flow system was connected with 1.59 mm outer
diameter, 0.5 mm inner diameter PTFE tubing (VWR, USA).
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Figure 4.1: Diagram showing device assembly. A 3D printed “flow cell” was used as
the base and holder for valves and microfluidic tubing (not shown in diagram). The
gold surface with assembled SAM was then placed on the base, followed by the PDMS
channels which was then clamped together by screwing in a perspex lid into the flow cell.
Tubing could then be connected to the PDMS microfluidic channels allowing the surface
to be functionalised with anti-TNAP antibody for cell separation. Scale bar represents 50
mm.
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Figure 4.2: 3D printed red microfluidic master mould for three parallel channels with
corresponding cured PDMS microfluidic channel designs. The PDMS is pored into the
microfluidic mould, cured and then peeled out. The pillars at either end are the input
and output, where the PTFE tubing is inserted into. The raised strip between the pillars
defines the microfluidic channel. Scale bar represents 20 mm.
Moulds for the microfluidic channels were designed on Solidworks (Dassault Systemes,
France) and then 3D printed using a Miicraft stereolithographic 3D printer (Miicraft,
Taiwan) with HT Miicraft resin used (Spot-A materials, Spain) (Figure 4.2). The PDMS
does not cure directly onto the master mould as the master mould may not be fully reacted
and this inhibits the polymerisation of the PDMS [119]. The master moulds were placed
in a reactive-ion etching (RIE) chamber for 2 min at 50 W power, which deposits a thin
coating of fluorocarbon by CHF3 deposition. This makes the surface highly hydrophobic
which allows the PDMS to cure and eases the peeling off of the PDMS from the master
moulds once cured [120]. PDMS was made using SYLGARD-184 silicone elastomer
kit (Dow Corning, USA) by thoroughly mixing base and curing agent in a 10:1 weight
to weight ratio. The PDMS mixture was degassed for 20 minutes at 5 mBar pressure,
to remove any air bubbles which would affect microscopy analysis of the channels, then
poured into the master moulds and placed in a 65◦C incubator for 3 hours. Once cured,
the PDMS was peeled out of the moulds (Figure 4.2), then an outflow hole for tubing was
cut using a 1.5 mm biopsy punch. The PDMS was then sonicated in isopropanol for 5
minutes and dried under nitrogen gas before being stored in a clean petri dish at room
temperature until required.
The device was assembled by first placing the gold substrate functionalised with the
carboxylic acid terminated SAM onto the alignment slot of the 3D printed flow cell.
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The PDMS microfluidic channels were then aligned on top of the functionalised surface,
before a perspex lid was placed on top of the PDMS and screwed into the flow cell
to clamp the PDMS to the surface and create a fluidic seal. Plasma bonding was not
utilised as the seal needed to be reversible for the retrieval of the PDMS chip for future
experiments. The microfludic tubing was then connected to the input and output of the
PDMS channels. The device, fully assembled is shown in figures 4.15 and 4.14. This
created a fully contained fluidic setup where valves allowed precise control over the
fluidic path, allowing the gold substrate to be exposed to antibodies for immobilisation
and subsequently cells for separation.
4.3.5 Immobilisation of anti-TNAP antibodies onto functionalised
gold surfaces within the device
An anti-TNAP antibody was needed to be immobilised onto a gold surface functionalised
with a carboxylic acid terminated SAM for TNAP+ DPSCs to be specifically captured
within the microfluidic device. The antibody was attached to the surface through
injections into the fully assembled device described in section 4.3.4. The gold surface
was bio-functionalised with anti-TNAP antibody by covalently attaching the antibody to
the monothiol-alkane-PEG acid SAM monolayer (Figure 4.3). All buffers and reagents
were directly injected into the channel through a 1 mL syringe (BD plastipak, USA). For
each injection, care was taken not to introduce air bubbles into the microfluidic channels
by first running the fluid through the input to waste in the 4-way valve before switching
the direction of flow to channel input. The first injection consisted of 100 mM MES
buffer at pH 5.5. The carboxylic head of the SAM was then activated by exposure to a
1:1 mixture of EDC/NHS in MES buffer at pH 5.5. The surface was then washed with
an injection of the same MES buffer followed by an injection of 2 µg/mL of anti-TNAP
Antibody (Biolegend, USA) in 10 mM acetate buffer pH 5.5 which was incubated on the
surface for 30 minutes. The surface was then washed by injecting acetate buffer before
residual activated acid sites were blocked with an injection of 1% BSA solution.
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Figure 4.3: Schematic illustration of the functionalisation of the surface for cell capture.
A monothiol-alkane-PEG carboxylic acid-terminated SAM is first assembled on a gold
electrode. The carboxylic acid groups of the SAM were then activated with EDC/NHS
to which the antibody was covalently attached. BSA was then used to quench unreacted
activated acid sites. The surface was then ready for the injection of cells.
4.3.6 Cell injection and release on antibody functionalised surfaces
within the device
For cell separation experiments, DPSCs and 16HBE cells were injected into the
functionalised microfluidic channel of the device. DPSCs between passage 3-7 were
cultured for 7 days at a seeding density of 5×104 cells/cm2. 16HBE cells were cultured
from passage 12-20 until 80-90% confluency. Cell suspensions of 2×106 cells/mL were
made up in α-MEM culture medium. Plain α-MEM culture medium was flown across the
surface at 100 µL/min for 3 minutes using a syringe pump (Havard PHD 2000, Havard
apparatus, USA). Cells at a concentration of 2×106 cells/mL were manually injected into
the device at approximately 500 µL/min (Figure 4.4). Manual injection was used as when
using the syringe pump for injection of cells, sedimentation within the syringe was a
problem leading to a lower cell concentration being injected onto the surface. After the
total cell input, both the 4-way input valve and stopper valve were closed and cells were
incubated on the surface for 5 minutes at room temperature. After incubation, the fluidic
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path was opened up and α-MEM culture medium was reintroduced at 100 µL/min for 10
minutes. Any unbound cells were washed from the surface and eluted from the device
leaving behind a bound population (Figure 4.5). To remove the cells from the surface
for characterisation, α-MEM culture medium was injected in a programmed sequence
of 1.5 mL/min for 2 seconds, 0.1 mL/min for 1 second, then repeated, for 1 minute
(Figure 4.6). Cell release was investigated in α-MEM culture medium, phosphate buffer
at pH 6.5 and phosphate buffer at pH 8.5. The antibody orientation in the these figures
represents an ideal situation of attachment onto the surface, when in reality there would
be antibodies attached to the surface via their variable regions resulting in attachment in
variable orientations.
Figure 4.4: Schematic showing injection of cell population into the device. First, 2 ×106
cells/mL were injected into the device at approximately 500 µL/min; all valves were
closed, then cells were incubated on the surface for 5 minutes.
Figure 4.5: Schematic illustrating specific cell binding to the antibody-functionalised gold
surface. Plain α-MEM culture medium was flown across the antibody-functionalised
surface at a rate of 100 µL/min, removing unbound cells, leaving only bound cells in the
channel.
130
Figure 4.6: Schematic showing method used for cell release. Cells were released from
the surface by using a programmed flow sequence (1.5 mL/min for 2 seconds, 0.1 mL/sec
for 1 second) repeated for 1 minute with either plain α-MEM culture medium, phosphate
buffer at pH 6.5 or pH 8.5.
4.3.7 Determination of the number of cells bound to the surface
following cell capture or release
To demonstrate capture efficiency of the antibody functionalised surface cells were
counted at various stages of the process to calculate the percentage of bound cells.
Either DPSCs or 16HBE cells were injected into the device and allowed to incubate on
the surface, as described above. During this incubation period five images at random
positions in the channel were taken of the microfluidic channel using an Olympus BX60
fluorescence microscope with a 10x magnification. After incubation, flow was resumed
and the unbound population eluted as described above. After the 10 minute period of flow,
five more images were taken from approximately the same area as before. Five images
were therefore acquired both before and after programmed flow release to calculate the
percentage of cells released from the surface. Images were imported into ImageJ [207];
an overview of the image processing used to automatically count the cells is shown in
figure 4.7. The threshold of each image was first adjusted to change it to a black and
white binary image (Figure 4.7 b). Next the empty space in the middle of the cell outline
was filled using the “fill holes tool” (Figure 4.7 c). Automated separation of fused cells
by a 1 pixel line was then carried out using the “watershed tool” (Figure 4.7 d). Finally
after processing the number of cells on the surface in each image were counted using the
“analyse particles” tool to obtain a cell count. The cell counts were then averaged across
the five random images acquired across the channel and then multiplied by the ratio of
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total channel surface area (94.6 mm2) to the area of image captured (2.6 mm2). This
was based on the assumption that cells were uniformly distributed across the surface as
represented by the five images taken. This provided an estimate for the number of cells
captured/released at each stage allowing the percentages of captured and released cells to
be calculated.
Figure 4.7: Figure demonstrating the image processing method used to measure the
number of cells either captured or released from the antibody functionalised surface. (a)
Original image captured (b) Image after threshold adjustment. (c) Image after application
of fill holes tool (arrows indicate examples of filled cell outlines). (d) Image after
watershed tool used to separate fused cells (Arrows indicate examples of separated fused
cells). These pictures were acquired in the middle of the channel
. Scale bar represents 250 µm.
4.3.8 Flow cytometric analysis of TNAP+ DPSCs before and after
cell capture using the microfluidic device
To determine the extent of TNAP+ cell enrichment using the device, flow cytometry
was utilised to measure the percentage of DPSCs expressing TNAP before and after
separation. A sample of the DPSCs suspended at 2×106 cells/mL in α-MEM culture
medium was taken so that the percentage of TNAP+ DPSCs could be measured before
separation in the device. Cell separation was undertaken as described in section 4.3.6,
allowing multiple released populations from 4-5 microchannels, to be pooled together in
order to provide sufficient cell numbers (a minimum of 1×105 cells was required) for
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flow cytometric analyses. Cell samples for both before and after cell separation, were
labelled with APC anti-TNAP antibody or APC mouse IgG1, isotype control antibody
(both Biolegend, USA) at 5 µL per 1×105 cells in a total volume of 100 µL in FACS
buffer at pH 7.4 consisting of PBS, 0.5% BSA, 2 mM EDTA for 20 minutes. Following
antibody incubation, 900 µL of the same FACS buffer was added and cells were then spun
down at 200×g for 5 minutes before being washed again in 1 mL of FACS buffer, spun
down and resuspended in 500 µL of the same buffer. Samples were then analysed using a
CytoFLEX flow cytometer (Beckman coulter) using 488 nm and 640 nm laser excitations.
Analysis of acquired data was performed using the CytExpert software.
4.3.9 Investigation to determine the possibility of any antibody
attachment to the cells after cell release from the device
DPSCs separated by the device should meet the requirements for minimal cell
manipulation. Therefore it was important to determine whether any antibodies remained
attached to the previously bound cells after release or if the programmed flow had released
the bound cells directly from the antibody functionalised surface as desired. This again
was investigated using flow cytometry. A sample of the DPSCs suspensions at 2×106
cells/mL in α-MEM culture medium was taken before cells were introduced into the
device so that the percentage of TNAP+ DPSCs could be measured before separation.
Cell separation was then undertaken as described in section 4.3.6, and multiple released
cells pooled together from the microfluidic channels. The cell population obtained before
separation was labelled with purified anti-TNAP antibody or purified mouse IgG1, isotype
control antibody (both Biolgened, USA) at 5 µL per 1×105 cells in a total volume of 100
µL in FACS buffer for 20 minutes. Following antibody incubation, 900 µL of FACS buffer
was added and cells were spun down at 200×g for 5 minutes before being washed again in
1 mL of FACS buffer. They were then spun down and resuspended in 100 µL FACS buffer.
All cell populations, including the cell population that underwent the separation, and a
control population of cells which had not been separated were labelled with APC goat
anti-mouse IgG antibody (Biolegend, USA) at 2.5 µL per 1×105 cells in a total volume
of 100 µL in FACS buffer for 20 minutes in the dark at room temperature. Following
incubation with the antibody, 900 µL of FACS buffer was added and cells were spun
down at 200×g for 5 minutes before washed again in 1 mL of FACS buffer spun down
and resuspended in 500 µL of the same FACS buffer. Samples were then analysed using a
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CytoFLEX flow cytometer (Beckman coulter) using 488 nm and 640 nm laser excitations.
Analysis of acquired data was performed using the CytExpert software.
4.3.10 Statistical analysis of data
All measurements were performed in at least triplicates and graphs displayed as the mean
± standard error of the mean (SEM) or ± standard deviation (SD) depending on the
measurement taken. Test for gaussian distribution was then carried utilising Shapiro-
Wilk test, with normally distributed data between two samples analysed using an unpaired
t-test. For multiple comparisons between three or more samples, ANOVA multiple
comparisons test with Tukey modification was used. All analyses were carried out in
Graphpad Prism 6. For all graphs, no significance = P > 0.05, * = P ≤ 0.05,** = P ≤
0.01,*** = P ≤ 0.001 and **** = P ≤ 0.0001.
4.4 Results
4.4.1 Specific capture of DPSCs on the antibody functionalised gold
surface
Before developing a microfludic device for cell capture, there was a need to ensure that
if gold substrates could indeed be functionalised with anti-TNAP antibodies and that was
specific for the capture of TNAP+ DPSCs. Immobilisation of anti-TNAP antibodies onto
gold substrates was achieved using an established protocol of cross linking via by primary
amine groups to a self assembled monolayer [168, 167]. Briefly the gold substrate was
functionalised with a carboxylic acid terminated SAM. The SAM contained polyethylene
glycol (PEG) moieties which aid in preventing non-specific binding of molecules to the
functionalised gold substrate [208]. The carboxylic acid groups were then pre-activated
with EDC and NHS so the anti-TNAP antibody can be covalently attached by primary
amine groups to the SAM. The activated carboxylic acid groups remaining were then
quenched with BSA to prevent non-specific binding.
Antibody functionalised surfaces were incubated with varying dilutions of DPSC and
16HBE cell numbers (1 ×106 - 0.06 ×106 cells), washed, and as described previously
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(Section 4.3.7), the remaining cells bound to the surface were counted. The results in the
previous chapter had shown expression of TNAP on the surface of DPSCs and that 16HBE
cells are TNAP negative with no expression on the surface (Section 3.4.1). Therefore as
16HBE cells do not express TNAP, they were used as a negative control throughout these
experiments. The results showed that at all dilutions of cell numbers, there was a higher
number of DPSCs remaining on the antibody functionalised gold surface after washing
compared to the numbers of 16HBE cells (Figure 4.8). These results suggested that the
bio-functionalised gold substrate was able to capture TNAP+ DPSCs in a specific way.
Figure 4.8: Graph showing the numbers of cells that were attached to 1 cm2 gold surfaces
that were functionalised with 2 µg/mL anti-TNAP antibody. DPSC and 16HBE cell
numbers between 1 ×106 - 0.06 ×106 cells were incubated on the surface, before being
washed and counted. A much larger number of DPSCs were bound to the anti-TNAP
antibody functionalised surfaces when compared to 16HBE cells. Data shown is the mean
of the cell counts from five images represented as mean ± SEM.
4.4.2 Investigation into the impact of antibody density on the
functionalised gold surface
Further investigations were carried out to determine the impact of the surface density of
immobilised anti-TNAP antibody on the gold surface to provide a better understanding
of the optimum concentration of antibody required for cell capture. A range of human
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TNAP protein concentrations (between 2 - 0.03 µg/mL) were incubated on surfaces
functionalised with three concentrations of anti-TNAP antibody (10, 2 and 1 µg/mL).
The presence of TNAP that was captured on the surface was detected by the enzymatic
activity using pNPP and the absorbance of the 4-nitrophenol product, that is yellow in
colour, was measured at 405 nm. Therefore the amount of TNAP protein that is bound
on the surface post washing was estimated by measuring the amount of dephosphorylated
substrate.
Figure 4.9: Graph showing the optical density from 1 cm2 gold surfaces that were
functionalised with 10, 2 and 1 µg/mL anti-TNAP antibody before a range of human
TNAP protein concentrations between 2 and 0.03 µg/mL were incubated on the surface,
then washed and detected with pNPP. Absorbance was measured at 405 nm. The
amount of TNAP protein bound onto the surface correlates with anti-TNAP antibody
concentrations used to functionalise the surface. Error bars represent the mean ± SEM.
n=2.
The anti-TNAP antibodies were able to capture TNAP protein at all three concentrations
used for functionalisation in this study (10, 2 and 1 µg/mL) (Figure 4.9). This indicates
that the method of covalently attaching anti-TNAP antibodies to the SAM via EDC/NHS
[168, 167] was effective and the surface was beginning to reach saturation even at the
lowest antibody concentration. However, there was a clear difference between the amount
of TNAP protein which was captured on the surface at the different concentrations of
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anti-TNAP antibodies used for functionalisation. For all dilutions of anti-TNAP antibody
used to functionalise the gold surface, the optical density measured after incubation with
different concentrations of TNAP protein and detection with the substrate, followed a
similar pattern. The optical density measured indicated the amount of TNAP protein that
was bound to the functional surface.
A gold surface prepared using 10 µg/mL anti-TNAP had the highest optical density
after incubation with TNAP protein followed by measurement of enzyme activity, then
followed by the gold surfaces prepared using 2 and 1 µg/mL anti-TNAP antibody (Figure
4.9). The higher optical density obtained indicated that a greater amount of TNAP protein
was bound to the functional surface, suggesting a higher surface density of anti-TNAP
antibodies at higher concentrations. These results suggest that lower dilutions of anti-
TNAP antibody covalently attached to the SAM, resulted in a lower surface density,
leading to reduced capture in the amount of TNAP protein. The observed plateau here
is caused by surface saturation, however it can also been seen that the surface at these
concentrations had not reached a saturation point, though this may not be a problem in
regards to optimal cell capture which is discussed in detail in section 4.4.3.
To further assess the optimisation of antibody density for surface capture of cells rather
than TNAP protein, the experiment was repeated using human DPSCs. Again the
number of cells captured by the surface was estimated using the pNPP assay as described
previously. DPSCs were present on the surface after washing at all starting concentrations
of antibodies used (Figure 4.10), but there was the clear difference between the result seen
when using cells compared to the results using TNAP protein (Figure 4.9) in that there
was no clear separation in optical density values for the different antibody concentrations
used. For each dilution of anti-TNAP antibody used to functionalise the surface (Figure
4.10) there was no correlation with final DPSC numbers remaining on the surface. This
suggests that the amount of DPSCs bound onto the surface was independent of the anti-
TNAP antibody concentrations used to functionalise the surface.
4.4.3 Specificity of capture of DPSCs on the antibody functionalised
gold surface at different antibody concentrations
In order to determine the specificity of the antibody functionalised surface prepared using
different antibody concentrations, varying numbers of DPSCs and 16HBE cells were
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Figure 4.10: Graph showing the optical density from 1 cm2 gold surfaces that were
functionalised with 10, 2 and 1 µg/mL anti-TNAP antibody before a range of human
DPSC numbers between 2 ×106 - 0.06 ×106 cells were incubated on the surface, before
being washed and detected with pNPP. Absorbance was measured at 405 nm. The
amount of DPSCs bound onto the surface showed a minimal relationship with the anti-
TNAP antibody concentrations used to functionalise the surface. Error bars represent the
measurement error (mean ± SEM.)
incubated onto gold surfaces functionalised with three concentrations (10, 2 and 1 µg/mL)
of anti-TNAP antibody. These surfaces were washed and then the remaining cells were
counted using the method described in section 4.3.3. The result (Figure 4.11) clearly
demonstrated the ability of the surface to capture TNAP+ DPSCs in contrast to TNAP-
16HBE cells. For example, when incubating 1 ×106 DPSCs or 16HBE cells on each
of the surfaces functionalised with 10, 2 or 1 µg/mL anti-TNAP antibody, after washing
there was a 40 fold greater number of DPSCs bound compared to 16HBE cells. For all of
the different samples with different starting cell numbers, the number of DPSCs attached
to the surface after washing was greater when compared to numbers of 16HBE cells. As
with the previous results detecting the bound cells by their TNAP activity (Figure 4.10),
the antibody surface density is sufficient for capture for the same amount of DPSCs at
all three antibody concentrations. There was also no difference in the amount of DPSCs
bound for each antibody dilution onto the functionalised gold surface at each number
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of cells incubated. This agreed with the result obtained when assessing DPSCs capture
via the pNPP assay (Figure 4.10). These results suggests that the functionalised surfaces
prepared with lower antibody dilutions of 2 and 1 µg/mL have a similar efficiency of
DPSC capture to surfaces prepared using 10 µg/mL antibody concentration.
Figure 4.11: Graph showing cell numbers remaining after washing from 1 cm2 gold
surfaces that were functionalised with 10, 2 and 1 µg/mL anti-TNAP antibody. A range of
human DPSCs and 16HBE cell numbers between 1 ×106 - 0.06 ×106 cells were incubated
on the surface, before being washed and counted. A greater number of DPSCs were bound
on all surfaces functionalised with different antibody concentrations compared to 16HBE
cells. The data within the dotted line is presented in Figure 4.12. Data shown is the mean
of the cell counts from five images represented as mean ± SEM.
The level of (non-specific) 16HBE cell attachment to the functionalised surfaces prepared
with different anti-TNAP antibody dilutions was also analysed. There were no observed
differences in the number of 16HBE cells bound at different anti-TNAP dilutions with
increasing 16HBE cell numbers (Figure 4.12). However, the expected increase in numbers
of 16HBE cells bound to the surface with increasing cell numbers introduced onto the
surface was seen across all antibody dilutions. As there was no difference in the numbers
of 16HBE cells attached to surfaces functionalised with different antibody dilutions, this
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suggests that the non-specific binding is due to the cell-surface interactions rather than
non-specific binding events between the cell and the antibody per se. This is important to
consider when developing a microfluidic device for cell capture as minimal non-specific
cell binding with the anti-TNAP antibody would be required.
Figure 4.12: Graph showing enhanced scale of data surrounded by a dotted line in Figure
4.11. Gold surfaces (1 cm2) were functionalised with 10, 2 and 1 µg/mL anti-TNAP
antibody. 16HBE cell numbers between 1 ×106 - 0.06 ×106 cells were incubated on
the surface, before being washed and counted. The number of 16HBE cells bound was
independent of the concentration of anti-TNAP antibody used to functionalise the surface.
Data shown is the mean of the cell counts from five images represented as mean ± SEM.
4.4.4 Microfluidic device development
A microfluidic device was developed in which populations of DPSCs could be flown
across the gold substrate functionalised with anti-TNAP antibodies for specific capture
and release of TNAP+ DPSCs. This first part of the device design was the requirement of
a flow cell (Figure 4.1) to allow all parts such as valves and microfluidic tubing to be held
together. The flow cell was designed then 3D printed using the fused filament fabrication
method where a filament of polylactic acid (PLA) is heated up, forced through a nozzle
and deposited on a print bed to create the required design. The microfluidic channels
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used within the device were created out of PDMS, an elastomer which can be cured onto
a mould to create the required channels. The PDMS master moulds were printed on a
stereolithography 3D printer where the microfluidic master moulds were formed layer-
by-layer using a photo-curable resin. The use of 3D printing technology allowed a new
flow cell and microfluidic channel set up could be designed, printed and assembled in just
one day.
The microfluidic channel height was chosen at 300 µm, which is much larger than the
expected size of DPSCs (∼ 23 µm). Whilst a smaller channel height would increase the
cells’ contact with the functionalised surface the one designed aimed to minimise any
issues with cell clogging within the channel, whilst providing a reasonable time for cells
to sediment onto the surface. The microfluidic channel was designed as a straight channel,
20 mm in length and 5 mm in width (Figure 4.13. b). Optimisation had been done prior
and investigated the use of a ‘S’ shape channel for an increase in surface area, however this
resulted in many problems with dead volume at the curvature of the channel, therefore a
straight channel was used to avoid this. The total surface area of the channel and therefore
the exposed functionalised gold substrate utilised for cell capture, was 94.63 mm2. Based
on these dimensions the total injectable volume into the device is approximately 140 µl.
The initial injection of buffer into the channel covered all of the gold substrate surface area
within the device enabling antibodies to be immobilised onto the surface. Air bubbles are
a common problem in microfluidics and once entered into the microfluidic system they
can be difficult to remove and detrimental for any experiment. Raised cylinders known
as “bubble traps”, 5 mm in diameter were added to the ends of the microfluidic channel.
The cylinders were 5 mm in height at the input and 1.3 mm in height at the output (Figure
4.13. a). These were designed so that any air bubble injected into the system would rise
to the top of the cylinders and not enter into the microfluidic channel.
To assemble the device, the gold surface functionalised with a SAM (Section 4.3.1) was
placed in the alignment slot on the flow cell (Figure 4.1). The PDMS microchannels
were cleaned by sonication in 100 % isopropyl alcohol, dried by nitrogen gas then placed
on top of the functionalised gold substrate. Then a custom laser-cut perspex clamp was
screwed into the flow cell on top of the PDMS, applying pressure to sandwich the PDMS
to the surface sealing the microchannels. The perspex lid applied enough pressure to
create a tight reversible fluidic seal. Once the channels were in place and clamped onto
the functionalised gold substrate, the fluidic tubing was then inserted into the inlet and
outlet of the PDMS channel creating a sealed fluidic system.
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Figure 4.13: (a) Schematic of microfluidic channel assembled over the gold surface
modified with anti-TNAP antibodies immobilised a the SAM layer. The fluidic path
through the channel is shown, with bubble traps utilised to capture any air that was
injected (b) Width and length of microfluidic channel designs.
The anti-TNAP antibodies were then immobilised onto the gold substrate through fluidic
injections and incubation as described in section 4.3.5. Briefly anti-TNAP antibodies were
immoblised onto the gold substrate functionalised with a carboxylic terminated SAM
by EDC/NHS cross-linking chemistry. Once the surface was functionalised with anti-
TNAP antibodies, the device could then be utilised for injecting DPSCs for cell capture
via recognition of surface marker TNAP and subsequent release. The device could be
connected via a syringe pump for precise control over flow rate through the microfluidic
channel. Two flow cells were fabricated, the first device (Figure 4.14) was capable of
running two parallel channels which enabled different controls or cell types to be flown
across the same surface through different channels. An additional flow cell was created
capable of running 3 parallel channels (Figure 4.15). This utilised the excess previously
unused area of the gold substrate for further functionalisation and cell separation.
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Figure 4.14: Photograph of 3D printed device capable of running two parallel microfluidic
channels used in this chapter. Two PDMS microchannels were clamped onto a gold
substrate functionalised with monothiol-alkane-PEG acid SAM before all tubing was
connected.
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Figure 4.15: Photograph of device cabaple of running three parallel microfluidic channels
used in this chapter. A 3D printed flow cell was used to support all the required tubing
and valves. Three PDMS microchannels were clamped onto a gold surface functionalised
with monothiol-alkane- PEG acid SAM before the tubing was connected. Four way input
valves were used for input into the channel with a stopper valve at the output to allow
necessary incubation in the channel.
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4.4.5 Specific cell capture of DPSCs within the microfluidic device
For cell capture experiments DPSCs were cultured at 5×104 cells/cm2 for 7 days to
increase TNAP expression (Section 2.4), before a cell suspension of 2×106 cells/mL in
α-MEM culture medium was prepared for injection into the microfluidic device. Plain
α-MEM culture medium was used instead of normal basal medium to minimise any non-
specific interactions that may of occurred with fetal calf serum on the antibody surface.
Any unwanted non-specific binding would decrease the capture efficiency of the antibody
functionalised surface. As described in section 4.3.6, the cell population was injected into
the device and incubated on the surface for 5 minutes at room temperature. During this
period five random images of the surface were taken for cell counts. After incubation, the
fluidic path was re-opened and α-MEM culture medium was introduced at 100 µL/min
for 10 minutes to elute unbound cells from the device. After fluidic flow another five
images were taken, allowing the percentage of captured cells to be calculated from these
cell numbers (see section 4.3.7). The same number of DPSCs and 16HBE cells were
incubated on the surface prior to flow (Figure 4.16, (a) and (c)). The number of DPSCs
remaining (Figure 4.16 b) was much greater compared to the number of 16HBE cells
remaining after fluidic flow (Figure 4.16 d). This agrees with the previous results in
section 4.4.1, and also demonstrates that DPSCs can be specifically captured utilising
fluidic flow in a microfluidic system.
To demonstrate specificity of the antibody functionalised surface and the ability to
specifically capture TNAP+ DPSCs within the microfluidic device, cell capture was
undertaken using DPSCs cultured at 5×104 cells/cm2 or 5×103 cells/cm2 for 7 days and
16HBE cells using the method as described in section 4.3.6. Varying the seeding density
would alter the TNAP expression of the DPSCs, with higher seeding densities having a
larger percentage of TNAP+ cells [17]. The percentage of captured cells could then be
calculated from counting the number of DPSCs and 16HBE cells at the initial injection
and comparing to the number of cells remain following incubation and washing (Figure
4.17). After cell incubation on the surface and subsequent reintroduction of plain α-
MEM fluidic flow of 100 µL/min for 10 minutes to elute the unbound cell population,
53.4 ± 14.2% of DPSCs cultured at 5×104 cells/cm2 were captured from the initial
cell population injected. This was a significant increase (P ≤ 0.001) compared to 8.0
± 4.0% of 16HBE cells captured using the same device. Cell capture in the device was
repeated with DPSCs cultured at 5×103 cells/cm2. After media flow to elute the unbound
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Figure 4.16: Microscopy images showing cell capture of DPSCs on the antibody
functionalised surface within the microfluidic device. Cells were injected, then incubated
on the surface for 5 minutes before washing for 10 minutes with 100 µL/min α-MEM
culture medium flow. (a). DPSCs initial cell injection during 5 minute incubation on the
antibody functionalised surface within the microfluidic device. (b). DPSCs remaining on
the surface after 10 minutes of 100 µL/min α-MEM culture medium flow. (c). 16HBE
cells after initial cell injection during five minute incubation. (d). 16HBE cells remaining
on the surface after 10 minutes of 100 µL/min α-MEM culture medium flow. Scale bar
represents 250 µm.
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population, 30.3 ± 17.2 % were captured. This was a significant decrease (P ≤ 0.05)
compared to the number of DPSCs captured from the 5×104 cells/cm2 DPSC population.
A significantly increased percentage (P ≤ 0.05) of the 5×103 cells/cm2 DPSCs were
captured compared to 16HBE cells. The low percentage of bound 16HBE cells most
likely accounts for any non-specific cell binding to the functionalised surface (as also seen
in section 4.12). The percentage of captured cells was higher in the cell population with
a larger amount of cells expressing TNAP. This combined with the significantly larger
population of DPSCs captured compared to 16HBE cells provides quantitative data to
support what was previously seen qualitatively in that TNAP+ DPSCs are being captured
on the functionalised surface within the microfluidic device.
Figure 4.17: Graph showing percentage of DPSCs cultured at 5×104 cells/cm2 or 5×103
cells/cm2 for 7 days and 16HBE cells, bound on the antibody functionalised surface within
the microfluidic device after a 5 minute incubation, followed by elution of the unbound
cell population with 100 µL/min α-MEM culture medium flow for 10 minutes. Data
represented as mean ± SD. n = 4. * = P ≤ 0.05. *** = P ≤ 0.001.
4.4.6 Release of captured DPSCs within the microfluidic device
Captured cells had to be released from the surface in order to deliver an enriched TNAP
population. A method of increasing the fluid flow was investigated as it was considered
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to be the simplest method to release the captured cells from the functionalised surface. It
was noticed that when manual injecting α-MEM culture medium at high flow rates the
majority of bound DPSCs could be released from the surface. This represented a ‘burst
flow’ where high flow rates at approximately 1 - 2 mL/min were pumped through for
short time periods and were able to provide enough shear force to release cells from the
surface. However to ensure reproducibility of the release mechanism, fluid flow needed
to be controlled with a syringe pump. A maximum flow rate of 1.5 ml/min was seen to
be sufficient for release and at higher flow rates the fluidic seal from the PDMS clamped
with perspex to the surface would leak and be detrimental to the experiment. A constant
high flow rate would result in an initial release, but once the flow became established there
was limited subsequent cell removal. By alternating between a high and low flow rates,
cells could be repeatedly be released from the surface via the initial burst from a high
flow rate. A flow rate sequence of 1.5 mL/min for 2 seconds, followed by 0.1 mL/min
for 1 minute repeated continuously for 1 minute was chosen to investigate cell release.
This interval times of 2 and 1 seconds provided enough time for the flow to be established
at the different high and low flow rates and after one minute there was no more release
of any of the remaining bound cells. The syringe pump could be programmed to change
the flow rate over a set time period, this allowed programming of a sequence where fluid
flow would alternate between high and low rates to simulate the manual release of burst
flow. This provided a simple release mechanism so enough cells could be released for
characterisation after separation.
Cell release by an increase in flow was carried out straight after the the unbound
population had been eluted from the surface (Figure 4.18 (a)). After this, the programmed
flow rate described above was then introduced for one minute. Cell release was carried out
using plain α-MEM culture medium, pH 7.4 (Figure 4.18 (b)), with cells being removed
from the surface throughout the programmed sequence. The programmed cell release
appeared to deliver an increase in fluidic shear force which was large enough to remove
cells that were bound via the antibody on the surface. A second strategy investigating
the use of a pH change for cell release was also investigated, as a change in pH may
also reduce the binding strength of the antigen-antibody complex [209]. Therefore a
pH change could potentially increase the percentage of cells released from the surface,
and may enable subsequent reduction in flow rates to minimise damage to the released
cell population. The programmed cell release was investigated using pH 6.5 and pH
8.5 phosphate buffers, these buffers were injected at the programmed release flow rate
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immediately following unbound cell removal. The effect of a 10 minute incubation of the
bound cells in pH 8.5 phosphate buffer prior to programmed release was also investigated,
to see incubation in a higher pH buffer would cause an effect on cell release.
Figure 4.18: Microscopy images showing DPSCs bound to the antibody functionalised
surface within the microfluidic device before and after programmed fluid flow with α-
MEM culture medium to enable cell release. (a). DPSCs remaining bound to the surface
after 10 minutes of 100 µL/min α-MEM culture medium flow. (b). DPSCs remaining
after utilising programmed flow (1.5 mL/min for 2 seconds, followed by 0.1 mL/min for
1 second and then repeated for 1 minute) in α-MEM culture medium. Scale bar represents
250 µm.
Using programmed flow to release the bound cells there was no significant difference
(P>0.05) in the percentage of released cells when buffers of different pH were used
(Figure 4.19). This suggests that the antibody binding strength was not decreased
sufficiently enough at the different pH to increase the percentage of released cells from
programmed flow. The effect of a 10 minute pH 8.5 incubation before programmed
release (Figure 4.19) showed that the percentage of cells released decreased significantly
(P ≤ 0.01) to that of 30 ± 4 %. This is probably either due to the increased incubation
time of the cells on the surface leading to a larger amount of antibody-cell binding,
or cells are beginning to form non-specific interactions with the functionalised surface
increasing the strength at which they are bound. However 58 ± 3 % cells can be
released using the programmed flow in plain α-MEM culture medium at pH 7.4. After
the cells had been released they were then counted using a hemacytometer as described
in section 2.4.3. After the programmed release in plain α-MEM culture medium,
approximately 1 - 4 ×104 cells were released for each microfluidic channel. Both devices
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had multiple channels so identical cell separations could be run in parallel across the
same antibody functionalised surface enabling released cells from multiple channels to
be pooled together for downstream analysis.
Figure 4.19: Graph showing percentage of DPSCs released from the functionalised
surface within the microfluidic device after removal of unbound cells using programmed
release with pH 7.4 plain α-MEM culture medium, and phosphate buffer at pH 6.5 and pH
8.5. A 10 minute incubation using phosphate buffer pH 8.5 prior to programmed release
was also investigated. Data shown as mean ± SD. n = 4. ** = P ≤ 0.01. n.s = not
significant.
4.4.7 Quantifying the level of TNAP+ DPSCs before and after cell
separation
After cells had been captured and released utilising programmed flow in plain α-MEM
within the microfluidic device, they were then analysed using flow cytometry to determine
the percentage of TNAP+ cells before and after cell separation. The released population
from multiple microfluidic channels was pooled together and the percentage of TNAP+
cells was compared to that of cells which were held in plain α-MEM culture medium, for
the experimental duration, that had not undergone separation. Gating for flow cytometry
was carried out as previously described in section 3.3.2. Briefly the intact cell population
was gated from forward and side scatter, before the gate for the isotype control, to factor
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for non-specific antibody binding, was set at 98%. Any positive staining past this gate
was taken to be significant and used to calculate as the percentage of TNAP+ DPSCs
(Figure 4.20). During this study, donor variability was assessed by using DPSCs for three
different donors. For each donor, the experiment was repeated on three separate occasions
with the device being assembled, cells separated then analysed on each repeat.
Figure 4.20: Representative histograms of flow cytometric analysis of TNAP+ DPSCs
for one DPSC donor before and after cell separation. (a). Histogram containing the
unstained, isotype control and anti-TNAP antibody for DPSCs before cell separation.
(b). Histogram containing gate set with isotype control at 98% allowing the percentage
of TNAP+DPSCs to be measured before cell separation. (c). Histogram containing the
unstained, isotype control and anti-TNAP antibody for DPSCs after cell separation. (d).
Percentage of TNAP+ DPSCs after cell separation.
DPSCs obtained from all three donors showed a significant increase in the percentage
of TNAP+ cells after undergoing cell separation compared to the percentages of DPSCs
expressing TNAP before separation (Figure 4.21). The percentage of cells expressing
TNAP increased significantly (P ≤ 0.01) for donor 1 from 23 ± 3 % to 50 ± 12 %.
This represents a 117 % increase in the number of TNAP+ DPSCs within the released
population. Donor 2 TNAP+ cells also increased significantly (P ≤ 0.01) from 37 ± 8 %
to 73 ± 4 %, representing a 97 % increase in TNAP+ DPSCs. The TNAP+ percentage
before separation was unusually high for donor 3, at 78 ± 5 %, however there still was a
significant increase (P ≤ 0.05) to 89 ± 1 % in the separated population. This was a 14 %
151
increase in the number of TNAP+ cells released after cell separation.
Figure 4.21: Graphs showing the results of flow cytometric analysis for TNAP+ DPSCs
before and after cell separation for cells from three different donors. In all cases DPSCs
obtained after binding and elution in the cell separator showed a significant increase in
the TNAP+ cell population. Data represented as mean ± SD. n = 3 .* = P ≤ 0.05. ** = P
≤ 0.01.
4.4.8 Investigation to determine the possibility of any antibody
attachment to the cells after cell release from the device
In order to be classed as a minimally manipulative therapy the separation process
developed here would need to have no alteration of the biological or physiological aspects
of the DPSCs. The device utilises antibody binding to capture TNAP+ cells, before
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washing the surface and releasing the cells with an increase in flow rate. However it
was not known whether the cells were being released by removing bound TNAP+ cells
directly from the antibody on the surface or whether the fluid flow caused the cells to be
released as a complex with the antibody still attached. To investigate if cells were released
with the antibody still attached, DPSCs obtained both before and after separation were
stained with a goat anti-mouse APC antibody which was capable of detecting the TNAP
antibodies used in binding. Flow cytometric analyses demonstrating the anti-TNAP
antibody can be recognised by the goat anti-mouse APC antibody is shown Appendix A.
Following incubation, DPSCs were then analysed with flow cytometry (Figure 4.22). For
the population before cell separation, 2.2 ± 2.6 % cells were positively stained compared
to the isotype control demonstrating minimal non-specific binding. The cell population
after separation through the microfluidic device had increased mean fluorescence intensity
values of 5.6 ± 2.8 %, but this was not significant when compared to the before cell
separation population. This data indicates that cells are released with minimal anti-TNAP
antibody still attached.
Figure 4.22: Graphs showing the results of flow cytometric analysis for DPSCs stained
with goat anti-mouse APC antibody before and after cell separation. There was no
significant difference in the amount of anti-TNAP antibody detected suggesting that
release of bound cells from the device was not due to antibodies being released from
the functionalised surface. Data shown as mean ± SD. n = 3.
153
4.5 Discussion
In this chapter a novel microfluidic device was developed, manufactured and assembled
to deliver an enriched TNAP+ cell population from a mixed (TNAP+/TNAP-) population
of DPSCs. Cells were injected into the device and captured on a gold substrate
functionalised with an anti-TNAP antibody. Following capture, the cells were then
released by an increase in fluid flow rate. This cell separating microfluidic device aims to
deliver a population of a minimally manipulated, label-free TNAP enriched DPSCs which
would have potential as a cell source for skeletal tissue repair.
4.5.1 Functionalsition of gold surfaces with anti-TNAP antibody
Before cell separation experiments with the microfluidic device, successful
immobilisation of an anti-TNAP antibody onto the gold surface functionalised with a
carboxylic terminated SAM using EDC/NHS had to be demonstrated, followed by the
ability of the antibody functionalised gold surface to specifically capture TNAP+ DPSCs.
TNAP protein was used to demonstrate that for the different concentrations of anti-TNAP
antibody (10, 2 and 1 µg/mL) incubated onto the surface there was a clear correlation
with the amount of TNAP protein which was captured. When a higher anti-TNAP
antibody concentration was used to functionalise the surface, a greater amount of TNAP
protein was captured on the surface.
The surface density of anti-TNAP antibody molecules immobilised on the surface of
functionalised gold surface can be estimated. TNAP protein bound to the antibody
functionalised surface can be detected through a pNPP assay, therefore the optical
density measurement of the product from the substrate provides an estimation of surface
density. By using the data of the highest concentration of TNAP protein (2 µg/mL)
incubated, before subsequent washing, and comparing to a known standard curve of
TNAP molecules, an estimation of the number of TNAP molecules bound to the 1 cm2
antibody functionalised gold surfaces can be made. The optical density used in the
calculation should be taken from the incubated TNAP protein concentration where the
saturation in the optical density had been reached. However, even at the highest dilution
of TNAP antibody saturation of the surface had not been reached in these experiments
(Figure 4.9). Therefore as the surface remains unsaturated with antibody the following
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estimation of the antibody surface density would be an under estimation of the true value.
If it is assumed the binding is monovalent meaning there is a 1:1 TNAP molecule to
antibody binding ratio an estimate of the antibody surface density immobilised on the gold
substrate can be made (Table 4.1). Another assumption made for this calculation is that
all antibody molecules have been covalently attached to the gold substrate functionalised
with carboxylic acid terminated SAM via primary amine groups within the Fc region
of the antibody, therefore leaving the antigen binding sites available for protein capture.
Therefore these calculations would most likely be an over estimation of the true value of
the antibody surface density.
The number of TNAP molecules per TNAP+ DPSC was estimated in the previous chapter
at 2.8 ×105 TNAP molecules per DPSC (see section 3.4.4). The average diameter of a
DPSC was measured at ∼ 23 µm. For this calculation DPSCs are assumed to be spherical
and therefore have an approximate surface area of 1.6 ×103 µm2. Therefore there is a
density of 168 TNAP molecules per µm2 on the surface of DPSCs. An estimation of the
ratio of anti-TNAP antibody molecules available on the surface for each molecules of
TNAP on the surface of DPSCs can made. It could be estimated at the highest antibody
concentration of 10 µg/mL there were 3.82 times the number of anti-TNAP antibodies
available for binding per µm2 compared to the number of TNAP molecules per µm2 on
the surface of each DPSC. Even at the lowest antibody concentration of 1 µg/mL there was
2.17 times the number of antibody molecules available for binding on the functionalised





Ratio of antibody molecules to TNAP
molecules on the surface of DPSCs
10 6.45 ×102 3.82
2 5.38 ×102 3.19
1 3.66 ×102 2.17
Table 4.1: Table depicting the surface density of antibody molecules on surfaces
functionalised with three concentrations of anti-TNAP antibody (10, 2 and 1 µg/mL) and
the ratio of antibody molecules per µm2 of the functionaslied surface compared to the
number of TNAP molecules per µm2 on the surface of DPSCs.
The capture of human TNAP protein with the anti-TNAP antibody functionalised
substrate demonstrates that anti-TNAP antibodies were cross linked through the
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carboxylic acid head group present on the SAM, which is a proven methodology of
attaching proteins to a functionalised surface within the Bioelectronics group at the
University of Leeds [168, 167], and the use of the pNPP assay showed that antibody
binding did not inhibit TNAP protein enzymatic function. The different concentrations
of antibody for covalent attachment to the SAM showed distinct surface densities from
differences in TNAP protein capture. However the different antibody surface density may
be sufficient in capturing the same amount of cells due to the vast difference in scale
of a TNAP protein (∼ 10 nm) to a DPSC (∼ 23 µm). The same experiment was then
repeated with a range of DPSC numbers incubated on the antibody functionalised surface
to understand further the optimal antibody concentration for cell capture. When DPSCs
were captured on the surface with varying concentrations of anti-TNAP antibody there
was no obvious relationship between antibody concentration and the number of DPSCs
bound (Figure 4.10). This suggests that even though there are differences in the antibody
density on the surface (Table 4.1), the antibody density even at the lower concentration
was sufficient to capture similar levels of DPSCs. This result was then supported with
the estimation of the surface density of antibody molecules because even at the lowest
antibody concentration (1 µg/mL) the density of antibody molecules was still in excess of
that of the number of TNAP molecules available for binding on the cells surface.
The experiment was repeated using 16HBE cells. These are TNAP negative and therefore
the pNPP assay cannot be used for detection, therefore the numbers of bound 16HBE
and DPSCs were counted after washing (Figure 4.11). The cell counts for DPSCs
confirmed there was no clear association with concentration of anti-TNAP antibody used
for capture of DPSCs. This is the same result as that seen when pNPP assays were
used to quantify cells bound and supports the hypothesis that the density of antibody
molecules on the surface at each concentration is in excess compared to the number
of TNAP molecules on the cell surfaces available for binding. It was also shown that
a significantly higher number, up to a 41 fold increase, of DPSCs that were bound
compared to 16HBE cells under all conditions used, demonstrating the specific binding
of TNAP+ DPSCs onto the functionalised gold substrate. Non-specific binding to the
functionalised surface was observed where a greater number of 16HBE cells were bound
with higher numbers of incubation. However the number of 16HBE cells bound at all
three antibody concentrations remained similar, suggesting that the surface density of
antibody molecules does not play a role in non-specific binding of 16HBE cells. These
results demonstrated that the gold substrates could be successfully functionalised with
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anti-TNAP antibodies and could specifically capture DPSCs presumably via cell surface
marker recognition. They also provided insight into the amount of antibody required to
be immoblised on the gold substrate for specific cell capture within a microfluidic cell
separator.
4.5.2 Microfluidic device development
A microfludic device was developed to be able to flow populations of DPSCs across the
anti-TNAP antibody functionalised surface for capture and then subsequent release of
TNAP+ cells. The flow cells designed to hold all components, such as valves and tubing,
of the microfluidic device were 3D printed using a fused filament fabrication method.
The microfluidic channels were created from PDMS. The advantages of using PDMS
within this device are that it is inexpensive, biocompatible, optically transparent and easily
bonded to other surfaces [116]. Typically the creation of PDMS channels for microfluidics
requires the use of a clean room facilities using photolithography to define the master
moulds [116], before using soft lithography to cast and cure the PDMS onto the mould.
An alternative approach is the use of 3D printing for the creation of the master moulds
which allows rapid prototyping and a much reduced cost.
The microfluidic channels master moulds were printed from 3D designs using a
stereolithography 3D printer. This allowed rapid prototyping of the PDMS channels
designs used within this device at a much reduced cost, with shorter fabrication times
and high reproducibility. However clean room facilities were still required to deposit a
thin fluorocarbon coating onto the PDMS master mould on the surface in a reactive-ion
etching chamber, as the PDMS cannot cure completely due to the acrylic chemistry of
the 3D printing resin. The fluorocarbon coating passivates the surface making it highly
hydrophobic, so the PDMS can cure completely and aids in removal of the cured PDMS
from the surface [120]. A desirable option would be a resin which PDMS can be cured
directly upon allowing true one step production of PDMS master moulds without any use
of clean room facilities. The 3D printing additive manufacturing processes served two
main purposes in cost saving whilst also allowing for rapid prototyping.
The PDMS microfluidic channels were then clamped onto the antibody functionalsied
surface by clamping between a perspex lid and the flow cell creating a sealed fluidic
system. This conformally fluidic sealing method cannot withstand as high a pressure as
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an irreversible sealing process such as plasma bonding, conformally sealed structures can
withstand pressures of 5 psi where irreversibly sealed structures can withstand pressures
of 30-50 psi [210]. However due to the nature of this work the PDMS channels were
required to be recovered, as the antibody functionalised surface could only be used
once per experiment. Once the device was sealed and fully assembled the anti-TNAP
antibody could be immobilised onto the surface via injections into the device followed by
subsequent TNAP+ cell capture and release.
4.5.3 Capture and release of TNAP+ cells on the antibody
functionalised surface within the device
When cells were captured on the functionalised surface in the device by incubation
and elution of the unbound cells, there was once again a significant increase in the
percentage of DPSCs captured to that of 16HBE cells. In addition, DPSCs cultured at
higher seeding densities (5×104 cells/cm2) and therefore having a greater percentage
of TNAP expressing cells [17], resulted in a larger percentage of cells captured on the
surface compared to DPSCs cultured at lower seeding densities (5×103 cells/cm2). This
provided further evidence that TNAP+ DPSCs can be captured specifically on an anti-
TNAP antibody functionalised surface. However, the main development was this specific
capture occurring within a microfluidic device which can deliver controlled fluidic flow
for cell capture and release.
The use of antibodies for positive cell capture on a surface is efficient [148] but
problematic when needing to release captured cells with minimal stress. The release of
bound cells from the surface in microfluidic devices through enzymatic digestion [211] or
through an external stimulus such as temperature change or electrical potential [212] has
been previously reported. Yet the use of an increased flow rate to increase the shear force
on the bound cells provides a simple method of release with no additional factors [204].
In this thesis the cells adhered to the antibody immobilised surface required a shear force
greater than that of the binding forces with the anti-TNAP antibody to achieve cell release.
The flow rate at which cells could be released was therefore investigated. It had been
observed that manual injection in short bursts at high fluid flow was sufficient to remove
cells from the surface, for repeatability this was programmed into a syringe pump. Plain
α-MEM culture medium at pH 7.4 could be used to release 58% of bound cells from the
antibody functionalised surface. However it must be noted that this programmed release
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mechanism within the microfluidic channel is a parabolic flow, therefore the velocity at
the edges of the channel would be much reduced. This caused the majority of the cells
released to be in the middle of the channel, with large numbers of cells remaining at the
edges after the release mechanism. Further work would be needed to address this issue
to increase recovery, but the number of cells recovered was sufficient for downstream
analysis. The effect of this release mechanism on the potential use of cells in downstream
applications for bone regenerative therapies will be reported in the next chapter.
Further investigations into specific flow rates and therefore detailed calculation of shear
stress for the flow release mechanism would be required to further optimise the release
of cells using the programmed flow release mechanism described. For example a
microfluidic device utilising an antibody functionalised surface to separate out CD4+
cells from whole blood has shown that different cell types respond differently to shear
stresses within the device [213]. Here it was shown that cells have optimal binding at
different ranges of shear stress under dynamic flow, which alters capture efficiency [213].
This could be investigated within this work to provide optimisation of the shear stress
required for a higher percentage of TNAP+ cell capture. The shear stress could be altered
through changes in the flow velocity or the microfluidic channel shape and dimensions.
However it must be noted that increases in the shear stress applied to cells for capture
or release may alter their biological characteristics and therefore may not be classed as
a minimally manipulating cell separation. Full optimisation of the release mechanism
was not performed as the number of cells released from the methodology developed, and
when pooled together with cell separations from multiple channels, was sufficient for
performing experiments to characterise the released cell population.
The use of a pH change was also investigated as a possible method to increase the
percentage of bound cells released from the surface as a mild change to basic or
acidic conditions from a neutral pH may reduce binding affinity through increasing the
equilibrium dissociation constant [209] weakening the antigen-antibody complex. If the
antigen-antibody complex is weakened a larger percentage of cells may be released from
the surface, or a lower release flow rate could be investigated which will minimise damage
to the cells. However, in these studies release of bound cells using either a pH 6.5 or 8.5
phosphate buffer resulted in no significant change in the percentage of cells released,
suggesting that small pH changes did not significantly affect the binding strength to
increase the percentage of released cells. An incubation in pH 8.5 buffer for 10 minutes
prior to programmed fluid flow was also investigated, but significantly fewer cells were
159
released from the surface in this case. This could possibly be due to cells forming non-
specific contacts with the surface during the incubation period or a greater number of
antibody-antigen complexes forming leading to greater cell binding onto the surface.
Buffers with higher or lower pH values were not investigated due to possible negative
effects on cell viability [214]. Nevertheless, the programmed fluid release in plain α-
MEM culture medium was able to release 58% of the cells captured which was between
1 - 4 ×104 cells per microfluidic channel, then multiple released cell populations were
combined together to allow characterisation of the separated population.
TNAP+ DPSC enrichment using the device was investigated for three different donors.
Donors 1 and 2 expressed levels of TNAP that would be expected when seeded at 5×104
cells/cm2 for 7 days [17], but donor 3 had higher levels of TNAP expression. This
highlights donor variability in TNAP expression by DPSCs which is dependent on a
variety of factors such as donor age and health [215]. It is important to assess donor
variability in the device as if used therapeutically, separation would occur on an individual
donor basis. After undergoing cell separation, the DPSCs expressing TNAP for donors 1
and 2 increased by 117 % and 97% respectively, demonstating a two fold enrichment of
TNAP+ cells.
An alternative approach into how well the device performs was to look at the depletion
of TNAP- cells (Table 4.2) from the starting population. From this it can be seen that
even though the enrichment of TNAP+ cells for donor 3 was low, the device was able
to remove 50% of the TNAP- cell population. This is comparable to what was seen for
both donor 1 and 2 with depletion percentages of 35% and 57% of TNAP- cells. It could
be possible that higher TNAP+ percentages may be recovered with better device design.
such as avoiding contamination with TNAP- cells clogged within the bubble traps and
to increase the amount of cells which could be released from the surface. However the
increase of TNAP+ cells for three separate DPSCs donors demonstrates the ability of the
device to isolate and release TNAP+ cells delivering an enriched cell population in a 20
minute period, demonstrating potential for novel cell therapies for bone repair.
The percentage of TNAP+ cells only increased by 14% for donor 3 due to the already
high TNAP expression prior to separation (>80 %), therefore there could be an argument
that no TNAP enrichment would be required on patients expressing these high levels. The
inter-donor variability of TNAP expression highlights the importance of further bioogical
studies into the effects of enrichment on the TNAP+ cell population. Whilst all donors
demonstrated an enrichment of TNAP+ cells and TNAP- cell depletion, Donor 3 had
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Table 4.2: Table depicting the enrichment and depletion percentages of TNAP+ and
TNAP- cells after cell separation
unusually high levels of TNAP expression (> 80 %) pre-sorting. This then asks the
question of relevance of an enrichment in a population already with high levels of TNAP
expression. This would also impact the performance of the microfluidic device with the
potential for high capture and recovery efficiencies. However, if it could be demonstrated
that even small levels of enrichment may lead to significant enhancements in osteogenesis
the device would still bear relevance for sorting cell populations already with high levels
of TNAP expression. Therefore further studies are required to investigate the specific
TNAP+ cell enrichment levels across multiple cell donors at which there is a possible
enhancement of osteogenic potential.
The device developed in this work represents a novel approach to the isolation of TNAP+
cells from a mixed population, however the cell isolation performance can be compared
to other novel microfluidic devices which rely on cell capture and release through the
same antibody to cell capture principle. For example, microfluidic devices which have
been developed to capture CD4+ cells via an antibody functionalised surface, were
shown to have a release efficiency of 59% using a temperature based release mechanism
[151]. This is comparable to the release efficiency of 58% measured using the device
developed in this chapter, using a fluid shear based release mechanism. Other devices
developed utilise the principle of cell rolling (described in detail in section 1.5.2), here
the devices have been shown to isolate cells with a capture efficiency of 40 - 70 %
[154, 155], which is comparable to the capture efficiency of the device developed (∼
53%). However these devices are limited in the number of cells recovered post sorting
and therefore detailed characterisation of enrichment and purity is lacking in the literature.
The isolation efficiency of TNAP+ cells from the total population (capture efficiency ×
recovery efficiency) is ∼ 30% if assuming all cells captured and released are TNAP+
within the device. Whilst this is low, it is reported that FACS experiments lose > 50%
through cell damage during droplet formation or rejection due to incorrect scanning [216].
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Recently a study involving the separation of TNAP +/- cell lines by comparing FACS and
MACS showed there was a ∼70% cell loss for FACS demonstrating similar isolation
efficiency as with the device developed in this chapter [217] . Yet the device developed
within this work had a comparable isolation efficiency to FACS, but was greatly benefited
from delivering a TNAP+ cell enrichment without any antibody labelling and within a
20 minute time period. Further experimental work would be of interest to provide a
comparison in the separation against MACS and FACS for recovery, purity and efficiency
when compared to the microfluidic device developed.
Currently one of the main limiting factors against clinical translation is the surface area
of the device to permit the required number of cells which can be released for use in bone
repair. Whilst DPSCs present an attractive source for tissue engineering they are present in
low numbers [51] and would require ex vivo expansion for any regenerative application.
MSCs provide a better alternative and the ability to enrich cells from surgical waste or
bone marrow aspirate would be desirable. It has been reported that as little as 3×103
progenitor cells have enhanced bone healing effect in non-union fractures [218], however
an absolute number is hard to define due to many variable factors such as size of defect
and age of patient. The microfluidic device described in this chapter can release between
1 - 4 ×104 cells per channel. This may be improved by implementing a batch system
of separation, however it is unknown how the efficiency of the functionalised surface
capture may change over repeated use. Instead it would be necessary to run multiple
parallel channels or to increase the surface area of the channel. This could be done by
increasing the width and length of the channel or by developing a 3D surface where cell
populations can flow through instead of across. For example polymer cryogels consisting
of large interconnected pores were functionalised with protein A ligand and then target
cells labelled with specific antibodies were captured when flown through the cryogel due
to antibody affinity with protein A [219]. Gold meshes and non-woven fibres which could
be functionalised with antibodies would provide alternatives with a much larger surface
area for specific cell capture and release.
Microfluidic devices which capture cells through antibody functionalised surfaces mostly
focus on releasing the bound cell population by removing the antibody from the surface.
This releases the cell population but with the antibody still attached to the cell [211, 151].
The antibody could be removed by introducing additional wash steps but this would
impact on cell viability and reduce the numbers of separated cells. Cell separation
with minimal manipulation for autologous cell therapies would require a device where
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the biological and physiological characteristics of the cell are in no way altered by the
separation process. Therefore a separated population without antibody labelling would
be desirable to meet this criteria. In addition, if TNAP antibody was still attached after
cells were released, downstream analysis would be difficult as TNAP on the cells surface
may no longer be available to be bound by fluorochrome-conjugated antibodies resulting
in false negatives of the enriched population [5]. To address this the released cells which
had undergone the full process of cell separation were characterised for any remaining
antibody attachment due to the slight possibility of the antibody to surface bond being
broken instead of the antibody to antigen bond. The cell population after separation
through the microfluidic device had increased mean fluorescence intensity values of 5.6
± 2.8 % after staining with a labelled secondary antibody, but this was not significant
when compared to the before cell separation population where 2.2 ± 2.6 % of cells
were positively stained. These results were not statistically significant, therefore the
separated released population had minimal cells with antibody still attached. However
for transaltion to clincial applications this would need to be further reduced, as there
may be a high degree of risk from unknown cellular effects when implanting cells with
antibody still attached.
Whilst this study focused on the creation of a device to deliver a TNAP+ enriched
population of cells, further studies are needed to better understand the effect of TNAP+
cell enrichment on increased cell mineralisation and therefore increased bone repair.
TNAP has been identified as a pro-mineralising marker in both MSCs and DPSCs. FACS
has been utilised to separate out TNAP+ MSCs from a mixed population and it was
observed that the TNAP+ cells were capable of higher levels of mineralisation with higher
levels of osteogenic related gene expression compared to TNAP- cells [96]. DPSCs which
had undergone FACS sorting for TNAP expression demonstrated both TNAP+ and TNAP-
cells were able to undergo in vitro mineralisation with deposits associated with TNAP+
cells being slightly more uniform [17]. However in vitro mineralisation associated
with TNAP- DPSCs requires the generation of a cell monolayer which increases the
cell density and potentially allowed TNAP- cells to upregulate TNAP production so
they are phenotypically similar to TNAP+ cells [17]. Whilst the device delivers an
enriched population of TNAP+ cells further work would be required to identify if the
enrichment levels delivered for TNAP expression would have significant increase in the
mineralisation potential of both DPSCs and MSCs. Also it would be desirable to have a
better understanding of what levels of enrichment are needed for enhanced bone repair.
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Future work might focus on the isolation of TNAP+ MSCs from a heterogeneous
population investigating enhanced bone repair due to enrichment of TNAP+ cells. An
important factor to consider is that due to TNAP being expressed on a wide variety
of cells within bone marrow aspirate [97], a highly enriched population of TNAP+
cells will mostly likely not result in a pure population of MSCs. This may not be a
problem as the expression of TNAP by these various cell types may pre-dispose them
to differentiate to a mineralising phenotype, but this possibility needs future study. The
device also offers a platform technology where the gold surface could be functionalised
with antibodies specific to alternative MSC surface markers, such as Stro-1 and CD271
[55, 220]. Multiple functionalised surfaces could be connected to first select MSCs and
then sort cells by their expression of TNAP, to deliver a more pure population of TNAP+
MSCs. One of the main limiting factors that would need to be addressed for this approach
would be the limited cells numbers retained from each cell sort. If cells are enriched
through TNAP expression alone it would be important to note, there may be a mixture
of cell types and at different stages of development which need to be considered when
designing cell separation experiments for future clinical translation.
The results presented in this chapter demonstrate the design and development of a
microfluidic cell separator where antibodies specific for TNAP were immobilised onto
a functionalised gold substrate to capture and release DPSCs. A TNAP+ enriched
population was obtained for DPSCs from three separate donors and the separated
population was shown to have minimal antibody still attached. Therefore this working
device demonstrates the ability to enrich TNAP+ cells for potential use in regenerative
therapies for bone repair.
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Chapter 5
The effect of use of the microfluidic
device for TNAP+ DPSC enrichment on
cell viability and osteogenic
differentiation
5.1 Aim
The aim of this chapter was to investigate if use of the microfluidic device and the
capture and release mechanism described in the previous chapter to enrich a population
of TNAP+ DPSCs would affect cell phenotype and their ability to be used in downstream
applications. This was achieved through first assessing cell viability before and after
exposure to the device followed by investigations to determine the retention of the cells’
ability to proliferate and differentiate towards an osteogenic lineage.
5.2 Introduction
A working microfluidic device was designed and built which was able to enrich a
population of TNAP+ DPSCs as described fully in chapter 4. The process of capture
and release within the device was predicted to subject the DPSCs to shear stress forces
from fluid flow. If the cells were to be used for example in live cell assays or clinical
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applications, they would need to meet the definition of “minimally manipulated”. This
means that their biological and physiological characteristics would need to be unaltered
by the cell separation process. The first major function that would need to be assessed
is the cell viability, as a separation process which delivers a non-viable population would
be of no value. In the present case, the final application of separated cells would be
for bone repair and so the ability of cells not only to proliferate, but to retain their
osteogenic differentiation potential is an important factor which needed to be investigated.
Therefore it was important that further assays were carried out after separation to properly
characterise the enriched cell population.
Microfluidic devices have previously used affinity based techniques to capture cells
expressing certain markers [148, 211, 151] and the results demonstrate encouraging
efficiency and throughput. However, the majority of the work reported in the literature
either focuses on positive selection for circulating tumor cell (CTC) cells [148] or negative
selection where the cells are not usually needed for downstream applications [221]. In
these cases, viability and cell function were rarely assessed after separation. The major
limitation for any surface-based isolation of stem cells is the difficulty of releasing viable
cells after surface capture. For studies where cells have been captured by immunoaffinity
on a functionalised surface, extra methodologies have been applied to increase the release
of viable cells under fluid flow. For example, CTCs captured on an aptamer (peptide
molecules that bind to a specific target molecule) functionalised surface utilised enzymatic
digestion to aid release in fluid flow with a resultant viability of 78-83 % for the released
cells [211]. Temperature responsive polymers have been developed which are able to
release the antibody attached on a functionalised surface by changing the hydrophobicity
of the surface with temperature. The temperature can be changed to release the antibody
and therefore any captured cells on the surface. CD34+ blood cells have been isolated in
this way, demonstrating a high viability of 94 % [151]. However, releasing cells using
these methods usually also removes the apatamer/antibody from the surface, thus cells
are released with binding molecules still attached. They would therefore fail to meet the
definition of “minimally manipulated” as their phenotype would be changed.
Devices have also utilised shear stress from fluid flow as the only force to remove cells
attached to a surface. CTCs have been captured and released by differences in shear
which affect cell attachment/detachment to/from the surface, with cells remaining viable
and able to subsequently proliferate [204]. Microfluidic devices which have captured
reprogrammed induced human pluripotent stem cells using an antibody functionalised
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surface and then released the cells using an increase in shear force have delivered
populations with 95-99% purity and 80% survival [146]. The work presented in the
previous chapter demonstrated a microfluidic device capable of enrichment of TNAP+
DPSCs which had been released using an increase in fluid flow and therefore a presumed
elevated shear stress. Thus it was necessary to determine the effect of that capture and
release on the viability of the released cell population along with their ability to recover
from any stress, retaining their proliferation and differentiation potential.
Effectively releasing the selected cells captured by antibody affinity to a surface
in microfluidic channels without compromising not only the viability but also any
phenotypic characteristics remains challenging. It is especially important to characterise
these characteristics in stem cell populations as shear forces may affect cell fate as stem
cell differentiation is sensitive to environmental cues [222]. It has been shown that shear
stress can induce osteogenic differentiation of mesenchymal stem cells [223], but these
studies were carried out over long culture periods (7 days) with constant fluid flow. In
contrast, the cells captured in the enrichment device developed here were only subject
to increased shear stress for less than 30 minutes. The use of harsh fluid shear based
methods for release of captured cells on a surface may theoretically adversely affect cell
function. However, studies have shown that release by shear flow may not be detrimental
to stem cell function. MSCs which were enriched for CD34 by cell adhesion using an
anti-CD34 antibody-coupled surface and released by shear flow were able to proliferate
as usual and retained their osteogenic potential after separation [153]. The retention
of osteogenic potential is especially important for any cells which may be used for
bone repair as any separation process needs to minimally affect the ability of cells to
differentiate down an osteogenic lineage. It is also important to assess if cell function is
altered by cell capture through antibody binding. For example, the cell surface marker,
CD3 is internalised following antibody binding, causing changes in the cell phenotype
[224]. Therefore proper assessment of the ability of cells to retain their biological and
physiological characteristic after separation is required.
The main objectives in this chapter were to:
1. Investigate cell viability after TNAP+ DPSC enrichment had been achieved using
the microfluidic device to capture TNAP+ DPSCs on an antibody functionalised
surface and released with an increase in fluid flow.
2. Investigate any effect on cell proliferation for the enriched population following cell
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separation.
3. Determine if the enriched TNAP+ DPSCs retained their osteogenic differentiation
capability after the separation process.
These objectives focus on further characterisation of the enriched TNAP+ DPSCs to see
whether cells have been adversely affected by capture and release during the separation
procedure. This would therefore begin to determine whether the isolated cells would
be fit for purpose. Cell viability measured after separation is an indicator of whether
cells are alive prior to cells being analysed for their proliferation potential. Given that
the device aims to deliver an enriched population which could have potential in future
regenerative therapies for bone repair, the osteogenic potential and ability of separated
DPSCs to differentiate down an osteogenic pathway was also analysed.
5.3 Methods
5.3.1 Experimental setup
Dental pulp stromal cells were obtained from extracted impacted third molars from the
University of Leeds School of Dentistry Research Tissue Bank (07/H1306/93+5) with full
ethical consent both from male and female donors aged between 21-46 years. The DPSC
isolation procedure is described in chapter 2 and equal cell numbers, between passage
3-7, were used in both the experimental and control samples. Prior to assessing the
viability, proliferation and differentiation potential of enriched TNAP+ DPSCs, a number
of control groups that were studied alongside of the experimental sample were defined.
These comprised of:
• “Culture Medium” group: DPSCs were held in α-MEM culture medium
(Corning, UK) supplemented with 10% foetal calf serum (FCS) (Sigma-Aldrich,
UK), 2 mM L-glutamine (Sigma-Aldrich, UK), 100 units/mL penicillin/100
µg/mL streptomycin (Sigma-Aldrich, UK) for the duration of cell separation
(approximately 30 minutes per channel) at room temperature. This provided a
positive control to assess any effects of the separation buffer.
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• “Plain α-MEM” group: DPSCs were held in plain α-MEM culture medium at pH
7.4, for the duration of cell separation (approximately 30 minutes per channel) at
room temperature. These cells were used to assess the effect of the separation buffer
per se on DPSCs, without them undergoing separation through the device.
• “PBS” group: DPSCs were held in PBS at pH 7.4 (Sigma-Aldrich, UK) for the
duration of the separation procedure (approximately 30 minutes per channel) at
room temperature. This allowed the effects of a non-culture medium buffer to be
compared to any effects associated with the separation buffer.
• “Phosphate Buffer at pH 8.5”: DPSCs were held in 0.1 M phosphate buffer (65 mM
Na2HPO4, 26 mM NaH2PO4) at pH 8.5 (Sigma-Aldrich, UK) for the duration of the
separation procedure (approximately 30 minutes per channel) at room temperature.
This allowed the effects of a high pH buffer to be compared to any effects associated
with the separation buffer at a lower pH.
• “Microfluidics” group: DPSCs were resuspend in plain α-MEM culture medium at
2×106 cells/mL before being flown through a microfluidic channel at 100 µL/min.
This was to assess the effect of shear forces from constant microfluidic flow without
any cell capture involvement.
• “Captured and released” group: These were DPSCs that had undergone the
separation procedure for TNAP+ cell enrichment as described in section 4.3.6,
using an increased fluid flow in either plain α-MEM or 0.1M phosphate buffer at
pH 8.5 for release.
5.3.2 Determination of cell viability using flow cytometric analysis
The effects on cell viability after cell separation using the device were investigated using
DPSCs isolated from three donors. Following cell separation in the device as described in
section 4.3.6, cells obtained from 3-4 microfluidic channels were pooled together and cell
viability was analysed in comparison with the relevant controls (Section 5.3.1). When
assessing the effect of cell viability on the release of DPSCs in phosphate buffer at pH
8.5, the phosphate buffer at pH 8.5 control group was also included. This allowed the
effects of using pH 8.5 buffer in cell release on cell viability to be measured. Cells were
spun down at 200×g for 5 minutes then re-suspended in FACS buffer (PBS, 0.5% BSA
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and 2 mM EDTA at pH 7.5) at 1×105 cells per tube. Cells were then stained with 1 µL of
7-AAD viability staining solution (Biolegend, USA) in 100 µL cell suspension, for five
minutes in the dark. Samples were then analysed using a CytoFLEX (Beckman coulter,
USA) at 488 nm laser excitation. Analysis of acquired data was performed using the
CytExpert software (Beckman coulter, USA).
To assess the effect of pH on cell viability, 1×105 cells were held in 100mM phosphate
buffer at pHs ranging from pH 5.5 - 9.5. Cells were also held in basal culture medium
and PBS to act as controls. Cells were held in the various buffers at different pHs for 30
minutes at room temperature before cell viability was measured using flow cytometry as
described above. The gating strategy used is described in figure 5.1.
Figure 5.1: Flow cytometry gating used in measurement of cell viability. Dot plots of
forward scatter against fluorescent intensity with cells previously gated for intact cellular
bodies (Section 3.3.2) (a) Gate set to include whole population of intact DPSCs. (b) Same
gate applied to DPSCs stained with 7-AAD to exclude non-viable cells. Cells which had
a greater fluorescence intensity due to staining with the 7-AAD stain than the gate set
using the unstained population, were classed as non-viable cells. Cells remaining within
the gate was assumed to represent the percentage of viable cells.
5.3.3 Effect of separation on DPSCs proliferation
The effect of the separation process (see section 4.3.6) on the ability of DPSCs to
proliferate was assessed for cells obtained from three separate donors with the DNA
quantity measured as an indirect measure of cell number. DPSCs were separated in
the device along, then along with the relevant controls (the Culture Medium, Plain α-
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MEM, PBS and Microfluidics control groups) were seeded into 24 well plates at 5×103
cells/cm2. The sample size was three (n=3) for all groups, except for the Culture Medium
control group where the sample size was six, as three samples were additionally used
as a control to be cultured in basal medium. Cells were then cultured in basal medium
overnight to allow attachment to the well. Medium was then replaced with osteoinduction
medium, StemMACS OsteoDiff Media (Miltenyi Biotec, USA), for all groups apart from
the control samples where DPSCs were cultured in basal medium as a negative control.
Cells were then cultured for periods of 7 and 14 days with a medium change occurring
every 3-4 days. At 7 or 14 days, cells were lysed with 200 µL of 0.1 % Triton X-100
(Sigma-Aldrich, UK) followed by scraping and three freeze-thaw cycles at −80◦C.
DNA quantity of the proliferating DPSCs was assessed using Quant-iT™ PicoGreen™
dsDNA Assay Kit (Thermo Fisher Scientific, UK). Picogreen™ is a sensitive fluorescent
nucleic acid stain which is used in quantitating double-stranded DNA (dsDNA). A DNA
standard was prepared from the Lambda DNA standard, provided within the kit, in 1×
Tris-EDTA (TE) buffer. A working stock solution of 2 µg/ml of the DNA standard was
prepared and diluted to prepare standards of 200 ng/ml, 20 ng/ml and 2 ng/ml. For each
standard, 100 µL was added to a 96 flat-bottom well plate (Sigma-Aldrich, UK) with TE
buffer added as a blank. Then 10 µL of cell lysate solution with 90 µL of 1× TE buffer
was then added. For every sample, standard and blank, 100 µL of PicoGreen™ (at a 1:200
dilution in 1× TE buffer) was added to the plates and incubated at room temperature
for 5 minutes protected from light. The resulting fluorescence was then measured at
480 nm excitation and 520 nm emission wavelength on a Varioskan Flash Multimode
Microplate Reader (Model 3001, Thermo Scientific, UK). Using the standard curve, DNA
concentration per well (ng/mL) was generated and then the total amount of DNA per well
(µg) was calculated.
DPSCs’ ability to proliferate after separation was also quickly assessed by light
microscopy. DPSCs were separated, then seeded at 5×103 cells/cm2 in a 6 well plate.
Cells were cultured in basal medium with medium change every 3-4 days. Images of the
plates were taken at days 1, 3 and 7 to asses cell proliferation after separation and cell
numbers were evaluated qualitatively.
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5.3.4 Effect of separation on the ability of DPSCs to undergo
osteogenic differentiation assessed through ALP activity
To assess the ability of DPSCs to undergo osteogenic differentiation after cell separation
alkaline phosphatase activity was measured using a quantitative p-nitrophenyl phosphate
(pNPP) biochemical assay. The ALP activity was then normalised to total DNA content
to provide a measurement for alkaline phosphatase specific activity (ALPSA). DPSCs
isolated from three donors were separated in the device along with the relevant controls
(the Culture Medium, Plain α-MEM, PBS and Microfluidics control groups) then seeded
into 24 well plates at 5×103 cells/cm2. The sample size was three (n=3) for all groups,
except for the Culture Medium control group where the sample size was six, as three
samples were additionally used as a control to be cultured in basal medium. Cells
were then cultured in basal medium overnight to allow attachment to the well. Medium
was then replaced with osteoinduction medium, StemMACS OsteoDiff Media (Miltenyi
Biotec, USA), for all groups apart from the control samples where DPSCs were cultured
in basal medium as a negative control.
Cells were then cultured for periods of 7 and 14 days with a medium change occurring
every 3-4 days. At 7 or 14 days, cells were lysed with 200 µL of 0.1 % Triton X-100
(Sigma-Aldrich, UK), by being frozen for 5 minutes at −80◦C before thawing at room
temperature, then carefully scraped from the well surface with a pipette tip to mix with
the lysis solution. The freeze-thaw process was repeated a further two times. An assay
buffer consisting of 10 mL 1.5 M alkaline buffer solution (Sigma-Aldrich, UK) diluted
with 20 mL of distilled water was prepared. Total ALP in the lysis was quantified using
pNPP liquid substrate system solution (Sigma-Aldrich, UK). Calibration standards were
made using a 4-nitrophenol solution (Sigma-Aldrich, UK) in concentrations of 10, 50,
100 and 200 nmol/ml with 100 µL of each standard added to the appropriate well with
100 µL of the alkaline buffer solution as a blank reading. Then 10 µL of the cell lysate,
was incubated with 90 µL of the substrate for 30 minutes at 37◦C. The reaction was then
stopped with the addition of 100 µL of 1M NaOH solution. The resulting absorbance was
measured at 405 nm on a Varioskan Flash multimode microplate reader (Model 3001,
Thermo Scientific, UK). Three repeat readings were taken of three biological repeats.
The standard curve generated was then used to quantify the amount of ALP in the cell
lysate (Equation 5.1). The ALP activity was then standardised to total DNA content per
well (Section 5.3.3) to calculate alkaline phosphatase specific activity (ALPSA) for each
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well.
ALP activity (nmol/min/well) =
Amount of substrate (nmol)×Harvest volume (µL)
Cell lysate volume (µL)
Reaction time (mins)
(5.1)
5.3.5 Determination of Alkaline phosphatase specific activity
(ALPSA) of DPSCs undergoing osteogenic differentiation
The ALP activity (nmol/min) was standardised to the total DNA content (µg) from the
same well to calculate the alkaline phosphatase specific activity (ALPSA) for each well
(nmol/hour/µg).
ALPSA (nmol/hour/µg) =
ALP activity (nmol/min)× 1 hour (mins)
Total DNA content (µg)
(5.2)
5.3.6 Effect of separation on the ability of DPSCs to undergo
osteogenic differentiation assessed through alizarin red
staining
Separated DPSCs were seeded onto 24 well plates (5×103 cells/cm2) together with
the relevant controls described in section 5.3.4. The negative control was cultured in
basal culture medium with all other groups cultured with StemMACS OsteoDiff Media
(Miltenyi Biotec, USA). Medium was changed every 3-4 days. DPSCs from three donors
were assessed and the sample size was three (n=3) for all groups. After 21 days, the
resulting cell monolayers were stained for calcium accumulation with alizarin red stain
in order to visualise any mineralised matrix in the DPSCs culture. Cell monolayers were
washed three times with PBS then fixed in chilled 70 % ethanol for 15 minutes and then
washed three times in deionised water. The alizarin red staining solution (40 mM alizarin
red at pH 4.1, Millipore, UK) was added to cover the cell monolayers in the culture
plates and incubated in the dark for 30 minutes at room temperature. Following staining,
the monolayers were washed in deionised water three times for five minutes each on an
orbital shaker (30 rpm). Stained cell monolayers were then air dried, photographed and
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observed using bright field microscopy under a Leica DMI6000 B inverted microscope
(Leica Microsystems, Germany).
The cell monolayers stained with alizarin red were destained to provide a quantitative
reading for each group. To extract the stain, 200 µL of 10% acetic acid was added to
each well of the 24 well plate containing the stained monolayers. The plate was then
incubated at room temperature for 30 minutes with shaking (30 rpm). Cells were then
lysed by methodologically scrapping with a pipette tip to mix the solution and lyse the
cells. Then the solution was transferred to a 1.5 mL microcentrifuge tube. The tube
was vortexed for 30 seconds. Samples were then heated at 85◦C for 10 minutes and then
incubated on ice for 5 minutes. The resulting slurry was then centrifuged for 15 minutes at
20,000×g for 15 minutes. After centrifugation, 200 µL of the supernatant was transferred
to a new tube. Then, 75 µL of 10 % ammonium hydroxide was added to neutralise the
acid. Afterwards, 50 µL of each sample was aliquoted in triplicate into wells of a 96-
well plate. The absorbance was measured at 405 nm on a Varioskan Flash multimode
microplate reader (Model 3001, Thermo scientific).
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5.4 Results
5.4.1 Determination of cell viability after capture and release of
DPSCs using the microfludic device and the effect of pH on cell
viability for potential use in the release mechanism.
As described in chapter 4, a microfluidic cell separation device was developed which was
capable of capturing TNAP+ DPSCs on an antibody functionalised surface, followed by
subsequently releasing the cells via an increase in fluid flow. For these cells to be used for
clinical applications in bone repair, they would need to meet the definition of “minimally
manipulated” where the separation process had not altered their biological characteristics.
Assessment of cell viability after the separation procedure was an important first step
towards demonstrating minimal manipulation. The flow cytometry dot plots for cells that
had been separated and the four control groups (the Culture Medium, PBS, Plain α-MEM
and Microfluidics control groups) is shown in Figure 5.2. Forward scatter, an indicator of
cell size, was plotted against fluorescence intensity, in this case from 7-AAD which is a
stain for non-viable cells [225]. A gate was then placed around the population of unstained
cells to identify viable versus non-viable cells. The same gate was kept for cells which
have stained for 7-AAD, the shift in fluorescent intensity from the gate then represented
the percentage of cells which had taken up the stain. As 7-AAD is a fluorescent compound
with strong affinity for DNA, only cells with a compromised cellular membrane can take
up the stain and are thus deemed non-viable, allowing cell viability to be measured.
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Figure 5.2: Dot plots obtained from flow cytometric analysis from one experiment
investigating the effects of the separation process on cell viability. Dot plots show forward
scatter (x axis) against fluorescence intensity (y axis), allowing the percentage of viable
cells to be determined. Samples of DPSCs analysed were: (a) Cells held in culture
medium for experimental duration. (b) Cells held in PBS for experimental duration.
(c) Cells held in plain α-MEM for experimental duration. (d) Cells flown through un-
functionalised microfluidic channels at 100 µL/min, and (e) cells which had been through
the full separation procedure of capture and release in the device. The proportion of non-
viable cells shown in blue remained similar for cells held in the various control buffers,
but was increased in the microfluidic control group and was further increased for the cells
which had undergone capture and release with the device.
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Cell viability after separation
The percentage cell viability for TNAP+ enriched DPSCs which had undergone cell
separation using the device, along with the various controls was obtained from the
flow cytometry data (Figure 5.3). The cell populations held in various control buffers
(the Culture Medium, PBS and Plain α-MEM control groups), showed no significant
difference in cell viability with a mean viability of 97.5 ± 1 %. There was also no
statistical difference between the Culture Medium group and the Microfluidic control
group, demonstrating minimal effect of the cell viability from constant microfluidic flow.
Cells which had undergone the full separation procedure of being captured on the antibody
functionalised surface and then released using the increase in fluid flow, had a viability of
92.2 ± 5 %. This was a significant decrease (P ≤ 0.01) when compared to the viability
from the Culture Medium control group. This demonstrated that further optimisation
of the release mechanism was potentially needed to increase cell viability. However,
the viability of the enriched TNAP+ DPSCs was still > 90 %, and whilst statistically
different from the unseparated control groups, this may not be a problem for downstream
applications or for potential therapeutic applications.
pH effects on cell viability
The use of a pH change to aid the release of captured DPSCs from the antibody surface
was investigated as described in the previous chapter (Section 4.4.6) but before this could
proceed, any effect of pH on cell viability needed to be investigated. Cell viability was
measured after DPSCs were held in a range of phosphate buffers from pH 5.5 to pH
9.5 compared with controls of DPSCs held in basal culture medium and PBS at pH 7.4
(Figure 5.5). Cell viability was not affected at pH values from pH 5.5 to pH 7.5 when
compared to cells held in basal culture medium (98 ± 0.2 %). At higher pH values, there
was a significant decrease in cell viability ( P ≤ 0.001) compared with cells held in basal
medium. At pH 8.5, the cell viability was 95.7 ± 0.4 % and this then further decreased at
pH 9.5 to 93.3 ± 0.06 %. However the viability remained > 90 % suggesting no overall
drastic decrease in cell viability due to higher pH.
The use of a phosphate buffer at pH 8.5 was investigated as a method to increase cell
release as a change in pH may reduce the binding strength of the antigen-antibody
complex. Here the cells captured on an anti-TNAP antibody functionalised surface were
incubated and released with an increase in fluid flow in a phosphate buffer at pH 8.5 as
fully described in section 4.4.6. The cells released through the increase in fluid flow in
177
Figure 5.3: Determination of cell viability after cell capture and release for TNAP+
DPSCs using the microfluidic device. Samples analysed were as follows: Captured and
released cells - DPSCs captured by the antibody functionalised surface and then released
with an increase in fluid flow using plain α-MEM. Microfluidics - Cells flown through
un-functionalised microfluidic channels at 100 µL/min. PBS - Cells held in PBS for
experimental duration. Plain α-MEM - Cells held in plain α-MEM for experimental
duration. Culture medium - Cells held in culture medium for experimental duration. The
percentage cell viability was reduced for cells captured and released within the device,
demonstrating an effect of the selection mechanism on cell viability. Data shown as mean
± SD. n = 3. ** = P ≤ 0.01.
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Figure 5.4: Percentage cell viability of DPSCs held in phosphate buffers ranging from
pH 5.5 - 9.5, compared with controls of DPSCs held in culture medium and PBS. The
percentage cell viability decreased when cells were held in phosphate buffers with higher
pH values. Data shown as mean ± SD. n = 3. **** = P ≤ 0.0001.
phosphate buffer at pH 8.5 were collected and the percentage of cell viability following
separation in the device was investigated (Figure 5.5). DPSCs from the Phosphate Buffer
at pH 8.5 control group (held in pH 8.5 phosphate buffer for the experimental duration)
decreased significantly (** = P ≤ 0.01) when compared to cells from the Culture Medium
control group (cells held in basal culture medium for the experimental duration). This
was a similar result to the experiment of assessing the viability of cells held in phosphate
buffers at various pH values (Figure 5.5). The cell viability of captured DPSCs released
from the antibody functionalised surface by an increase in fluid flow in phosphate buffer
at pH 8.5 was 92.2 ± 5 %, which was a significant decrease (P ≤ 0.0001) compared to the
Culture Medium control group (cells held in basal culture medium for the experimental
duration) for the experimental durations. There was no statistical difference between the
percentage cell viability for DPSCs released from the device using phosphate buffer at pH
8.5 and the Phosphate Buffer control group at pH 8.5 (cells held in phosphate buffer at pH
8.5 for the experimental duration) indicating that the reduction of cell viability was due
to the capture and release mechanism within the device. However viability was still high
(> 90 %) and was similar to that of captured cells released from the device using plain
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α-MEM (Figure 5.3), demonstrating that if pH 8.5 phosphate buffer was able to increase
the number of released cells, it would be a viable option for release within future work as
cell viability was not severely compromised.
Figure 5.5: The effect on cell viability of capture and release using phosphate buffer at pH
8.5, for TNAP+ DPSC enrichment using the microfludic device. The samples analysed
for cell viability percentage were as follows: Captured and released in pH 8.5 phosphate
buffer - DPSCs captured by the antibody functionalised surface and then released with
an increase in fluid flow using phosphate buffer at pH 8.5; pH 8.5 phosphate buffer
- Cells held in culture medium for experimental duration; Microfluidics - Cells flown
through un-functionalised microfluidic channels at 100 µL/min; PBS - Cells held in PBS
for experimental duration; Plain α-MEM - Cells held in plain α-MEM for experimental
duration; Culture medium - Cells held in culture medium for experimental duration. Cell
viability was decreased for cells which had been held in the phosphate buffer at pH 8.5 and
for cells released from the device using the phosphate buffer at pH 8.5. Data represented
as mean ± SD. n = 3. ** = P ≤ 0.01, **** = P ≤ 0.0001.
5.4.2 The effect of the separation process on DPSCs proliferation
To be classed as a minimally manipulative cell separation therapy, the retrieved cells’
biological characteristics must remain unaltered by the separation process. Therefore
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it was important to demonstrate whether or not proliferation of separated DPSCs was
affected by their undergoing separation in the device. In preliminary experiments, DPSCs
that had undergone the full separation process for TNAP enrichment were seeded onto 6
well plates as described previously. Their ability to attach to and proliferate on the plates
when cultured in basal medium was then assessed (Figure 5.6). The results showed that
separated DPSCs were able to attach to the well plate and then, over a period of 1, 3
and 7 days were able to proliferate, eventually reaching confluency. This confirmed that
the separated cells had retained their ability to proliferate. However, a more detailed
study to investigate whether the separation process had affected cell proliferation by
quantifying DNA concentration of cells undergoing osteogenic differentiation with the
relevant controls, was later undertaken.
Figure 5.6: Images of DPSCs that had undergone separation using the device then
cultured in basal medium for the duration of 1, 3 and 7 days. This preliminary qualitative
assessment suggested that separation using the device had not inhibited cell proliferation.
Scale bars represent 200 µm.
The effect of the separation process on DPSCs proliferation was then analysed under
osteogenic culture conditions. The experimental group, described as “captured and
released cells” (Figure 5.7), were DPSCs that had undergone the full separation
process using the device, and then seeded onto 24 well plates before being cultured in
osteoinductive medium. Control cells held in basal medium for the separation duration
were divided into two groups, the first group was cultured in basal culture medium
(described as the “Culture Medium” control group), whilst the other group was then
cultured in an osteoinductive medium (described as the “Osteogenic Medium” control
group). This would investigate the effect of proliferation on un-separated cells cultured
in osteoinductive conditions. Other experimental controls to investigate the effect of the
181
separation process on proliferation were cells held in either plain α-MEM or PBS for the
experimental duration of cell separation in the device, before seeding into 24 well plates
and being cultured in osteoindutive medium (described as “PBS” and “Plain α-MEM”
control groups). The final experimental control was cells flown through un-functionalised
microfluidic channels at 100 µL/min before again being seeded into 24 well plates and
cultured in osteoinductive medium (described as “Microfluidics” control groups).
The DNA content of each well containing DPSCs that had undergone separation using
the device was compared with the appropriate controls as described above. DNA content
was taken to be an indication of cell number and therefore proliferation (Figure 5.7). The
results showed that for the DPSCs isolated from donor 1 (Figure 5.7 (a)), there was no
significant difference in DNA content between cells separated in the device, the Culture
Medium, Plain α-MEM, PBS and Microfluidics control groups when compared to the
Osteogenic Medium control group at day 7. At day 14, cells in the Plain α-MEM control
group and the captured and released group had a significantly greater DNA content ( P ≤
0.05) when compared to the Osteogenic Medium control group. For the DPSCs isolated
from donor 1, the DNA concentration remained consistent across the experimental group
of captured and released cells alongside the appropriate controls from day 7 and 14
indicating that the cells had reached confluency by day 7, and cell proliferation had
halted. Therefore all cell groups cultured in the osteoinductive culture medium (captured
and released cells, Osteogenic Medium, Plain α-MEM, PBS and Microfluidics) were
likely to be undergoing osteogenic differentiation. Further studies to analyse the extent of
osteogenic differentiation are explored in the following section.
The results for the DPSCs isolated from donor 2 (Figure 5.7 (b)) at day 7 showed there
was only a statistically significant ( P ≤ 0.05) increase in DNA concentration between
the Microfluidic control group and the positive control of the Osteogenic Medium group.
There was no statistical significance between the separated cells from the captured and
released cells group, Culture Medium, Plain α-MEM, PBS and Microfluidics control
groups when compared with the other Osteogenic Medium control group at day 7. At
day 14 there was no significant difference in the DNA concentration across all groups
(captured and released cells, Culture Medium, Plain α-MEM, PBS and Microfluidics)
when compared to the Osteogenic medium control group. The minimum changes in
DNA concentration for the separated cells from the captured and released cell group
when compared to the positive control of un-separated cells cultured in the osteoinducitve
culture medium (the Osteogenic Medium control group) indicated that the separated
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Figure 5.7: Cell proliferation as assessed using Quant-iT™ PicoGreen™ (DNA content)
analysis of DPSCs that had undergone separation in the device compared with controls
of cells that had experienced a constant microfluidic flow or had been held in plain-α-
MEM, PBS and basal culture medium for the separation duration, before being cultured
in osteoinductive medium. A negative control of un-separated cells cultured in basal
medium (“Culture medium”) was also carried out. The separation method did not appear
to have any effect on DPSC proliferation. Data represented as mean ± SD. n = 3. *= P ≤
0.05, ** = P ≤ 0.01. 183
DPSCs isolated from donor 2 were unaffected by the separation procedure and retained
their normal ability to proliferate.
The results for the DPSCs isolated from donor 4 (Figure 5.7 (c)) had a statistically
significant reduction (P ≤ 0.01) in DNA content between un-separated cells cultured in
basal culture medium (Culture Medium control group) compared to un-separated cells
cultured in osteoinductive culture medium (Osteogenic Medium control group). This
difference in DNA content could be a result of the effects of the osteoinductive medium
(StemMACS OsteoDiff Media, human), which contains various supplements and growth
factors designed to increase the rate of osteogenic differentiation. There was also a
statistically significant reduction in the DNA content (P ≤ 0.01) between separated cells
from the capture and released cell group and the positive control of un-separated cells
cultured in osteoinductive medium (the Osteogenic Medium control group) at day 7.
This may indicate that the capture and release method of TNAP+ DPSC enrichment
may be affecting the proliferation of the separated population. However, at day 14
of donor 4 results show no significant difference in DNA content (P > 0.05) across
all groups (captured and released cells, Osteogenic Medium, Plain α-MEM, PBS and
Microfluidics) compared to the positive control of cells cultured in osteoinductive medium
(the Osteogenic Medium control group), suggesting that even if the proliferation ability
of DPSCs was affected by the separation process at the earlier time point they have the
ability to recover in longer term culture.
Statistical differences in the DNA content between the separated cells (the capture and
released cell group) and the appropriate control groups (Culture Medium, PBS, Plain
α-MEM and Microfluidics control groups) were present when compared to the positive
control of un-separated cells cultured in the osteoinductive culture medium (Osteogenic
Medium control group). These statistical differences were present for DPSCs isolated
from all three donors at either the 7 or 14 day time period. However, there was no
statistical difference in DNA concentration that was consistent at day 7 or day 14 between
the capture and released cells, Culture Medium, PBS, Plain α-MEM and Microfluidics
control groups when compared to the Osteogenic Medium control group for DPSCs
isolated from all three donors. This absence of a consistent statistical difference across
three independent cell separation experiments, using DPSCs isolated from three different
donors, demonstrates that there is no conclusive evidence that the separation method of
capturing cells on an antibody functionalsied surface within a microfluidic device and
then subsequently releasing the cells with an increase in fluid flow affects the ability of
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separated DPSCs to proliferate. These results suggest that the capture and release method
used to enrich TNAP+ DPSCs has a minimal effect on DPSCs proliferation.
5.4.3 Osteogenic differentiation of separated DPSCs characterised
by alkaline phosphatase specific activity
Alkaline phosphatase (ALP) is an enzyme which is an early marker of osteogenic
differentiation in MSCs, including DPSCs, expressed in elevated levels after 1-2 weeks
of osteoinductive culture [17]. ALP expression was therefore used to asses the ability
of DPSCs that had been separated using the device to differentiate along an osteogenic
lineage. The ALP levels of separated DPSCs, together with the relevant controls (section
5.3.1) were assessed using a pNPP biochemical assay after 7 and 14 days in osteoinductive
culture. Cells separated using the device (“captured and released cells”), were investigated
in comparison with controls of un-separated cells held in either basal culture medium,
PBS and Plain α-MEM for the experimental duration before seeding into 24 well
plates and cultured in osteoinductive culture medium (“Osteogenic Medium”, “PBS” and
“Plain α-MEM” control groups respectively) were carried out. Cells flown through un-
functionalised microfluidic channels at 100 µL/min before again seeding into 24 well
plates and culturing in osteoindutive medium (“Microfluidics” control groups) were used
as a control for the effect of flow on cell differentiation. A negative control of un-separated
DPSCs cultured in basal culture medium (“Culture Medium” control group), was used to
assess the effect of the osteoinductive medium on cell osteogenic differentiation. ALP
levels were then normalised to DNA content of the same cultures, to calculate the ALP
specific activity. This was carried out using DPSCs isolated from three donors to also
investigate donor variability (Figure 5.8).
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Figure 5.8: Alkaline phosphatase specific activity for DPSCs that had undergone
separation in the device compared with controls of cells that had experienced a constant
microfluidic flow or that were held in plain-α-MEM, PBS and culture medium before
being cultured in osteoinductive medium. A negative control of un-separated cells
cultured in basal medium was also carried out. The separation method did not appear
to have an effect on early DPSC osteogenic differentiation. Data represented as mean ±
SD. n = 3. * = P ≤ 0.05, ** = P ≤ 0.01.
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In the case of DPSCs isolated from donor 1 (Figure 5.7 (a)) there was no significant
difference in the ALP specific activity between the separated cells (Captured and released
cells group) and the appropriate controls (Culture Medium, Plain α-MEM, PBS and
Microfluidics control group) when compared to the positive control of un-separated
DPSCs cultured in osteoinductive culture medium (Osteogenic Medium control group).
After 14 days the ALP specific activity for the separated cells and appropriate controls
had increased consistently compared to day 7. As expected, the ALP specific activity of
the un-separated cells cultured in osteoinductive culture medium (Osteogenic Medium
control group) was significantly increased (P ≤ 0.05) compared to the un-separated
cells cultured in basal culture medium (Culture Medium control group). The remaining
groups consisting of the captured and released cells, and cells in the Plain α-MEM, PBS
and Microfluidics control groups had a similar ALP specific activity, with no statistical
differences compared to the un-separated cells cultured in osteoinductive culture medium
(Osteogenic Medium control). These results for DPSCs isolated from donor 1 indicated
that osteogenic differentiation of DPSCs was unaffected by the separation process.
The ALP specific activity after 7 days for DPSCs isolated from donor 2 (Figure 5.7
(b)) showed no statistical difference between the separated cells (Captured and released
cells group) and the appropriate controls (Culture Medium, Plain α-MEM, PBS and
Microfluidics control group) when compared to the positive control of un-separated
DPSCs cultured in osteoinductive culture medium (Osteogenic Medium control group).
The levels of ALP specific activity for the separated population and the appropriate
controls then increased consistently across all groups from 7 to 14 days. However,
after 14 days in culture, there was again no statistical difference in the ALP specific
activity between the separated cells (Captured and released cells group) and the controls
(Culture Medium, Plain α-MEM, PBS and Microfluidics control group) when compared
to the positive control of un-separated DPSCs cultured in osteoinductive culture medium
(Osteogenic Medium control group). The lack of a statistical difference between the un-
separated population cultured in basal culture medium (Culture Medium control group)
and the un-separated population cultured in osteogenic culture medium (Osteogenic
medium control group) suggests that potentially DPSCs isolated from donor 2 either had
not reached peak ALP specific activity or had already bypassed it and were at a further
point along the osteogenic differentiation pathway.
The results seen in DPSCs isolated from donor 4 after 7 days in culture (Figure 5.7 (c))
showed a significant increase (P ≤ 0.01) in the ALP specific activity of the captured
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and released cells compared to the positive control of un-separated DPSCs cultured in
osteoinductive medium (Osteogenic Medium control group). This is possibly due to
the fact that the separated DPSCs were already enriched for TNAP. In all other control
groups of DPSCs (Culture Medium, Plain α-MEM, PBS and Microfluidics), there was
no significant difference when compared to the positive control of un-separated DPSCs
cultured in osteoinductive medium (Osteogenic Medium control group). After 14 days,
the ALP specific activity of the un-separated population cultured in osteogenic culture
medium (Osteogenic medium control group) appeared to be increased when compared to
the un-separated population cultured in basal culture medium (Culture Medium control
group), however it was not statistically significant. This is most likely due to the large
standard deviation in the ALP specific activity of the un-separated cells cultured in
osteogenic culture medium (Osteogenic medium control group). Statistical significance
may have been reached by increasing the number (n) of repeat experiments. After 14
days in culture there was no statistical difference in the ALP specific activity between
the separated cells (Captured and released cells group) and the appropriate controls (Plain
α-MEM, PBS and Microfluidics control group) when compared to the positive control
of un-separated DPSCs cultured in osteoinductive culture medium (Osteogenic Medium
control group). This indicates that the separation procedure for TNAP+ DPSC enrichment
did not had a negative effect on the ability of DPSCs to undergo osteogenic differentiation.
There was no statistical difference in ALP specific activity that was consistent at day 7 or
day 14 between the capture and released cells, Culture Medium, PBS, Plain α-MEM and
Microfluidics control groups when compared to the Osteogenic Medium control group
across DPSCs isolated from all three donors. Therefore the capture and release separation
process used in the device to enrich TNAP+ DPSCs does not seem to affect DPSC
osteogenic differentiation, further meeting the criteria for a “minimally manipulative”
cell separation technology. However, cell separation was carried out to enrich cells
that were expressing TNAP and therefore the capture and released cells would have an
increased number of cells expressing ALP compared to non-separated controls which
may increase the ALP specific activity at different time points of differentiation, cloaking
any negative effects of the separation process on the osteogenic differentiation of DPSCs.
Therefore a further assay to assess the ability of DPSCs to produce a mineralised matrix
was undertaken.
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5.4.4 Investigating the ability of separated DPSCs to produce a
mineralised matrix
Alizarin red staining was carried out to assess the ability of separated DPSCs to undergo
osteogenic differentiation and deposit a mineralised matrix. Separated DPSCs (the
“capture and released cells” group) were cultured in osteoinductive culture medium
together with the appropriate experimental controls, as described in section 5.3.1, of
un-separated cells held in either PBS or Plain α-MEM for the experimental duration,
then cultured in osteoinductive culture medium (the “PBS” and “Plain α-MEM” control
groups). Cells flown through un-functionalised microfluidic channels at 100 µL/min
before, and then cultured in osteoindutive culture medium (“Microfluidics” control
groups) were used as a control for the effect of flow on cell differentiation. Controls of
un-separated DPSCs cultured in either basal culture medium (“Culture Medium” control
group) or osteoinductive culture medium (“Osteogenic Medium” control group), were
used as negative and positive control groups respectively to assess the effect of the
osteoinductive culture medium on cell osteogenic differentiation. Alizarin red stains
calcium accumulations with a red stain indicating calcium deposition. In all three donors
(Figure 5.9) minimal staining for un-separated DPSCs in basal culture medium used as
a negative control. All other groups cultured in osteogenic medium showed positive
staining as could be seen by a much stronger red coloured stain.
In the case of DPSCs isolated from donor 1 (Figure 5.9 (a)), all control groups used to
compare to the cells separated by capture and release showed positive red staining with no
obvious qualitative difference in staining intensity. The cells cultured in osteoinduction
medium from donor 2 (Figure 5.9 (b)) were positively stained but with less intensity than
DPSCs isolated from donor 1. This again demonstrated donor variability for DPSCs with
respect to osteogenic differentiation as DPSCs isolated from donor 1 had produced a
larger amount of mineralised matrix after 21 days in culture compared to DPSCs isolated
from donor 2. There was no qualitative difference in the staining intensity observed
between the control groups and the captured and released cells obtained from donor 4
(Figure 5.9). Unfortunately, areas of the cell monolayer had begun to detach from the well
plate for DPSCs isolated from donors 2 and 4 (Figure 5.9 (b) and (c)), a known problem
in long term osteoinduction experiments where the cells can become over confluent and
detach from the well plate. They can also be detached during the staining procedure which
requires many fixing, staining and washing steps.
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Figure 5.9: Photographs of alizarin red stained DPSC monolayers of cells isolated from
three different donors, for DPSCs that had undergone separation with the microfluidic
device compared with appropriate controls, cultured for 21 days in either osteogenic
medium or basal culture medium. Culture medium - Cells cultured in basal culture
medium (no separation). Osteogenic medium - Cells cultured in osteogenic culture
medium (no separation). Plain α-MEM - Cells held in plain α-MEM for experimental
duration before culture in osteoinductive medium. PBS - Cells held in PBS for
experimental duration before culture in osteoinductive medium. Microfluidics - Cells
flown through un-functionalised microfluidic channels at 100 µL/min before culture in
osteoinductive medium. Captured and released cells - Cells which had been through the
full separation procedure of capture and release in the microfluidic device. The arrows
indicate areas where the monolayer had detached from the well plate in the staining
procedure. There was a strong deep red staining in all groups except for the basal culture
medium group. 190
The stain from these cell cultures was then extracted using 10 % acetic acid solution
(section 5.3.6) to provide a quantitative reading for each group. Quantitative data is only
shown for DPSCs isolated from donor 1 as these were the only cultures where all of the
monolayer was still attached to the well plate after staining, allowing comparison of the
extracted stain between wells and each of the different sample groups (Figure 5.10). The
results supported the observations of the qualitative analysis reported previously. The
stain extracted from all groups cultured in osteoinductive culture medium (the capture
and released cells, Microfluidics, PBS, Plain α-MEM and Osteogenic Medium control
groups) had a higher staining intensity as measured from the increased absorbance at
405 nm, compared to the un-separated DPSCs cultured in basal culture medium (Culture
Medium control group). There was a large significant increase ( P ≤ 0.0001) when the
absorbance measured from the stain extracted from the alizarin red stained monolayers of
un-separated DPSCs cultured in basal culture medium (the Culture Medium group) was
compared to the group of un-separated DPSCs cultured in osteogenic culture medium (the
Osteogenic Medium group). There was no significant difference between the absorbance
measurement from the extracted stain of the captured and released cells and control
groups (Microfluidics, PBS, Plain α-MEM) when compared un-separated cells cultured
in osteoinductive medium (Osteogenic medium control group).
DPSCs in osteogenic cultures produce calcium deposits within mineralised nodules
demonstrating their differentiation towards a mineralising phenotype [76]. The presence
of such nodules allowed for further assessment to investigate the ability of the separated
DPSCs to differentiate along the osteogenic lineage. The stained cell monolayers were
analysed under a light microscope, before the stain was extracted for quantification
(Figure 5.11). As previously observed there was no evidence of osteogenic differentiation
in the un-separated cell population cultured in basal culture medium acting as a negative
control group (Figure 5.11 (a)). The control groups of the un-separated DPSCs cultured in
osteoinductive medium, and the cells held in plain α-MEM or PBS for the experimental
procedure before being cultured in osteoinductive medium all produced a strong alizarin
red stain with visible mineral deposits uniform across the well (Figure 5.11 (b -
d)). DPSCs which were subject to a constant microfluidic flow before cultured in
osteoinductive medium (Figure 5.11 (e)) and cells which had been separated through
capture and release within the microfluidic device before cultured in osteoinductive
medium (Figure 5.11 (f)) appeared to have no differences in the ability to produce
mineralised nodules. The mineralised nodules appeared uniform in size and distribution
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Figure 5.10: Quantitative measurement of alizarin red stain after 21 days in culture. The
stain was extracted from cell monolayars of alizarin red stained DPSCs isolated from
donor 1 that had undergone separation using the device, alongside with controls of cells
that had experienced a constant microfluidic flow or held in plain-α-MEM, PBS and
culture medium before being cultured in osteoinductive medium. A negative control of
cells cultured in basal medium was carried out. The separation process had minimal
effect on the ability of the separated DPSCs to produce a mineralised matrix. Average
absorbance readings were taken at 405 nm. (n=3). **** = P ≤ 0.0001.
across all groups.
These results demonstrated that DPSCs separated using the capture and release
mechanism within the microfludic device were able to produce a mineralised matrix
within the same timescale and apparently to the same degree as all control groups. This
suggests that there was no negative impact of the separation process on the osteogenic
potential of DPSCs.
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Figure 5.11: Light microscope images of alizarin red stained cell monolayer from DPSCs
isolated from donor 1, which had undergone separation within the microfluidic device
compared with appropriate controls, cultured for 21 days in either osteogenic medium
or basal culture medium. (a) Cells cultured in basal culture medium (no separation).
(b) Cells cultured in osteogenic culture medium (no separation). (c) Cells held in plain
α-MEM for experimental duration before cultured in osteoinductive medium. (d) Cells
held in PBS for experimental duration before being cultured in osteoinductive medium.
(e) Cells flown through un-functionalised microfluidic channels at 100 µL/min before
cultured in osteoinductive medium. (f) Cells which had been through the full separation
procedure of capture and release in the microfluidic device. Arrows indicate mineralised
nodules. Scale bar represents 100 µm.
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5.5 Discussion
The effect of capture and release of DPSCs using the microfluidic device for TNAP+
DPSCs enrichment on their viability, proliferation and osteogenic potential was explored
in this chapter. DPSCs were captured following recognition of TNAP molecules by anti-
TNAP antibodies on a functionalised surface in the microfluidic device and subsequently
released using an increased fluid flow with either plain α-MEM or phosphate buffer at pH
8.5. In such circumstances, the cells were subject to a variety of environmental stimuli
which may have had an effect on their future function. This would therefore begin to
determine whether this method of separation of specific cells was potentially useful for
future clinical applications. The captured cells were subject to shear stress as a result of
the release mechanism which may have an adverse affect. In addition, for cell capture to
occur, there requires to be an interaction between an anti-TNAP antibody and the TNAP
molecule on the cells’ surface. Alteration of the cell phenotype from interaction with
the antibody could therefore be a possibility. Some cell surface markers are stimulated
upon antibody binding setting up internal cell signalling cascades. For example, CD3
is internalised following antibody binding causing changes in the cell phenotype [224].
The ability for the cells to be alive and to retain their function is highly critical in a cell
separation methodology where cells are needed downstream for further assays or clinical
use. In this chapter, cell viability was first investigated as this is an obviously important
pre-requisite for any new cell separation technology. The proliferation and osteogenic
potential of the separated cells were then investigated as these are also important factors
to consider when looking at future use of a medical device with the potential use in bone
regenerative therapies.
5.5.1 Effect of the separation process on cell viability
Maintenance of cell viability after separation is an essential as cells which are not alive are
of little value for any downstream applications in live cell assays or for any future clinical
applications. DPSCs separated in a phosphate buffer at pH 8.5 had a reduced viability
compared with an un-separated population of cells which were held in a phosphate buffer
at pH 8.5 buffer for the experimental duration, but the percentage cell viability for the
released cells was still over 90 %, which would be promising for future applications.
However, using buffer with an increased pH did not increase the percentage of released
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cells captured on the surface compared with cells released using a plain α-MEM buffer
(Section 4.4.6). Therefore, given that cell viability was decreased in high pH phosphate
buffers compared with plain α-MEM, remaining work focused on cells which had been
separated in plain α-MEM culture medium in an assessment to reduce any effect on cell
viability associated with buffer composition. Cells which had undergone separation using
plain α-MEM medium did however, have a decrease in viability of 5.3 % compared to the
un-separated cells held in basal culture medium for the length of the separation process,
but their viability, at 92 %, was still relatively high and potentially not a problem for
future biological analysis or clinical use. The “gold standard” common techniques for
marker-specific cell separation for research, diagnostic or clinical applications is the use
of FACS and MACS. However, cell separation utilising antibody labelling through MACS
and FACS does result in a reduced viability for the separated population, yet cells are able
to recover from the stress from the separation methodology [226]. The ability of DPSCs
separated using the antibody capture microfluidic device to recover from the stress of
the separation method is also an important factor in downstream applications which was
investigated.
The future potential application of the device would be to deliver an enriched TNAP+
MSC population from bone marrow aspirate or orthopaedic surgical waste, using the
patient’s autologous stem cells for re-implantation for enhanced bone repair. The healing
rate of non-union bone fractures has been shown to improve with injected MSCs which
were aspirated from patients and concentrated via centrifugation. It had been reported that
patients fractures did not heal when less than 30,000 MSCs were implanted, whilst full
fracture healing was observed in all patients when above 54,000 MSCs were injected into
the fracture site. However, the exact number of progenitor cells required to sufficiently
heal a defect is hard to define due to the many confounding factors such as patients age,
health, gender, size of defect and cell osteogenic potential varying from patient to patient
[16, 227]. The success of any cell therapy is highly dependent on the viability of the cells
isolated for re-implantation [215], therefore it is highly important that any separation
process for cell therapy in a clinical application not only delivers an enriched population
of the target cell. For the device described here, this would be an enriched population
of TNAP+ MSCs. It is also important that the separated cells maintain a high viability
after separation. It is of interest to isolate not only as many progenitor cells as possible
for the required applications but also to ensure that the isolated cells meet the important
requirements of being viable for the required therapeutic application.
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If the separated cell population were to contain a large percentage of non-viable cells there
would be a possible danger of the non-viable cells setting up an inflammatory response
when used in re-implantation for bone repair. As a response to injury in the body, when
cells die and undergo necrosis, due to insult such as trauma, the site of cell death is rapidly
infiltrated with leukocytes consisting initially of neutrophils followed by accumulations of
monocytes [228]. This inflammatory response may cause rejection of the implanted cells
by triggering a response from the innate immune system. The TNAP+ enriched DPSCs
isolated from the device had a viability greater than 90 %, demonstrating good potential
for minimising any inflammatory response, though further in vitro and in vivo studies
would be required to properly assess the immune response associated with implantation
of these enriched cells. It also must be noted that any cells implanted into the injury site of
damaged bone, would already be arriving into a harsh environment of nutrient and oxygen
depletion, coupled with a microenviroment of inflammation and oxidative stress that could
itself lead to a poor survival of the transplanted cells [229]. For example, approximately
90 % of cardiomyocytes injected into the heart for cardiac repair die within the first week
of transplant [230]. Therefore it is important that the separated cell population from the
device retains a high cell viability before implantation for bone repair to ensure greater
chance of survival of the implanted cells.
The DPSCs may be viable following separation using the device developed here, but they
still may not be in a suitable state for future applications. Being alive does not necessarily
mean that cells were unaffected by the separation procedure. Senescent cells, for example,
are viable but they lack the ability to proliferate or to differentiate [231]. In addition,
the cells may be viable but the separation procedure may trigger them to become pre-
apoptotic, where they are on a pathway to programmed cell death [5]. Viability in this
study was only measured directly after separation without the use of an apoptotic cell
marker. Therefore it was necessary to perform further assays to demonstrate that cells
meet the requirements for “minimal manipulation” and retain the same phenotype after
separation as they had before separation. Cells which had been separated demonstrated
the ability to proliferate when cultured in basal medium when analysed qualitatively over
a period of 7 days and proliferation was measured quantitatively for longer term (14 days)
osteoinductive cultures of TNAP+ enriched DPSCs after their recovery from the device.
The separated cells from the device were also capable of osteogenic differentiation with
no significant differences between them and populations of un-separated cells cultured in
osteoinductive medium. As cells are able to proliferate and differentiate after separation,
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this suggests that they retain their normal functions and are not following a programmed
cell death.
5.5.2 Effect of the separation process on cell proliferation and
osteogenic potential
It is known that factors such as donor and passage number can cause variability in the
proliferation capability of DPSCs [215]. Proliferation was therefore determined for
DPSCs, between passage 3-7, isolated from three separate donors. The proliferation
measurements again demonstrated the effect of donor variability on DPSCs behaviour,
as previously described in chapter 3. It has been reported that human DPSCs from
older donors lose their proliferation and differentiation capabilities after repeated passage,
whilst those from young donors have been reported to exhibit no significant differences
in proliferation or differentiation potential with passage number [232]. However,
other studies have shown significant variability in the proliferative and differentiation
capabilities of DPSCs from amongst young donors of a similar age [200]. Different
donors were used in this experiment to assess whether any observed changes in
DPSC proliferation capability associated with cell separation were independent of donor
variability.
For the DPSCs isolated from donor 1, cells which had been separated through the device
along with controls of cells held in basal culture medium, PBS and plain α-MEM for
the separation duration, as well as cells which were flown through un-functionalised
microfluidic channels, before then being cultured in osteoinductive medium, the DNA
content stayed consistent from 7 to 14 days. The cells had most likely reached confluency
before the 7 day time period. The exit from the cell cycle usually coincides with
proliferation arrest switching from a proliferating phenotype to a differentiating one [186].
Therefore as the cells had reached confluency and stopped proliferating, and as they were
cultured in an osteoinductive medium, it was highly likely that the cells were undergoing
osteogenic differentiation. This was later confirmed through use of osteo-differentiation
assays of ALP assays and alizarin red staining. Donor variability was evident for DPSC
proliferation, as for DPSCs isolated from donor 2 separated within the device along with
the appropriate controls (Section 5.3.1) cultured in osteoinductive medium, the DNA
content increased from day 7 to 14 suggesting a slower proliferation rate than that of
DPSCs isolated from donor 1. This is expected as factors such as age and health of the
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donor/cells can have signifiant variability on the proliferation and differentiation potential
of DPSCs [199, 200]. DPSCs isolated from donor 3 and separated within the device
along with the appropriate controls cultured in osteoinductive medium showed that the
DNA content decreased slightly from day 7 to 14, which could potentially be because of
cell detachment and death in very confluent long term cultures.
It was important, for potential future clinical applications, that the separated cells enriched
through capture and release within the microfluidic device were not altered by the
separation procedure. The separated cells need to retain their ability to proliferate to
meet the requirements of “minimal manipulation”. Whilst there were some statistical
differences between the DNA content of separated cells from the device cultured in
osteoinductive medium and the DNA content of the various controls (cells held in
Plain α-MEM, PBS or culture medium for the experiment duration and cells which
experienced constant flow through the microfluidic channels), these were most likely
due to experimental varissation as there was no consistent difference observed when
compared to a positive control of un-separated cells cultured in osteoinductive medium
for three repeat separation experiments using DPSCs isolated from three different donors.
There was no consistent statistical difference between the DNA content of cells which had
undergone the full separation process when compared with un-separated cells cultured in
osteoinductive medium across DPSCs isolated from three different donors, at both time
periods of 7 and 14 days. This suggested that the separation process was not having an
adverse effect on the proliferation of DPSCs.
The ability of DPSCs to retain their osteogenic potential post separation and enrichment
was then investigated, again alongside the appropriate controls as described previously.
Alkaline phosphatase is an early marker of osteogenic differentiation; in DPSCs ALP
specific activity increases early in osteogenic induction [181]. ALP expression was
analysed through pNPP biochemical assays normalised to DNA content to provide a
quantitative measure of ALP specific activity. For the separated and un-separated controls,
for DPSCs isolated from three different donors, the ALP specific activity was much
lower at day 7 compared to day 14 in all groups. This was presumably due to the
low seeding density of DPSCs from the limited availability of captured and released
cells as at low seeding densities the percentage of DPSCs expressing TNAP on the
cells surface is decreased [17]. By day 14 for all DPSCs isolated from three donors,
the ALP specific activity of the un-separated DPSCs cultured in osteoinductive medium
was increased compared to un-separated cells cultured in basal culture medium for the
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same time period. This indicated that DPSCs cultured in the osteoinductive medium were
differentiating down an osteogenic lineage. There was no significant difference between
the cells separated by the capture and release mechanism cultured in osteoinductive
medium compared with the un-separated cells cultured in osteoinductive medium. This
suggests that the DPSCs which had undergone the capture and release process for TNAP+
DPSC enrichment had retained their ostoegenic potential. However as the device was
enriching DPSCs for TNAP during the separation process there was already an increased
percentage of cells expressing ALP which could be a confounder in the data presented
here.
As ALP expression is an early marker of osteogenic differentiation it is thought that
enriching a cell population for TNAP+ cells might provide a cell population with the
greatest potential to differentiate down a mineralising phenotype. In the ALP activity
studies, for DPSCs isolated from two separate donors there was no significant difference
in the ALP specific activity between the separated captured and released cells cultured in
osteoinductive medium and the un-separated cells cultured in osteoinductive medium at
day 7. However, for DPSCs isolated from a third donor there was an increase in the ALP
specific activity of the separated captured and released cells and the un-separated cells,
both cultured in osteoinductive medium. This most likely suggests that the separated
cells are at an equivalent TNAP expression level compared to the appropriate controls,
with the capture and released cells not at a higher activity even though the cell population
was enriched for ALP. As DPSCs’ TNAP expression is upregulated with the inhibition
of proliferation [17], the formation of a cell monolayer for the ALP activity experiments
would potentially give time for the TNAP- cells to upregulate TNAP expression as density
increases. Separated TNAP- DPSCs have been shown to be phenotypically similar
to TNAP+ DPSCs cultured in osteoinduction medium for 7 days [17] due to TNAP
upregulation when cell density increases as the cells reach confluency. This inhibition
of proliferation combined with an osteoinductive medium, would allow unseparated cells
to reach the same level of TNAP production as the enriched population. Then by day
14 as DPSCs are confluent at a high density the separated cells and the various control
groups are expressing similar levels of TNAP which was seen across three independent
separation experiments using DPSCs isolated from three separate donors. Future work is
needed to provide a better understanding of the early stages osetogenic differentiation of
TNAP enriched DPSCs in vitro.
The ALP activity studies demonstrated that DPSCs which have been separated by the
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capture and release method are not adversely effect by the process as they are still capable
of undergoing the early stages of osteogenic differentiation. Yet further confirmation
of ostoegenic differentiation was provided by assessing the mineralisation phenotype.
The effect of separation on the DPSCs to deposit a mineralised matrix when cultured in
osteoinductive medium was explored with an alizarin red stain for calcium accumulation
and the presence of mineralised nodules. Overall the calcium accumulation for the
separated DPSCs collected from the device was similar to the controls which had not
undergone separation, with only the un-separated DPSCs cultured in basal medium
negative showing a lack of staining. This was confirmed qualitatively for the DPSCs
isolated from three donors and then quantified for DPSCs isolated from donor 1. However
as the DPSCs isolated from donor 2 and 3 had issues with the cell monolayer detachment
in the long culture periods required for osteogenic differentiation, the quantification
data would not be accurate as it is not normalised to cell numbers. The mineralised
nodule formation and distribution was also unaffected due to the cell separation process.
These results are consistent with the literature that DPSCs are able differentiate down
an osteogenic lineage [17, 79, 51]. However the main finding from these results was
that DPSCs osteogenic potential is apparently retained even after an external stimulus,
such as the antibody binding and increased fluid flow, is applied to the cells. This has
been observed for a different external stimulus when DPSCs were separated by SAW-
DEP forces, there were no adverse effects on the osteogenic capability of DPSCs [131].
Therefore DPSCs retain normal function after a variety of different external forces and
osteogenic potential is unaffected when cells were separated using the microfluidic device
to capture and release cells on an anti-TNAP functionalised surface for TNAP+ DPSC
enrichment.
DPSCs have a very high mineralising potential [17], so observing changes in the
osteogenic differentiation between the enriched TNAP+ DPSC population compared
with the controls in vitro will be challenging. Whilst these cells have been shown to
be of interest in regenerative therapies, MSCs isolated from bone marrow would be
a more likely source for bone tissue repair, from isolation in bone marrow aspirate
or orthopedic surgical waste. Bone marrow stem cells would be expected to behave
differently when separated into TNAP+/TNAP- populations, where higher amounts of
matrix mineralisation has been found in enriched TNAP+ BMSCs [96]. Therefore the
work would need to be repeated with BMSCs to focus on the isolation of an enriched
TNAP+ BMSCs to fully characterise the enhanced mineralising potential and whether
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an appropriate number of viable BMSCs which had undergone “minimal manipulation”
could be separated for bone regenerative therapies. The prolonged culture period of
14-21 days could also be a reason why there was minimal differences in osteogensis
seen between the un-enriched and enriched TNAP cells. This gives the cells time for
the formation of a cell monolayer and for TNAP- cells to upregulate TNAP expression.
Ideally changes in the DPSC osteogenic potency should be measured straight away after
separation, without a prolonged culture period. This could be done using gene expression
for common osteogenic markers such as RUNX2, DLX and MSX genes. However
this approach would require device optimisation to significantly increase the number of
released cells for further downstream analysis.
Separated DPSCs had a high viability which combined with the retention of their
proliferation and osteogenic potential suggests that the separation process is having
minimal effect on the cells. These data indicate that the cell function is not altered
through interaction with an anti-TNAP antibody. Therefore the enriched TNAP+
population isolated through the capture and release mechanism developed here retained
key physiological capabilities, necessary for any downstream therapeutic applications.
This microfluidic cell separation device may therefore be potentially useful in future
regenerative therapies for bone repair as the device is able to deliver an enriched TNAP+
cell population with minimal manipulation to the cell population.
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Chapter 6
General Discussion, Future Directions
and Conclusions
6.1 General Discussion
Bone repair and regeneration are major clinical challenges, and despite much research,
there remains a pressing need for novel therapies. Bone is the second most commonly
transplanted tissue, with 2.2 million bone grafts performed worldwide at a cost of $2.5
billion [14]. Current clinical approaches for bone repair for non-union fractures and large
defects rely on the use of autologous, allogenic or synthetic bone grafts. Whilst these
provide the osteoconductive or osteoinductive properties required for bone repair, they
rarely provide both. These grafts also come with added risks and complications such
as donor site morbidity, risk of infection or disease transmission and immune rejection
[32, 33]. The use of cell therapy in bone regeneration offers an alternative approach
and the re-implantation of bone marrow mesenchymal stem cells (BMSCs), crucial for
bone repair due to their ability to differentiate down an osteogenic lineage, seeded
onto an appropriate scaffold material offer the most promising future benefit [15, 16].
The research described within this thesis has focused on developing a cell separation
device aiming to isolate an osteoinductive cell population using the pro-mineralising cell
surface marker present on both DPSCs and BMSCs [17, 96], tissue non-specific alkaline
phosphatase (TNAP), for use in bone repair and enhanced regenerative therapies. Within
a clinical setting, this novel cell separation device would ideally deliver an enriched
population of pro-mineralising bone stromal cells, from autologous orthopaedic surgical
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waste or bone marrow aspirate in an intraoperative time period (less than two hours).
To achieve this aim a number of objectives were required: 1) a model primary cell system
that approached clinical reality; 2) a suitable cell marker to be identified and characterised
on the cells’ surface, that would test the method of cell isolation on a capture surface
and allow isolation of cells relevant for bone regeneration; 3) identify a suitable binder
that was capable of being covalently linked to a gold surface in the microfluidic cell
separator that could identify TNAP on the cells’ surface, bind to TNAP to capture the
desired cell population and cells could be released when required; 4) design and develop
an appropriate microfluidic system and 5) characterise cells that had been separated using
the prototype microfluidic system in terms of their viability and biological characteristics,
including their ability to differentiate towards an osteogenic lineage. Ultimately, this
would begin to progress to a technology which has the ability to deliver a minimally
manipulated TNAP+ enriched MSC cell population that could enhance bone regenerative
therapies.
6.1.1 TNAP as a marker to enrich populations of stromal cells
TNAP has been the main target of this work as it has been identified as a pro-mineralising
cell surface marker present on the surface of both DPSCs and BMSCs [17, 96]. Utilising
TNAP as the ligand for cell capture has been advantageous in this project, as the number
of DPSCs expressing TNAP within the population can be increased by increasing the
cell seeding density which provided a useful tool in optimisation of the device. This
tuneable model of TNAP expression allows to see if the microfluidic device developed
is able to perform with the same levels of efficiency, sensitivity and specificity for a
fixed cell number but with a raised percentage of cells expressing TNAP. Also as the
number of cells expressing TNAP can be increased larger populations can be captured
onto the functionalised gold surface which provides a greater amount of released cells for
subsequent characterisation. One of the main benefits of utilising TNAP in a test system
is the enzymatic properties of the protein which greatly facilitates its detection. This
property allowed for the calculation of the number of molecules of TNAP on the surface
of each cell to be computed by comparing the optical density of a substrate which has
been turned over by TNAP on the cells’ surface to that of purified recombinant TNAP
protein. This provided a novel, and simple method for estimating the number of TNAP
molecules on the surface of DPSCs compared with other techniques such as quantitative
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flow cytometry [193, 194]. The enzymatic activity of TNAP protein also provided an easy
detection system to determine bound protein to the antibody functionalied gold surfaces
in order to optimise the concentration of the immobilised antibody. The TNAP protein,
captured by the surface-bound antibody, can be detected directly without the use of a
secondary antibody. Whilst this property has been a useful factor throughout this project,
the assumption has always been made that TNAP on the cells’ surface and purified TNAP
protein turnover of the substrate at the same rate and this remains to be confirmed.
TNAP+ MSCs have been identified to have a greater capability for osteogenic
differentiation when compared to TNAP- MSCs [94, 95, 96]. However TNAP is not
solely expressed on the surface of MSCs and one of the main limitations of isolating
MSCs from a mixed population within the device utilising antigen-antibody binding, is
there is no unique cell surface marker present on the surface of MSCs for identification
[233]. Whilst TNAP is present on the surface of MSCs, it is not a unique stem cell
surface marker and therefore the purity of MSC isolation obtained using TNAP as the sole
selection marker may be compromised. However, the microfluidic cell separation device
developed here presents a platform technology where different antibodies can be used in
the surface functionalisation procedure and therefore MSCs could be isolated utilising
different markers by flowing over serial surfaces, each with a different capture surface.
Potential alternative markers for MSC isolation include those that define minimal criteria
to for MSC populations, including CD105, CD73 and CD90 [52]. The device could also
use negative selection by first isolating any unwanted cells via identification and capture
using common markers of hematopoietic progenitors which are not expressed by MSCs,
such as CD45, CD34 or CD14 [52].
Alternative markers for MSC isolation include Stro-1. Cell populations negative for
Stro-1, do not form fibroblast colony-forming units (CFU-Fs) [55], however Stro-1 is
unlikely to be a unique MSC marker as its expression is not exclusive to MSCs and it is
present on other bone marrow cells [56]. The cell surface marker CD271 (also known
as low-affinity nerve growth factor receptor) has been identified as a novel marker for
MSC isolation. BMSCs negative for CD271 have no CFU-F activity, and also CD271+
BMSCs have a greater capacity for osteogenic and adipogenic differentiation compared
to CD271- BMSCs [220]. It has also been shown that bone marrow adherent fibroblastic
cells that were capable of proliferation and mesenchymal lineage differentiation, were
positive for CD271 [234]. These cells have been shown to express the commonly
defined MSC markers of CD73 and CD105 alongside CD271 [235, 94]. However,
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CD271 is not expressed in all MSC types [110] and CD271 is downregualted when
cultured on tissue culture plastic in vitro [235, 94], which would then lead to difficulties
in experimentally identifying the MSC subset, especially in a device which relies on
cell capture via antibody binding. Incorporating further functionalised surfaces into the
device, to capture and release cells based on the expression of multiple cell markers will
however, ultimately affect cell throughput and recovery. This may lead to a reduction in
the numbers of cells recovered, and this is especially problematic for a cell population as
rare as MSCs, potentially resulting in non-delivery of the number of cells needed for the
bone regeneration.
Whilst the device developed here would most likely not isolate a pure population of stem
cells as only one surface marker is targeted, it would be able to deliver an enriched
population of TNAP+ stromal cells. The proposed technology would therefore deliver
an osteoinductive cell population [96], but this would still need to be combined with
an osteoconductive scaffold to retain cells at the site of the injury and also to provide
mechanical support in large defects. The bone micro-environment in vivo is highly
important for bone regeneration, with the stem cell niche playing an important part [89].
Providing an osteoinductive cell source by enriching multiple cell types along with MSCs
which are TNAP+ could potentially have a greater osteogenic potential than MSCs alone,
which may lead to enhanced bone regeneration. For example, enhanced mineralisation
has been identified in the osteogenic differentiation of MSCs co-cultured with osteoblasts
and osteocytes compared to MSCs alone [90]. However, this theory requires extensive
further work with the importance on repeating the work carried out within this thesis
to enrich a population of TNAP+ cells from clinical samples of bone marrow aspirate,
and then use in vivo animal models to characterise bone repair of the TNAP enriched
population.
6.1.2 DPSCs for use as a model system for device optimisation
The work carried out throughout this thesis utilised dental pulp stromal cells as the cell
source. These cells are able to be extracted from pulp tissue through digestion and
adherence to tissue culture plastic and they are capable of mass expansion when cultured
in vitro [51]. The cell populations used throughout this work therefore have mainly
consisted of stromal cells, with stem cells present within this population. Dental pulp
stem cells (DPSCs) are of a mesenchymal lineage, capable of multilineage differentiation
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down an adipogenic, chondrogenic or osteogenic pathway [74, 77, 73]. However, the
chondrogenic and adipogenic potential of DPSCs appears to be weaker in comparison
with bone marrow derived MSCs, but both cell types have similar capabilities for
osteogenic differentiation. Here the cells are capable of producing mineralised nodules
in in vitro culture, indicative of the osteoblast phenotype in bone [236, 74, 71]. Due to
their osteogenic differentiation capabilities, DPSCs have provided an alternative cell type
to BMSCs for research in bone regeneration with many key benefits. Firstly, they are a
readily available cell source of mesenchymal stromal cells derived from human tissue,
obtained from the University of Leeds, School of Dentistry Research Tissue Bank, with
full ethical consent. The DPSCs were extracted from the pulp of impacted third molars
and can be stored long term within liquid nitrogen, making use of a cell source with would
otherwise be discarded. Therefore, the first stages of optimisation of the device could
take place with a clinically relevant primary cell source, avoiding the use of cell lines.
The other major advantage of utilising DPSCs was that previous research had shown that
when the cells are cultured at high seeding densities, there is an increase in the number
of cells which express TNAP within the mixed population [17], this provided a tunable
model of TNAP expression. Here, the numbers of TNAP+ DPSCs can be increased in
the total DPSC population which is beneficial in the optimisation of capture within the
microfluidic device.
The advantages of utilising DPSCs were discussed in section 3.5.2, where the
experimental results demonstrated that even when the number of TNAP+ cells increased
in the mixed population of DPSCs (TNAP+/TNAP-) due to an increase in seeding density,
the amount of TNAP molecules on the cells surface per DPSC was not altered. The
effect of the passage number and cell donor demonstrated minimal difference in the
number of TNAP molecules on the cells’ surface. Therefore this tunable model system of
altering TNAP expression could be used in the optimisation of the capture and release of
TNAP+ cells via an anti-TNAP antibody, in the knowledge there would be no confounding
results due to a change in the number of molecules on the cell surface between different
seeding densities, passage number or donors. This is an important result for any clinical
translation, as the efficiency of the device would not change with different patients due
to different cell donors expressing similar numbers of TNAP molecules on the surface
of DPSCs. However, a larger study with a greater number of donors would be needed
to confirm this result. Also for translation of the cell separation device to the clinic, the
work would have to be repeated using a primary cell source of BMSCs, which would be
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the target cell in clinical applications, to ensure that the number of TNAP molecules per
BMSCs is also consistent between patients.
For any potential future clinical translation of the cell separation technology,
investigations into the enrichment of BMSCs is vital. Whilst DPSCs are a good cell source
for research applications, for any therapeutical applications they are limited mainly due
to the low tissue volume and the subsequent low numbers of cells available. Never the
less there have been clinical trials utilising DPSCs for bone regeneration. For example,
there was successful repair of mandibular defects shown in patients when DPSCs seeded
onto a collagen sponge scaffold was used [237]. However, this required the extraction of a
third molar with significant cell expansion over 21 days to achieve sufficient cell numbers
before re-implantation and this would therefore not meet the regulatory requirements for
minimal manipulation. The microfluidic device that was developed here to capture and
release TNAP+ cells, was required to separate cells within an intraoperative time period
of less than two hours. This would not be achievable with DPSCs as they need to be
extracted from the tissue by means of enzymatic digestion and then expanded to achieve
desired numbers. Any cell expansion ex vivo requiring multiple passaging may lead to
potential problems such as telemore shortening [82], which can lead to changes in the
gene expression profiles and a decrease in the osteogenic ability of cells [238]. Enhanced
bone healing has been shown with fractions implanted from bone marrow aspirate that
had a concentrated number of MSCs following centrifugation, without the need for cell
expansion in an intraoperative time period [16]. The use of BMSCs would provide an
easily accessible autologous cell source, which can be isolated in large numbers from the
iliac crest and therefore available for enrichment through the device in the required time
period without any cell expansion.
The use of BMSCs would be an obvious cell source in clinical translation, however a
sample of bone marrow aspirate is significantly different to the samples tested within
this device, therefore there would be a large degree of development required for the
separation of real life samples from the operating theatre. The sample collected would
be a heterogeneous mixture of different cell types consisting mainly of leukocytes,
lymphocytes, granulocytes, platelets and progenitor cells where a small percentage of
MSCs (approximately 0.001-0.01%) are present within the bone marrow aspirate [54].
This would be significantly different to the samples used in this PhD research where
a large numbers of cells were grown on culture plates for all experiments. Also the
quality of the bone marrow aspirate sample can become diluted with peripheral blood
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as bleeding into the extraction site is unavoidable, volumes of < 5mL are recommended
for collection in the aspiration procedure. Therefore it would be most likely that prior
to using the device on a sample of bone marrow aspirate an initial separation may be
required by concentrating the BMSCs using a volume reduction technique such as density
based centrifugation. However further research and development of the device would be
required for the processing and separation of clinical samples.
6.1.3 Characterisation of a non-antibody TNAP binding proteins for
potential use within the microfluidic cell separator
The development of the cell separation device utilises the attachment of a binding protein
to specifically capture TNAP+ cells on a functionalised gold surface. Affimer proteins
are novel non-antibody binding proteins, which are robust, with high stability and a
relatively low molecular weight of approximately 12-14 kDa [11, 165]. Affimers have
been used extensively in a wide range of biochemical and cell biology assays [11], and
have also been used as recognition molecules in label-free biosensors [167, 168]. One
objective of this thesis was to investigate development of the microfluidic device utilising
a surface functionalised with anti-TNAP Affimers. Affimer proteins potentially binding
TNAP that were previously identified prior to the commencement of this PhD project were
characterised by using flow cytometry and protein pull-down assays for investigation of
binding to TNAP molecules on the surface of DPSCs. However, there was little evidence
to suggest that the anti-TNAP Affimers were capable of binding specifically to TNAP on
the surface of DPSCs. For this reason, demonstration proof of concept of the prototype
separation technology with the microfluidic device utilised an anti-TNAP antibody as
a binder instead. Affimers have been demonstrated as useful biological research and
diagnostic reagents [11] and have been identified which are capable to bind to specific
target molecules in live cells [166]. As the successful isolation of Affimers is highly
dependent on the source and quality of the purified target protein [177], it would be of
interest in future work to screen Affimers against multiple sources of TNAP proteins for
isolation of a large pool of Affimer variants for characterisation for binding to TNAP
present on the cells surface.
Alternative approaches for the generation of Affimers specific to TNAP on the cells’
surface include utilising the Affimer phage library for phage display on cells which
only express TNAP, so the Affimers isolated from screening are specific to the native
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conformation of TNAP protein. However, there are many difficulties with cell based
panning, including non-specific binding of phage particles in the screening process, as
well as difficulties with low density targets and a high background of non-target proteins
[177, 179]. Future production and characterisation of an Affimer or alternative non-
antibody binding protein specific to TNAP on the cells’ surface would never the less
be valuable for this cell separation technology. An Affimer specific for TNAP protein
on the cells’ surface could easily be substituted into the cell separation device and be
conjugated to the surface functionalised with a carboxylic acid terminated self assembling
monolayer. Generating a pool of anti-TNAP Affimers would allow selection of TNAP
specific binding proteins which could be further characterised for their binding affinities.
This would be advantageous in aiding the release mechanism as a specific Affimer with
a low binding affinity, could potentially allow a larger percentage of captured cells to be
released from the surface with a decrease in the fluid shear force required. Alternative
release mechanisms could be investigated such as a lower fluid flow to release cells, or a
slight pH change to lower the binding affinity of when cells are captured which would aim
in releasing as large of population of cells as possible with minimal force. Therefore the
cell separation using anti-TNAP Affimers would be classed as minimally manipulative as
the cells biological characteristics would not be altered from the separation process.
Due to a suitable anti-TNAP Affimer not being found, the current cell separation device
utilised antibodies instead to capture TNAP+ DPSCs on a functionalised surface for
demonstration of proof of concept. However, whilst antibodies are commonly used and
exquisite tools for research and therapeutic applications, they are with there disadvantages
where the production and use of an Affimer instead would be advantageous. Antibody
production requires the use of animals or mammalian cell culture which is expensive and
time consuming, and can also result in batch to batch variations [160]. There is also
concern of the validation and reproducibility of commercially available antibodies [158],
and as such results in a waste of materials, time and money across biological research. The
production of Affimers provides a less expensive and easier process for the development
of novel binding reagents. However for production of the prototype cell separation
device there was a commercial source of anti-TNAP antibody available and was also
thoroughly validated for specificity to TNAP on the cells’ surface through flow cytometry
experiments where the results showed that the number of cells expressing TNAP in a
mixed DPSC population increased with seeding density which was as described by a
previous study [17]. This provided an easy alternative to Affimers which allowed the
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production of the proof-of-concept cell separation device.
6.1.4 Development of a novel microfluidic cell separator for TNAP+
cell enrichment
The device developed throughout this work was able to enrich a population of TNAP+
DPSCs, ultimately for potential use in bone regenerative therapies. The current gold
standards of marker-specific cell separation are FACS and MACs [5], which rely
on antibodies conjugated with fluorophores or magnetic nanoparticles to enable the
separation procedure. Whilst these methods provide highly specific and exquisite tools
for research applications, they are less practical for use in a clinical setting. For cells
to be used in a clinical setting they need to be classed as “minimally manipulated”
after separation, as described by the EU directive No. 1394/2007 [19]. The method
used for separation must not alter the relevant biological characteristics of the cells. By
using FACS or MACS, cells that are isolated remain labelled with antibodies conjugated
with fluorophores or magnetic nanoparticles after separation. The retention of a labelled
antibody may alter the cells behaviour, and may interfere with the expansion and
differentiation potential of a stem cell population [7]. Therefore there may be unknown
cellular effects if the separated cell population is re-implanted into patients that could be
of a potential harmful nature. As discussed in section 4.5.3, cells which had been through
the capture and release procedure within the microfluidic separation device developed
here, had no significant amount of antibody detected after their release. This demonstrated
that cells were being released following their capture on the antibody functionalised
surface without removing the antibody from the surface. The resulting TNAP enriched
cell population is therefore not labelled with anti-TNAP antibodies and begins to meet
some of the criteria of a minimally manipulated cell population.
Whilst the microfludic device is capable of enriching a TNAP+ cell population, for
translation into a clinical setting it would be highly likely that this method of cell
separation would be combined with an initial cell separation method to first remove any
unwanted cell populations and to begin to isolate MSCs. Centrifugation of bone marrow
aspirate is a commonly used research technique to isolate a fraction of mononuclear
cells containing MSCs [105] (see section 1.4.1) before MSCs can be further selected by
adherence to tissue culture plastic. The bone marrow aspirate is combined with a solution
that has a known separation gradient, centrifuged at the required force, and then the
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specific fraction containing the mononuclear cells can be extracted. In a clinical setting,
centrifugation of extracted bone marrow aspirate to concentrate the MSC containing
fraction, has shown to enhance bone repair [60]. Therefore if the microflduidic device was
to be used within a clinical setting the bone marrow aspirate or orthopaedic surgical waste
would first need to be centrifuged to remove a large amount of undesirable cell types,
before being separated within the microfluidic device using the antibody functionalised
surface. This would remove any unwanted cell types prior to separation in the device,
delivering an MSC containing fraction, which would be able to be further enriched for
cells that are positive for TNAP expression.
There are other interesting approaches to novel microfluidic cell separation for the
isolation of stem cell populations. Stem cell populations have been separated by size
and deformability using microfilters [7], deterministic lateral displacement [124, 126]
or inertial microfluidics [128, 129]. These devices mainly rely on distinct differences
between the sizes of cells [7]; the efficiency of separating cells that are expressing
a particular marker would be difficult due to a large degree of overlap in the size
characteristics of cells which are both negative and positive for the cell surface marker
of interest. Thorough characterisation would be needed to identify if there are any unique
physical proprieties in cells which are positive for the marker of interest. When compared
to the device developed in this work these methods offer a higher throughput as cells
can be continuously separated, for example MSCs isolated using inertial microfluidics
can be separated at a flow rate of 1.6 mL/min allowing rapid processing to sort large
amounts of cells that are relatively rare populations [127]. The microfluidic device that
was developed in this thesis used an antibody functionalised surface and in its present
form relied on a one time capture and release mechanism. It would be of interest in further
work to investigate whether this may be increased by implementing a batch flow system
to increase cell throughput, with the need to demonstrate if the antibody functionalised
surface is capable of repeated cell binding and multiple episodes of capture and release.
Other unique separation methods for the isolation of cells include dielectrophresis and
acoustophoresis, which rely on unique differences in cells’ dielectrophoretic or acoustic
properties to achieve separation. These devices can offer a continuous cell separation,
and can isolate specific populations of cells not only by their extrinsic characteristics,
but also by intrinsic characteristics (such as ion gradients and organelle structure) [7].
Dielectrophresis has been used to sort a wide range of cell types [7], and has been shown
to be an efficient sorting methodology, capable of isolating MSCs from osteoblasts, as
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these cell types experience differences in dielectrophoretic force [9]. These separation
approaches differ to the device developed in this thesis as they are limited to separation of
cells that posses significantly different dielectrophoretic or acoustic responses. Therefore
these methods would be unable to separate cells with dielectrophoretic or acoustic
properties that overlap, such as where cells of the same type have varying expression
of a cell surface marker of interest. Cells can be labelled with antibodies to alter their
dielectrophoretic or acoustic properties to achieve marker specific cell separation. For
example, rare bacterial cells were separated using DEP by altering their dielectrophoretic
response by labelling with antibodies conjugated to polymeric beads [239]. Also specific
populations of CD4+ lymphocytes were separated from peripheral blood progenitor cells
using acoustophoresis by altering their acoustic properties by labelling with antibodies
conjugated to magnetic beads [141]. Whilst presenting alternative solutions to FACS and
MACS, these approaches would suffer the same limitations in translation to clinical use
as the cells that are separated would still retain the antibody and the separated cells could
not be classed as a minimally manipulated population.
Alternative microfluidic cell separation methods have been developed which are similar to
the device developed in this thesis as they utilise the interaction of cells with an antibody
functionalised surface to deliver a marker specific cell separation [148]. This interaction
has been applied to microfluidic devices where cells are not captured by the surface, but
are allowed to roll across the antibody functionalised surface such that cells which express
the marker of interest will be temporarily bound and subsequently released and so move
across the surface at a slower velocity. This allows for separation by eluting, as the cells
negative for the marker will be eluted from the device first, before the specific population
of interest [152, 153]. This may be beneficial to the cell population as no external force
has to be applied to remove the cells from the surface and cells have not been modified
with fluorescence or magnetic bead labelled antibodies, and thus cells released by cell
rolling have a high viability. However, as this method relies on taking different elution
fractions for separation there is large cross-contamination, resulting in a low purity in
the fraction containing cells expressing the marker of interest. In the microfluidic device
developed in chapter 4 here, cells were captured on the antibody functionalised surface,
and TNAP negative cells washed away, allowing a greater enrichment of the desired
TNAP+ population.
The prototype microfluidic device to deliver an enriched TNAP+ cell population relies on
incubation of cells on an antibody functionalised surface, before their subsequent release
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with an increase in shear stress from an increased flow. As discussed in section 4.5.3,
the captured cells are removed from the surface in a programmed flow sequence of 1.5
mL/min for 2 seconds then, 0.1 mL/min for 1 second in plain α-MEM culture medium
at pH 7.4, repeated for one minute. This was a simple method of cell release, which
enabled subsequent recovery of the captured cells for downstream analysis. However,
this method was only able to release 58% of the bound cells off the surface. For
translation and use in isolation of rare cell populations, the percentage of bound cells
removed from the surface would need to be increased, to increase the capture and release
efficiency of the device. Alternative approaches to either increase the amount of bound
cells released using programmed flow or as an entire alternative release mechanism, may
include the use of enzymatic digestion to remove cells attached to the surface [149]
or the use of thermoresponsive polymers to release antibodies off the surface, along
with the cell population, at specific temperatures [150, 151]. Ideally, as discussed in
chapter 2, alternative binding proteins to antibodies which would be specific to the native
conformation of TNAP on the cells’ surface would be developed and their affinities
thoroughly characterised [165, 11]. This would enable specific capture of the desired
cell population, but at a low enough affinity for subsequent release using minimal force
so as to not alter the cells’ biological characteristics. The binding proteins may also
be developed to have changes in their affinity associated with changes in the external
environment, such as temperature or subtle pH changes, acting as a “switch” to release
bound cells on the functionalised surface.
6.1.5 Characterisation of the enriched TNAP population from the
microfluidic device
Once the prototype device had been developed and an enrichment in the TNAP+ cell
population was demonstrated, it was important to determine the viability, proliferation and
osteogenic differentiation potential of the enriched cell population, as discussed in chapter
5. This was needed to meet the requirement of the separated cells being characterised as
a minimally manipulated cell population [19] and that the separation process does not
alter the cells future function for bone regeneration and repair. The DPSCs captured and
then released from the device retained a high viability of 92%, which would increase the
likelihood of survival for when cells are re-implanted back at the defect site [229] for
potential treatment. However, this viability was decreased by 5% when compared to an
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unseparated population of cells, therefore it would be of interest in the future to investigate
influences such as the buffer used in cell release, effects of channel geometry or the flow
rate used for release to minimise any damage to the captured cells and further increase the
viability percentage of the enriched cells.
The fact that cells separated in the prototype device were not bound to antibodies is an
important factor in meeting the criteria of minimal manipulation in that the biological
characteristics of the enriched cell population are not altered by the separation process.
Antibody labelling has been shown to effect cells’ proliferation and differentiation
potential [7] and there could potentially be unknown cellular effects which could be of
a harmful nature when cells are re-implanted back into patients. As shown in section
4.4.8, cells which had been captured and released from the functionalised surface of
the prototype device developed here demonstrated minimal retention of the anti-TNAP
antibody, indicating cells were being released after capture without stripping the antibody
from the surface. This is an important criteria which differentiates this separation process
from separation techniques, such as FACS and MACS, and allows the separation process
to begin to meet the criteria for minimal manipulation. The separated population of
TNAP+ enriched DPSCs was assessed for their viability, proliferation and differentiation
ability compared to an unseparated population of DPSCs. There were no significant
differences, suggesting that the separation process was not affecting these biological
characteristics and therefore the cells can begin to be classed as minimally manipulated.
The separated population of TNAP+ enriched DPSCs demonstrated no differences in
proliferation ability or osteogenic potential when compared to an unseparated population.
However, the future application of this device would be to deliver a enriched population
of TNAP+ stem cells, which would be pro-mineralising and therefore potentially able
to deliver enhanced bone repair. The focus of this project was to develop a proof of
concept prototype device able to deliver an enriched TNAP population, but for any
clinical translation the pro-mineralising capabilities of the enriched cells needed to be
investigated. In the current device, there was up to a 117% increase in the percentage of
TNAP+ cells and up to a 57% decrease in the TNAP- cell population after cell capture
and release. However, the specific ALP activity after 7 and 14 days, along with the
alizarin red assays after 21 days for calcium accumulation, did not indicate any significant
enhancement of the osteogenic potential in the TNAP enriched population compared to
the unseparated control population. This could be expected as DPSCs are a cell source
with a very high mineralising potential as it has been shown that separated TNAP- DPSCs
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are phenotypically similar to TNAP+ DPSCs when cultured in osteoinduction medium
for 7 days [17] due to upregulation of TNAP expression when the cell density increases
as the cells reach confluency during cell monolayer formation in vitro. To gain further
insight the work within this thesis needs to be repeated with a more clinically relevant
population of BMSCs, as separated TNAP+ BMSCs have been shown to have greater
matrix mineralisation, as well as a higher level of osteogenic-related gene expression [96]
than TNAP- BMSCs. If a significant increase in the osteogenic potential in vitro of TNAP
enriched BMSCs is found, at a desired percentage of TNAP+ cell enrichment, the work
will need to be investigated in vivo to determine the capability of cells to differentiate into
bone in vivo. There is evidence that even when cells are capable of depositing mineralised
nodules in vitro, there still can be limited hard tissue regeneration in vivo, possibly due to
factors such as cell age and health [238]. Therefore, the TNAP enriched cells need to be
seeded upon a scaffold material and implanted in vivo to investigate their potential for a
therapy for enhanced bone repair and regeneration.
The ability of cells to undergo osteogenic differentiation after the capture and release
mechanism within the device was assessed through ALP activity and alizarin red stain
for calcium deposits. To further characterise the osteogenic potential from the TNAP
enriched population for both DPSCs and BMSCs in future work, it would be of interest
to measure the gene expression of common genes associated with osteogenesis. For
example, measuring expression levels of the key osteogenic transcription factor RUNX2
would provide information on the ability of cells to undergo osteogenic differentiation.
As RUNX2 is a transcription marker for early committed osteo-progenitor cells and
is considered the central control gene for stem cells to commit down an osteogenic
lineage [85]. Other key common osteogenic-related genes include at least six DLX and
three MSX genes which play key parts during multiple phases of skeletal development,
where targeted gene disruption results in numerous alterations in skeletal developmental
[84, 240]. The expression levels of various Dlx proteins vary during the course of
osteogenic differentiation, Dlx3 is expressed in the early stages while Dlx5 and 6 are
expressed at the later stages of osteogenic differentiation [240]. MSX2 which is one of the
three members of the Msx gene family, promotes osteogenesis of MSCs and proliferation
of osteoblasts [241]. By analysing the expression of various DLX and MSX genes,
progenitor cells could be identified which are committed down an osteogenic lineage,
but are at the pre-osteoblast differentiation stage. The gene expression of common bone
matrix proteins such as osteocalcin, osteopontin and osteonectin can be analysed for
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identification of cell populations which have differentiated into mature osteoblasts. By
analysing the enriched population of TNAP+ DPSCs or MSCs for the gene expression of
common osteogenic-related genes a more detailed insight into the potentially increased
osteogenic ability of that enriched population could be provided.
One of the main limitations with translating this technology for clinical use currently is
the low cell number output of the separated population. Currently, 58 % of the captured
DPSCs were released using the programmed fluid flow mechanism which resulted in
collecting a population of approximately 1 - 4 ×104 cells per microfluidic channel.
For downstream analysis, multiple channels were run in parallel and the separated cell
populations were pooled together to allow characterisation of the separated population. It
has been reported that re-implantation of just 3×103 progenitor cells has lead to significant
enhanced bone healing in non-union fractures [218], however defining an absolute number
of MSCs needed for repair is difficult due to the many variable factors such as size of
defect, health and age of patient. Improving the cell number output of the separated
population would be necessary for future clinical translation. This could be achieved
through running multiple channels in parallel or by increasing the channel size to increase
the surface area of the antibody functionalised surface. An alternative approach would be
to develop a porous material which is able to be functionalsied with binding proteins,
where the cell population could be flown through, for example polymer cryogels with
large interconnected pores and surface-immobilised protein A ligands have been used to
isolate antibody labelled CD34+ umbilical cord blood cells in an affinity based separation
[219]. Gold meshes and non-woven fibres which could be functionalised with antibodies
would provide alternatives with a much larger surface area for specific cell capture and
release, but this would require work into developing the specific conjugation chemistry
needed for attachment of the binding proteins.
6.2 Future Directions
This study has demonstrated the proof of concept of a prototype microfluidic cell
separation device which can deliver an enriched population of TNAP+ cells which are
label free. However, despite the novel work presented in this thesis there remain a number
of areas for further work and also interests for scientific enquiry before finalisation of a
medical device which can be translated to the clinic and provide a real benefit in enhanced
216
bone repair and regeneration for patients.
Future studies would need to focus on the separation of a more clinically relevant cell
population of BMSCs isolated from bone marrow aspirate. To optimise the separation
device for isolation of BMSCs, the number of TNAP molecules of the cells surface per
TNAP+ BMSC would need to be determined, this would be straightforward by using
the method as described in chapter 3. As optimisation using BMSCs would take place
with cells cultured in vitro, the effect of cells isolated from different donors and passage
number would need to be analysed repeating what was carried out here for DPSCs. It
would also be of interest to see how the number of TNAP molecules on the surface of cells
cultured in vitro compares to the number of TNAP molecules on the surface of primary
cells extracted directly from the tissue source without any passaging, to understand if the
number of TNAP molecules is similar for the in vivo population of cells. This would be
important for translation of the technology for clinical use. It has currently be assumed
that the number of TNAP molecules on the surface of DPSCs is not altered by in vitro
culture but it is not known if this is the case for BMSCs. After characterisation of
the number of TNAP molecules at the BMSC surface, a mixed population of TNAP+/-
BMSCs would be separated in the device by capture and release, and therefore subsequent
TNAP+ cell enrichment demonstrated.
At present the microfluidic device was able to deliver a 117% enrichment of TNAP+
cells in the recovered population. Subsequent work needs to investigate the percentage
of TNAP+ cell enrichment that results in enhanced osteogenic potential, this could be
done with both DPSCs and BMSCs. Populations of cells would be separated using the
microfluidic cell separation device and then subsequently compared to the gold standard
cell separation methods for isolation of cells specific for certain markers using FACS and
MACS. The isolated cells would then be cultured under osteoinductive conditions and
the ALP activity and degree of matrix mineralisation would be measured at certain time
points, along with measuring the expression of key common osteogenic-related genes.
TNAP is a pro-mineralising cell surface marker and there is enhanced osteogenesis for
TNAP+ isolated cells [96, 17]. By analysing what percentage of TNAP+ cells in the
population would lead to a significant increase in the osteogenic potential, it would
provide confirmation that the cell separation device can deliver the required enrichment
for enhancement of the osteogenic potential in the cell population.
Any enhanced osteogenic potential would first have to be characterised in vitro, but
then would also have to be thoroughly confirmed in vivo. A suitable scaffold material
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would need to be identified which would provide the osteoconductive properties for the
osteoinductive cell population and would keep cells at the defect site whilst also providing
mechanical support. Then characterisation of the osteogenic differentiation potential of
TNAP+ enriched cells seeded onto the scaffold would need to be demonstrated in vivo.
TNAP+ populations of cells enriched using the device would be seeded onto a scaffold,
such as on bioglass or collagen scaffolds, and implanted into a small animal model
[79, 75] with an appropriate size defect and compared to a scaffold seeded with cells
separated by MACS or FACS. Bone formation would then be analysed by histological
evaluation and by microcomputed tomography to provide a detailed analysis of any
enhanced osteogenic potential of the enriched cell population.
Further characterisation into the effects of the cell separation process would be important
to understand if the methodology used had caused a cell stress response which may
potentially lead to sub-lethal effects on the retrieved cells. This could be determined
using quantitative RT-PCR to test for a potential cell stress response caused by the capture
and release process within the device, by measuring the expression of marker genes for
cell stress such as heat shock transcription factor 1 (HSF), hypoxia inducible factor 1
(HIF) and lactate dehydrogenase (LDH) and comparing these with unseparated control
cells [242]. Re-implantation of the cells in vitro, along with a suitable scaffold, would
provide further confirmation on whether the TNAP enriched cell population is minimally
manipulated in that there are no alterations in the cells’ biological characteristics after
being captured and released. This would help confirm that the cells retain their
proliferation and osteogenic differentiation capability in vivo after the separation process,
in their ability to differentiate and deposit new bone matrix.
At present there are no suitable anti-TNAP Affimers identified to bind to TNAP on the
cells’ surface within the device. For this reason, functionalisation of the gold surface
for cell separation was carried out with an anti-TNAP antibody instead. Future work
would focus on the identification of a suitable anti-TNAP Affimer or equivalent non-
antibody binding protein to potentially increase the amount of cells released from the
surface using as minimal force as possible. This could be achieved by re-screening a
different source of human TNAP protein to identify a wider selection of Affimer targets
or ideally the development of a method to perform the phage display identification using
cells expressing TNAP. The characterisation work performed in this study would need to
be repeated after a suitable Affimer protein that is specific for TNAP on the cells’ surface
had been identified. The Affimer protein could also be engineered with a cysteine at
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the C-terminal end of the protein and then labelled with biotin. Gold surfaces for cell
capture could be functionalised with streptavidin before immobilisation of the Affimer
protein which would provide a functionalised surface with the binding region of the
Affimer in the correct orientation for cell capture. If a pool of Affimer proteins were
identified, further characterisation into measuring the Affimer’s affinity through surface
plasmon resonance could be carried out. This would provide a non-antibody binding
protein, specific to TNAP with a known affinity, which potentially would be lower than
that of the antibody used to allow for specific cell capture, but also subsequent release
of the cells from utilising minimal force. A variety of different cell release mechanisms
could be investigated for example, cells could be released with a reduced fluid flow or the
affinity of the Affimer protein could be reduced with a subtle change in the pH to aid cell
release off the functionalised surface. A long term objective would be to utilise the device
developed as a platform technology, where Affimers which have been identified to target
a wide range of markers could be easily functionalised onto the surface within the device
to capture MSCs from other regenerative therapies to repair different tissue sources.
The prototype device developed here acted as a proof of concept in the label free
enrichment of TNAP+ cells. One of the main limitations of the current design is the
number of cells which are collected after the enrichment which is currently between 1 -
4 ×104 cells per microfluidic channel. If the separation process was to utilise BMSCs
this captured and released number would decrease rapidly due to the low percentages of
TNAP+ BMSCs. Therefore, to increase the number of cells released, a variety of solutions
could be implemented. Further more detailed characterisation into the specific flow rates
used for release along with a more detailed optimisation of flow rate for both cell capture
and release would be beneficial. For example it would be of interest to know at which flow
rate non-specific binding is significantly reduced for benefit of higher levels of TNAP+
cell capture and also further more detailed experiments into the ability to recover cells
at different flow rates (and therefore different shear rates) could enhance the purity and
amount of recovered TNAP+ cells. For increasing the recovery of cells with the device
design, a simple solution would be to scale up the work achieved in this study and run
multiple channels in parallel to increase the numbers of release cells. The microfluidic
channel could also be re-designed to cover a larger surface area, however it would be
then beneficial to perform computer modelling on the flow dynamics in various different
theoretical channels to model how the fluidic forces would change and how this may have
potential negative effects on the cells. Alternatively, the surface area could be increased
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by instead of flowing across a surface, the cell population could flow through a porous
mesh material functionalised with anti-TNAP binding proteins.
6.3 Conclusions
The main goal of this thesis was to design and develop a prototype microfluidics based
cell separation device which was able to deliver an enriched population of minimally
manipulated, label-free, autologous TNAP+ cells via cell capture and release using
either antibody or non-antibody protein binding. This would be for potential clinical
applications, where cells would be isolated from bone marrow aspirate or orthopaedic
surgical waste within intraoperative time of less than two hours. To summarise, the
objectives within the introduction are outlined along with the subsequent findings:
• The first objective of this thesis was to characterise previously identified anti-
TNAP Affimers for their binding to TNAP present on the surface of DPSCs, to
determine their potential use within a microfluidic cell separator. Three Affimer
proteins were identified from the previous work for expression and purification of
the proteins. The purified proteins demonstrated ability to bind to a recombinant
TNAP protein through sandwich ELISAs and protein pull-down assays. However,
fluorescently labelled Affimers demonstrated inconclusive evidence of specificity
to TNAP on the cells’ surface and the use of pull-down assays using the anti-TNAP
Affimers against DPSC lysate demonstrated no evidence of their binding to TNAP.
Mass spectrometry of isolated bands from the pull-down product suggested that
the Affimers also bound to non-specific proteins present in the lysate and therefore
subsequent development of the device utilised an anti-TNAP antibody instead.
• The second objective of this thesis was to investigate and characterise the expression
of TNAP on the surface of DPSCs and determine whether the number of TNAP
molecules on the surface of DPSCs is affected by seeding density, passage number
or donor. Previous findings [17] were confirmed in that the percentage of TNAP+
DPSCs increased with cell seeding density. A method was then developed to
calculate the number of TNAP molecules on the DPSCs surface by comparing
the dephosphorylation of pNPP substrate with a known quantity of purified TNAP
protein. It was shown that whilst the percentage of TNAP+ cells increased with
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the seeding density, the number of TNAP molecules per cell was not significantly
altered. The cell donor and passage number also had minimal effects on the number
of TNAP molecules per DPSC. It was calculated across multiple passages, seeding
densities and three cell donors that for each TNAP+ DPSCs there was 2.8 ± 1.3
×105 TNAP molecules expressed on the surface. This is a novel finding for this
work.
• The third objective was to design and develop a microfluidic cell separator which
captures TNAP+ DPSCs via a surface functionalised with a binding protein,
followed by subsequent cell release, for the enrichment of TNAP+ cells. It was
demonstrated that an anti-TNAP antibody could be conjugated to a gold surface
functionalised with a carboxylic acid terminated SAM. The surface was reaching
saturation with the anti-TNAP antibody and there were sufficient amounts of
binders for the capture of up to 53.4 ± 14.2% of TNAP+ DPSCs from the mixed cell
population, which was significantly increased compared to the capture of TNAP-
16HBE cells. A microfluidic cell separator was designed and built utilising the
gold surface and PDMS channels to flow DPSCs isolated from three cell donors, at
varying seeding densities, across an antibody functionalised surface. Specific cell
capture with TNAP+ DPSCs was demonstrated when compared to TNAP- 16HBE
cells. DPSCs could be captured and up to 58% of the population was released via an
increase in the flow rate. The released cells were characterised using flow cytometry
to demonstrate a TNAP+ enriched population with up to a two fold enrichment
of TNAP+ cells. The enriched cell population was also investigated to see if any
anti-TNAP antibodies had been removed from the surface during the separation and
release process and it was found that minimal antibody could be detected, indicating
that the device was beginning to meet the requirements for a minimally manipulated
cell separation.
• The fourth and final objective of the thesis was to investigate if use of the
microfluidic device and the capture and release mechanism used to provide
an enriched population of TNAP+ DPSCs would affect the cells’ biological
characteristics and their potential to be used in downstream applications. The cell
viability of the recovered enriched population was 92%. This was significantly
decreased compared with cells which had not undergone the separation procedure,
but was still a high viability and potentially not a problem for future biological
analysis or clinical use. The separated and recovered DPSCs also showed no
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alteration in their ability to proliferate and were also shown to be capable of
osteogenic differentiation as demonstrated by no alterations in the ALP specific
activity or the accumulation of calcium and the presence of mineralised nodules.
Together, the achieving of these objectives demonstrate a novel cell separation technology
capable of providing an enriched population of viable TNAP+ cells with no obvious
alterations in their biological characteristics. This provides a platform technology for
potential future clinical use in the separation of an osteoinductive cell source, which when




A Demonstrating using flow cytometry that primary
anti-TNAP antibodies can be detected with goat anti-
mouse APC secondary antibodies
Figure A.1: Representative histogram of flow cytometric analysis for DPSCs stained
with anti-mouse APC before and after separation. (a) Histogram of the isotype control
and before cell population stained with anti-mouse APC. (b) Histogram containing gate
set with isotype control set at 98% measuring the staining of anti-mouse APC before
separation. (c) Histogram of the isotype control and after cell population stained with
anti-mouse APC. (d) Percentage of stained cells after separation
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Figure A.2: Graphical representation of flow cytometric analysis for DPSCs directly
labelled (anti-TNAP APC) and indirectly labelled (anti-TNAP + anti-mouse APC). Data
represented as mean ± SD. n=3.
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[13] E. Gómez-barrena, P. Rosset, D. Lozano, J. Stanovici, C. Ermthaller, and
F. Gerbhard, “Bone fracture healing : Cell therapy in delayed unions and
nonunions,” Bone, vol. 70, pp. 93–101, 2015.
[14] P. V. Giannoudis, H. Dinopoulos, and E. Tsiridis, “Bone substitutes: An update,”
Injury, vol. 36, no. 3, pp. S20–S27, 2005.
[15] J. F. Connolly and R. O. Y. Guse, “Autologous marrow injection as a substitute
for operative grafting of tibial nonunions.” Clin Orthop Relat Res., vol. 266, pp.
259–70, 1991.
[16] P. Hernigou, A. Poignard, F. Beaujean, and H. Rouard, “Percutaneous autologous
bone-marrow grafting for nonunions. Influence of the number and concentration of
progenitor cells.” The Journal of bone and joint surgery. American volume, vol. 87,
no. 7, pp. 1430–1438, 2005.
228
[17] M. J. Tomlinson, C. Dennis, X. B. Yang, and J. Kirkham, “Tissue non-specific
alkaline phosphatase production by human dental pulp stromal cells is enhanced
by high density cell culture,” Cell and Tissue Research, 2015.
[18] C. W. th Shields, C. D. Reyes, and G. P. Lopez, “Microfluidic cell sorting: a review
of the advances in the separation of cells from debulking to rare cell isolation,” Lab
Chip, vol. 15, no. 5, pp. 1230–1249, 2015.
[19] T. H. E. E. Parliament, T. H. E. Council, O. F. The, and P. Union, “REGULATION
(EC) No 1394/2007 OF THE EUROPEAN PARLIAMENT AND OF THE
COUNCIL of 13 November 2007 on advanced therapy medicinal products,”
Official Journal of the European Union, no. 1394, 2007.
[20] R. Bartl and B. Frisch, Osteoporosis. Springer-Verlag Berlin Heidelberg, 2009.
[21] M. J. Olszta, X. Cheng, S. S. Jee, R. Kumar, Y.-Y. Kim, M. J. Kaufman, E. P.
Douglas, and L. B. Gower, “Bone structure and formation: A new perspective,”
Materials Science and Engineering: R: Reports, vol. 58, no. 3-5, pp. 77–116, 2007.
[22] S. Viguet-carrin, P. Garnero, and P. Delmas, “The role of collagen in bone strength,”
Osteoporos Int, vol. 17, pp. 319–336, 2006.
[23] H. Witwicka, S. Y. Hwang, and P. R. Odgren, The Structure of Bone. Princeton
University Press, 2014.
[24] B. Clarke, “Normal Bone Anatomy and Physiology,” Clinical Journal of the
American Society of Nephrology, vol. 3, no. Supplement 3, pp. S131–S139, 2008.
[25] B.-r. O. Cell and Z. Bar-shavit, “The Osteoclast : A Multinucleated ,
Hematopoietic-Origin ,,” vol. 1139, pp. 1130–1139, 2007.
[26] Pbroks13, “Bone cross section,” 2008.
[27] V. Campana, G. Milano, E. Pagano, M. Barba, C. Cicione, G. Salonna, W. Lattanzi,
and G. Logroscino, “Bone substitutes in orthopaedic surgery: from basic science
to clinical practice,” Journal of Materials Science: Materials in Medicine, vol. 25,
no. 10, pp. 2445–2461, 2014.
[28] T. Albrektsson and C. Johansson, “Osteoinduction, Osteoconduction and
Osseointegration,” Eur Spine J, vol. 10, pp. 96–101, 2001.
229
[29] T. Albrektsson, P. Brånemark, H. Hansson, and J. Lindström, “Osseointegrated
titanium implants. Requirements for ensuring a long-lasting, direct bone-to-
implant anchorage in man.” Acta Orthop Scand, vol. 52, no. 2, pp. 155–170, 1981.
[30] T. J. Cypher and J. P. Grossman, “Biological Principles of Bone Graft Healing,”
The journal of Foot and Ankle Surgery, vol. 35, no. 5, pp. 413–417, 1996.
[31] A. Oryan, S. Alidadi, A. Moshiri, and N. Maffulli, “Bone regenerative medicine:
classic options, novel strategies, and future directions.” Journal of orthopaedic
surgery and research, vol. 9, no. 1, p. 18, 2014.
[32] E. Arrington, W. Smith, H. Chambers, A. Bucknell, and N. Davino,
“Complications of iliac crest bone graft harvesting.” Clin Orthop Relat Res., vol.
329, no. August 1996, pp. 300–309, 1996.
[33] E. Younger and M. Chapman, “Morbidity at Bone Graft Donor Sites,” J Orthop
Trauma, vol. 3, no. 3, pp. 192–5, 1989.
[34] G. Carter, “Harvesting and Implanting Allograft Bone,” AORN Journal, vol. 70,
no. 4, pp. 659–670, oct 1999.
[35] G. Zimmermann and A. Moghaddam, “Allograft bone matrix versus synthetic bone
graft substitutes,” Injury, vol. 42, pp. S16–S21, 2011.
[36] G. E. Friedlaender, D. M. Strong, W. W. Tomford, and H. J. Mankin, “Long-
term follow-up of patients with osteochondral allografts. A correlation between
immunologic responses and clinical outcome.” The Orthopedic clinics of North
America, vol. 30, no. 4, pp. 583–8, 1999.
[37] J. F. Keating and M. M. Mcqueen, “Substitutes for autologous bone graft in
orthopaedic trauma.” J Bone Joint Surg Br., vol. 83, no. January, pp. 3–8, 2001.
[38] T. Malinin and H. T. Temple, “Comparison of frozen and freeze-dried particulate
bone allografts,” Cryobiology, vol. 55, pp. 167–170, 2007.
[39] R. C. Kinney, B. H. Ziran, K. Hirshorn, D. Schlatterer, and T. Ganey,
“Demineralized Bone Matrix for Fracture Healing : Fact or Fiction ?” J Orthop
Trauma, vol. 24, no. 3, pp. 52–55, 2010.
230
[40] L. Polo-corrales, M. Latorre-esteves, and J. E. Ramirez-vick, “Scaffold Design for
Bone Regeneration,” Journal of Nanoscience and Nanotechnology, vol. 14, no. 1,
pp. 15–56, 2014.
[41] R. Marsel and T. Einhorn, “The Biology of Fracture Healing,” Injury, vol. 42, no. 6,
pp. 551–555, 2012.
[42] P. V. Giannoudis, T. A. Einhorn, and D. Marsh, “Fracture healing: The diamond
concept,” 4th European Clinical Symposium on Bone and Tissue Regeneration, vol.
38, Supple, no. 0, pp. S3–S6, 2007.
[43] Y.-z. Jin and J. H. Lee, “Mesenchymal Stem Cell Therapy for Bone Regeneration,”
Clinics in Orthopedic Surgery, pp. 271–278, 2018.
[44] M. Marcacci, E. Kon, V. Moukhachev, A. Lavroukov, S. Kutepov, R. Quarto,
M. Mastrogiacomo, and R. Cancedda, “Stem cells associated with macroporous
bioceramics for long bone repair: 6- to 7-year outcome of a pilot clinical study.”
Tissue engineering, vol. 13, no. 5, pp. 947–55, 2007.
[45] R. Quarto, M. Mastrogiacomo, R. Cancedda, S. Kutepov, V. Mukhachev,
A. Lavroukov, E. Kon, and M. Marcacci, “Repair of large bone defects with the
use of autologous bone marrow stromal cells.” N Engl J Med., vol. 344, no. 5, pp.
381–387, 2001.
[46] E. Kholinne, Y. P. Djaja, M. Merlina, and N. D. Yulisa, “Mesenchymal stem cell
implantation in atrophic nonunion of the long bones,” Bone Joint Res, vol. 5, no. 7,
pp. 287–293, 2016.
[47] R. Binato, T. de Souza Fernandez, C. Lazzarotto-Silva, B. Du Rocher,
A. Mencalha, L. Pizzatti, L. F. Bouzas, and E. Abdelhay, “Stability of human
mesenchymal stem cells during in vitro culture: Considerations for cell therapy,”
Cell Proliferation, vol. 46, no. 1, pp. 10–22, 2013.
[48] C. D. Bari, F. D. Accio, P. Tylzanowski, and F. P. Luyten, “Multipotent
Mesenchymal Stem Cells From Adult Human Synovial Membrane,” Arthritis
Rheumatism, vol. 44, no. 8, pp. 1928–1942, 2001.
[49] P. A. Zuk, D. Ph, M. I. N. Zhu, H. Mizuno, P. Benhaim, and H. P. Lorenz,
“Multilineage Cells from Human Adipose Tissue : Implications for Cell-Based
Therapies,” Tissue engineering, vol. 7, no. 2, pp. 211–228, 2001.
231
[50] P. S. Zammit and J. R. Beauchamp, “The skeletal muscle satellite cell : stem cell
or son of stem cell ?” Differentiation, vol. 68, pp. 193–204, 2001.
[51] S. Gronthos, M. Mankani, J. Brahim, P. G. Robey, and S. Shi, “Postnatal human
dental pulp stem cells (DPSCs) in vitro and in vivo.” Proceedings of the National
Academy of Sciences of the United States of America, vol. 97, no. 25, pp. 13 625–
13 630, 2000.
[52] M. Dominici, K. Le Blanc, I. Mueller, I. Slaper-Cortenbach, F. Marini, D. Krause,
R. Deans, A. Keating, D. Prockop, and E. Horwitz, “Minimal criteria for defining
multipotent mesenchymal stromal cells. The International Society for Cellular
Therapy position statement,” Cytotherapy, vol. 8, no. 4, pp. 315–317, 2006.
[53] A. J. Friedenstein, R. K. Chailakhjan, and K. S. Lalykina, “The development of
fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen
cells,” Cell Tissue Kinet, vol. 3, no. 4, pp. 393–403, 1970.
[54] M. F. Pittenger, A. M. Mackay, S. C. Beck, R. K. Jaiswal, R. Douglas, J. D. Mosca,
M. A. Moorman, D. W. Simonetti, S. Craig, and D. R. Marshak, “Multilineage
potential of adult human mesenchymal stem cells,” Science, vol. 284, no. 5411, pp.
143–147, 1999.
[55] W. Dc and M. Antibody, “Identification of stromal cell precursors in human bone
marrow by a novel monoclonal antibody, STRO-1,” Blood, vol. 78, no. 1, pp. 55–
62, 1991.
[56] M. Maleki, Ghanba, F. Rvand, M. Reza Behvarz, M. Ejtemaei, and
E. Ghadirkhomi, “Comparison of mesenchymal stem cell markers in multiple
human adult stem cells.” International journal of stem cells, vol. 7, no. 2, pp. 118–
26, 2014.
[57] S. Gronthos, “Molecular and cellular characterisation of highly purified stromal
stem cells derived from human bone marrow,” Journal of Cell Science, vol. 116,
no. 9, pp. 1827–1835, 2003.
[58] H. Aslan, Y. Zilberman, L. Kandel, M. Liebergall, R. Oskouian, D. Gazit, and
Z. Gazit, “Osteogenic Differentiation of Noncultured Immunoisolated Bone,” Stem
Cells, vol. 7, pp. 1728–1737, 2006.
232
[59] P. Bianco, X. Cao, P. S. Frenette, J. J. Mao, P. G. Robey, P. J. Simmons, and C.-
Y. Wang, “The meaning, the sense and the significance: translating the science of
mesenchymal stem cells into medicine.” Nature medicine, vol. 19, no. 1, pp. 35–42,
2013.
[60] P. Hernigou, G. Mathieu, A. Poignard, O. Manicom, F. Beaujean, and H. Rouard,
“Percutaneous Autologous Bone-Marrow Grafting for Nonunions: Surgical
Technique,” JBJS Essential Surgical Techniques, vol. os-88, no. 1 suppl 2, pp.
322–327, 2006.
[61] K. Lorenz, M. Sicker, E. Schmelzer, T. Rupf, J. Salvetter, M. Schulz-Siegmund,
and A. Bader, “Multilineage differentiation potential of human dermal skin-derived
fibroblasts,” Experimental Dermatology, vol. 17, no. 11, pp. 925–932, 2008.
[62] M. Crisan, S. Yap, L. Casteilla, C.-W. Chen, M. Corselli, T. S. Park, G. Andriolo,
B. Sun, B. Zheng, L. Zhang, C. Norotte, P.-N. Teng, J. Traas, R. Schugar, B. M.
Deasy, S. Badylak, H.-J. Bhring, J.-P. Giacobino, L. Lazzari, J. Huard, and
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McCarley, D. Nikitopoulos, M. C. Murphy, and S. A. Soper, “Highly efficient
circulating tumor cell isolation from whole blood and label-free enumeration using
polymer-based microfluidics with an integrated conductivity sensor,” Journal of
the American Chemical Society, vol. 130, no. 27, pp. 8633–8641, 2008.
242
[150] H. J. Yoon, A. Shanker, Y. Wang, M. Kozminsky, Q. Jin, N. Palanisamy, M. L.
Burness, E. Azizi, D. M. Simeone, M. S. Wicha, J. Kim, and S. Nagrath, “Tunable
Thermal-Sensitive Polymer-Graphene Oxide Composite for Efficient Capture and
Release of Viable Circulating Tumor Cells,” Advanced Materials, vol. 28, pp.
4891–4897, 2016.
[151] U. A. Gurkan, T. Anand, H. Tas, D. Elkan, A. Akay, H. O. Keles, and
U. Demirci, “Controlled viable release of selectively captured label-free cells in
microchannels,” Lab on a Chip, vol. 11, no. 23, pp. 3979–3989, 2011.
[152] A. Mahara and T. Yamaoka, “Antibody-immobilized column for quick cell
separation based on cell rolling,” Biotechnology Progress, vol. 26, no. 2, pp. 441–
447, 2010.
[153] A. Mahara, “Continuous separation of cells of high osteoblastic differentiation
potential from mesenchymal stem cells on an antibody-immobilized column,”
Biomaterials, vol. 31, no. 14, pp. 4231–4237, 2010.
[154] T. Yamaoka and A. Mahara, “Cell rolling column in purification and differentiation
analysis of stem cells,” Reactive and Functional Polymers, vol. 71, no. 3, pp. 362–
366, 2011.
[155] M. A. Qasaimeh, Y. C. Wu, S. Bose, and A. Menachery, “Isolation of Circulating
Plasma Cells in Multiple Myeloma Using CD138 Antibody-Based Capture in a
Microfluidic Device,” Nature Publishing Group, no. December 2016, pp. 1–10,
2017.
[156] P. J. Conroy, S. Hearty, P. Leonard, and R. J. O’Kennedy, “Antibody
production, design and use for biosensor-based applications,” Seminars in Cell and
Developmental Biology, vol. 20, no. 1, pp. 10–26, 2009.
[157] D. E. Steinmeyer and E. L. Mccormick, “The art of antibody process development,”
vol. 13, no. July, pp. 613–618, 2008.
[158] J. Bordeaux, A. W. Welsh, S. Agarwal, E. Killiam, M. T. Baquero, J. A. Hanna,
V. K. Anagnostou, and D. L. Rimm, “Antibody validation,” BioTechniques, vol. 48,
no. 3, pp. 197–209, 2010.
243
[159] A. Bradbury and A. Plückthun, “Reproducibility: Standardize antibodies used in
research,” Nature, vol. 518, no. 7537, pp. 27–29, 2015.
[160] M. Gebauer and A. Skerra, “Engineered protein scaffolds as next-generation
antibody therapeutics,” Current Opinion in Chemical Biology, vol. 13, no. 3, pp.
245–255, 2009.
[161] A. Skerra, “Alternative non-antibody scaffolds for molecular recognition,” Current
Opinion in Biotechnology, vol. 18, no. 4, pp. 295–304, 2007.
[162] K. Skrlec, S. Borut, and A. Berlec, “Non-immunoglobulin scaffolds : a focus on
their targets,” pp. 1–11, 2015.
[163] A. Koide, C. W. Bailey, X. Huang, and S. Koide, “The Fibronectin Type III Domain
as a Scaffold for Novel Binding Proteins,” 1998.
[164] K. Nord, E. Gunneriusson, J. Ringdahl, S. Ståhl, M. Uhlén, and P. Nygren,
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